10-Q

0001193125-13-314932.txt : 20130801 0001193125-13-314932.hdr.sgml : 20130801 20130801152523 ACCESSION NUMBER: 0001193125-13-314932 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20130630 FILED AS OF DATE: 20130801 DATE AS OF CHANGE: 20130801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VICAL INC CENTRAL INDEX KEY: 0000819050 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 930948554 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21088 FILM NUMBER: 131002488 BUSINESS ADDRESS: STREET 1: 10390 PACIFIC CENTER COURT STREET 2: . CITY: SAN DIEGO STATE: CA ZIP: 92121-4340 BUSINESS PHONE: 858-646-1100 MAIL ADDRESS: STREET 1: 10390 PACIFIC CENTER COURT STREET 2: . CITY: SAN DIEGO STATE: CA ZIP: 92121-4340 10-Q 1 d554396d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number: 000-21088

VICAL INCORPORATED

(Exact name of registrant as specified in its charter)


Delaware		93-0948554
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

10390 Pacific Center Court San Diego, California		92121
(Address of principal executive offices)		(Zip Code)

(858) 646-1100

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨ Accelerated filer x Non-accelerated filer ¨ Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Total shares of common stock outstanding at July 25, 2013: 86,711,402

VICAL INCORPORATED

FORM 10-Q

INDEX


PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements

Balance Sheets (unaudited) as of June 30, 2013, and December 31, 2012			3

Statements of Operations (unaudited) for the three and six months ended June 30, 2013 and 2012			4

Statements of Comprehensive Loss (unaudited) for the three and six months ended June 30, 2013 and 2012			5

Statements of Cash Flows (unaudited) for the six months ended June 30, 2013 and 2012			6

Notes to Financial Statements (unaudited)			7

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			13

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk			19

ITEM 4. Controls and Procedures			20

PART II. OTHER INFORMATION

ITEM 1A. Risk Factors			20

ITEM 6. Exhibits			31

SIGNATURE			32

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

VICAL INCORPORATED

BALANCE SHEETS

(In thousands, except par value data)

(Unaudited)


	June 30, 2013			December 31, 2012
ASSETS
Current assets:
Cash and cash equivalents	$	45,033		$	43,159
Marketable securities, available-for-sale		19,406			37,639
Restricted cash		3,059			3,059
Receivables and other assets		2,083			2,152

Total current assets		69,581			86,009
Long-term investments		2,037			2,225
Property and equipment, net		4,735			5,284
Intangible assets, net		2,741			2,813
Other assets		191			191

Total assets	$	79,285		$	96,522

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	5,984		$	5,629
Deferred revenue		75			150

Total current liabilities		6,059			5,779
Long-term liabilities:
Deferred rent		1,483			1,657
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value, 5,000 shares authorized, none issued and outstanding		—			—
Common stock, $0.01 par value, 160,000 shares authorized, 86,495 and 86,136 shares issued and outstanding at June 30, 2013, and December 31, 2012, respectively		865			861
Additional paid-in capital		437,844			435,915
Accumulated deficit		(367,100	)		(347,937	)
Accumulated other comprehensive income		134			247

Total stockholders’ equity		71,743			89,086

Total liabilities and stockholders’ equity	$	79,285		$	96,522

See accompanying notes to unaudited financial statements

VICAL INCORPORATED

STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
Revenues:
Contract and grant revenue	$	1,170		$	1,364		$	2,306		$	2,585
License and royalty revenue		286			201			724			10,440

Total revenues		1,456			1,565			3,030			13,025
Operating expenses:
Research and development		3,930			3,791			7,580			10,219
Manufacturing and production		3,891			2,933			7,604			5,405
General and administrative		3,478			2,778			6,996			5,478

Total operating expenses		11,299			9,502			22,180			21,102

Loss from operations		(9,843	)		(7,937	)		(19,150	)		(8,077	)
Other income (expense):
Investment and other income, net		(38	)		69			(13	)		453

Net loss	$	(9,881	)	$	(7,868	)	$	(19,163	)	$	(7,624	)

Basic and diluted net loss per share	$	(0.11	)	$	(0.09	)	$	(0.22	)	$	(0.09	)

Weighted average shares used in computing basic and diluted net loss per share		86,730			86,282			86,623			85,412

See accompanying notes to unaudited financial statements

VICAL INCORPORATED

STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)

(Unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
Net loss	$	(9,881	)	$	(7,868	)	$	(19,163	)	$	(7,624	)
Other comprehensive loss:
Unrealized (losses) gains on available-for-sale and long-term marketable securities:
Unrealized (losses) gains arising during holding period		(100	)		38			(113	)		234
Less: Reversal of unrealized losses in accumulated other comprehensive loss upon the sale of long-term marketable securities included in investment and other income		—			—			—			(590	)

Other comprehensive (loss) gain		(100	)		38			(113	)		(356	)

Total comprehensive loss	$	(9,981	)	$	(7,830	)	$	(19,276	)	$	(7,980	)

See accompanying notes to financial statements

VICAL INCORPORATED

STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


	Six Months Ended June 30,
	2013			2012
Cash flows from operating activities:
Net loss	$	(19,163	)	$	(7,624	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,023			981
Write-off of abandoned patents		82			22
Gain on sale of property and equipment		—			(8	)
Compensation expense related to stock options and awards		1,954			1,843
Changes in operating assets and liabilities:
Receivables and other assets		69			(647	)
Accounts payable and accrued expenses		325			(1,328	)
Deferred revenue		(75	)		(99	)
Deferred rent		(144	)		(114	)

Net cash used in operating activities		(15,929	)		(6,974	)

Cash flows from investing activities:
Proceeds from the sale of marketable securities		—			3,750
Maturities of marketable securities		21,346			9,470
Purchases of marketable securities		(3,037	)		(27,211	)
Purchases of property and equipment		(273	)		(433	)
Proceeds from the sale of property and equipment		—			8
Patent expenditures		(212	)		(209	)

Net cash provided by (used in) investing activities		17,824			(14,625	)

Cash flows from financing activities:
Net proceeds from issuance of common stock		380			48,772
Payment of withholding taxes for net settlement of restricted stock units		(401	)		(152	)

Net cash (used in) provided by financing activities		(21	)		48,620

Net increase in cash and cash equivalents		1,874			27,021
Cash and cash equivalents at beginning of period		43,159			38,696

Cash and cash equivalents at end of period	$	45,033		$	65,717

See accompanying notes to unaudited financial statements

VICAL INCORPORATED

NOTES TO FINANCIAL STATEMENTS

June 30, 2013

(Unaudited)

1. GENERAL

Vical Incorporated, or the Company, a Delaware corporation, was incorporated in April 1987 and has devoted substantially all of its resources since that time to its research and development programs. The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

All of the Company’s potential products are in research and development phases. No revenues have been generated from the sale of any such products, nor are any such revenues expected for at least the next several years. The Company earns revenue from research and development agreements with pharmaceutical collaborators and grant and contract arrangements with government entities. Most of the Company’s product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. There can be no assurance that the Company’s research and development efforts, or those of its collaborators, will be successful. The Company expects to continue to incur substantial losses and not generate positive cash flows from operations for at least the next several years. No assurance can be given that the Company can generate sufficient product revenue to become profitable or generate positive cash flows from operations.

The unaudited financial statements at June 30, 2013, and for the three and six months ended June 30, 2013 and 2012, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC, and with accounting principles generally accepted in the United States applicable to interim financial statements. These unaudited financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company’s financial position as of the interim date and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year or future periods. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. These unaudited financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2012, included in its Annual Report on Form 10-K filed with the SEC.

Cash, Cash Equivalents and Marketable Securities

Cash and cash equivalents consist of cash and highly liquid securities with original maturities at the date of acquisition of ninety days or less. Investments with an original maturity of more than ninety days are considered marketable securities and have been classified by management as available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from sales of these securities to fund its operations, as necessary. Such investments are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Realized gains and losses from the sale of available-for-sale securities or the amounts, net of tax, reclassified out of accumulated other comprehensive income, if any, are determined on a specific identification basis.

Restricted Cash

The Company is required to maintain a letter of credit securing an amount equal to twelve months of the current monthly installment of base rent for the term of its primary facilities lease, which ends in August 2017. Under certain circumstances, the Company may be able to eliminate the need for the letter of credit. As of June 30, 2013, and December 31, 2012, restricted cash of $3.1 million was pledged as collateral for this letter of credit.

Revenue Recognition

Revenue is recognized when the four basic criteria of revenue recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Certain of the Company’s revenue is generated through manufacturing contracts and stand-alone license agreements.

The Company has entered into multiple-element arrangements. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.

The delivered item(s) must have value to the customer on a standalone basis and, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the Company’s control.

A delivered item is considered a separate unit of accounting when the delivered item has value to the partner on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the partner and the availability of research expertise in this field in the general marketplace. Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence, or VSOE, of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement. If facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of drug products, the license is identified as a separate unit of accounting and the amounts allocated to the license are recognized upon the delivery of the license, assuming the other revenue recognition criteria have been met. However, if the amounts allocated to the license through the relative selling price allocation exceed the upfront license fee, the amount recognized upon the delivery of the license is limited to the upfront fee received. If facts and circumstances dictate that the license does not have standalone value, the transaction price, including any upfront license fee payments received, are allocated to the identified separate units of accounting and recognized as those items are delivered.

The terms of the Company’s partnership agreements provide for milestone payments upon achievement of certain regulatory and commercial events. The Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following three criteria: (1) the consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (2) the consideration relates solely to past performance, and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due to the Company.

Contract Services, Grant and Royalty Revenue

The Company recognizes revenues from contract services and federal government research grants during the period in which the related expenditures are incurred and related payments for those services are received or collection is reasonably assured. Royalties to be received based on sales of licensed products by the Company’s partners incorporating the Company’s licensed technology are recognized when received.

Net Loss Per Share

Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted average number of shares used to compute diluted net loss per share excludes any assumed exercise of stock options and warrants, and any assumed issuance of common stock under restricted stock units as the effect would be antidilutive. Common stock equivalents of 1.4 million and 1.1 million for the three months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect. Common stock equivalents of 1.5 million and 1.4 million for the six months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect.

Recent Accounting Pronouncement

Effective January 1, 2013, the Company adopted Accounting Standards Update, or ASU, No. 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.” The adoption of ASU No. 2013-02 concerns presentation and disclosure only and did not have an impact on the Company’s financial position or results of operations. The Company elected to present the information required by ASU No. 2013-02 in the Statements of Comprehensive Loss.

2. STOCK-BASED COMPENSATION

Total stock-based compensation expense was allocated to research and development, manufacturing and production and general and administrative expense as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Research and development	$	242	$	272	$	554	$	558
Manufacturing and production		60		56		128		106
General and administrative		514		595		1,272		1,179

Total stock-based compensation expense	$	816	$	923	$	1,954	$	1,843

During the six months ended June 30, 2013 and 2012, the Company granted stock-based awards with a total estimated value of $3.8 million and $3.9 million, respectively. At June 30, 2013, total unrecognized estimated compensation expense related to unvested stock-based awards granted prior to that date was $4.1 million, which is expected to be recognized over a weighted-average period of 1.5 years. Stock-based awards granted during the six months ended June 30, 2013 and 2012, were equal to 2.2% of the outstanding shares of common stock at the end of the applicable period.

3. OTHER BALANCE SHEET ACCOUNTS

Accounts payable and accrued expenses consisted of the following (in thousands):


	June 30, 2013		December 31, 2012
Employee compensation	$	2,877	$	3,858
Post-termination benefit accrual		252		—
Clinical trial accrual		644		660
Accounts payable		1,295		377
Deferred rent		337		307
Other accrued liabilities		579		427

Total accounts payable and accrued expenses	$	5,984	$	5,629

4. MARKETABLE SECURITIES, AVAILABLE FOR SALE

The following is a summary of available-for-sale marketable securities (in thousands):


June 30, 2013	Amortized Cost		Unrealized Gain		Unrealized Loss		Market Value
U.S. treasuries	$	6,528	$	2	$	—	$	6,530
Government-sponsored enterprise securities		7,000		—		3		6,997
Corporate bonds		4,859		—		6		4,853
Certificates of deposit		1,026		—		—		1,026

	$	19,413	$	2	$	9	$	19,406


December 31, 2012	Amortized Cost		Unrealized Gain		Unrealized Loss		Market Value
U.S. treasuries	$	10,135	$	1	$	—	$	10,136
Government-sponsored enterprise securities		15,507		—		1		15,506
Corporate bonds		11,509		—		8		11,501
Certificates of deposit		496		—		—		496

	$	37,647	$	1	$	9	$	37,639

At June 30, 2013, $6.7 million of these securities were scheduled to mature outside of one year. The Company did not realize any gains or losses on sales of available-for-sale securities for the six months ended June 30, 2013. As of June 30, 2013, none of the securities had been in a continuous material unrealized loss position longer than one year.

5. LONG-TERM INVESTMENTS

In March 2012, the Company sold two auction rate securities classified as long-term investments with a par value of $4.0 million. Included in interest and other income for the six months ended June 30, 2012, is a gain of $0.3 million related to the sale.

As of June 30, 2013, the Company held an auction rate security with a par value of $2.5 million. This auction rate security has not experienced a successful auction since the liquidity issues experienced in the global credit and capital markets in 2008. As a result, the security is classified as a long-term investment as it is scheduled to mature in 2038. The security was rated BBB by Standard and Poor’s as of June 30, 2013. The security continues to pay interest according to its stated terms.

The valuation of the Company’s auction rate security is subject to uncertainties that are difficult to predict. The fair value of the security is estimated utilizing a discounted cash flow analysis. The key drivers of the valuation model include the expected term, collateralization underlying the security investment, the creditworthiness of the counterparty, the timing of expected future cash flows, discount rates, liquidity and the expected holding period. The security was also compared, when possible, to other observable market data for securities with similar characteristics. Based on the valuation of the security, the Company has recognized cumulative losses of $0.6 million as of June 30, 2013. The losses when recognized are included in investment and other income. The market value of the security has partially recovered. Included in other comprehensive income are unrealized (losses) gains of $(113,000) and $36,000 for the six months ended June 30, 2013 and 2012, respectively. As of June 30, 2013, the Company had recorded cumulative unrealized gains of $0.2 million. The resulting carrying value of the auction rate security at June 30, 2013, was $2.0 million. Any future decline in market value may result in additional losses being recognized.

6. FAIR VALUE MEASUREMENTS

The Company measures fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

•

Level 1: Observable inputs such as quoted prices in active markets;

•

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

•

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Cash equivalents, marketable securities and long-term investments measured at fair value are classified in the table below in one of the three categories described above (in thousands):


	Fair Value Measurements
June 30, 2013	Level 1		Level 2		Level 3		Total
Certificates of deposit	$	1,026	$	—	$	—	$	1,026
Money market funds		17,845		—		—		17,845
U.S. treasuries		6,530		—		—		6,530
Corporate bonds		—		4,853		—		4,853
Government-sponsored enterprise securities		—		6,997		—		6,997
Auction rate securities		—		—		2,037		2,037

	$	25,401	$	11,850	$	2,037	$	39,288


	Fair Value Measurements
December 31, 2012	Level 1		Level 2		Level 3		Total
Certificates of deposit	$	496	$	—	$	—	$	496
Money market funds		18,500		—		—		18,500
U.S. treasuries		10,136		—		—		10,136
Corporate bonds		—		11,501		—		11,501
Government-sponsored enterprise securities		—		15,506		—		15,506
Auction rate securities		—		—		2,225		2,225

	$	29,132	$	27,007	$	2,225	$	58,364

The Company’s investments in U.S. treasury securities, certificates of deposit and money market funds are valued based on publicly available quoted market prices for identical securities as of June 30, 2013. The Company determines the fair value of corporate bonds and other government-sponsored enterprise related securities with the aid of valuations provided by third parties using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company validates the valuations received from its primary pricing vendors for its level 2 securities by examining the inputs used in that vendor’s pricing process and determines whether they are reasonable and observable. The Company also compares those valuations to recent reported trades for those securities. The Company did not adjust any of the valuations received from these independent third parties with respect to any of its level 2 securities at June 30, 2013. The Company did not reclassify any investments between level categories during the three months ended June 30, 2013. The valuation of the Company’s investments in auction rate securities, which includes significant unobservable inputs, is more fully described in Note 5.

Activity for assets measured at fair value using significant unobservable inputs (Level 3) is presented in the table below (in thousands):


	Six Months Ended June 30, 2013
Balance at December 31, 2012	$	2,225
Total net unrealized losses, excluding tax impact, included in other comprehensive income		(188	)

Balance at June 30, 2013	$	2,037

Total gains or losses for the period included in net loss attributable to the change in unrealized gains or losses relating to assets still held at the reporting date	$	—

7. COMMITMENTS AND CONTINGENCIES

The Company prosecutes its intellectual property estate vigorously to obtain the broadest valid scope for its patents. Due to uncertainty of the ultimate outcome of patent enforcement actions, their impact on future operating results or the Company’s financial condition is not subject to reasonable estimates.

In the ordinary course of business, the Company may become a party to lawsuits involving various matters. The Company is unaware of any such lawsuits presently pending against it which, individually or in the aggregate, are deemed to be material to the Company’s financial condition or results of operations.

8. STOCKHOLDERS’ EQUITY

In January 2012, the Company sold 13,333,334 shares of its common stock in a public offering at a price to the public of $3.75 per share. In February 2012, the Company sold an additional 576,358 shares pursuant to a partial exercise of the underwriters’ overallotment option at a price to the public of $3.75 per share. Net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, totaled $48.7 million. All of the shares of common stock were offered pursuant to two effective shelf registration statements.

In November 2012, the Company entered into an At-The-Market Equity Offering Sales Agreement, or Sales Agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, under which the Company may issue and sell up to $50,000,000 of shares of its common stock from time to time. Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, shares may be sold through Stifel acting as sales agent or directly to Stifel acting as principal, by means of ordinary brokers’ transactions on the Nasdaq Global Select Market, in privately negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.

9. ASTELLAS AGREEMENTS

In July 2011, the Company entered into license agreements with Astellas Pharma Inc., or Astellas, granting Astellas exclusive, worldwide, royalty-bearing licenses under certain of the Company’s know-how and intellectual property to develop and commercialize certain products containing plasmids encoding certain forms of cytomegalovirus, or CMV, glycoprotein B and/or phosphoprotein 65, including ASP0113 (TransVax™) but excluding CyMVectin™.

Under the terms of the license agreements, Astellas paid a nonrefundable upfront license fee of $25.0 million in 2011. The Company also received a $10.0 million milestone payment in March 2012 upon finalization of the general trial design for a Phase 3 registration trial of ASP0113 in hematopoietic stem cell transplant recipients. The Company recognized $0.3 million and $10.2 million in license revenue under the Astellas agreements during the six months ended June 30, 2013 and 2012, respectively.

Under the terms of the agreements, the Company is also performing research and development services which are being paid for by Astellas. During the three and six months ended June 30, 2013, the Company recognized $1.1 million and $2.2 million, respectively, of revenue related to these contract services. During the three and six months ended June 30, 2012, the Company recognized $1.3 million and $2.3 million, respectively, of revenue related to these contract services.

In August 2012, the Company amended its license and supply agreements with Astellas to, among other things, extend the time period that the Company is obligated to supply licensed products for commercial use to Astellas, at Astellas’ expense, modify the allocation of $95.0 million of milestone payments among certain milestones through commercial launch and modify the structure of the royalties on net sales from a fixed double digit royalty to tiered double digit royalties.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q, or Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding our business, our financial position, the research and development of biopharmaceutical products based on our patented DNA delivery technologies, the funding of our research and development efforts, and other statements describing our goals, expectations, intentions or beliefs. Such statements reflect our current views and assumptions and are subject to risks and uncertainties, particularly those inherent in the process of developing and commercializing biopharmaceutical products based on our patented DNA delivery technologies. Actual results could differ materially from those projected herein. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K for the year ended December 31, 2012, and in our other filings with the SEC, and those identified in Part II, Item 1A entitled “Risk Factors” beginning on page 20 of this Report. As a result, you are cautioned not to rely on these forward-looking statements. We disclaim any duty to update any forward-looking statement to reflect events or circumstances that occur after the date on which such statement is made.

Overview

We research and develop biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. We believe the following areas of research offer the greatest potential for near-term commercialization for us and our partners:

•

Vaccines for use in high-risk populations for infectious disease targets for which there are significant needs;

•

Vaccines for general pediatric, adolescent and adult populations for infectious disease applications;

•

Cancer vaccines or immunotherapies that complement our existing programs and core expertise; and

•

Gene-based delivery of therapeutic proteins, such as angiogenic growth factors for treatment of cardiovascular diseases.

We currently have three active independent clinical and preclinical development programs in the areas of infectious disease and cancer including:

•

A fully enrolled ongoing Phase 3 clinical trial using our Allovectin^® immunotherapeutic in patients with metastatic melanoma which has been funded, up to certain limits, by AnGes MG, Inc., or AnGes, through cash payments and equity investments under a research and development agreement;

•

A completed preclinical program, with an allowed investigational new drug application, or IND, using our CyMVectin™ prophylactic vaccine formulated with our proprietary Vaxfectin^® adjuvant to prevent CMV infection before and during pregnancy; and

•

A preclinical program with therapeutic and prophylactic vaccines for herpes simplex virus type 2, or HSV-2, formulated with our proprietary Vaxfectin^® adjuvant.

We have leveraged our patented technologies through licensing and collaboration arrangements, such as our licensing arrangements with Astellas Pharma Inc., or Astellas, AnGes, Aqua Health Ltd. of Canada, or Aqua Health, an affiliate of Novartis Animal Health, and Merial Limited, or Merial, a subsidiary of Sanofi, among other biopharmaceutical companies.

In addition, we have licensed complementary technologies from leading research institutions and biopharmaceutical companies. We also have granted non-exclusive, academic licenses to our DNA delivery technology patent estate to 11 leading research institutions including Stanford, Harvard, Yale and the Massachusetts Institute of Technology. The non-exclusive academic licenses allow university researchers to use our technology free of charge for educational and internal, non-commercial research purposes. In exchange, we have the option to exclusively license from the universities potential commercial applications arising from their use of our technology on terms to be negotiated.

Product Development

We, together with our licensees and collaborators, are currently developing a number of DNA-based vaccines and therapeutics for the prevention or treatment of infectious diseases, cancer and cardiovascular diseases. The table below summarizes our independent programs and corporate and government collaborations.


Product/Concept	Intended Use	Development Status¹	Lead Developer
*Independent Programs*

Allovectin^® cancer immunotherapeutic	First-line treatment for metastatic melanoma	Phase 3	Vical

CyMVectin™ prophylactic vaccine for CMV	Prevent infection before pregnancy to preclude fetal transmission	Preclinical complete	Vical

Therapeutic and prophylactic vaccines for HSV-2	Prevent and protect against recurring flare-ups, reduce viral shedding and transmission	Preclinical	Vical

*Corporate Collaborations*

ASP0113 therapeutic vaccine for CMV	Protect against CMV infection after stem cell transplants	Phase 3	Astellas

ASP0113 therapeutic vaccine for CMV	Protect against CMV infection after solid organ transplants	Phase 2 preparation	Astellas

Collategene^® angiogenic therapy encoding Hepatocyte Growth Factor	Induce local growth of blood vessels to restore blood flow to limbs affected by critical limb ischemia	Phase 3 preparation	AnGes

Apex^®-IHN prophylactic vaccine for infectious hematopoietic necrosis virus	Prevent infection and disease in farm-raised salmon when exposed to infected wild salmon	Marketed in Canada	Aqua Health (Novartis)

ONCEPT^® therapeutic cancer vaccine encoding human tyrosinase	Adjunct treatment to increase survival time of dogs with oral melanoma	Marketed in the United States	Merial

*Government Collaboration*

Tetravalent dengue vaccine	Prevent dengue disease caused by all 4 dengue serotypes	Phase 1	Naval Medical Research Center

“Preclinical” indicates that a specific product candidate in a nonclinical setting has shown functional activity that is relevant to a targeted medical need, and is advancing toward initial human clinical testing. “Phase 1” clinical trials are typically conducted with a small number of patients or healthy subjects to evaluate safety, determine a safe dosage range, identify side effects, and, if possible, gain early evidence of effectiveness. “Phase 2” clinical trials are conducted with a larger group of patients to evaluate effectiveness of an investigational product for a defined patient population, and to determine common short-term side effects and risks associated with the product candidate. “Phase 3” clinical trials involve large scale, multi-center, comparative trials that are conducted with patients afflicted with a target disease to evaluate the overall benefit-risk relationship of the investigational product and to provide an adequate basis for product labeling.

Recent Events

The following events have recently occurred with respect to our business and our development programs:

•

In June 2013, we announced that Astellas had initiated a multinational Phase 3 registration trial of ASP0113 in approximately 500 hematopoietic cell transplant recipients. In 2011, we entered into exclusive worldwide license agreements with Astellas to develop and commercialize ASP0113, our investigational therapeutic vaccine designed to control CMV in transplant recipients. Astellas is conducting the trial, and we are providing development, regulatory and manufacturing support. Astellas expects to begin a separate Phase 2 trial of ASP0113 in solid organ transplant recipients later this year.

•

In May 2013, we announced the appointment of two additional members to our Board of Directors: Richard M. Beleson, a former analyst and institutional investor in the life sciences industries, and Stephen A. Sherwin, M.D., a broadly accomplished and highly respected medical oncologist and biotechnology entrepreneur.

•

Also in May 2013, we announced the online publication of preclinical evaluations of our Vaxfectin^® adjuvant by Baxter International Inc., or Baxter, in combination with Baxter’s cell culture-derived seasonal and pandemic influenza vaccines. The addition of Vaxfectin^® to the influenza vaccines substantially increased both antibody and T-cell responses compared with nonadjuvanted vaccines in mice and guinea pigs.

Research, Development and Manufacturing Programs

To date, we have not received revenues from the sale of our independently developed pharmaceutical products and have received minimal revenues from the sale of commercially marketed products by our licensees. We earn revenues by performing services under research and development and manufacturing contracts, from grants and from licensing access to our proprietary technologies. Since our inception, we estimate that we have received approximately $218.8 million in revenues from these sources. Revenues by source were as follows (in millions):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
Source	2013		2012		2013		2012
Astellas supply and services contract	$	1.1	$	1.3	$	2.2	$	2.3
Other contract and grants		0.1		0.1		0.1		0.3

Total contract and grant revenues		1.2		1.4		2.3		2.6

Astellas license	$	0.1	$	0.1	$	0.3	$	10.2
Other royalties and licenses		0.2		0.1		0.4		0.2

Total royalty and license revenues		0.3		0.2		0.7		10.4

Total revenues	$	1.5	$	1.6	$	3.0	$	13.0

Research, development, manufacturing and production costs by major program, as well as other costs, were as follows (in millions):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
Program	2013		2012		2013		2012
Allovectin^®	$	5.5	$	3.7	$	10.4	$	7.7
CMV		1.3		1.3		2.6		5.1
Other research, development, manufacturing and production		1.0		1.7		2.2		2.8

Total research, development, manufacturing and production	$	7.8	$	6.7	$	15.2	$	15.6

Since our inception through June 30, 2013, we estimate that we have spent approximately $488 million on research, development, manufacturing and production. Our current independent development focus is on our cancer immunotherapeutic Allovectin^®, novel DNA vaccines for CMV and HSV-2, and other clinical and preclinical targets.

We are conducting a Phase 3 clinical trial using Allovectin^® in patients with recurrent metastatic melanoma which has been funded, up to certain limits, by AnGes through cash payments and equity investments under a research and development agreement. We are also developing CyMVectin™ and HSV-2 vaccine candidates, and these programs will require significant additional funds to advance through development to commercialization. From inception through June 30, 2013, we have spent approximately $177 million on our Allovectin^® program and $76 million on our CMV programs including ASP0113.

We have other product candidates in the research stage. It can take many years to develop product candidates from the initial decision to screen product candidates, perform preclinical and safety studies, and perform clinical trials leading up to possible approval of a product by the U.S. Food and Drug Administration, or FDA, or comparable foreign agencies. The outcome of the research is unknown until each stage of the testing is completed, up through and including the registration of clinical trials. Accordingly, we are unable to predict which potential product candidates we may proceed with, the time and cost to complete development, and ultimately whether we will have a product approved by the FDA or comparable foreign agencies.

As a result, we expect to incur substantial operating losses for at least the next several years, due primarily to the advancement of our research and development programs, the cost of preclinical studies and clinical trials, spending for outside services, costs related to maintaining our intellectual property portfolio, costs due to manufacturing activities, costs related to our facilities, and possible advancement toward commercialization activities.

Critical Accounting Policies and Estimates

The preparation and presentation of financial statements in accordance with accounting principles generally accepted in the United States requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, revenues and expenses in our financial statements and accompanying notes. Management bases its estimates on historical information and assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and circumstances that may impact us in the future, they are inherently uncertain and actual results may differ materially from these estimates.

Our critical accounting policies are those that affect our financial statements materially and involve a significant level of judgment by management. Our critical accounting policies regarding revenue recognition are in the following areas: license and royalty agreements, manufacturing contracts, contract services and grant revenues. Our critical accounting policies also include recognition of research and development expenses and the valuation of long-lived and intangible assets.

There have been no material changes to our critical accounting policies and estimates discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012.

Recent Accounting Pronouncements

For information on the recent accounting pronouncements which may impact our business, see Note 1 of the Notes to Financial Statements included in this Report.

Results of Operations

Three Months Ended June 30, 2013, Compared with Three Months Ended June 30, 2012

Total Revenues. Total revenues decreased $0.1 million to $1.5 million for the three months ended June 30, 2013, from $1.6 million for the three months ended June 30, 2012. This decrease was primarily due to a reduction in contract revenue recognized related to our ASP0113 license agreements with Astellas.

Research and Development Expenses. Research and development expenses increased $0.1 million, or 3.7%, to $3.9 million for the three months ended June 30, 2013, from $3.8 million for the three months ended June 30, 2012. This increase was primarily due to an ASP0113 sub-license milestone being achieved during the three months ended June 30, 2013.

Manufacturing and Production Expenses. Manufacturing and production expenses increased $1.0 million, or 32.7%, to $3.9 million for the three months ended June 30, 2013, from $2.9 million for the three months ended June 30, 2012. This increase was primarily the result of an increase in scientific supplies expenses to support the Allovectin^® and ASP0113 programs combined with a decrease in capitalized manufacturing costs associated with our license agreements with Astellas.

General and Administrative Expenses. General and administrative expenses increased $0.7 million, or 25.2%, to $3.5 million for the three months ended June 30, 2013, from $2.8 million for the three months ended June 30, 2012. This increase was primarily the result of higher legal and consulting costs related to our Allovectin^® program.

Investment and Other Income, Net. Investment and other income, net decreased $107,000 to $(38,000) for the three months ended June 30, 2013, from $69,000 for the three months ended June 30, 2012. This decrease was primarily the result of tax losses recognized related to the revaluation of auction rate securities during the three months ended June 30, 2013.

Six Months Ended June 30, 2013, Compared with Six Months Ended June 30, 2012

Total Revenues. Total revenues decreased $10.0 million to $3.0 million for the six months ended June 30, 2013, from $13.0 million for the six months ended June 30, 2012. This decrease was primarily the result of a $10.0 million decrease in license revenue related to an achievement of a milestone under our ASP0113 license agreements with Astellas.

Research and Development Expenses. Research and development expenses decreased $2.6 million, or 25.8%, to $7.6 million for the six months ended June 30, 2013, from $10.2 million for the six months ended June 30, 2012. This decrease was primarily due to a sub-license payment we made to the City of Hope related to an achievement of a milestone under the license of our ASP0113 program to Astellas during the six months ended June 30, 2012.

Manufacturing and Production Expenses. Manufacturing and production expenses increased $2.2 million, or 40.7%, to $7.6 million for the six months ended June 30, 2013, from $5.4 million for the six months ended June 30, 2012. This increase was primarily the result of an increase in contract manufacturing expenses and a decrease in capitalized manufacturing costs associated with our license agreements with Astellas during the six months ended June 30, 2013.

General and Administrative Expenses. General and administrative expenses increased $1.5 million, or 27.7%, to $7.0 million for the six months ended June 30, 2013, from $5.5 million for the six months ended June 30, 2012. This increase was primarily the result of post-termination benefit costs accrued related to the resignation of our Chief Financial Officer and higher legal and consulting costs related to our Allovectin^® program.

Investment and Other Income, Net. Investment and other income, net decreased $466,000 to $(13,000) for the six months ended June 30, 2013, from $453,000 for the six months ended June 30, 2012. This decrease was primarily the result of a gain recognized on the sale of auction rate securities during the six months ended June 30, 2012.

Liquidity and Capital Resources

Since our inception, we have financed our operations primarily through private placements and public offerings of equity securities, and revenues from our operations. From our inception through June 30, 2013, we have received approximately $218.8 million in revenues from performing services under research and development and manufacturing contracts, from grants and from licensing access to our proprietary technologies, and we have raised net proceeds of approximately $420.4 million from the sale of equity securities. Cash, cash equivalents, marketable securities, and long-term investments, including restricted cash, totaled $69.5 million at June 30, 2013, compared with $86.1 million at December 31, 2012. The decrease in our cash, cash equivalents and marketable securities for the six months ended June 30, 2013, was primarily the result of the use of cash to fund our operations.

Net cash used in operating activities was $15.9 million and $7.0 million for the six months ended June 30, 2013 and 2012, respectively. The increase in net cash used in operating activities for the six months ended June 30, 2013, compared with the prior year period, was primarily the result of a $10.0 million decrease in license revenue related to our ASP0113 license agreements.

Net cash provided by (used in) investing activities was $17.8 million and $(14.6) million for the six months ended June 30, 2013 and 2012, respectively. The increase in net cash provided by investing activities for the six months ended June 30, 2013, compared with the prior year period, was primarily the result of an increase in net maturities of marketable securities.

Net cash (used in) provided by financing activities was $(21,000) and $48.6 million for the six months ended June 30, 2013 and 2012, respectively. The decrease in net cash provided by financing activities for the six months ended June 30, 2013, compared with the prior year period, was the result of net proceeds received from the sale of our common stock in a public offering during the six months ended June 30, 2012.

A discussion of our exposure to auction rate securities is included in Part 1, Item 3 of this Report under the heading “Quantitative and Qualitative Disclosures About Market Risk.”

We expect to incur substantial additional research and development expenses, manufacturing and production expenses, and general and administrative expenses, including continued increases in costs related to personnel, preclinical and clinical testing, outside services, facilities, intellectual property and possible commercialization. Our future capital requirements will depend on many factors, including continued scientific progress in our research and development programs, the scope and results of preclinical testing and clinical trials, the time and costs involved in obtaining regulatory approvals, the costs involved in filing, prosecuting, enforcing and defending patent claims, the impact of competing technological and market developments, the cost of manufacturing scale-up and validation, and possible commercialization activities and arrangements. We may seek additional funding through research and development relationships with suitable potential corporate collaborators. We may also seek additional funding through public or private financings. We currently have on file an effective shelf registration statement that allows us to raise up to $150.0 million from the sale of common stock, preferred stock, debt securities and/or warrants. However, additional financing may not be available on favorable terms or at all. If additional financing is not available, we anticipate that our available cash and existing sources of funding will be adequate to satisfy our cash needs at least through December 31, 2014.

In November 2012, we entered into an At-The-Market Equity Offering Sales Agreement, or Sales Agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, under which we may issue and sell up to $50.0 million of shares of our common stock from time to time. Under the Sales Agreement, we will set the parameters for the sale of shares, including the number of shares to be issued and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, shares may be sold through Stifel acting as sales agent or directly to Stifel acting as principal, by means of ordinary brokers’ transactions on the Nasdaq Global Select Market, in privately negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. Any sales other than by methods deemed to be an “at the market” offering as defined in Rule 415 promulgated under the Securities Act will require our prior consent. Stifel is obligated to use commercially reasonable efforts in conducting sales activities consistent with its normal trading and sales practices. The Sales Agreement may be terminated by us upon prior notice to Stifel or by Stifel upon prior notice to us, or at any time under certain circumstances, including but not limited to the occurrence of a material adverse change in the company.

The Sales Agreement provides that Stifel will be entitled to compensation for its services in an amount of 2.5% of the gross proceeds from the sale of shares sold through Stifel under the Sales Agreement. We have no obligation to sell any shares under the Sales Agreement, and may at any time suspend offers under the Sales Agreement. We agreed in the Sales Agreement to provide indemnification and contribution to Stifel against certain liabilities, including liabilities under the Securities Act, and to reimburse Stifel for certain legal expenses incurred in connection with the Sales Agreement.

Contractual Obligations

Under our Merck & Co., Inc., Sanofi, AnGes, Merial and Aqua Health agreements, we are required to pay up to 10% of certain initial upfront monetary payments, and a small percentage of some royalty payments, to the Wisconsin Alumni Research Foundation and/or the University of Michigan. Under our license agreements with Astellas, we are required to make certain payments to the City of Hope and CytRx Corporation in connection with the development and commercialization of our products licensed by Astellas. In addition, certain technology license agreements require us to make other payments if we or our sublicensees advance products through clinical development. For programs developed with the support of U.S. government funding, the U.S. government may have rights to resulting products without payment of royalties to us.

We may be required to make future payments to our licensors based on the achievement of milestones set forth in various in-licensing agreements. In most cases, these milestone payments are based on the achievement of development or regulatory milestones, including the exercise of options to obtain licenses related to specific disease targets, commencement of various phases of clinical trials, filing of product license applications, approval of product licenses from the FDA or a foreign regulatory agency, and the first commercial sale of a related product. Payment for the achievement of milestones under our in-license agreements is highly speculative and subject to a number of contingencies.

The aggregate amount of additional milestone payments that we could be required to pay under all of our in-license agreements in place at June 30, 2013, is approximately $16.4 million, of which approximately $7.8 million is related to our independent programs and corporate and government collaborations which are currently in clinical development. These amounts assume that all remaining milestones associated with the milestone payments are met. In the event that product license approval for any of the related products is obtained, we may be required to make royalty payments in addition to these milestone payments. Although we believe that some of the milestones contained in our in-license agreements may be achieved, it is highly unlikely that a significant number of them will be achieved. Because the milestones are contingent, we are not in a position to reasonably estimate how much, if any, of the potential milestone payments will ultimately be paid, or when. Additionally, under the in-license agreements, many of the milestone events are related to progress in clinical trials which will take several years to achieve.

In addition, we have undertaken certain commitments under license agreements with collaborators and under indemnification agreements with our officers and directors. Under the license agreements with our collaborators, we have agreed to continue to maintain and defend the patent rights licensed to the collaborators and, in the case of our agreements with Astellas, have agreed to undertake certain development and manufacturing activities. Under the indemnification agreements with our officers and directors, we have agreed to indemnify those individuals for any expenses and liabilities in the event of a threatened, pending or actual investigation, lawsuit, or criminal or investigative proceeding.

We have employment agreements that contain severance arrangements with each of our two executive officers and four of our other executives. Under the agreements with the executive officers, we are obligated to pay severance if we terminate the executive officer’s employment without “cause,” or if the executive officer resigns for “good reason,” as defined in the agreements, within the periods set forth therein. The severance for the executive officers consists of continued base salary payments at the then-current rate, including the payment of health insurance premiums, for the period specified in each agreement, which ranges from 12 to 18 months, plus a payment equal to between one and one and a half times the executive’s cash bonus in the previous year. In addition, the executive officers receive accelerated vesting on all their unvested stock awards as if they had remained employed by us for between 12 and 18 months from the date of termination. In the event that the termination occurs within 24 months of a “change in control,” as defined in the agreements, the severance for the executive officers consists of lump sum payments equal to between 18 and 24 months of base salary at the then-current rate, the payment of health insurance premiums for the period specified in each agreement, which ranges from 12 to 18 months, plus a payment equal to between one and one and a half times the executive’s cash bonus in the previous year. In addition, all outstanding unvested stock awards will vest immediately. The severance for the other executives consists of continued payments at the then-current base compensation rate for a period of six months. All of the agreements specify that any earnings from employment or consulting during this period will offset any salary continuation payments due from us. The maximum payments due under these employment agreements would have been $2.8 million if each such executive officer and other executive were terminated at June 30, 2013.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are subject to interest rate risk. Our investment portfolio is maintained in accordance with our investment policy which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. Our investment portfolio consists of cash equivalents, both restricted and non-restricted, marketable securities and long-term investments. The average maturity of our investments, excluding our auction rate securities, is approximately six months. Our investments are classified as available-for-sale securities.

To assess our interest rate risk, we performed a sensitivity analysis projecting an ending fair value of our cash equivalents and current marketable securities using the following assumptions: a 12-month time horizon, a 9-month average maturity and a 150-basis-point increase in interest rates. This pro forma fair value would have been $0.2 million lower than the reported fair value of our investments at June 30, 2013.

Our investment securities consist of auction rate securities, corporate debt securities and government agency securities. As of June 30, 2013, our long-term investments included a (at par value) $2.5 million auction rate security secured by municipal bonds. At June 30, 2013, the auction rate security we held maintained a Standard and Poor’s credit rating of BBB. The auction rate security is a debt instrument with a long-term maturity and with an interest rate that is reset in short intervals through auctions. The conditions in the global credit markets have prevented some investors from liquidating their holdings of auction rate securities because the amount of securities submitted for sale has exceeded the amount of purchase orders for such securities. If there is insufficient demand for the securities at the time of an auction, the auction may not be completed and the interest rates may be reset to predetermined higher rates. When auctions for these securities fail, the investments may not be readily convertible to cash until a future auction of these investments is successful or they are redeemed or mature.

Since February 2008, there has been insufficient demand at auction for our auction rate security held at June 30, 2013. As a result, this security is currently not liquid, and we could be required to hold it until it is redeemed by the issuer or to maturity. As of June 30, 2013, we had recognized $0.6 million of losses related to the auction rate security by adjusting its carrying value. The market value of the security has partially recovered from the lows that created the losses. As of June 30, 2013, we had recorded cumulative unrealized gains of $0.2 million. Any future decline in market value may result in additional losses being recognized.

The valuation of our auction rate security is subject to uncertainties that are difficult to predict. The fair value of the security is estimated utilizing a discounted cash flow analysis or other type of valuation model as of June 30, 2013. The key drivers of the valuation model include the expected term, collateralization underlying the security investment, the creditworthiness of the counterparty, the timing of expected future cash flows, discount rates, and the expected holding period. This security was also compared, when possible, to other observable market data for securities with similar characteristics.

In the event we need to access the funds that are not currently liquid, we will not be able to do so without the possible loss of principal, until a future auction for this investment is successful or it is redeemed by the issuer or it matures. If we are unable to sell this security in the market or it is not redeemed, then we may be required to hold it to maturity. We do not anticipate a need to access the funds for operational purposes for the foreseeable future. We will continue to monitor and evaluate this investment on an ongoing basis for impairment. Based on our ability to access our cash and other short-term investments, our expected operating cash flows, and our other sources of cash, we do not anticipate that the potential illiquidity of this investment will affect our ability to execute our current business plan.

ITEM 4.

CONTROLS AND PROCEDURES

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as such term is defined in Rule 13a-15(e) promulgated under the Exchange Act as of the end of the period covered by this Report. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective and were operating at the reasonable assurance level as of June 30, 2013.

Changes in Internal Control over Financial Reporting

Management has determined that there were no significant changes in our internal control over financial reporting that occurred during the three months ended June 30, 2013, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1A.

RISK FACTORS

You should consider carefully the risks described below, together with all of the other information included in this Report, and in our other filings with the SEC, before deciding whether to invest in or continue to hold our common stock. The risks described below are all material risks currently known, expected or reasonably foreseeable by us. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment.

The risk factors set forth below with an asterisk (*) next to the title are new risk factors or risk factors containing changes, including any material changes, from the risk factors previously disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC.

(*)None of our independently developed product candidates has been approved for sale, and we have a limited number of independently developed product candidates in clinical trials. If we do not develop commercially successful products, we may be forced to curtail or cease operations.

All of our independently developed product candidates are either in research or development. We must conduct a substantial amount of additional research and development before any U.S. or foreign regulatory authority will approve any of our product candidates. Limited data exist regarding the efficacy of DNA vaccines or therapeutics compared with conventional vaccines or therapeutics. Results of our research and development activities may indicate that our product candidates are unsafe or ineffective. In this case, regulatory authorities will not approve them.

Our independently developed product candidates currently in clinical development include Allovectin^®, for which we announced the completion of enrollment of a Phase 3 clinical trial in 2010. We have an allowed IND for CyMVectin™ and we are in the process of completing preclinical work on a HSV-2 vaccine. We may not conduct Phase 1 CyMVectin™ or HSV-2 vaccine trials, and the future trials, if any, may not demonstrate sufficient efficacy to support further product

development. Because we have a limited number of independent clinical-stage product candidates, if we experience a significant delay, set-back or failure in the development of any of these product candidates, it could have a material adverse impact on our business prospects. In particular, we believe that our near-term prospects are substantially dependent on the results of our Phase 3 clinical trial for Allovectin^®. If we do not meet our pre-specified endpoints of the trial or the results are otherwise negative or are perceived negatively, our stock price could decline significantly.

Additionally, we are in early stages of development with other product candidates. These product candidates will require significant costs to advance through the development stages. If such product candidates are advanced through clinical trials, the results of such trials may not support approval by the FDA or comparable foreign agencies. Even if approved, our products may not be commercially successful, particularly if they do not gain market acceptance among physicians, patients, healthcare payers and relevant medical communities. If we fail to develop and commercialize our products, we may be forced to curtail or cease operations.

(*)We are dependent on our license agreements with Astellas to further develop and commercialize ASP0113. The failure to maintain these agreements, or the failure of Astellas to perform its obligations under these agreements, could negatively impact our business.

Pursuant to the terms of our license agreements with Astellas, we granted to Astellas exclusive worldwide rights to develop and commercialize certain products, including ASP0113 but excluding CyMVectin™, for the control and prevention of CMV infection in immunocompromised patients, including transplant recipients and transplant donors, and pursuant to the terms of our supply and services agreement with Astellas, we are obligated to perform certain development activities and supply Astellas with its product requirements for development and initial commercialization activities. Consequently, our ability to generate any revenues from ASP0113 depends on Astellas’ ability to develop, obtain regulatory approvals for and successfully commercialize ASP0113. We have limited control over the amount and timing of resources that Astellas will dedicate to these efforts.

We are subject to a number of other risks associated with our dependence on our license agreements with Astellas, including:

•

Astellas may not comply with applicable regulatory guidelines with respect to developing or commercializing ASP0113, which could adversely impact sales or future development of ASP0113;

•

We and Astellas could disagree as to future development plans and Astellas may delay, fail to commence or stop future clinical trials or other development;

•

There may be disputes between us and Astellas, including disagreements regarding the license agreements, that may result in (1) the delay of or failure to achieve developmental, regulatory and commercial objectives that would result in milestone or royalty payments, (2) the delay or termination of any future development or commercialization of ASP0113, and/or (3) costly litigation or arbitration that diverts our management’s attention and resources;

•

Astellas may not provide us with timely and accurate information regarding development, sales and marketing activities or supply forecasts, which could adversely impact our ability to comply with our service and supply obligations to Astellas and manage our own inventory of ASP0113, as well as our ability to generate accurate financial forecasts;

•

Business combinations or significant changes in Astellas’ business strategy may adversely affect Astellas’ ability or willingness to perform its obligations under our license agreements;

•

Astellas may not properly defend our intellectual property rights, or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation;

•

The royalties we are eligible to receive from Astellas may be reduced based upon Astellas’ and our ability to maintain or defend our intellectual property rights and the presence of generic competitors;

•

Limitations on our or an acquiror’s ability to maintain or pursue development or commercialization of products that are competitive with ASP0113 could deter a potential acquisition of us that our stockholders may otherwise view as beneficial; and

•

If Astellas is unsuccessful in developing, obtaining regulatory approvals for or commercializing ASP0113, we may not receive any additional milestone or royalty payments under the license agreements and our business prospects and financial results may be materially harmed.

The license agreements and supply and services agreement are subject to early termination, including through Astellas’ right to terminate upon advance notice to us if Astellas reasonably determines that further development and/or commercialization will not be beneficial for Astellas. If the agreements are terminated early, we may not be able to find another collaborator for the commercialization and further development of ASP0113 on acceptable terms, or at all, and we may be unable to pursue continued development or commercialization of ASP0113 on our own.

Our revenues partially depend on the development and commercialization of products in collaboration with others to whom we have licensed our technologies. If our other collaborators or licensees do not successfully develop and commercialize products covered by these arrangements, or if we are unable to find collaborators or licensees in the future, we may not be able to derive revenues from these arrangements, we may lose opportunities to validate our DNA delivery technologies, or we may be forced to curtail our development and commercialization efforts in these areas.

In addition to our license agreements with Astellas, we have licensed, and may continue to license, our technologies to corporate collaborators and licensees for the research, development and commercialization of specified product candidates. Our revenues partially depend upon the ability of these collaborators and licensees to successfully develop and commercialize products covered by these arrangements. In addition, our licensees Astellas and AnGes have product candidates in advanced stages of clinical development, for which we believe regulatory approval would provide important further validation of our DNA delivery technologies. The development and commercialization efforts of our collaborators and licensees are subject to the same risks and uncertainties described above with respect to our independently developed product candidates.

Some collaborators or licensees may not succeed in their product development efforts. It is possible that AnGes or any of our other collaborators or licensees may be unable to obtain regulatory approval of product candidates using our technologies or successfully market and commercialize any such products for which regulatory approval is obtained. In September 2010, AnGes announced that after a series of extensive consultations with the Japanese Pharmaceuticals and Medical Devices Agency, it would be withdrawing its New Drug Application, or NDA, in Japan. Also in September 2010, another one of our licensees, Sanofi, announced that NV1FGF, an angiogenic growth factor therapeutic for which Sanofi had licensed our DNA delivery technology, did not meet the primary endpoint in a global Phase 3 trial. Other collaborators or licensees may not devote sufficient time or resources to the programs covered by these arrangements, and we may have limited or no control over the time or resources allocated by these collaborators or licensees to these programs. The occurrence of any of these events may cause us to derive little or no revenue from these arrangements, lose opportunities to validate our DNA delivery technologies, or force us to curtail or cease our development and commercialization efforts in these areas.

Our collaborators and licensees may breach or terminate their agreements with us, including some that may terminate their agreements without cause at any time subject to certain prior written notice requirements, and we may be unsuccessful in entering into and maintaining other collaborative arrangements for the development and commercialization of products using our technologies. If we are unable to maintain existing collaboration arrangements or enter into new ones, our ability to generate licensing, milestone or royalty revenues would be materially impaired.

Some of our independent product candidates and some of those under development by our sublicensees incorporate technologies we have licensed from others. If we are unable to retain rights to use these technologies, we or our sublicensees may not be able to market products incorporating these technologies on a commercially feasible basis, if at all.

We have licensed certain technologies from corporate collaborators and research institutions, and sublicensed certain of such technologies to others, for use in the research, development and commercialization of product candidates. Our product development efforts and those of our sublicensees partially depend upon continued access to these technologies. For example, we or our licensors may breach or terminate our agreements, or disagree on interpretations of those agreements, which could prevent continued access to these technologies. If we were unable to resolve such matters on satisfactory terms, or at all, we or our sublicensees may be unable to develop and commercialize our products, and we may be forced to curtail or cease operations.

(*)We have a history of net losses. We expect to continue to incur net losses and we may not achieve or maintain profitability.

To date, we have not sold, or received approval to sell, any pharmaceutical products. We do not expect to sell any pharmaceutical products for at least the next several years. Our net losses were approximately $22.9 million, $7.3 million and $30.4 million for the years ended December 31, 2012, 2011 and 2010, respectively. As of June 30, 2013, we had incurred cumulative net losses totaling approximately $367.1 million. Moreover, we expect that our net losses will continue and may increase for the foreseeable future. We may not be able to achieve projected results if we generate lower revenues or receive lower investment income than expected, or we incur greater expenses than expected, or all of the above. We may never generate sufficient product revenue to become profitable. We also expect to have quarter-to-quarter fluctuations in revenues, expenses, and losses, some of which could be significant.

We may need additional capital in the future. If additional capital is not available, we may have to curtail or cease operations.

We may need to raise more money to continue the research and development necessary to bring our products to market and to establish marketing and additional manufacturing capabilities. We may seek additional funds through public and private stock offerings, government contracts and grants, arrangements with corporate collaborators, borrowings under lease lines of credit or other sources. We currently have on file a shelf registration statement that allows us to raise up to an aggregate of $150.0 million from the sale of common stock, preferred stock, debt securities and/or warrants. However, we may not be able to raise additional funds on favorable terms, or at all. Conditions in the credit markets and the financial services industry may make equity and debt financing more difficult to obtain, and may negatively impact our ability to complete financing transactions. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants, such as limitations on our ability to incur additional indebtedness and other operating restrictions that could adversely impact our ability to conduct our business.

In November 2012, we entered into a Sales Agreement with Stifel, under which we may issue and sell up to $50.0 million of our common stock from time to time. However, Stifel is not obligated to sell any shares that we may request to be sold, and any attempt to sell shares under this facility, if made, may not be successful or result in sufficient proceeds to meet our capital requirements.

If we are unable to obtain additional funds, we may have to scale back our development of new products, reduce our workforce or license to others products or technologies that we otherwise would seek to commercialize ourselves. The amount of money we may need would depend on many factors, including:

•

The progress of our research and development programs;

•

The scope and results of our preclinical studies and clinical trials; and

•

The time and costs involved in: obtaining necessary regulatory approvals; filing, prosecuting and enforcing patent claims; scaling up our manufacturing capabilities; and the commercial arrangements we may establish.

(*)The regulatory approval process is expensive, time consuming and uncertain, which may prevent us and our collaborators and licensees from obtaining required approvals for the commercialization of our products.

Our product candidates under development and those of our collaborators and licensees, including Astellas, are subject to extensive and rigorous regulations by numerous governmental authorities in the United States and other countries. The regulatory approval process takes many years and will require us to expend substantial resources. For example, the FDA has provided only limited guidelines concerning the size and scope of clinical trials required for gene-based therapeutic and vaccine products.

Therefore, U.S. or foreign regulations could prevent or delay regulatory approval of our products or limit our and our collaborators and licensees’ ability to develop and commercialize our products. Delays could:

•

Impose costly procedures on our activities and those of our collaborators and licensees;

•

Delay or prevent our receipt of developmental or commercial milestones from our collaborators and licensees;

•

Diminish any competitive advantages that we or our products attain; or

•

Otherwise negatively affect our results of operations and cash flows.

We have no experience in filing a Biologics License Application, or BLA, or NDA with the FDA. Because a BLA or NDA must be submitted to and approved by the FDA before any of our product candidates may be commercialized, our lack of experience may impede our ability to obtain FDA approval in a timely manner, if at all, which in turn would delay or prevent us from commercializing those products. Similarly, our lack of experience with respect to obtaining regulatory approvals in countries other than the United States may impede our ability to commercialize our products in those countries.

We believe that the FDA and comparable foreign regulatory bodies will regulate separately each product containing a particular gene depending on its intended use. Presently, to commercialize any product we and our collaborators and licensees must file a regulatory application for each proposed use. We and our collaborators and licensees must conduct clinical studies to demonstrate the safety and efficacy of the product necessary to obtain FDA or foreign regulatory authority approval. The results obtained so far in our clinical trials and those of our collaborators and licensees may not be replicated in ongoing or future trials, or the results may be subject to varying interpretation on whether they are sufficient to support approval for commercialization. This may prevent any of our product candidates from receiving approval for commercial sale.

We anticipate that we would commercially manufacture any of our product candidates that are approved for marketing. Therefore, our manufacturing facilities will have to be approved by the FDA pursuant to inspections conducted after we submit an application for regulatory approval. If we cannot successfully manufacture material that conforms to applicable specifications and the strict regulatory requirements of the FDA, we will not be able to secure and/or maintain regulatory approval for our manufacturing facilities. If the FDA does not approve our facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, our ability to develop, obtain regulatory approval for or market our product candidates will be adversely effected.

We use recombinant DNA molecules in our product candidates, and therefore we and our collaborators and licensees also must comply with guidelines instituted by the National Institutes of Health, or NIH, and its Office of Biotechnology Activities. The NIH could restrict or delay the development of our product candidates.

If any of our product candidates receive regulatory approval, the FDA or other foreign regulatory agencies may still impose significant restrictions on the indicated uses or marketing of our product candidates or impose ongoing requirements for potentially costly post-approval studies. In addition, regulatory agencies subject a product, its manufacturer and the manufacturer’s facilities to continual review and periodic inspections. If a regulatory agency discovers previously unknown problems with a product or a product class, including adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product or product class, our collaborators and licensees or us, including requiring withdrawal of a product from the market. Our product candidates will also be subject to ongoing FDA and other foreign regulatory agency requirements for the labeling, packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information on the product. If we or our collaborators and licensees fail to maintain regulatory compliance after receiving marketing approval, we or our collaborators and licensees may be unable to market our products and our business could suffer.

(*)Adverse events or the perception of adverse events in the field of gene therapy, or with respect to our product candidates, may negatively impact regulatory approval or public perception of our products.

The commercial success of some of our product candidates will depend in part on public acceptance of the use of gene therapy for preventing or treating human diseases. Serious adverse events, including patient deaths, have occurred in clinical trials utilizing viral delivery systems to deliver therapeutic genes to the patient’s targeted cells. Although none of our current products or studies utilize viral delivery systems, these adverse events, as well as any other adverse events in the field of gene therapy that may occur in the future, may negatively influence public perception of gene therapy in general. If public perception is influenced by claims that gene therapy is unsafe, our product candidates may not be accepted by the general public or the medical community.

Future adverse events in gene therapy or the biotechnology industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products. Any increased scrutiny could delay or increase the costs of our product development efforts or clinical trials. In addition, any adverse events that may occur in our clinical trials and any resulting publicity may cause regulatory delays or otherwise affect our product development efforts or clinical trials.

Some of our potential products may be administered to patients who are suffering from, or are vulnerable to, serious diseases or other conditions which can themselves be life-threatening and often result in the death of the patient. For example, one patient in our Allovectin^® Phase 2 trial conducted in 2000, died from progressive disease more than two months

after receiving Allovectin^® and other cancer therapies. The death was originally reported as unrelated to the treatment. Following an autopsy, the death was reclassified as “probably related” to the treatment because the possibility could not be ruled out. We do not believe Allovectin^® was a significant factor in the patient’s death. Patient deaths in our clinical trials, even if caused by pre-existing diseases or conditions, could negatively affect the perception of our product candidates. In addition, in our ASP0113 Phase 2 trial, we administered ASP0113 to patients who were at risk of CMV reactivation. Although we do not believe our vaccine candidates could cause the diseases they are designed to protect against, a temporal relationship between vaccination and disease onset could be perceived as causal. Some of our products are designed to stimulate immune responses, and those responses, if particularly strong or uncontrolled, could result in local or systemic adverse events, including latent adverse events.

(*)Our patents and proprietary rights may not provide us with any benefit and the patents of others may prevent us from commercializing our products.

As of June 30, 2013, we were the assignee or co-assignee of 87 issued U.S. and foreign patents. We maintain our issued patents by paying maintenance fees to the patent office in each country when due. Where appropriate, we participate in legal proceedings to vigorously defend against the revocation or withdrawal of our patents. The scope and nature of these proceedings generally differ depending on the country in which they are initiated. If we are not successful in defending our patents, we may lose all or part of our proprietary rights related to those patents in these geographic regions.

As of June 30, 2013, we were also prosecuting 55 pending patent applications in the United States and in foreign countries that cover various aspects of our proprietary technologies, not including patent applications for which we are a co-assignee and that are being prosecuted by our partners.

We may not receive any patents from our current patent applications. Issued patents provide exclusivity for only a limited time period, after which they no longer serve to protect proprietary technologies or to provide any commercial advantage. Moreover, if patents are issued to us, governmental authorities may not allow claims sufficient to protect our technologies and products. Others may also challenge or seek to circumvent or invalidate our patents. In that event, the rights granted under our patents may be inadequate to protect our proprietary technologies or to provide any commercial advantage.

In addition, the Leahy-Smith America Invents Act, or AIA, was signed into law on September 16, 2011, and significantly changed certain aspects of the United States patent laws. These changes include, but are not limited to, authorizing fee setting authority to the United States Patent Office, transitioning the United States to a first-inventor-to-file patent system, expanding the scope of prior art that may be utilized against a pending patent application, and adding post-patent grant proceedings before the Patent Office in which third parties may challenge the validity of the granted patent. It is not clear, what, if any, impact the AIA will have on the cost of prosecuting our patent applications, our ability to obtain patents based on our patent applications, and our ability to enforce or defend our issued or granted United States patents. An inability to obtain, enforce, and defend patents covering our proprietary technologies would materially and adversely affect our business prospects and financial condition.

Some components of our gene-based product candidates are, or may become, patented by others. As a result, we may be required to obtain licenses to conduct research, to manufacture, or to market such products. Licenses may not be available on commercially reasonable terms, or at all, which may impede our ability to commercialize our products.

The legal proceedings to obtain and defend patents, and litigation of third-party claims of intellectual property infringement, could require us to spend money and could impair our operations.

Our and our collaborators’, including Astellas’, success will depend in part on our, or our collaborators’, ability to obtain patent protection for our products and processes, both in the United States and in other countries. The patent positions of biotechnology and pharmaceutical companies, however, can be highly uncertain and involve complex legal and factual questions. Therefore, it is difficult to predict the breadth of claims allowed in the biotechnology and pharmaceutical fields.

We also rely on confidentiality agreements with our corporate collaborators, employees, consultants and certain contractors to protect our proprietary technologies. However, these agreements may be breached and we may not have adequate remedies for such breaches. In addition, our trade secrets may otherwise become known or independently discovered by our competitors.

Protecting intellectual property rights can be very expensive. Litigation may be necessary to enforce patents issued to us or to determine the scope and validity of third-party proprietary rights. If we or, as applicable, our commercialization partners, including Astellas pursuant to its first right to enforce patents licensed to it under our license agreements, choose to go to court to stop someone else from using our inventions, that individual or company has the right to ask the court to rule

that the underlying patents are invalid and/or should not be enforced against that third party. Moreover, if a competitor were to file a patent application claiming technology also invented by us or our collaborators or licensees, we would have to participate in an interference proceeding before the U.S. Patent and Trademark Office to determine the priority of the invention. We or our collaborators or licensees may be drawn into interferences with third parties or may have to provoke interferences ourselves to unblock third-party patent rights to allow us or our collaborators or licensees to commercialize products based on our technologies. Litigation could result in substantial costs and the diversion of management’s efforts regardless of the results of the litigation. An unfavorable result in litigation could subject us to significant liabilities to third parties, require disputed rights to be licensed or require us to cease using some technologies.

Our products and processes may infringe, or be found to infringe, patents not owned or controlled by us. Patents held by others may require us to alter our products or processes, obtain licenses, or stop activities. If relevant claims of third-party patents are upheld as valid and enforceable, we or our collaborators or licensees could be prevented from practicing the subject matter claimed in the patents, or may be required to obtain licenses or redesign our products or processes to avoid infringement. In addition, we or our collaborators or licensees could be required to pay money damages. A number of genetic sequences or proteins encoded by genetic sequences that we are investigating are, or may become, patented by others. As a result, we or our collaborators or licensees may have to obtain licenses to test, use or market these products. Our business will suffer if we or our collaborators or licensees are not able to obtain licenses at all or on terms commercially reasonable to us or them and we or they are not able to redesign our products or processes to avoid infringement.

We have incurred costs in several legal proceedings involving our intellectual property rights in Europe, Japan and Canada. We may continue to incur costs to defend and prosecute patents and patent applications in these and other regions.

Competition and technological change may make our product candidates and technologies less attractive or obsolete.

We compete with companies, including major pharmaceutical and biotechnology firms that are pursuing other forms of treatment or prevention for diseases that we target. We also may experience competition from companies that have acquired or may acquire technologies from universities and other research institutions. As these companies develop their technologies, they may develop proprietary positions which may prevent us from successfully commercializing products.

Some of our competitors are established companies with greater financial and other resources than we have. Other companies may succeed in developing products and obtaining regulatory approval from the FDA or comparable foreign agencies faster than we do, or in developing products that are more effective than ours. Research and development by others may seek to render our technologies or products obsolete or noncompetitive or result in treatments or cures superior to any therapeutics developed by us.

The NIH and the FDA jointly developed the Genetic Modification Clinical Research Information System, or GeMCRIS, an Internet-based database of human gene transfer trials. GeMCRIS enables individuals to easily view information on particular characteristics of clinical gene transfer trials. Although GeMCRIS includes special security features designed to protect patient privacy and confidential commercial information, these security features may be inadequately designed or enforced, potentially resulting in disclosure of confidential commercial information. In addition, the NIH, in collaboration with the FDA, has developed an Internet site, ClinicalTrials.gov, which provides public access to information on clinical trials and their results for a wide range of diseases and conditions. Future disclosures of such confidential commercial information may result in loss of advantage of competitive secrets.

If we lose our key personnel or are unable to attract and retain additional personnel, we may not be able to achieve our business objectives.

We are highly dependent on our principal scientific, manufacturing, clinical, regulatory and management personnel, including Vijay B. Samant, our President and Chief Executive Officer. The loss of the services of these individuals might significantly delay or prevent the achievement of our objectives. We do not maintain “key person” life insurance on any of our personnel. We depend on our continued ability to attract, retain and motivate highly qualified management and scientific personnel. We face competition for qualified individuals from other companies, academic institutions, government entities and other organizations in attracting and retaining personnel. To pursue our product development plans, we may need to hire additional management personnel and additional scientific personnel to perform research and development, as well as additional personnel with expertise in clinical trials, government regulation and manufacturing. However, due to the reasons noted above, we may not be successful in hiring or retaining qualified personnel and therefore we may not be able to achieve our business objectives.

(*)We have limited experience in manufacturing our product candidates in commercial quantities. We may not be able to comply with applicable manufacturing regulations or produce sufficient product for contract or commercial purposes.

The commercial manufacturing of vaccines and other biological products is a time-consuming and complex process, which must be performed in compliance with the FDA’s current Good Manufacturing Practices, or cGMP, regulations. We may not be able to comply with the cGMP regulations, and we have in the past encountered and may in the future encounter delays, disruptions or quality control problems in our manufacturing process. In addition, we may need to complete the installation and validation of additional large-scale fermentation and related purification equipment to produce the quantities of product expected to be required for commercial purposes. We have limited experience in manufacturing at this scale. We will also depend on third parties for any commercial scale filling of product vials. Noncompliance with the cGMP regulations, the inability to complete the installation or validation of additional large-scale equipment, or other problems with our manufacturing process may limit or delay the development or commercialization of our product candidates, and cause us to breach our contract manufacturing service arrangements or our obligations under our agreements with collaborators, including our obligations under our supply and services agreement with Astellas.

We currently depend on third parties to conduct our clinical trials and may initially depend on third parties to manufacture our product candidates commercially.

We rely on third parties, including clinical research organizations, medical institutions and contract laboratories, to perform critical services for us in connection with our clinical trials. These third parties are responsible for many aspects of the trials, including finding and enrolling subjects for testing and administering the trials. Although we rely on these third parties to conduct our clinical trials, we are responsible for ensuring that each of our clinical trials is conducted in accordance with its protocol and applicable regulations, including good clinical practices established by the FDA and foreign regulatory authorities, which govern the conduct, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that trial subjects are adequately informed of the potential risks associated with participating in clinical trials. Our reliance on third parties does not relieve us of the responsibility to ensure these requirements are met. These third parties may not comply with all regulatory and contractual requirements or may not otherwise perform their services in a timely or acceptable manner, and we may need to enter into new arrangements with alternative third parties and our clinical trials may be extended, delayed or terminated. In addition, if such third parties fail to perform their obligations in compliance with our clinical trial protocols or applicable good clinical practice regulations, our clinical trials may not meet regulatory requirements or may need to be repeated, and we may not be able to obtain regulatory approval for or commercialize the product candidate being tested in such trials. These risks also apply to the development activities of our collaborators and licensees, and we do not control our collaborators’ and licensees’ research and development, clinical trials or regulatory activities.

We may also initially depend on collaborators, licensees or other third parties to manufacture our product candidates in commercial quantities. There are a limited number of third parties that could manufacture our product candidates. We may be unable to enter into any arrangement for the commercial manufacture of our product candidates, and any arrangement we secure may not meet our requirements for manufacturing quality or quantity. Our dependence on third parties for the commercial manufacture of our product candidates may also reduce our profit margins and our ability to develop and deliver products in a timely manner.

We have no marketing or sales experience, and if we are unable to develop our own sales and marketing capability, we may not be successful in commercializing our products.

Our current strategy is to market our proprietary products directly in the United States, but we currently do not possess pharmaceutical marketing or sales capabilities. To market and sell our proprietary products, we will need to develop a sales force and a marketing group with relevant pharmaceutical industry experience, or make appropriate arrangements with strategic partners to market and sell these products. Developing a marketing and sales force is expensive and time-consuming and could delay any product launch. If we are unable to successfully employ qualified marketing and sales personnel or develop other sales and marketing capabilities, we may not be able to generate sufficient product revenue to become profitable.

Healthcare reform and restrictions on reimbursement may limit our returns on potential products.

Our ability to earn sufficient returns on our products will depend in part on how much, if any, reimbursement for our products and related treatments will be available from:

•

Government health administration authorities;

•

Government agencies procuring biodefense products for military or public use, including some for which we may become a sole-source vendor;

•

Private health coverage insurers;

•

Managed care organizations; and

•

Other organizations.

If we fail to obtain appropriate reimbursement, we could be prevented from successfully commercializing our potential products. There are ongoing efforts by governmental and third-party payers to contain or reduce the costs of healthcare through various reform measures. In the United States, the Federal government passed comprehensive healthcare reform legislation in 2010. Many of the details regarding the implementation of this legislation are yet to be determined and we currently cannot predict whether or to what extent such implementation or adoption of reforms may impair our business.

Additionally, third-party payers are increasingly challenging the price of medical products and services. If purchasers or users of our products are not able to obtain adequate reimbursement for the cost of using our products, they may forego or reduce their use. Significant uncertainty exists as to the reimbursement status of newly approved healthcare products, and whether adequate third-party coverage will be available.

We use hazardous materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.

Our research and development processes involve the controlled storage, use and disposal of hazardous materials and biological materials. Our hazardous materials include certain compressed gases, flammable liquids, acids and bases, and other toxic compounds. We are subject to federal, state and local regulations governing the use, manufacture, storage, handling and disposal of materials and waste products. Although we believe that our safety procedures for handling and disposing of these hazardous materials comply with the standards prescribed by law and regulation, the risk of accidental contamination or injury from hazardous materials cannot be completely eliminated. In the event of an accident, we could be held liable for any damages that result. We could incur significant costs to comply with current or future environmental laws and regulations.

We may have significant product liability exposure.

We face an inherent business risk of exposure to product liability and other claims in the event that our technologies or products are alleged to have caused harm. We also have potential liability for products manufactured by us on a contract basis for third parties. Although we currently maintain product liability insurance in the amount of $10 million in the aggregate plus additional coverage specific to the foreign countries where our clinical trials are being conducted, this insurance coverage may not be sufficient, and we may not be able to obtain sufficient coverage in the future at a reasonable cost. Our inability to obtain product liability insurance at an acceptable cost or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of any products developed by us or our collaborators, or our ability to manufacture products for third parties. If we are sued for any injury caused by our technologies or products, or by third-party products that we manufacture, our liability could exceed our insurance coverage and total assets.

(*)Negative conditions in the global credit markets may impair the liquidity of a portion of our investment portfolio.

Our investment securities consist of auction rate securities, corporate debt securities and government agency securities. As of June 30, 2013, our long-term investments included a (at par value) $2.5 million auction rate security secured by municipal bonds. At June 30, 2013, the auction rate security we held maintained a Standard and Poor’s credit rating of BBB. Our auction rate security is a debt instrument with a long-term maturity and with an interest rate that is reset in short intervals through auctions. The conditions in the global credit markets have prevented some investors from liquidating their holdings of auction rate securities because the amount of securities submitted for sale has exceeded the amount of purchase orders for such securities. If there is insufficient demand for the securities at the time of an auction, the auction may not be completed and the interest rates may be reset to predetermined higher rates. When auctions for these securities fail, the investments may not be readily convertible to cash until a future auction of these investments is successful or they are redeemed or mature.

Since February 2008, there has been insufficient demand at auction for our auction rate security held at June 30, 2013. As a result, this security is currently not liquid, and we could be required to hold it until it is redeemed by the issuer or to maturity. As of June 30, 2013, we had recognized $0.6 million of losses related to the auction rate security. The market value of the security has partially recovered from the lows that created the losses. As of June 30, 2013, we had recorded cumulative unrealized gains of $0.2 million. Any future decline in market value may result in additional losses being recognized.

In the event we need to access the funds that are in an illiquid state, we will not be able to do so without the possible loss of principal, until a future auction for this investment is successful or it is redeemed by the issuer or it matures. If we are unable to sell this security in the market or it is not redeemed, then we may be required to hold it to maturity.

(*)Our stock price could continue to be highly volatile and you may not be able to resell your shares at or above the price you pay for them.

The market price of our common stock, like that of many other life sciences companies, has been and is likely to continue to be highly volatile. From January 1, 2010, to June 30, 2013, our stock price has ranged from $1.70 to $5.30. The following factors, among others, could have a significant impact on the market price of our common stock:

•

The results of our preclinical studies and clinical trials or announcements regarding our plans for future studies or trials, or those of our collaborators, licensees or competitors;

•

Evidence or lack of evidence of the safety or efficacy of our potential products or those of our collaborators, licensees or competitors;

•

The success of our collaborators and licensees, including Astellas, in the development or commercialization of our product candidates;

•

The announcement by us or our collaborators, licensees or competitors of technological innovations or new products;

•

Developments concerning our patent or other proprietary rights or those of our collaborators, licensees or competitors, including litigation and challenges to our proprietary rights;

•

Other developments with our collaborators or licensees, including our entry into new collaborative or licensing arrangements;

•

Geopolitical developments, natural or man-made disease threats, or other events beyond our control;

•

U.S. and foreign governmental regulatory actions;

•

Changes or announcements in reimbursement policies;

•

Period-to-period fluctuations in our operating results;

•

Market conditions for life science stocks in general;

•

Changes in the collective short interest in our stock;

•

Changes in estimates of our performance by securities analysts; and

•

Our cash balances, need for additional capital, and access to capital.

We are at risk of securities class action litigation due to our expected stock price volatility.

In the past, stockholders have brought securities class action litigation against a company following a decline in the market price of its securities. This risk is especially acute for us because life science companies have experienced greater than average stock price volatility in recent years and, as a result, have been subject to, on average, a greater number of securities class action claims than companies in other industries. To date, we have not been subject to class action litigation. However, we may in the future be the target of this litigation. Securities litigation could result in substantial costs and divert our management’s attention and resources, and could seriously harm our business.

Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

Our certificate of incorporation and bylaws include anti-takeover provisions, such as a classified board of directors, a prohibition on stockholder actions by written consent, the authority of our board of directors to issue preferred stock without stockholder approval, and supermajority voting requirements for specified actions. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law,

which generally prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years. These provisions may delay or prevent an acquisition of us, even if the acquisition may be considered beneficial by some stockholders. In addition, they may discourage or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.

The issuance of preferred stock could adversely affect our common stockholders.

We currently have on file a shelf registration statement that allows us to raise up to an aggregate of $150.0 million from the sale of common stock, preferred stock, debt securities and/or warrants and our restated certificate of incorporation authorizes us to issue up to 5,000,000 shares of preferred stock. The issuance of preferred stock could adversely affect the voting power of holders of our common stock, and reduce the likelihood that our common stockholders will receive dividend payments and payments upon liquidation. The issuance of preferred stock could also decrease the market price of our common stock, or have terms and conditions that could discourage a takeover or other transaction that might involve a premium price for our shares or that our stockholders might believe to be in their best interests.

ITEM 6.

EXHIBITS


Exhibit Number		Description of Document

3.1(i)(1)		Restated Certificate of Incorporation.

3.2(ii)(2)		Amended and Restated Bylaws.

3.3(i)(2)		Certificate of Amendment to Restated Certificate of Incorporation.

4.1(1)		Specimen Common Stock Certificate.

10.1^a		Sixth amendment effective July 1, 2013 to Consulting Agreement dated August 1, 2010, by and between the Company and Gary A. Lyons.

10.2(3)^a		Amended and Restated Stock Incentive Plan of Vical Incorporated.

31.1		Certification of Vijay B. Samant, Chief Executive Officer and acting Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Vijay B. Samant, Chief Executive Officer and acting Chief Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*		XBRL Instance Document.

101.SCH*		XBRL Taxonomy Extension Schema Document.

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF*		XBRL Taxonomy Extension Definition Linkbase.

101.LAB*		XBRL Taxonomy Extension Label Linkbase Document.

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document.

(1)	Incorporated by reference to the exhibit of the same number filed with the Company’s Registration Statement on Form S-3 (No. 33-95812) filed on August 15, 1995.

(2)	Incorporated by reference to the exhibit of the same number filed with the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2010.

(3)	Incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed on May 28, 2013.

^a	Indicates management contract or compensatory plan or arrangement.

^*	Furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.


	Vical Incorporated

Date: August 1, 2013	By:	/s/ ANTHONY A. RAMOS
		Anthony A. Ramos
		Chief Accounting Officer (on behalf of the registrant and as the registrant’s Principal Accounting Officer)

EX-10.1 2 d554396dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

LOGO

CONSULTING AGREEMENT

SIXTH AMENDMENT

This Sixth Amendment, to the Consulting Agreement, is made effective as of July 1, 2013 (the “Sixth Amendment Effective Date”) and is entered into by and between Vical Incorporated (“Vical”), a Delaware Corporation, having a place of business at 10390 Pacific Center Court, San Diego, CA 92121-4340 and Gary A. Lyons (the “Consultant”), an individual having a principal address of 1344 Stratford Court, Del Mar, CA 92014.

Whereas, Vical and Consultant entered into the Consulting Agreement (the “Agreement”), effective August 1, 2010 which has been further amended thereby extending the Term until June 30, 2013;

Whereas, Vical and Consultant wish to further amend the Agreement to extend the Term until December 31, 2013;

Now, therefore, in consideration of the covenants and promises contained herein, the parties agree as follows:

Exhibit A of the Agreement, a previously amended, is hereby amended to be replaced in its entirety as follows:

Term:

This Agreement shall terminate on December 31, 2013, unless renewed in a writing signed by both parties for an additional six (6) months. Either party shall have the right to terminate this Agreement at any time with thirty (30) days’ written notice to the other party.

Except as amended hereby, all other terms and conditions of the Agreement shall remain unchanged and shall continue in full force and effect.

In witness whereof, the parties have executed this Sixth Amendment to the Consulting Agreement to be effective as of the Sixth Amendment Effective Date.


Vical Incorporated		Gary A. Lyons

By:	/s/ Anthony Ramos
Name:	Anthony Ramos	By:	/s/ Gary A. Lyons
Title:	Chief Accounting Officer	Name:	Gary A. Lyons
Date:	5/29/13	Date:	5/30/13

EX-31.1 3 d554396dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

I, Vijay B. Samant, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Vical Incorporated;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 1, 2013

By:		/S/ VIJAY B. SAMANT
		Vijay B. Samant
		Chief Executive Officer and acting Chief Financial Officer

EX-32.1 4 d554396dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350, as adopted), Vijay B. Samant, the Chief Executive Officer and acting Chief Financial Officer of Vical Incorporated (the “Company”), hereby certifies that, to the best of his knowledge:

The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2013, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Periodic Report and results of operations of the Company for the period covered by the Periodic Report.


		Dated: August 1, 2013

		/s/ VIJAY B. SAMANT
		Vijay B. Samant
		Chief Executive Officer and acting Chief Financial Officer

THIS CERTIFICATION “ACCOMPANIES” THE FORM 10-Q TO WHICH IT RELATES, IS NOT DEEMED FILED WITH THE SEC AND IS NOT TO BE INCORPORATED BY REFERENCE INTO ANY FILING OF THE COMPANY UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (WHETHER MADE BEFORE OR AFTER THE DATE OF THE FORM 10-Q), IRRESPECTIVE OF ANY GENERAL INCORPORATION LANGUAGE CONTAINED IN SUCH FILING. A SIGNED ORIGINAL OF THIS CERTIFICATION HAS BEEN PROVIDED TO THE COMPANY AND WILL BE RETAINED BY THE COMPANY AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.

EX-101.INS 5 vicl-20130630.xml XBRL INSTANCE DOCUMENT

3.75

50000000

3.75

86711402

65717000

86495000

5000000

160000000

0.01

579000

437844000

1295000

6059000

134000

2877000

71743000

5984000

-367100000

75000

1483000

865000

337000

79285000

252000

2083000

2037000

69581000

6700000

2741000

191000

3059000

19406000

79285000

39288000

45033000

2000000

19413000

19406000

2037000

4100000

4735000

200000 644000 600000 0 9000 2000

6530000

6997000

1026000

4853000

2037000

17845000

6528000

6530000

2000

7000000

6997000

3000

1026000

4859000

4853000

6000

25401000

11850000

2037000

38696000

86136000

5000000

160000000

0.01

427000

435915000

377000

5779000

247000

3858000

89086000

5629000

-347937000

150000

1657000

861000

307000

96522000

2152000

2225000

86009000

2813000

191000

3059000

37639000

96522000

58364000

43159000

37647000

37639000

2225000

5284000

660000 9000 1000

10136000

15506000

496000

11501000

2225000

18500000

10135000

10136000

1000

15507000

15506000

1000

496000

11509000

11501000

8000

29132000

27007000

2225000

VICL VICAL INC false Accelerated Filer 2013 10-Q 2013-06-30 0000819050 --12-31 Q2

<div> 2.      STOCK-BASED COMPENSATION  Total stock-based compensation expense was allocated to research and development, manufacturing and production and general and administrative expense as follows (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="72%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended June  30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">    2013    </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">    2012    </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">    2013    </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">    2012    </td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">242</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">272</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">554</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">558</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Manufacturing and production </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">60</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">128</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">106</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">514</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">595</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,272</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,179</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">816</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">923</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,954</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,843</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> During the six months ended June 30, 2013 and 2012, the Company granted stock-based awards with a total estimated value of $3.8 million and $3.9 million, respectively. At June 30, 2013, total unrecognized estimated compensation expense related to unvested stock-based awards granted prior to that date was $4.1 million, which is expected to be recognized over a weighted-average period of 1.5 years. Stock-based awards granted during the six months ended June 30, 2013 and 2012, were equal to 2.2% of the outstanding shares of common stock at the end of the applicable period.  </div>

<div> The following is a summary of available-for-sale marketable securities (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">  <tr> <td width="66%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> June 30, 2013 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Gain</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Loss</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Market Value</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,528</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,530</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,997</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,859</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,853</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,413</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,406</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> December 31, 2012 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Gain</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Loss</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Market Value</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,135</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,136</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,507</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,506</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,509</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,501</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—   </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,647</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,639</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Accounts payable and accrued expenses consisted of the following (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">  <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">June 30, 2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Employee compensation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,877</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Post-termination benefit accrual </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">252</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Clinical trial accrual </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">644</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">660</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Accounts payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,295</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">377</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Deferred rent </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">337</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">307</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Other accrued liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">579</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">427</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total accounts payable and accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,984</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,629</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Recent Accounting Pronouncement Effective January 1, 2013, the Company adopted Accounting Standards Update, or ASU, No. 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.” The adoption of ASU No. 2013-02 concerns presentation and disclosure only and did not have an impact on the Company’s financial position or results of operations. The Company elected to present the information required by ASU No. 2013-02 in the Statements of Comprehensive Loss.  </div>

<div> 7.      COMMITMENTS AND CONTINGENCIES  The Company prosecutes its intellectual property estate vigorously to obtain the broadest valid scope for its patents. Due to uncertainty of the ultimate outcome of patent enforcement actions, their impact on future operating results or the Company’s financial condition is not subject to reasonable estimates. In the ordinary course of business, the Company may become a party to lawsuits involving various matters. The Company is unaware of any such lawsuits presently pending against it which, individually or in the aggregate, are deemed to be material to the Company’s financial condition or results of operations.  </div>

<div> Revenue Recognition Revenue is recognized when the four basic criteria of revenue recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Certain of the Company’s revenue is generated through manufacturing contracts and stand-alone license agreements.   The Company has entered into multiple-element arrangements. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The delivered item(s) must have value to the customer on a standalone basis and, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the Company’s control. A delivered item is considered a separate unit of accounting when the delivered item has value to the partner on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the partner and the availability of research expertise in this field in the general marketplace. Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence, or VSOE, of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement. If facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of drug products, the license is identified as a separate unit of accounting and the amounts allocated to the license are recognized upon the delivery of the license, assuming the other revenue recognition criteria have been met. However, if the amounts allocated to the license through the relative selling price allocation exceed the upfront license fee, the amount recognized upon the delivery of the license is limited to the upfront fee received. If facts and circumstances dictate that the license does not have standalone value, the transaction price, including any upfront license fee payments received, are allocated to the identified separate units of accounting and recognized as those items are delivered. The terms of the Company’s partnership agreements provide for milestone payments upon achievement of certain regulatory and commercial events. The Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following three criteria: 1) the consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, 2) the consideration relates solely to past performance, and 3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due to the Company. </div>

<div> 6.      FAIR VALUE MEASUREMENTS  The Company measures fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="4%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left"> Level 1: Observable inputs such as quoted prices in active markets; </td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="4%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left"> Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and </td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="4%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left"> Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </td> </tr> </table> Cash equivalents, marketable securities and long-term investments measured at fair value are classified in the table below in one of the three categories described above (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="73%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center">Fair Value Measurements</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> June 30, 2013 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,845</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,845</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,530</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,530</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,853</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,853</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,997</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,997</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Auction rate securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,401</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,850</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,288</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="73%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center">Fair Value Measurements</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> December 31, 2012 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,500</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,136</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,136</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,501</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,501</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,506</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,506</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Auction rate securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,132</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,007</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,364</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The Company’s investments in U.S. treasury securities, certificates of deposit and money market funds are valued based on publicly available quoted market prices for identical securities as of June 30, 2013. The Company determines the fair value of corporate bonds and other government-sponsored enterprise related securities with the aid of valuations provided by third parties using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company validates the valuations received from its primary pricing vendors for its level 2 securities by examining the inputs used in that vendor’s pricing process and determines whether they are reasonable and observable. The Company also compares those valuations to recent reported trades for those securities. The Company did not adjust any of the valuations received from these independent third parties with respect to any of its level 2 securities at June 30, 2013. The Company did not reclassify any investments between level categories during the three months ended June 30, 2013. The valuation of the Company’s investments in auction rate securities, which includes significant unobservable inputs, is more fully described in Note 5.   Activity for assets measured at fair value using significant unobservable inputs (Level 3) is presented in the table below (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="90%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Six Months Ended June 30, 2013</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Total net unrealized losses, excluding tax impact, included in other comprehensive income </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(188</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total gains or losses for the period included in net loss attributable to the change in unrealized gains or losses relating to assets still held at the reporting date </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Restricted Cash The Company is required to maintain a letter of credit securing an amount equal to twelve months of the current monthly installment of base rent for the term of its primary facilities lease, which ends in August 2017. Under certain circumstances, the Company may be able to eliminate the need for the letter of credit. As of June 30, 2013, and December 31, 2012, restricted cash of $3.1 million was pledged as collateral for this letter of credit. </div>

<div> 3.      OTHER BALANCE SHEET ACCOUNTS  Accounts payable and accrued expenses consisted of the following (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="83%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">June 30, 2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Employee compensation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">  2,877</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Post-termination benefit accrual </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">252</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Clinical trial accrual </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">644</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">660</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Accounts payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,295</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">377</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Deferred rent </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">337</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">307</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Other accrued liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">579</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">427</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total accounts payable and accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,984</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,629</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Cash equivalents, marketable securities and long-term investments measured at fair value are classified in the table below in one of the three categories described above (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">  <tr> <td width="69%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center">Fair Value Measurements</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> June 30, 2013 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,845</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,845</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,530</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,530</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,853</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,853</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,997</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,997</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Auction rate securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,401</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,850</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,288</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="16"></td> <td height="16" colspan="16"></td> </tr> <tr> <td valign="bottom">  </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center">Fair Value Measurements</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> December 31, 2012 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,500</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,136</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,136</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,501</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,501</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,506</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,506</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Auction rate securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,132</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,007</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,364</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

more than ninety days

86623000

<div> 8.      STOCKHOLDERS’ EQUITY  In January 2012, the Company sold 13,333,334 shares of its common stock in a public offering at a price to the public of $3.75 per share. In February 2012, the Company sold an additional 576,358 shares pursuant to a partial exercise of the underwriters’ overallotment option at a price to the public of $3.75 per share. Net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, totaled $48.7 million. All of the shares of common stock were offered pursuant to two effective shelf registration statements. In November 2012, the Company entered into an At-The-Market Equity Offering Sales Agreement, or Sales Agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, under which the Company may issue and sell up to $50,000,000 of shares of its common stock from time to time. Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, shares may be sold through Stifel acting as sales agent or directly to Stifel acting as principal, by means of ordinary brokers’ transactions on the Nasdaq Global Select Market, in privately negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.  </div>

<div> Activity for assets measured at fair value using significant unobservable inputs (Level 3) is presented in the table below (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="90%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Six Months Ended June 30, 2013</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Total net unrealized losses, excluding tax impact, included in other comprehensive income </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(188</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total gains or losses for the period included in net loss attributable to the change in unrealized gains or losses relating to assets still held at the reporting date </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-15929000

-0.22

1500000

<div> Total stock-based compensation expense was allocated to research and development, manufacturing and production and general and administrative expense as follows (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">  <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended June  30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">242</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">272</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">554</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">558</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Manufacturing and production </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">60</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">128</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">106</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">514</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">595</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,272</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,179</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">816</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">923</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,954</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,843</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> 1.      GENERAL  Vical Incorporated, or the Company, a Delaware corporation, was incorporated in April 1987 and has devoted substantially all of its resources since that time to its research and development programs. The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. All of the Company’s potential products are in research and development phases. No revenues have been generated from the sale of any such products, nor are any such revenues expected for at least the next several years. The Company earns revenue from research and development agreements with pharmaceutical collaborators and grant and contract arrangements with government entities. Most of the Company’s product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. There can be no assurance that the Company’s research and development efforts, or those of its collaborators, will be successful. The Company expects to continue to incur substantial losses and not generate positive cash flows from operations for at least the next several years. No assurance can be given that the Company can generate sufficient product revenue to become profitable or generate positive cash flows from operations. The unaudited financial statements at June 30, 2013, and for the three and six months ended June 30, 2013 and 2012, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC, and with accounting principles generally accepted in the United States applicable to interim financial statements. These unaudited financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company’s financial position as of the interim date and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year or future periods. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. These unaudited financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2012, included in its Annual Report on Form 10-K filed with the SEC. Cash, Cash Equivalents and Marketable Securities Cash and cash equivalents consist of cash and highly liquid securities with original maturities at the date of acquisition of ninety days or less. Investments with an original maturity of more than ninety days are considered marketable securities and have been classified by management as available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from sales of these securities to fund its operations, as necessary. Such investments are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Realized gains and losses from the sale of available-for-sale securities or the amounts, net of tax, reclassified out of accumulated other comprehensive income, if any, are determined on a specific identification basis. Restricted Cash The Company is required to maintain a letter of credit securing an amount equal to twelve months of the current monthly installment of base rent for the term of its primary facilities lease, which ends in August 2017. Under certain circumstances, the Company may be able to eliminate the need for the letter of credit. As of June 30, 2013, and December 31, 2012, restricted cash of $3.1 million was pledged as collateral for this letter of credit. Revenue Recognition Revenue is recognized when the four basic criteria of revenue recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Certain of the Company’s revenue is generated through manufacturing contracts and stand-alone license agreements.   The Company has entered into multiple-element arrangements. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The delivered item(s) must have value to the customer on a standalone basis and, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the Company’s control. A delivered item is considered a separate unit of accounting when the delivered item has value to the partner on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the partner and the availability of research expertise in this field in the general marketplace. Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence, or VSOE, of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement. If facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of drug products, the license is identified as a separate unit of accounting and the amounts allocated to the license are recognized upon the delivery of the license, assuming the other revenue recognition criteria have been met. However, if the amounts allocated to the license through the relative selling price allocation exceed the upfront license fee, the amount recognized upon the delivery of the license is limited to the upfront fee received. If facts and circumstances dictate that the license does not have standalone value, the transaction price, including any upfront license fee payments received, are allocated to the identified separate units of accounting and recognized as those items are delivered. The terms of the Company’s partnership agreements provide for milestone payments upon achievement of certain regulatory and commercial events. The Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following three criteria: (1) the consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (2) the consideration relates solely to past performance, and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due to the Company. Contract Services, Grant and Royalty Revenue The Company recognizes revenues from contract services and federal government research grants during the period in which the related expenditures are incurred and related payments for those services are received or collection is reasonably assured. Royalties to be received based on sales of licensed products by the Company’s partners incorporating the Company’s licensed technology are recognized when received. Net Loss Per Share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted average number of shares used to compute diluted net loss per share excludes any assumed exercise of stock options and warrants, and any assumed issuance of common stock under restricted stock units as the effect would be antidilutive. Common stock equivalents of 1.4 million and 1.1 million for the three months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect. Common stock equivalents of 1.5 million and 1.4 million for the six months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect.   Recent Accounting Pronouncement Effective January 1, 2013, the Company adopted Accounting Standards Update, or ASU, No. 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.” The adoption of ASU No. 2013-02 concerns presentation and disclosure only and did not have an impact on the Company’s financial position or results of operations. The Company elected to present the information required by ASU No. 2013-02 in the Statements of Comprehensive Loss. </div>

<div> Net Loss Per Share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted average number of shares used to compute diluted net loss per share excludes any assumed exercise of stock options and warrants, and any assumed issuance of common stock under restricted stock units as the effect would be antidilutive. Common stock equivalents of 1.4 million and 1.1 million for the three months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect. Common stock equivalents of 1.5 million and 1.4 million for the six months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect. </div>

<div> 4.      MARKETABLE SECURITIES, AVAILABLE FOR SALE  The following is a summary of available-for-sale marketable securities (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="71%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> June 30, 2013 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Gain</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Loss</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Market Value</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,528</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,530</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,997</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,859</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,853</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,413</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,406</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="71%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> December 31, 2012 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Gain</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Loss</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Market Value</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,135</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,136</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,507</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,506</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,509</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,501</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,647</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,639</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> At June 30, 2013, $6.7 million of these securities were scheduled to mature outside of one year. The Company did not realize any gains or losses on sales of available-for-sale securities for the six months ended June 30, 2013. As of June 30, 2013, none of the securities had been in a continuous material unrealized loss position longer than one year.  </div>

ninety days or less

3030000

-19276000

144000

3037000

-19150000

212000

401000

-188000

-69000

-19163000

-113000

273000

300000

-113000

325000

7604000

6996000

-21000

-75000

1954000

1874000

380000

17824000

7580000

1023000

1954000

21346000

22180000

<div> 9.      ASTELLAS AGREEMENTS  In July 2011, the Company entered into license agreements with Astellas Pharma Inc., or Astellas, granting Astellas exclusive, worldwide, royalty-bearing licenses under certain of the Company’s know-how and intellectual property to develop and commercialize certain products containing plasmids encoding certain forms of cytomegalovirus, or CMV, glycoprotein B and/or phosphoprotein 65, including ASP0113 (TransVax™) but excluding CyMVectin™. Under the terms of the license agreements, Astellas paid a nonrefundable upfront license fee of $25.0 million in 2011. The Company also received a $10.0 million milestone payment in March 2012 upon finalization of the general trial design for a Phase 3 registration trial of ASP0113 in hematopoietic stem cell transplant recipients. The Company recognized $0.3 million and $10.2 million in license revenue under the Astellas agreements during the six months ended June 30, 2013 and 2012, respectively. Under the terms of the agreements, the Company is also performing research and development services which are being paid for by Astellas. During the three and six months ended June 30, 2013, the Company recognized $1.1 million and $2.2 million, respectively, of revenue related to these contract services. During the three and six months ended June 30, 2012, the Company recognized $1.3 million and $2.3 million, respectively, of revenue related to these contract services. In August 2012, the Company amended its license and supply agreements with Astellas to, among other things, extend the time period that the Company is obligated to supply licensed products for commercial use to Astellas, at Astellas’ expense, modify the allocation of $95.0 million of milestone payments among certain milestones through commercial launch and modify the structure of the royalties on net sales from a fixed double digit royalty to tiered double digit royalties. </div> -113000 2306000 82000 <div> Contract Services, Grant and Royalty Revenue The Company recognizes revenues from contract services and federal government research grants during the period in which the related expenditures are incurred and related payments for those services are received or collection is reasonably assured. Royalties to be received based on sales of licensed products by the Company’s partners incorporating the Company’s licensed technology are recognized when received. </div> 724000 3800000 <div> Cash, Cash Equivalents and Marketable Securities Cash and cash equivalents consist of cash and highly liquid securities with original maturities at the date of acquisition of ninety days or less. Investments with an original maturity of more than ninety days are considered marketable securities and have been classified by management as available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from sales of these securities to fund its operations, as necessary. Such investments are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Realized gains and losses from the sale of available-for-sale securities or the amounts, net of tax, reclassified out of accumulated other comprehensive income, if any, are determined on a specific identification basis. </div> 2200000 <div> 5.      LONG-TERM INVESTMENTS  In March 2012, the Company sold two auction rate securities classified as long-term investments with a par value of $4.0 million. Included in interest and other income for the six months ended June 30, 2012, is a gain of $0.3 million related to the sale. As of June 30, 2013, the Company held an auction rate security with a par value of $2.5 million. This auction rate security has not experienced a successful auction since the liquidity issues experienced in the global credit and capital markets in 2008. As a result, the security is classified as a long-term investment as it is scheduled to mature in 2038. The security was rated BBB by Standard and Poor’s as of June 30, 2013. The security continues to pay interest according to its stated terms. The valuation of the Company’s auction rate security is subject to uncertainties that are difficult to predict. The fair value of the security is estimated utilizing a discounted cash flow analysis. The key drivers of the valuation model include the expected term, collateralization underlying the security investment, the creditworthiness of the counterparty, the timing of expected future cash flows, discount rates, liquidity and the expected holding period. The security was also compared, when possible, to other observable market data for securities with similar characteristics. Based on the valuation of the security, the Company has recognized cumulative losses of $0.6 million as of June 30, 2013. The losses when recognized are included in investment and other income. The market value of the security has partially recovered. Included in other comprehensive income are unrealized (losses) gains of $(113,000) and $36,000 for the six months ended June 30, 2013 and 2012, respectively. As of June 30, 2013, the Company had recorded cumulative unrealized gains of $0.2 million. The resulting carrying value of the auction rate security at June 30, 2013, was $2.0 million. Any future decline in market value may result in additional losses being recognized. </div> 0.022 -13000 Company is required to maintain a letter of credit securing an amount equal to twelve months of the current monthly installment of base rent for the term of its primary facilities lease, which ends in August 2017.

1272000

554000

128000

85412000

-6974000

-0.09

1400000

13025000

-7980000

114000

8000

27211000

-8077000

209000

152000

647000

-7624000

-356000

433000

10200000

234000

-1328000

5405000

5478000

48620000

-99000

1843000

27021000

3750000

48772000

8000

-14625000

10219000

590000

981000

1843000

9470000

21102000

36000 2585000 22000 300000 10440000 3900000 2300000 0.022 453000

1179000

558000

106000

576358

13333334

48700000

4000000 2 95000000

25000000

10000000

86282000

-0.09

1100000

1565000

-7830000

-7937000

-7868000

38000

2933000

2778000

3791000

923000

9502000

1364000 201000 1300000 69000

595000

272000

56000

86730000

-0.11

P1Y6M

1400000

1456000

-9981000

-9843000

-9881000

-100000

3891000

3478000

3930000

816000

11299000

1170000 286000 2038 2500000 1100000 -38000

514000

242000

60000

0000819050 vicl:ManufacturingAndProductionMember 2013-04-01 2013-06-30 0000819050 us-gaap:ResearchAndDevelopmentExpenseMember 2013-04-01 2013-06-30 0000819050 us-gaap:GeneralAndAdministrativeExpenseMember 2013-04-01 2013-06-30 0000819050 2013-04-01 2013-06-30 0000819050 vicl:ManufacturingAndProductionMember 2012-04-01 2012-06-30 0000819050 us-gaap:ResearchAndDevelopmentExpenseMember 2012-04-01 2012-06-30 0000819050 us-gaap:GeneralAndAdministrativeExpenseMember 2012-04-01 2012-06-30 0000819050 2012-04-01 2012-06-30 0000819050 2012-01-01 2012-03-31 0000819050 2011-01-01 2011-03-31 0000819050 2012-08-01 2012-08-31 0000819050 2012-03-01 2012-03-31 0000819050 2012-01-01 2012-01-31 0000819050 2012-02-01 2012-02-29 0000819050 vicl:ManufacturingAndProductionMember 2012-01-01 2012-06-30 0000819050 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-06-30 0000819050 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-06-30 0000819050 2012-01-01 2012-06-30 0000819050 vicl:ManufacturingAndProductionMember 2013-01-01 2013-06-30 0000819050 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-06-30 0000819050 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-06-30 0000819050 2013-01-01 2013-06-30 0000819050 us-gaap:FairValueInputsLevel3Member 2012-12-31 0000819050 us-gaap:FairValueInputsLevel2Member 2012-12-31 0000819050 us-gaap:FairValueInputsLevel1Member 2012-12-31 0000819050 us-gaap:CorporateDebtSecuritiesMember 2012-12-31 0000819050 us-gaap:CertificatesOfDepositMember 2012-12-31 0000819050 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2012-12-31 0000819050 us-gaap:USTreasurySecuritiesMember 2012-12-31 0000819050 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2012-12-31 0000819050 us-gaap:MoneyMarketFundsMember 2012-12-31 0000819050 us-gaap:AuctionRateSecuritiesMemberus-gaap:FairValueInputsLevel3Member 2012-12-31 0000819050 us-gaap:AuctionRateSecuritiesMember 2012-12-31 0000819050 us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2012-12-31 0000819050 us-gaap:CorporateDebtSecuritiesMember 2012-12-31 0000819050 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Member 2012-12-31 0000819050 us-gaap:CertificatesOfDepositMember 2012-12-31 0000819050 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2012-12-31 0000819050 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2012-12-31 0000819050 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member 2012-12-31 0000819050 us-gaap:USTreasurySecuritiesMember 2012-12-31 0000819050 2012-12-31 0000819050 2011-12-31 0000819050 us-gaap:FairValueInputsLevel3Member 2013-06-30 0000819050 us-gaap:FairValueInputsLevel2Member 2013-06-30 0000819050 us-gaap:FairValueInputsLevel1Member 2013-06-30 0000819050 us-gaap:CorporateDebtSecuritiesMember 2013-06-30 0000819050 us-gaap:CertificatesOfDepositMember 2013-06-30 0000819050 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2013-06-30 0000819050 us-gaap:USTreasurySecuritiesMember 2013-06-30 0000819050 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member 2013-06-30 0000819050 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member 2013-06-30 0000819050 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2013-06-30 0000819050 us-gaap:MoneyMarketFundsMember 2013-06-30 0000819050 us-gaap:AuctionRateSecuritiesMemberus-gaap:FairValueInputsLevel3Member 2013-06-30 0000819050 us-gaap:AuctionRateSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2013-06-30 0000819050 us-gaap:AuctionRateSecuritiesMemberus-gaap:FairValueInputsLevel1Member 2013-06-30 0000819050 us-gaap:AuctionRateSecuritiesMember 2013-06-30 0000819050 us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member 2013-06-30 0000819050 us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2013-06-30 0000819050 us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member 2013-06-30 0000819050 us-gaap:CorporateDebtSecuritiesMember 2013-06-30 0000819050 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Member 2013-06-30 0000819050 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member 2013-06-30 0000819050 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Member 2013-06-30 0000819050 us-gaap:CertificatesOfDepositMember 2013-06-30 0000819050 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2013-06-30 0000819050 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member 2013-06-30 0000819050 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2013-06-30 0000819050 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member 2013-06-30 0000819050 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member 2013-06-30 0000819050 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member 2013-06-30 0000819050 us-gaap:USTreasurySecuritiesMember 2013-06-30 0000819050 2013-06-30 0000819050 2012-06-30 0000819050 2013-07-25 0000819050 2012-02-29 0000819050 2012-11-30 0000819050 2012-01-31 iso4217:USD shares iso4217:USD shares pure vicl:Investment

EX-101.SCH 6 vicl-20130630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 104 - Statement - BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - STATEMENTS OF OPERATIONS link:calculationLink link:presentationLink link:definitionLink 106 - Statement - STATEMENTS OF COMPREHENSIVE LOSS link:calculationLink link:presentationLink link:definitionLink 107 - Statement - STATEMENTS OF CASH FLOWS link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - General link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Other Balance Sheet Accounts link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Marketable Securities, Available for Sale link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Long-Term Investments link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Astellas Agreements link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - General (Policies) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Other Balance Sheet Accounts (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Marketable Securities, Available for Sale (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - General - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Other Balance Sheet Accounts - Summary of Accounts Payable and Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Marketable Securities, Available for Sale - Summary of Available-for-Sale Marketable Securities (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Marketable Securities, Available for Sale - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Long-Term Investments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Fair Value Measurements - Summary of Cash Equivalents, Marketable Securities and Long-Term Investments Measured at Fair Value (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Fair Value Measurements - Summary of Activity for Assets Measured at Fair Value Using Significant Unobservable Inputs (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Astellas Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 vicl-20130630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 vicl-20130630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 vicl-20130630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable And Accrued Liabilities Current Accounts payable and accrued expenses Total accounts payable and accrued expenses Accounts Payable Current Accounts payable Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated other comprehensive income Additional amount received upon finalization of general trial design. Additional Amount Received Upon Finalization Of General Trial Design Additional amount received upon finalization of the general trial design Additional Cash And Cash Equivalent Related Text Maximum period for cash and highly liquid securities with original maturities Additional Paid In Capital Additional paid-in capital Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Agreements disclosure. Agreements Disclosure [Text Block] Astellas Agreements Allocated Share Based Compensation Expense Total stock-based compensation expense Amendment Flag Amendment Flag Amortized Cost and Fair Value Debt Securities [Abstract] Amortized Cost And Fair Value Debt Securities [Abstract] Amortized Cost and Fair Value Debt Securities [Abstract] Amount payable under license agreement on achievement of milestone. Amount Payable Under License Agreement On Achievement Of Milestone Amount payable under license agreement on achievement of milestone Amounts Reclassified Out Of Accumulated Other Comprehensive Income Loss [Abstract] Amounts Reclassified Out Of Accumulated Other Comprehensive Income Loss [Abstract] Amounts Reclassified Out Of Accumulated Other Comprehensive Income Loss [Abstract] Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Common stock equivalents excluded from the calculation of diluted net loss per share Assets Total assets Assets [Abstract] ASSETS Assets Current Total current assets Assets Current [Abstract] Current assets: Assets Fair Value Disclosure Fair Value Auction rate securities held, at par value. Auction Rate Securities Held At Par Value Auction rate securities held, at par value Auction Rate Securities [Member] Auction rate securities [Member] Auction Rate Securities Noncurrent Carrying value of auction rate security Auction rate securities sold, at par value. Auction Rate Securities Sold At Par Value Auction rate securities sold, at par value Available For Sale Debt Securities Amortized Cost Basis Amortized Cost Amount of accumulated pre-tax unrealized gains before deducting pre-tax unrealized losses on investments in available-for-sale securities impacting investments. Available For Sale Debt Securities Gross Unrealized Gain Accumulated In Investments Unrealized Gain Amount of accumulated pre-tax unrealized loss on investments in available-for-sale securities that have been in a loss position for twelve months or longer impacting investments. Available For Sale Securities Continuous Unrealized Loss Position 12 Months Or Longer Aggregate Losses Accumulated In Investments Available-for-sale securities in a continuous material loss position longer than one year Available For Sale Securities Current Marketable securities, available-for-sale Available For Sale Securities Debt Securities Market Value Available For Sale Securities Debt Securities Noncurrent Available-for-sale securities maturing outside of one year Available For Sale Securities Gross Realized Gain Loss Net Realized gains or losses on sales of available-for-sale securities Amount of accumulated pre-tax unrealized loss before deducting pre-tax unrealized gain on investments in available-for-sale securities impacting investments. Available For Sale Securities Gross Unrealized Loss Accumulated In Investments Unrealized Loss Available For Sale Securities Restrictions Additional Information Minimum period for marketable securities classified as available-for-sale with original maturities Cash And Cash Equivalents At Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Net increase in cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease [Abstract] Cash flows from operating activities: Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy Restricted Cash Cash, cash equivalents and marketable securities policy. Cash Cash Equivalents And Marketable Securities Policy [Text Block] Cash, Cash Equivalents and Marketable Securities Certificates Of Deposit [Member] Certificates of deposit [Member] Carrying value as of the balance sheet date of clinical-related obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Clinical Trial Accrual Clinical trial accrual Commitments And Contingencies Commitments and contingencies Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments And Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common Stock Value Common stock, $0.01 par value, 160,000 shares authorized, 86,495 and 86,136 shares issued and outstanding at June 30, 2013, and December 31, 2012, respectively Comprehensive Income Net Of Tax Total comprehensive loss Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, manufacturing contracts, and any other contract related to a particular project or product. Also may include revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Contract And Grant Revenue Contract and grant revenue Corporate Debt Securities [Member] Corporate bonds [Member] Cumulative unrealized gain on auction rate securities recognized. Cumulative Unrealized Gain On Auction Rate Securities Recognized Cumulative unrealized gains Current Fiscal Year End Date Current Fiscal Year End Date Deferred Rent Credit Current Deferred rent Deferred Rent Credit Noncurrent Deferred rent Deferred Revenue Current Deferred revenue Depreciation Depletion And Amortization Depreciation and amortization Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Stock-Based Compensation Document Document and Entity Information [Abstract] Document Document And Entity Information [Abstract] Document Documentand Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share Basic And Diluted Basic and diluted net loss per share Earnings Per Share Policy [Text Block] Net Loss Per Share Employee Related Liabilities Current Employee compensation Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1 Unvested stock-based awards expected to be recognized, weighted-average period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Unrecognized compensation cost related to unvested options Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Estimated value of stock-based awards, granted. Estimated Value Of Stock Based Awards Granted Estimated value of stock-based awards, granted Fair value adjustment loss on auction rate securities recognized. Fair Value Adjustment Loss On Auction Rate Securities Recognized Recognized cumulative losses Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block] Summary of Cash Equivalents, Marketable Securities and Long-Term Investments Measured at Fair Value Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss Total gains or losses for the period included in net loss attributable to the change in unrealized gains or losses relating to assets still held at the reporting date Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Asset Class [Domain] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Summary of Activity for Assets Measured at Fair Value Using Significant Unobservable Inputs Fair Value By Asset Class [Axis] Asset Class [Axis] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value, Hierarchy [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Inputs Level 1 [Member] Level 1 [Member] Fair Value Inputs Level 2 [Member] Level 2 [Member] Fair Value Inputs Level 3 [Member] Level 3 [Member] Fair Value Measurement Inputs Disclosure [Text Block] Fair Value Measurements Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss Total net unrealized losses, excluding tax impact, included in other comprehensive income Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value Balance at June 30, 2013 Balance at December 31, 2012 Gain Loss On Sale Of Property Plant Equipment Gain on sale of property and equipment Gain related to auction rate securities. Gain Related To Auction Rate Securities Gain related to auction rate securities General And Administrative Expense General and administrative General And Administrative Expense [Member] General and administrative [Member] Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Increase Decrease In Accounts Payable And Accrued Liabilities Accounts payable and accrued expenses Increase Decrease In Deferred Charges Deferred rent Increase Decrease In Deferred Revenue Deferred revenue Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase Decrease In Receivables Receivables and other assets Intangible Assets Net Excluding Goodwill Intangible assets, net Investment income is derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money. Other income includes the aggregate amount of other nonrecurring expenses, not previously categorized, that are infrequent in occurrence or unusual in nature. Investment And Other Income Net Investment and other income, net Investments Debt And Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Marketable Securities, Available for Sale Investments Schedule [Abstract] Investments Schedule [Abstract] Letter of credit securing an amount equal to twelve months of the current monthly installment of base rent for the term of the primary facility lease, which ends in August of 2017. Letter Of Credit Description Amount of letter of credit, description Liabilities And Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Current Total current liabilities Liabilities Current [Abstract] Current liabilities: Liabilities Noncurrent [Abstract] Long-term liabilities: License revenue earned during the period relates to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, or manufacturing process. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's licensed property. License And Royalty Revenue License and royalty revenue License And Services Revenue Recognized license revenue Long Term Investments Long-term investments Long term investments. Long Term Investments [Text Block] Long-Term Investments Major Types Of Debt And Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types Of Debt And Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Manufacturing and production. Manufacturing And Production [Member] Manufacturing and production [Member] Manufacturing Costs Manufacturing and production Marketable Securities [Text Block] Summary of Available-for-Sale Marketable Securities Maturity year of auction rate long term securities. Maturity Year Of Auction Rate Long Term Securities Maturity of long-term investment Maximum value of common stock issuable under agreement. Maximum Value Of Common Stock Issuable Under Agreement Maximum value of common stock issuable under agreement Money Market Funds [Member] Money market funds [Member] Net Cash Provided By Used In Financing Activities Net cash (used in) provided by financing activities Net Cash Provided By Used In Financing Activities [Abstract] Cash flows from financing activities: Net Cash Provided By Used In Investing Activities Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities [Abstract] Cash flows from investing activities: Net Cash Provided By Used In Operating Activities Net cash used in operating activities Net Income Loss Net loss Net loss New Accounting Pronouncements Policy Policy [Text Block] Recent Accounting Pronouncement Nonoperating Income Expense [Abstract] Other income (expense): Number of long-term investments sold during the period . Number Of Long Term Investments Sold During Period Number of long-term investments sold during the period Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income Loss Loss from operations Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] General Other Accrued Liabilities Current Other accrued liabilities Other Assets Noncurrent Other assets Other Comprehensive Income Available For Sale Securities Adjustment Net Of Tax Period Increase Decrease [Abstract] Unrealized (losses) gains on available-for-sale and long-term marketable securities: Other Comprehensive Income Loss Net Of Tax Other comprehensive (loss) gain Other Comprehensive Income Loss Reclassification Adjustment From A O C I For Sale Of Securities Net Of Tax Less: Reversal of unrealized losses in accumulated other comprehensive loss upon the sale of long-term marketable securities included in investment and other income Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Unrealized (losses) gains arising during holding period Payables And Accruals [Abstract] Payables and Accruals [Abstract] Payments Related To Tax Withholding For Share Based Compensation Payment of withholding taxes for net settlement of restricted stock units Payments To Acquire Intangible Assets Patent expenditures Payments To Acquire Marketable Securities Purchases of marketable securities Payments To Acquire Property Plant And Equipment Purchases of property and equipment Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current Post-termination benefit accrual Preferred Stock Par Or Stated Value Per Share Preferred stock, par value Preferred Stock Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, shares issued Preferred Stock Shares Outstanding Preferred stock, shares outstanding Preferred Stock Value Preferred stock, $0.01 par value, 5,000 shares authorized, none issued and outstanding Proceeds From Issuance Of Common Stock Net proceeds from issuance of common stock Proceeds From Sale And Maturity Of Marketable Securities Maturities of marketable securities Proceeds From Sale Of Available For Sale Securities Proceeds from the sale of marketable securities Proceeds From Sale Of Property Plant And Equipment Proceeds from the sale of property and equipment Property Plant And Equipment Net Property and equipment, net Receivables Net Current Receivables and other assets Recognized revenue related to contract services. Recognized Revenue Related To Contract Services Recognized revenue related to contract services Research And Development Expense Research and development Research And Development Expense [Member] Research and development [Member] Restricted Cash And Cash Equivalents At Carrying Value Restricted cash Retained Earnings Accumulated Deficit Accumulated deficit Revenue recognition contract services grant and royalty policy. Revenue Recognition Contract Services Grant And Royalty Policy [Text Block] Contract Services, Grant and Royalty Revenue Revenue Recognition Policy [Text Block] Revenue Recognition Revenues Total revenues Revenues [Abstract] Revenues: Sale Of Stock Price Per Share Common stock, public offering price Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block] Summary of Accounts Payable and Accrued Expenses Schedule Of Available For Sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Schedule Of Available For Sale Securities [Table] Schedule of Available-for-sale Securities [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Summary of total stock-based compensation expense Share based award granted portion to common stock outstanding. Share Based Award Granted Portion To Common Stock Outstanding Portion of stock-based awards granted from outstanding common shares Share Based Compensation Compensation expense related to stock options and awards Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Stockholders Equity Total stockholders' equity Stockholders Equity [Abstract] Stockholders' equity: Stockholders Equity Note Disclosure [Text Block] Stockholders' Equity Stock Issued During Period Shares New Issues Number of shares of common stock sold in public offering Stock issued during period shares on partial exercise of underwriters overallotment option. Stock Issued During Period Shares On Partial Exercise Of Underwriters Overallotment Option No of common stock issued on partial exercise of underwriters' overallotment option Stock Issued During Period Value New Issues Net proceeds from offering Supplemental Balance Sheet Disclosures [Text Block] Other Balance Sheet Accounts Text Block [Abstract] Text Block [Abstract] Trading Symbol Trading Symbol Unrealized gain loss on auction rate securities. Unrealized Gain Loss On Auction Rate Securities Unrealized (losses) gains on auction rate securities EX-101.PRE 10 vicl-20130630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 11 g554396ex10_1logo.jpg GRAPHIC begin 644 g554396ex10_1logo.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`/`&T`P$1``(1`0,1`?_$`+```0`!!0$!`0$!```` M```````(!@<)"@L%!`$#`@$!``("`@,!``````````````8'"`D$"@(#!0$0 M```&`@$#`P(#!`<&!P$```(#!`4&!P$(`!$2"1,4%2$*(A88,4$7>",S)+:W M.#DR0B6U=C?P48%#LS1W&1$``@(!`P,#`00)`@/M!9KBN2,J0T2M6(L. M?01DFG"_"6+@$'?'OYF="O)[+;%@FI5D223RZKXZT2V3L4N@',YG M+=V@N0I$WRZ1`Y@*)5B)SGVPU2?`^GJAX!E1X`X`X!&;<#;RB=%=?9QLYLC* MCX?4M?982GUT0M2Y^=CELFD#9&&-L9F%K*/0.)WM8.OT)@.X"JM#?+?H5Y*WFRXWJ'=.+!DE3^V52V.NT1 MET'>\,"U8-O02UF;I@S,RA[BZI<#T//R1WBMUYU>F%E/ME-\&?[$4HI95LBAS6&,QIR8VIT/P[.F/ M;Y5EK)$FP`G/08\"%G'^SG@&9;@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@# M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@%-S*(1NP8A*H%,FA(_Q";QM M\B$J87`O!R!ZCH0J&W)?UR' M/`.M,$6!8P(.<""+&!!$'.,X%C..N,XSCZ9QG'`/W@#@'/N^]3WH]TZZX>/" M'/&G-SG&0JF\[`?H$7`,_ MO@Y\6D/UZ\,T?UFN^)'`D.Y==S">[.,P^YJ?1%W[$0L14-5*R<>^;7*)588W M-HP]V"5BHI"G-R ME2+%/HIC0,3U<[R;=[)5AX^([2#?KO!M@ML=09=M]:$HLR,6+,*EA+%`D].L MJF%0^'1JF*7JWK_`(4SH%1XDZM2804$"U\Q\H6SR:F-4]LV MJ+:\PJF+T3ZV1HBII8DM*4V-8MKV;8*"#7O'4UQM2F+U/KG#*:]]DUED,K2N MJ&2&$#PHRV=Y)8P/Y2/R]2^M+0F$ILR0ZU$4RR;@7CJ+G6M@/DHMQXN13S/8 MRAGNZ3*UTQRR*6JPU5>ENQ+'B*HDZ:)2!L7%O*D_.4ZD"4^G>VFTDUMFG*[V MB9J0+)VFU"5;@U$.FFJ;,JNLB(](*M;)K2L_/ETHE*>P7!G:KNCQZ*3H"V(I M<>F<@#:R`839R!!"\/+-?%<6'N^1'[STD!)=7-A5M25)HQ)X#8+EM%LXUH:Z MJ*7L[7"9#%[O^6332SGVPEK,PGIH&Y-R=N7JTI!#F>2.CZFE3HE;XM&G+MD1+&*)* ME:`Y.0ZFFAP'(%LDWE%KJ?PIEET*@FPE9LW=;9+F'WO66Q-ZPR MI(P_5,I332/IP#F1TJ3%IL/:ML>V5,Z)'A0R*D./3-`C#K'Y-;G0N9MR1GAZ.=_ M+,GL'201&:,KE&5Y9I"QE=W!.%1@U(>(E80>04!$K7"V_(_P*WEMS[QO+5)0&'``I:S?+ZR,J:+MM>:S[&*;#'M1 MJ=1T]J^RJZ30F<,=:;4JI"?";D9&LZ6Y1.3+)VV'.J-J*/6$+$[TE&EA60+LZ`[-2#4 MC@A^15I#T2M.1P":LL\C50P"_(50,XKN]HVJG5IQ2AV>W5M=93T>JNZ9Q(B7 ML->-$L<7=ME,JPM2J0),/S2Q+8P6Y"]F:XE*0&E%@>=JQY-*+VVFD*AD%@=^ MPD-J5C-K=IN66U5XH5#;@AM9RJ,0NR%,"=@OCLI4K84_S1J"H)7)T'NTRXI4 MARK2Y$<$"SCU>/D'M#97>NO];I3JDRQ;4.1U)&8?`;?J6SWQ]M=VGFN->W8O M1OUK12ZHVB@2=8\S$UM3*R(N[>Q*``\PA5VB*&!2]<>8^E)!`$%KR8F5'_Q' MB&HSI6%"Q2")-5957YNENO<&I&6/$!LIWNML+ MD"1*P&L08LP!72SRH:X)):S,@8Q>2Z$&+J(C M\^O1!6"A11]*SC95AA4DIN`6S-?E@*66321JLN-#5#0(G-L9,R!O^46(\*09 MX!,Z_;@8->J+N>^Y6C7N,7I*J;"MN1-[7@O+FX,E4*0+X>Z'$D*0/>K7;KVS;2OD`<4-H:(>BLUU\BD,9\8+6`_39>*A M(GSU]T2%UEE.25=Z6:$YP-GE4HFYJ2/CB/`NXQ9-(.I9WPT>` M9JN`>!*Y1'X/%Y)-98ZI&**P]@>)1)7M>9Z2%FC\?;E+L\NJTWIGTTC>W)## MC!?N`#.>`GPL:71$2>5WEC!WEXZASCKC@&G#]ISY*M[=W]JM MGX9MALS8MX12&:^-,GC#%,C64Q"SR!18\?:C79+AM9V\["L3:I,)ZB'D.0&9 MZXSGIG`&\%9=EP"FX!,+5M28,$`KBOX^Y2F:3.4N)#2P1N/M*<:IPI$` MHD@@H'TQ]1F#S@`,"&((<@:"7D8^\>LF0S%RJ3Q;56W-[$6ZY96_8&W(PHDT MQFJG*CVQ"FN*>%Z;>PH5Q^,92&/N')QO00O+>9&==015@4HSA9,(,8XD@K)J3*6[([KUR!MK_; M;;3^5K;2I-AIAY)5"HMKKF>L-2UBEFM*)*?ME9*F)G&\6.KE"1N:(BD6-+:E M>F=,0,;0$XU:)5W'YR4('`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`T$;DEY,\<16Q-Z>KYOFKNLBL56K,$,S@I(,$H4E($1!`%8:G:"K]<9Y' MI[.=B[#V%7U50Z;5S7Q--8O!XJ&J:()>XV]KFAS/AK8@,L.PI(."1Q.ZR1=@ M@Q4G84W8E)-,5FJ0+_4%K-&:$E&Q\L:WI9)7/8W8F1;#.IKLV-:8Z)NDBKBL M:X/BK*K1E84J65.BK,I2$P\63LFK#0Y_`$/`,CCR0"4K(5F M$:7)0%SHCXQI6V0Z`UI/-TKLLVKZ1>=7@T-`W6*US'FB%0[5B[ZWN2((9EF, MLS>.TK">DM6M<;52A=A,>2S^N(A*!6J4J#@/@>O$-5K%=N?>K,8$X&]C593&KT[$-^RL3EL.=5$NOI)!\6M;2.M6B;+RHTF7 M+D8PE9*"Z'N@B2QX`R?6SK)7-X:SOVK%DC?'*`22O&F`KW9FB#,8;Q-+RYD?$,PRSQ(F@@ M2L\0P*?D/BXF<[R^V59.YUDS/:_,WUOET!V"%5=5,+-7[=JP^6$_UK$4],,S M8GB#ZRO;A;\K/D@SU(%+FH><"3&("TB0HD"ZVMOCI:-?K.CMMN-W3RU)BUBW M/6/R^4,,09/S6\[K7+5-U3AT6)XLW-:!J#%'VK2TC6F1D$I\(UH@C#U*+SP" MOM0=9;6U,B%,4*GN,FRZ!IBDGJMF?YZ&Q^.3E<[-TS9QU6J6JH^3A*H##JP3 M*F=Q/QDD+LJR0LR06;DW@%H=@_'1,KH=-AX]&=P[;K/7_;U`H;MCJ)-AE MW.!+W!FNLIN;2LOL9H>'>D3)]!6<@AP(()=6].XX,Z>%6NE MNSL?V(2W4^)TT-V0J39.'1]RJ:J9-8C2Z52U1:/(*C4;$R)E<;B/H4+!&\EM ML:2KD)38I49-$6SMHU-O#8] M"Q';E?!'"V85"JCJ=]E+>?"JK M0'-3BKRB<@@380^*(P:5NB;ALG.VFCILNUBGNRNO<>BD)41:V[?UCA5/Q%B? M8[83PT&V!7D+FI-#Q7$C:$AAHW0EJR$I0BRL6^L!D.8JXDLVJ.PJQV34QVRD M%AN5U1=\;DC8!K:76EYU*9>WQ&&/"9#A*$]:DJ=V1-;B>7VB4'@,,[A"%DP0 M$"VSQKW,1'X;`GKR(;$/M<4=%I,T:U,9<4KB.2B#2936\DJZMIO;T\C#6U.^ MPSE3$?DQBEF1NA3>W+WA,F<'@ER5D%FX`K**>)_4VI3-3GS7JOX305CZHRJ& M.K?;5=UG`&JR;;B++73]5A"1,`:-"VA(P)=[%=>[&651TWWB8JECSE8,%:V(8H<,F'FJP"&:,P9QHQ`7U_3/2W3%<53;!MKP6S1A^%A*?'-C:%$]"=(X-.> M,($#F^PD#VG5AQGU#E;*C)QC(L!QP#I9\`UBONOMZ0ZF^,61TY&'D*"U-T7P M5),A!!WIN*:L$I!#Y=+V6`)A8QH#XW[:/'Y^O;F1@ST^GT`BC]F]H<*E-,[* MW:F;*)).=M93B/U^>L($!4CHVJW!Q:DRQ)ZH0FIBYI8IKJ:=C&.Q2E:D!V,Y M#VYX!LR^0C_(/N__`"@[*_X,33@&A#]D?_G1W'_E?8O\5XSP"N_O"/)3-['O MJ%^+:GG=RS!Z\2Q">7TTQXP\Q98%O3$A.[UO7Z\A`8,US;(7&G!$Z%HNT0%# MN[E"&7DY`G$$#8A\#'@8I3QJ4I";@N"#QV=[USV.-K_/)S(6](]YI0;NF*7! MJZK<+2#28Z?'RCL)GAW2X"N=%P3L8/\`9!((`!L@<`<`P8^>O>9_U&U010&M M7HQCM[9!P>(,R/*%0).[16!-B`DZPY.U'DF`/1NPD[FC:TAX>@R#'(1Y0L&D M!SB`^0-\MVO:XX6))QS,MN/NO*MKE'NKR,N]R@I8J>E-;ZQEVO1V27I):]()ZKHY-=499_Y#?F3R+C M&]6^!O%.9/"RZJ8_FV;1+MNB[8J<,''LB^ZI_2E&>39!JS\<:8RAVW*6X800 M0E()2I22DR9,460G3D%@)((()!@LHDDHO`2RBBBPX"$(<8P'&.F/IRYTE%*, M4E%+HC2?999=9*ZZ4I6RDW*3;;;;U;;?5MOJV^K90=HU16MV0A[K>VX/&[#@ MLB2FI'B,RIK3.K8I`84:3@\LM0#)B)P3A.%DA40(I2F,Z#*,`/&!8XV;@X>X MX\L3.KA;CR76,EJO^S^QK1KV9(>)08TU*N_'LE7..C3 MT;724):+OKFI0FOPSC*+:-!GR#ZGV5X:=WZYM;7B1O:.!.CF=8U"2=P-.5*6 M_P")5D)YC4\N4A](#\F;D[B!*H"9G_B3(XE>KU-R=TQ_Y#M&7Q#>Z[<"4E7_ M`#,>;?7I^U7-^^GH]=>Z#U:U1V)_C=YAXM\X?`FY\/\`)6-1/D5-2PMVH@E& M,_J1;QMPQUU^B['!V033S22"S#0`1(Q\]F-GV=:=.(*)@E)O[]?46L:CT2Y=;T>G->94I#H[^0"48/>*L MJ341N%J0:8Y04J(,&![%@>3G7>KI;&8?.8W>C&L51.E9E:CJ;4,A41[69LV' MD"B(T\EV1=T@SR:W=Y=*4*E%E,'"XQMRF,4+_:H\!4"`F+=%QUWK[5DXN>V' M\,8KRO&,]_DSQA"X.JHM*684F2H6MF:$JYX?GUY<5)*-O;T1!ZU>N4%)TY9A MQH`"`LO3FY]46W#K:F+NQ6C0H:(#A7;L>V2KUWIZ00=@.C&)H@E[AA]R:R+H MBX1C!BH+@B7*B"!)STZC)*I.>06!8(SRQ:NN%5TK:]?,5^7(AOBN)?=$,A-0 M4=-)Q9S?2L!>R8[+K8F4%1)B7:)Q%K>E:=*4!7@+HY*U`4R!&J4A-)+`R)Q* M5,,ZBL9FT57_`"L8F,>995''/VRQ%\BPR%M3.[.O]FXITC@D]XWJRS/2/**. M+[NT8`BQG&`(P53OEJG=+=L;)(!;\6<8!JK+APJX[36.*-JJUF=TL-9IR[*6 MN>+U!$??&!B9GTD"MS3G"0`5`-*":/)8LX`M^1Y*=;7O76H=E8&7:5H1782= M26N*$@U>UE(GJWK>E42=I^A?4T2KQ46VNB=`W,U7OCVH6.@FY*C9$(E*DPG. M0EY`HB4^6K4V.PV"3AM3W;/6J65Q,;AEB"O:2G4EDM%U36LO75[9\ZON+@;T MKY6S?74^9G-F=$1Q!SQ[]F<0)D:@*!4,H#)*SN[7(&EK?F-P1N[(]MR)W9W5 MO4%JV]S:W),4M;W!"J)$,E2C6I#@&%&`SD(P"QG&+E4;,UTS\M61C66\7#7YDK%[E4DDFP<3LV;H MHL"*+4$CJ",TPX&1>UG#85J3SZ9R9 MN:VI,GQG"A6M*QD8"\B,"!$9=Y1J!2UY%YBAK_9&0S:37S)=:,Z\1RDI`Z;% M1^YH;7;O;DKBLCK8"DO*(ABJ]J"_FN)2P]M,:EJ0\D\T"@O.0/LM;R>Z_P!* M%1+-D0K8=A6.E0M^P%FM(*1E3D[:U4BXOR^,$V;L MM`4T+U&4_MD9YP`)RSZPX35U?S"U+`DK9%J[@$2?)W,9:YFB"T,,1C32I?'Q M]6&D@.,RB;VE&8>+TPC&((>@0BSG&,@1RH#=BK+_`"[`]*(W32BRMHQ';`?V M[9*J)-2*D^KY"*N05&1J"E[0:B,+FZ;N>J4%SWDW["OUNM%*0&GZAE,IM6PFVB96]1"TILVPA24TJFJ!1AQ M9@C&ZN9J`@T+BWE%]ZI>D3F@3BJFSX?=-:P:VH`K<%T+L2,-$MC2EW8WJ,.X MFIY2%JTQ3O&Y&@:Y!'W9,$STU2%L(_?R369A_AC!7>52BTK<8((8@1-%8!6+WE8C$KG$&>X)Q,H,+SC(>N.`=*?7"]X1M!0--;%5LK M"M@UUUM$+*C0_5`:*:<5X-(+WC0DFRZ0E*[[GZHDL?8!/&9&>K2 MN)^!=HFV*EF=>@>`=-2BZ;@^N]+U30U:-H&B`4[7L1K:'MX`%@$2P0UC1,+< M)1DH(`FK5"=%@U09T[C3QC&+J(6<\`LMY"/\@^[_`/*#LK_@Q-.`:$/V1_\` MG1W'_E?8O\5XSP"WMA:GJ['^YY53^SY6Q.<;5^3>,NBJ/NB)?DQ2QQBQV?$. M8SSC\Y2C*]@S-Z8.,Y],1>,8QCMSC'(#_?V)^>_D6W?'C_\`0F-R/;+=L_MY[M_11Q\AW_357UI4]_\`+^I"*<92 M_9UBWZ=#IOA1BQ%'4WU_:()8>OTQCE$^4+G+>ZX0?6O#?3['*>O7(QYSGZ]>7%LF.L79\7'BNU0QZUI M]_8M?^)I6\S[]?RCR_RGD&1:[K7;VZ?9(]%0M:9,J=#"7FMK#6R$HLM0I2?V'T&-.8 M=G`_]LLKKC.>G(;S/CN3R+#IJPW7'(JN[M9MI=KBU)+1/J^AFA\(ODCQGXU^ M1=SY'S.G<X[1+&E7APJLL=\;Z;:9N-MU,.V,8W1[NYR7?HEHV7;^WFMM MON+PQ9?VC+I\.RR39*,M9;N462K)3)5K@[F%X**4JRP$96/1H@XP/_>_9CG, MXCM&;L>S+;\Z4)71MFUV-M*,I:I=4GT]^A"OEWY?X9YU\V9ODG@V-FXNSYF' MB0E'*A77<[J*8TSDXU6W0T<802??J].J1J$_9P_ZN4Q_E&N7^_E1\DQC(=2_ M@#@&/+R:TA9=_P"NC#"*]ABJT&9MO.EYU<%0LZ('`MW85)@6TQ(0Z-YJH"HL#%2Q:%S-BK.#EVWXRU^RE9-5S M[C2>F*)7;/1,G8;6.#WZ?6;M&&ZP)8_6I':QNA;/)I'9"YOKTOETCD\0+7,Y M:-6YB2K3BP+5S'QM[RK$\(06/73_`+`[%(J`TAA=%;2-%_,K55NN=BT-)U$P MG8]H8/*Y*P/^T#;%IFIR[H'1TC4Y521*'VQ1#(L$:I-`].U_"#O`];'^1W8= M7O%,+KK?9=3#9E4.KJZ<3B`8RNK[8VH]@8W7:Z8B<5\>K/\`)\?K!5#8H]LR M<*A&6Z@6&C2!*/*.`D%!/'MM39J>RDD#<'#0K7%9>E*VI!]2MC`$;E-LJ>JQ MB3^;,W>:L<-V/):(?!II:ZV/OQ4;03)P1N3I$`.#BE!AR5I3@(J0#QB[4UW6 M-'OVPNN\EVYF:?52S-?UE[-K4MIVR"=AK#MNHI\[N1MX,K))4"I+8BG) MLC;GE>[1A202:E9SC!F&E@2>KKQ+[_$>1W3G>BT?(O+7^&TWK'55;7E229;, M%"&?V9%J9Q`[&3-27WZ"%N4%LNQ#396O7N+?AS^0,%V$8,PF/3`9/]<]?I#` MMA?(%(97!V)NJN[+;H=^J9&',?7,[S$H#JA1]9.O2-HS#\,*9FFT*7)"4RI. M0+.$P3B@9*$6/($#81JYM'1=/Z%V8AI9?:5E:F[0;LS>PJ*C4]KMLE\EJW9Z M5;,M[1)8+)99)V2N7"7,#?8L?=Q-R]X;_6;CER?!X%H`$&`6(BNI>]="(+PG MS#K*AM><[V:][&0N7U\P7#6:!#K!;EN[6;17_`&R>2"6O$>;935S=%=IQH9( MYQ3#TM*=8T;E&WK25J%YS*I&$BM5%FBU[C14QCDC9CS%&4)&&Q8M, M4G9+6`-%@"RU)>/S<31I^U+V`C-H3?<*9PZ/W%`=FJ5)9=?JZ/>&;9C#U?5L MRZ$SU2@@#G,WEKW"9VE>A!)7E:<6S/#F(LP(QF>H!4>INEVUVL&P062V= MK_`YTUN(H+6\[%"&50TLCNW.21&WKDY64+F@ZDN2<#&)&]$)8XXUZCWK M_&2SK)1)-DW>;2>+O6TM306/N-=H2U:]!.DJ_P#(CB6./C,>0-ZE-=;5:D3FH870"I;-6:,MMB2*`1QG8F-S2&+7:)1.LXG,V$ MQ/O:JXG&W&>O6>1^.K7J9)Z`<)MK_L+*B-X M6:_[7KV4V))K6?7UCCFQIP&&N)^0XQAJ?#2I0A76`F9!`>&P"0PS"P"UL8\; M^T,7A]%3#:>D%.YP('+?)5%)90U!3UCUL=@1W:?:QDO2KK,`6Y7VT0V;,JQT MA2MQ.:%$I;U$<32=L"%(L6L1J@8'O03Q"^1E_P!M?&=MM9GD)FD:9]6Z:@\7 MO6ABI;.)F?(G6.O$K=G.&ERGY%OC5ED32+OS=&Y3(GI)\FY9:AK\"4C-3@3` M9@:DH.313=?=&R7>&,R&F+AI+4.$0@11C"41I)L,N\:E MN4P367Y>G$LV30V#KU0;_8<>F#YKEKP?L]45@I:7%9RY]3FUN M=UC4V^Y*9D)ZDA"E$(#/7P!P!P!P!P!P!P!P!P!P!P!P#7.^Z&T2_6AXM[)E MD89N9DF.G7& M,\`P(^`[S5->LGA`WOBT\>TRBQ=`&EQEE"-3LI+$*0-.Q#JJ9ZOC25,I%DU> MCC^PKHH^0P#N]NW.Y&,!P$'`+8?9O:6O%U[1[#^22TR%;\342=UKJO9"\X&H M4/EY6Z0:[V3*RUA@,X/=HW`%HDZG.1=19E>!?M#P#HW<`B#Y"/\`(/N__*#L MK_@Q-.`:$/V1_P#G1W'_`)7V+_%>,\`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`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'` M'`'`'`'`'`/B6YP9W9$E/'QR:W:X+&X ME#8**(%3^Z#`!#ZZNY+&[)1.B%1X?_M_EE8M+8TQN?KE"U$8_=P#*%P"(GD$ M+,.T+W<*)+,..-U$V3+*))+&:<:8.FIH$!91181&&F&"SC`0AQG(LYZ8QUX! MH:?90,#ZS[G;A&.S([M91VL+&$DUQ;%J(HT>+5C0NPLQ204`8^W&<],9ZYQC M.?W9X!T%=C=<&>WY\>ZB?ZG%KTE%^TD^J?\`TU1/_&/D MWF7B#FF'SW@>7+$Y!ASU3]:[:Y=+*+Z]4K:+8_AL@_7I*+C.,91TL;\\-_D< M\>]I*;?TMD,]LZ*-)BI1'IY2R\YKMIH9>\*G++.*]1'A62`H02L!.`WE.K>M MP7W&D$]WHAI'UNVZJ/[-M+TM2^R<%Z_?IW1?\*-Z7COYN_&/Y M)<2CPKSIC;=M6\7*,;L3N0\] M/]^-VR MZ_AG*5L^S[-+?3W*<3:P>9;R[S%C=[C3V.BKX+AA4CDUQHE%2TY$$YW]:YQ6 MOR6UK,>E>$BC("SVQI6*3@]`&J,`ZBQX0VSF'+LB-N2KIUZZJ=J==,/OC#1: M_P#K%OV[D?3M\K_"#X7[)D87"9;79R5U]LJ-MDMPW+(DO2&1EN=GTH]RU<;\ MBN$7JX5M]'MNZ#>,J@=$:2?ZM8FQ%9,CLIN$DNR>3!E;U)]DDJ$)[>HC:AD4 M!6HD%?ITBP\DAG$(\D0#S1GB.--,'FX^-<9P^.8KA4_J9EFGU+6M'+3T27[L M%[17Z7JS3!\F/D[SGY+\OCO?(M,/C6'W1P-OKDY58T)/\4Y2:7ULFS1?5N<5 MJE&$(PA%1-.3RR_:97575F.^SGB26FN\=R]"F@-;Q2T$/LRK)`2K"Y%G4;.' M!F"(CJ!:K<'(1V,\`IF<;,_:%7)3C_34E6'8"U/&&=^;0A58$:A=WQ84( M``Y"G$(..`57Y)?MVQ>+?Q6QB_KN0+,6 M9L]G*1:D4)5/09"7LS@@\LLW.!_NSC'US].`:ROV>$F?I],\`ZBW`'`,=/DWN>SM M8:!C>UU>*)4XL&MMMPRPKNKF)-N7EQM:B7@AYK>?1@+42A7+E)\:'.D@BC>VM-P1G8$ZEK^UQU'7%+(Z:<\((;`6VUX2X)$O8L"I0- MF1CP9C'0"^^EFY&W-L;*,+;<$YL*+T&]H;:\L9LFD\;(8&J-Z(VC"'BNM;]7 MGYP`PE9*4PV7B62YQ2BSAW[&<.#AY*SD`@))6[>NT"??B#ZG5Y.9POK+<.P- M<]IZLM5J8PJF&LM:J>C#NZ[=50DE>6@:5K3SQ\K&&)D):K(UAA=L+LIC"_;! MP4!`FE]J;8*Y#5 M;N&WY,B$SQV/'1!(:U8CS*O^9],D2K#BF`LS9VZ&P=D;#6[!&:TKE?:^M2-> M5JHK=I>PI2TO[C"F>L]?-B'>FX^]:^P[7MDC^LBHEZKA("+JU=@ODGG3.8)6 MI3G>Z,$E`RI7!?BV&:*:50^*W)+J4B+"X:;5SNW;%;M@!V!KA2$TUV72I*^* MG%RC=LQMDADB+S4"]%?*:'0ADA26*LR5M:UC=^FNN$JV" M0,R.05[)EJUZ:+,F[X-FD"EDMFO-'6-&[4G$VLE MWJ+;+;FCXQ.K)+1#GTDK6I=@9Y#:W6RQT;V=A1R1W*AS:D)$ZA2%"<0%!/'D M9@QF#`G_`,`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`< M`^%1\9ZX/=>Q]ST!Z?N/;^OV]XO3[/4_I.GJ=>WI^_KT^O`/NX`X!_D?9V#] M3M]/M%W]_3L[.F>[O[OP]O;^WK].G`/B2?&=XO8^P]3LQW^T]OW^GU^G=Z/X MNSN_\_IUX!]_`'`'_C'`'`'`'`/S/3IGKTZ?OZ_L_P#7KP#]X!\RKVGIX][[ M;T>_'3W7I>GZG3/;T]7\/?TZ]/W\`)_:>C_9/;>WZCZ^W]+T>[K^/^J_!UZ_ MMX!_!-\5ZG]C^/\`6[<]?;>V]3LZX[OZK\7;UZ=?W<`]#@#@#@#@#@#@#@#@ M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'__9 ` end XML 12 R8.xml IDEA: Stock-Based Compensation 2.4.0.8109 - Disclosure - Stock-Based Compensationtruefalsefalse1false falsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]2false 2us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 2.      STOCK-BASED COMPENSATION  Total stock-based compensation expense was allocated to research and development, manufacturing and production and general and administrative expense as follows (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="72%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended June  30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">    2013    </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">    2012    </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">    2013    </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">    2012    </td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">242</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">272</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">554</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">558</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Manufacturing and production </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">60</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">128</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">106</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">514</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">595</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,272</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,179</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">816</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">923</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,954</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,843</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> During the six months ended June 30, 2013 and 2012, the Company granted stock-based awards with a total estimated value of $3.8 million and $3.9 million, respectively. At June 30, 2013, total unrecognized estimated compensation expense related to unvested stock-based awards granted prior to that date was $4.1 million, which is expected to be recognized over a weighted-average period of 1.5 years. Stock-based awards granted during the six months ended June 30, 2013 and 2012, were equal to 2.2% of the outstanding shares of common stock at the end of the applicable period.  </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 40 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 false0Stock-Based CompensationfalseStock-Based CompensationUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock12 ZIP 13 0001193125-13-314932-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-13-314932-xbrl.zip M4$L#!!0````(`#-[`4/*U')K*W0``#[:!0`1`!P`=FEC;"TR,#$S,#8S,"YX M;6Q55`D``S*V^E$RMOI1=7@+``$$)0X```0Y`0``[%U;]@1":]=ENVVMK9F?VQ8%%V>(,`BT@7\ZO/UF@&PA)2!8EY)%? MNB6*JOPRL[(RLZI2/_W]=>!QSR2,W,"_:*`SH<$1OQ>YVYON7;@^\3SR!OW6X]X)+1CPEWZ](T> M@8>]T8#X\2?NP8Z(PP4^]UOK]BN'SQ#']>-X>-YLOKR\G(6A,^GFK!<,FAS/ M3X;X-:7NG..4,PP4SCVZ#4:^<\Y)B M<([$_\RW#H9OH?O4C[D?>W^#QH+,TS>XV[/;LSE@/W!W@1]!Z\'0]M\XP_.X M6_I6Q-V2B(3/Q#D;=_KZ$'H<\-2/+AIS\.C79T'XU(0AQ*8[YDXC;7E.GWHK MVGNN_P=EW[0]_2+3_D5,6B-=UYO)TTE3-PHDC-15Q*0MIGU';E'/T!0U?_OV M]:[7)P.;SR,`37FR[>'TS4<[>DC>&S]HIG)`O(@FKSAD-E!"441Z9T_! M%#1_=GM9%L$7MI?H"FTL**(P1TS\-B11(37)DX+^*0E.G*5H#%QNI@\S3=W" MIDK:U)TTC>)A6(R2/J%DH"P9/=#H.'PK?F?\L(#ZWB@,8=XN>V_\E+Z(LR^2 MUUZ_^"7ZI&`DUW\F45S\2OJLX"5_-"C60"<.FU0B36A!0K*PZ6JKC?A:0,F*<-*B^\A/-/'N-G"TF;WF[T$QAC6?;^9WMD>O'NSCH_7$#W"$W M)+SKVR'A>H$?D]?XEE)(`N_^QA)U4>?A#XE(X/\E"()T?]=MWPOW5%>`?'0/ M\VKDN^D[8V-Q_\M=^WY(PON(]AHU.(?TW('MP93##P3VY1XUOHAGJOQ3 M=1:`F[K<0AIN\YK8P;RDRR9O*!V#[[147=$$U;"P>4_Y^T46TK^?FMM@JDCV M&.O,9(\WE3TL$N>6'[OQVQQ[DN?1]2A.W!5P83;$+`HJEC.8%S$6"=HRQ#;2 M-8M7$%)Y2>BHO-:Q!+ZE(%5O=0Q!ZD#_]XF4Y<8735$1D@3\4[,5P6S+5C(%&0Y%3%6&U\4645JHND;X=;4@,`7G2=,&*] M%,:4\BR\&U@I";@F3L6B!)_VW'=A)8W#$=D:I[RPS!;1;XSB?A"Z_U`4K);8KPM$" MX==Q'YS;7@]Z=;ZZ]H/KN;%+(C,)8C=UX-=@6&EQVE:GHVI(XUM(:`,$3>`- M417YCHY;@F49IF%1".#1R:J>L3:K(63A&H[CTH25[=W8KG/IF_;0C6V/(;S08>=1,)DI-4Z`AZ1,_(+B4Q`W21\I6F"4+1.JP]9>R M0Q_BKVANGK3)H]MS:\@!$?P\7E14E'/XUV/)8F^/O:5;\DS\T1Y6J+(2!W=# MS2Y0Q:0O@^?')OSKQE>!WZLM2!K$29JX!.8BA*4Q7`5^[TZB5(4F39:F3`IR M7HOH:[O<@$T2176-[-:Y46"U#F+-H=-1QYJ\S*LJQ)&+U*CC$?C0,O%&;H(H M#DGLADER'[ZE7Y!DN:9?M(@/]BN^\6P_.@3G`Z(&+.-LWFF'@!=GOAL/D@RR M[YC`"[#]Q.]!^QH&OTA?"'YO28^XSW39INYG;5FY^1WX3UT2 M#BZ3C>)$3/7#IE)L.?M50'C.BXPB$M?73Z2AGRYK*.LGSM.<@_-LNQX592<( MZ4;<'8&%-IEV;?(0SSXQ<"+DQ7U5L=,R34/F556T>`E)F-B.Q8_!X'SXGHU3-[H MH-2JE)5_&21%J;FT<9W=1Y`[TK-@"TG/VUY8A]P>1`A5[+$RP$T=KWR"9T-0 M9$(UVNVFS M!I35$91.VQ)Y1=4E`-5J\2U#Q+QF29HE6))@X-:]1)=;$3!I!9@*Z*_^+`2+ MZ*_Q19(%,>L^;3,]1SV:>;^U8[+G)=DPV[B%6PHOJ"HLR2J,0K/HO"Q@2U#T M#C9:0KHDB]2[RB_)JW&LMDG95=L8!&%,=W5-B"%:=N2RG,9&1^\H@FGP8AN+ MO-3"*J_KJ,6;EFI8JBHI6,>4"S(-BL!*(7&EE5J';#N7K9;\D#:SVEE$63Y, MC<8W8E.+09WU?[MQ_Q<_>*!GM6F'E_YP%$<0L(".03B9'!B_I?V%,-$2WB8& MB+7YT#NFJK8QYF7(;6_^.57=JR#^G<24A">?JG.2 M';D>TL?5Z>:BQ;+,-BQ/5ALX;(+%,ML6KZF&PDL=K"&L88@H]#1[(>53RTQ8 MD=_,#X8DC-]H$H1F2.@*,:0"!I^]?NN;!DQ3Q:R7L@K!W'%>,TW2N\_D%S\D MMD?9\K/M^M=^X2(QXUTM%SL\6>S&!WNW1C?/(<_UZ=6';NC:7K*QP_2P0,FL M'R!7Q@<%EE(]!VIJNPSG?T=I@H7NP!ZFU&G685[JVX*;X\^*`";)<8Z"4313 M*=K[31`EQS(0_@8M^M%U2'-8]-3X4TB>8$3:B,QOBUWZ#-)RPCNR.?1$UYBE MS/E12A8_A]!'=EC6_'V7%P:^N3Y3VYW@7,&WK!.7ZY-:Q8/BW=C4+^'=UE@K M#>OO=:SHLO*J8U%3*PSR$1U_&O9!'42ZRDRSAVSJO&) M$Z;,D8KRLAL=/]GWUE`Y=JV>,>7Y-4MRUF%KAZFJL-GH86Q_MLXDE^5;4N!+ M73CX=Q#VAP%SI*(D[(':'P;L$NE!]X^Z45V.D[NQY(6.'6/;LW6RORS()5>S:S8R1:NO[L,"^?VNQ]29#69!B@V)P$2ZZ8RY)0=!U[#TE%-F=- M*&B$DKN+-0)=[?:!6%A,8(^7&Q'"RRNZ[Z+00 M[Z[J+!X7>D9B#C'C0L_58DP+/:_%6'VAY^4P=U"5!5=>Z+EB*=6GT'/%0&M7 MZ'D1;X45CG%M"SVS9D.]"CU7;9RJ*/2\4F*[(KSB0L]K,+S_3F-R4EK"65>. M?:'G]^`LZ\PDA9YE'>4./3`K],Q`EG0'(5<1ETF=9P;BHW6>956M4YUG%DI+ M"XM("Q*M3YUG!DHMT+!+SA[Q8%WGF86H)0A$=$'+!B+[J_/,8D[3.L\*UE<9 MK#W6>68A]*3.LZ3JN63*7NH\LY`X>!LHERQC7.B9!T+$2ML-`S@_4FJ3=8AT+/+.P/S$==D3%>YE:5*/2\N^K$+"*VBJH3,Y`5 MK4Z,@U*G(#JBS!^QY0+4D1 M1SA1\F0-$I+?WE:5?/*LCB?>V/!#VLR`U;@:[7OX5:H:+1X7/%SP M2:NM1KO#>J@,C(T&]A7G?J2M;#W4]U?[9)`(H-4^%6%VSG%-M<]]'/YD8SD^ M9@5%-KRC-ZVKOUBW6Z]L!Q442_EHDPJ*P"AQK^6:"G'OX.!L62Z@>G)AZSMO MI7!/*O$A6V+YU5"O>T=%8^M*H#[!W5^7*7.N3JFW)$* M@X/#N)ZZ$;]VFU] M'Q;8]V\K*B^^HB6>"I+SYPH/PEHPX$YQ2NU`[04#?H&GHOT)/)7J2_EH%9;R MF<%ALR.9G,?6D5AT'G`/23HV&W$):(C_]EH2?P%TM8EHL?#D_1K,#G'/NZ%- M3W/?O0T>@@V.[B`-97Z\,E]^R!#;2-772_/K3\T%TDW,&ZJI\3K&G7;+ M0"U5%M-?!W\$K2(IH1E2\JSMN!X)3;#63T&XP?6F'7(6UGM8,PB00=<,+B%H MGL,9"F?DMP-89R@HT&W;^YW880>^V6"9V0VKZ?5NZ"0E>`E-BT1WWX:[4^.2 ME-*;#]!KEE)*R")Y-R1T`\?RG3:PG36=..4H+RB\*&2IS="5UV03&H2V=^D[ MY/6?9#^Z3&N^P)^&=$$6YI4X1]R,]O$M@YG&[)KKFY`/R@S=8UY$*>W+B%LV M"U/Y[&4>@A7Y%RZ:A7,TY2ZT3A?%ZT=:@8'XT?BD;^*\TD`K2@KN0+A%G!O[ M+7%CNX"IY06]/W8'4!,%LZ-J?,=LMWGP#5J\9AH@)5776UAH2UBUTNG[@Q=_ M=MSG'Y[BSZ\=WKFW,.:#>'SYO^[ZUZ;_^1;QIW5/CTQK[_=6%=W1O?R^HKVWWR8 MC-2D1$X_#&>0_\+SW.M#Z'UZ")PWCN?7,$.AO.A:OW7YRZNV==4]YZ3OES(G M[6<[]G2#V/9.3R)ZU99_H!H#"C)3*HZ\TO\3[L6..-L#!4H6NSC@0A+!Q.KU M.=MW3D\<\DR\(#EP_8F#04:/=B\>T7/G]#DW#`-GU$LZI!^?B`^KII>^:CL# MUT]\D=A])M,!8;S'``9\B;@?79^+^\$H@O;1W\Y7\KF0FT*Q9GWF$C[=7?[' M`O7#,V[.Y)_K/:81Y62$UO5MV[KES>NO7XV;.^BB!_3:PP@BN8<@=$AXT8!9 M`QZ"%PWM'K!B^GEH.\[D\XOKQ/V+!L1QWS>`P^Z3?]'H`1M)V,AJ3PL\-I_K M)A3\@]A.1HGB<.[_SJ13%7\_G0/-V,DT>1Z/]1#$<3"8TB$M?6,G7Q^'K7S8 M9D87PE7T9"UK8A50^F5V!F0FVVJ(9;HLWWEVIDVF[G=)%"9P:/C*18'G.HT% M1L-4A$D'7RA%DVH;NM'L\_@B,*G5:O2^P5XU(E".=RYKURJ"*U2`_8K_:'[F50U7I&IEW5;J MOY=V=H\VH]:"Q$=!?@Q!'F?D!Q'D(NFPTVF3.@^]>-W#HXEO/'P?O`2VL.+1OKO>U-[.^?_ M4;A3X:I'X7Y8X'0%/DHY,W-E7(4\H<7,L('MR8=I;RYE(6#F\LYSZ/N^8V?EQ^<.'HB52Y2 MZ!@P_0FDK,M'*7]X*:-/Q]S6GT/.2-4/32M M?S7G^8RW\9+#EHM[>`4ZL9EO4MUH!8V/?#OR[E) MT1'[#QK`[74O1$,'EY$X"K?LX#H6C\+]J,)%G_3C)O5'%J\F'=SL_4#!F0AN MF!.,'CS"Q.O;=K@:NLM'SATY=^3MYXUO4IR?P MC3[YYA.]D#TD/;H5Z+V=<4:\A+)/Z0BG)R,_)+W@R:<%L.;&*[S]'::U!>B] M[U%2&FL)AC$^;ABZ04A;QWT[YAQ:%X)>(/^K=(:F!)^>O/3=7I]SHV28WKC_ M!SK:E*[@F83`E!="?0[B\#9\MI\(-TRJ(YR>`%_0F3Q#^4;L,#KC[I:3YF2$ MR:6R/#TI*ZD#'NZ]TH"@;5SJ0]W/W_SCLSH;=X*IQ4>A8[`DMO8KVF?OW9;O[ MC_]G[TI_V\:U_7<#_A^(`09H`3GC/7%[[P42)[VW%]-IWZ2=][&0)3KF/%GT MD%(2SU__SCFD%CM[LTDR^Z&(;8G+67YG(7D(&#)>)8]`C+O.;I/)H>G-\EE7 M(BU9796\CVI`?NT7C>QJ+'L^49FFP"IXN:K9L\Q0JNCB$58@B6Z74, M>06&&$]]DQE_8`SYBMS8J3/(W_9.]UBBZ)IN\.FK8[^;LWHP]D;N0$%SV>MV M9S:6M7;2$.(,GX04CO-UX3Q@]J!VYSDKO:_LWY@(YS7S@VM=!YE MRE4BY@)OML$M>U@W=B6U:&K-V&J(<<_K]AU<-9_/SBMQ(N!$8-=%H)9HWZ#C M?DVH\>#HYNCFZ%9]NCTN%5UO:_NZ9^HGWK!7N]2`XZ_;%K?SK'7K,XUE+:)R M_>MBUSCV:4;Q!$GLHT#/LMG7HFUP>J>1'2GLG>%T^Y4=DT8XDYENU/9 M-QGKJN\9=N>JK_>CGC)7T?5Z`W<'3G/YZUC;5-:Z33:[RGD"[;HGF*OE:KB3 MU179-C;R1MW:G<5SC';6RXF`\TT=CZ_%\[J[*E7/D[BSU2\HT#T0:+=YI_F, M=@[*SHN`*SC9?!X3GM?.$ZUT+L6=KGX%.1Y.:N=E.RX[I\2)P&-$H-UR0K"3 M0E!#M&_0^8(FG-ET='-TI7,K&#?6\\="O1C>5O[7(^CK7N;/7. MLQ91>5`[_C8H]FG&:4U'.4^^@]QWO?^Z.!]WO MW9^8"/_YDPB_]WKCX6@\^#[I[H]&TY-^9S+H]SK#X_U!YW#_P[0S.#@^.O@P M.NJ.I^/O/7CQ7SA?.]TM5I5OBQ_CS?`;:X##GZ^[/K[$\A^SDAG-VJV5H1KS M@6N^H1OCERL>:W@;Z*2%3N`K.6?)@K.YC")Y(>(S]D;$[5:RD*F&-_7;=U=M M[.J.R79QLE?G]IZ5+6^_F.R-\DH"LR7YT\^__GKXY12:@(@\\E>:_\1F4H4< M@G/@8\`C/&$8P$SRSRL_#+//]KKT_?'/UQU`+&2]?#=JZ>K4:Y=^2VW>US/* M7GF=R^*?M=L'E":XC[O]JAY\=<^Y7KG-GG[)C[S>=;7]XXGH^'+_FA97>'-K M@8MGYLU.W1%]LEQ%]P[V7=ZVL>P=>`>C MVFW,K/1^O2]2)QVP/$L1$RBQ&8_Y7"3M%GGK?M10E*K&5H[^R%5Y;3Z7F[9Q MKVXGI"(1B\"/6**$'SE@>PF1'P^'=9-JQ^6' M(A4SQV![V>598'M9-EQ^6'<[E^19`J M[59]3A9<9:O/[594K-L[L'I&,1[MUVZOGN/RPT^C]>L.5G7>D=F$4RZ.;D^P M,Z[Z4<)7F?@16N&-%`=N#+,IV=+.L(;:Y5==.QUYDP.7E&TP>\?]VOE;#;+$ MS=AM[2CW)-;XD?O4'[/Y?',;.VBJ;4+$9U^4C.'/@&.I:_T%'))@;?Y_^JWK M_>G@L'OP8=#I]P?#SO!PW._@YTYO>C38'QP?C0X&!P_9NG[#;N['(A:\*?"/ MWSENP&0%K=JM#6H1GT3.P9M>\W?JO'Z>^6A?R:JXT&WBT MS7XJERL_7C,_E"O:&*5!QA7>`03-RS@Z7]@@`T#;RM19S`5U]3A/Z,0C291KYV+M)S^"8 M%%^`^P<38!_C0"[Y7M'X,5#F*PR=AHS[E+"1TV_7#@J%..`J!B=3<0W<,SN; MR-,,A0XBJ5/%F8RC-9U+"$4(AC!A"_\<_5$F@#H!##,N$ZL8RN0]3&HN8C\. M!'BT5-Z,1J08=)=&"18^8W+%%?6K]]C7$LUY!#R"62>RW;+#HVY$/)=J:4:J M^%^IP(3Z;'WS)`4-K]T"CB5&H[';33+B!5![MTHL(M7E3$5>G.^IO0F5'HHE MFT@$`UN*A)X&%)M*:H4#";D^SGGR]#@T&DZ[!\.C86=Z/#GN#+N3H\[A_GC4 MF4R[1\#8@FN$?^WO7&MM[_C7]_.G3QZ^?`&1.V>%OQ^W6 M%$;P\;=_G_PV_7AR2FR=W0EBN4C,MG=:ORZ\E;0(54?BK0Q895"`Y`N0E@@U M*T6-5*A\">B:1MU@Y^),*IEJ4/=$,CE+?'.XB+.9DGX(3Y$K$3(=P(L,])#: M7,&[(*U[[#CE^")*N\)WH65S7JG=`FT72^Q#I@DB%OY@WF,<%=KH!T2]A`2$ MOD(5``,XDB:$108M`#ES"%$WH@\KP`?4)"3T:;>$)A#3Z>Q/H`,.&"_/DC&Y M(#!'&N<=:'"]R/=?BL,?#>)*%<($U1JWRZ=*$U%GJ18QUWK3@"W]-9MQ(KP/ M=$>>P[PC_T*G`DV/B,]E=(YD/?>5`!&`-Y*$JRU,!M*EL7_A*^H*O]%IL&BW MLH8R.P("M.(QGN)B_AD(`@B.2-C%0@0+#T00T$.$((#P&(J0Q6?_[$SQ,[*D MV$'(0200_F'@.!J.F]+PXWUL3<[NFXW-4Z']P_!Z$^M_Y^<\3CD8?GD6TWB? MS%[0(1UJE/;@L'/0)1L]H(+R@?9(^0E%\*G6B8RIM^Z=V01_">6H,+ M!_H`OB5M1P`=T5R=BP"FI4!O.7SYGKT9E%XD#9USG!>@ZJ5Y*>1V0SP@YWOR M$-\,2^_@B4]`6!-_K2U%+-*"0ZE1,<(]-C7&(CO:>BV0JQ)50;E0B1$;%F"M MSA:`#G$Z!T.1*D0<5!D%GS2-2*.?WO$C&7,&JH594X0:Q8U#]L,P?]>!V7N< ME[TY?GMA+P&EP=[C!%0%NRW9$@WV*N(=<,.-92YD"XS"1P16D!/$8YNI1G?` M.`NWOKMIEU!\L0PR#),DS,HG"A3Z*D&4AJ@$ED8*\%RSA%S.;@C*550)MNR M];[B6=R@.=@\]#[26!A#X.<.^AX[C/UH_3>*CK%#)2V"Z=DAKME6VQ1YT+!9 M:DSOGVEXAF]YT`8.S@\6Y9>L$49%E;-(G)D0!GJPS^0Z"/8/-`53G:AD5FC) ML=+T-F@.3RC<],&1P9@0((&"(H""=JMHO-(^#,J?G3EN-@`H7+[1;T%XM`TP MD;<\,_@!?`W>B$@TS=*;70:H90T':@N#(*4&6AE")Y@!C(IAAI)N51,1R4QW+0E!N4S@`KC:^9AK"']@E+T=&>Y:?[P?'$\2>"'*#, M^[D6]@C*9%1I/AYNBUQC<*`/R/-LD2,^O> MSS(@V`#P&?`"@2HW#H%00;K$QM#T83R#2KL!`7OL`SPNU<:@^Z+*+.36`P^?QL7^E2"=^ME?0)81G8$ M/)?I)17L6$5^P/?:K<.2`FR2`E4E`L>2S*>?)50"OBH1JF0>"=ZCJ(#I\#H$ MW2"^4#AZJU$:8DU\8*4`Q$PH8/U\P-(_ M33(O]X8`">"!/TX_GW@XT,V.*%P4*NR8**CL06T\2&B";;!0F8>'W"A*XRS[_L"N>N,HZ.'C8C)QMKE6JS)U"#Z0)GKS-=L<,K(8+V MT90;RLYX^X^\@,>5QS*GXXXAHFMAHI7D9A0LB2B_##@W!$Y7 MP,$X*<@(<9A7ZO36F;/-B5/ZJZ3ZI?:QV5R?"P&\:BAQ<>`&`U;L#,_7^8!*\\5M,*1\A`LT1),FND+ODH!=P1[:0%.6KA+E M?,0_B4**FF%34%9;*NV`(2@C2)L)WAA"6Y]#+\2JP!E$/XGVBBS+4@`>)L`N M*D=E?B>!`I05(.VD_R!/-KT+U#O#I2FIS/)0()?@H0=T=A15*=G*'N;$UEM& MA,3(>(TF>0:RG@OR5M]^,4H$=N0K\AM\>4PI%(D"F[@&[TE(0$^@)QG M@`,2]-9,X8KE)CK'.B71QMB867<$G\:1)=N)T7+40A$[S7F+&#)K8.';Y:K< M"3&.N!WQI@W!8(>`W&19#8L*Y\QD^\FAQ:P`3#.W1M>,E-T\T'8K'ZG'^F_9 M5P+:LG5@'+B8IR M"'&X)5$AGY-'BX0#J$==86_$1KH--`+=#)+*&2_$U/C:*-X7"YBH3:"C81^['_C M#P?CD,SC9/^H,NZ.#SN'1=-(9C4?C@TEO-)J.'U1%\?FVHM#:[/A1*\`? M#C_^SOXX_/7;2;OUZ>3P]-OO)[0(:H">BUYIE(2HOYPCA@Z-K-,9IAV>FA-:XN4M(3$\8( MS"7W+XNZ3/Z"8$P$`D:/1C*QN%_H`$$"P*FF=4>O/"\TY;:9CL'(TGMH2*$Y MO<@F4\HJY,D+B@@H$6(C8=,:^D*E41EZI"8A@Q0TKF1!BGS>F#G*AKEE\O)TT_X5\PNL]XY]GF%ZP>3^C'"CHB-H_97*A#+IE'M`1+$[ M^(R6ZMOA^N8=J-N;3)T:.#5X737HOV/&U_-L7@J,D8DI[M(!K\C@RD*1;$P0 M0L`:)-F6F^S3>PJ)G.XXW6F$[@S>L6^QO&)$RND?$WN"@Y:8Z#F6F?Z@=^EG M*7&[P&^SM=EV;1/UFD5[2HE3-DA>0#A> MX%>4E+(I39L<`_?_#%Q@7`/A.E!BABW/Y#G'.OBLZ67P":B>O`[^X,%U\/NO M4P??=?MDW;JJ_^7J\KWA,Y67IP3`'R8!4$KEF6/;-R29'D^Z6YM\`.>O._1Z M_;G!&XG^GOWOQ^.O_P$3-5XECS!(=UVGP.ZZ0>&UCL57]^H#&W._HBCN.NU? M\UJ)7:>]NV[E-6A/I4VJ8OR:?ID*GJO`55Q:%,U[!T-7N;_YC'9&RHF`$X%=%X%ZPGW-BO-^VSO=8XDR.RT;6W^W&@(]]D:# MVMV;Y?CL;)<3`2<"3@1V`>TKG6^92K62=$AT)EVNQ0&8`[#GO>#'.Q@-')\; MSV>GZCLO`K54]9IE6OXMS[F*<;ML1Z]DK"75U*#M2"N%!=&*`PC.LW%PY^#N M.4.SR:1VEQZ2S,86I*G6`B!LMA.J?%(9E#,B<"3@2>703Z M7G=0.V/F^+P;?&[0E:Y-N"3L-NKFY5U M_+WW]N&>=S"JW08-O@X*@`;@[H4QG$7\1[^I' MNZN@6^HHYRCG*/?H8&BSGDVI8(UY\HE*];H2F(TM"KE;W;H2F*X$YIVASG'><=YQOB&`7NG#`*X$YLO*;^_`&W7=IH;F,]J9*"<" M3@1V703J"?[;P(]$:`=[6+SARC MG:X[$=@-7:]T)L85PG10YJ#,B8`3@1<7@;[7[]?N9E#'Y]W@8*8;Z6D9UXO4&_;E;6\??>_-WWNEU7*;&Y_*VCD^S8>]_.1P?> M8#RL&W\;%`0UH[2>HYRCG*-<72CWQ(4PL[:Q)#;\^;K2F*5I_YBE^+K@ M[=94+E=^O"X2]9/WFHGXG.N$:N7!WZQ\ZFI=VO3CM5O!9H4;9@O<,!]HL"P= M.&=TWISYBB/S4AZRF:_A?QFW6RM@B0BB-?//?1$1X?Y*90*_VG=72@30_%PJ M)D(8%'07E8;!?-UN0=__36->\&G0I9)T@ST&\V1VFC"^A*NEB.&M!+Z>8X5` M&A"5YPDV-VS3+"0\I]C9-5NA6&DGE.(1O!:6UQ;9A4@6U(LO0J0-]N/C,J2& M&@89[X0/#\/:!HR",S+#_VH[6A1")E MI&F:&AAZKZ=9"F,N41>[!.IJL00&J'9+Q#I1J1&`9.$GQ#C0M@63LS]YD(AS M3NU>99V'+P=1BL53H8=$B-U(V0=$%4@!Z`!F@XVVE(%6"L:Y`]G!X MMM&=[U&^^N3KT M2]C$0\0VD:Q1T$%VM09@84M3.S9$P2I9#(/4=Y"[W7ICRQV^1<(#>FDT&U;Q M07;HV1F/Y`5[(\`:@G:E&K17OWWW<"[L:A7M2??!5;3'KL#S_1JO;BW+4W%9 MS.,3P2]-8)9/I3ROF6*__#@\;'5]@BC_4IU=,2;%![0JMPSC"03E_JFCIE?S M//(C/P[`M0*OYHX2V,W;4NC2YA7:$#MXM"Q3&6`6<_19(&J(X">(%R()#@]X MB/PRB^`2_Y()<$Z#Q,L\3')=3%2,(83B"QYK\.4I\)-+WE`%J,8NJS>]U[YH MZ^T.+BNX/1NO:&QOBN4;BC/NHD:W?MFD%9&J'04RGL^9+V*-"6GC\IAT#^9C M5EP)&6[X.N@EX6.`18D2L]3D1A))^9M@X<=GF.QIMPI/ZDKSM#Q`_I1D-JFD M$Q%%;,$C2BM1YMDD6_$Q3$<[?'/G41STU1GZMM=[_Y^]*VUNW$;:WU6E_X#7 ME:U*JD2'%'5F,U-%72"2,A"0I$*0?IX?_UV`R1%R9+'&A\2 M)20UR4@BZPL66V;+- M*_.$<._="?>N+*O5:+;L*WO8;S9Z/=-P&D[3:%AUR^@Z@Y;1M;I6O=_LCYJ] MQI4%+[['^:?3?\R+T%E_@/UZ(\"8S,#0Q!3=0\1G<A.LFU]`R"7+5/R9?`PY,$%LEIN#QRDQGT"FM_=/(6ICZC M]V0,&P)E?*L5YO,9#]!9CT\%#)V)TCO)'I#BE#ARCAMV$C7I6-U\I%=#UV,J M-\0%L<&VOK-/+3(#&\XQAN&6POQ]YEVCET@H!PD,`8BMQL3%PT$];N`?8,5S M%'X9.BZ2.8P5N4K]=)]U,64L7F".R$'GQ:#"[/>Z@^'(,>Q&JP]0,;*,CMFO M&[VZXS3K+;,W;)A[`A7R+-T^76OOGOBW\\M?AY])S_GHG/6'Y.+7X?"R6G'Z M_?,O9Y<7DK\;#NP+(H!'YG?CR*^-5\_*=XM'CNLBF&!\`KW/@@T(==T(XWK8 MW9P%N.8%P1%.[8JWF\'%^[!GI#KN^R'NM1^;*'L[D?WC.&,:\S--@R'NWQ%:D^ M:.O;1[%:[P?+CZ%(K84''/*G!VS`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`,1*&6) M<=8I?;VN[T/DR]66N85MFLK.;OD\.' MK5JG6;H`',W?@UXD:_8^.45^MU;OE+T29)DW08>1M%%33E-.4ZXLE'O,\35E M:%7`.K8V8F3AD4(RO`W/;YLR<&G4CUGKG2X`=/+`;;BQH^2!K<9+)@\<,)?- MQBQ:3-JV9`+!1_.QZ02".H'@OM%>)Q#4"02/B_9[E4!P_V.H=0K`-[P3T"U= MMBC-7!U,I#FO.:\Y?R"`OM>!T#K]W]O*K]6I-4WMT#U\1FL3I45`B\"QBT`Y MX;YD!RHZ_=\;"K19L^S2+<$UH[7QTB*@14"+P%'`_5Z?N.@$@!K!-(*]Y0V* MIKXA[H1F&:UU78O`<>CZ M7I_$Z"2`&LHTE&D1T"+PYB)0K]7KI:N*J/E\''P^H/P7AY!<3---TTW3;?_I MII,`[LK(=FN672^;E=7\?3)_VS73U%GB#I>_95PD:_8^M?-FIV:W&F7C[P%M M@@XCK9BFG*:.220C>D%WKWQ#`6\(C?%M[T^`U^^OG' M1!C7E,Y_PIQS?V#*.4<(%@LG\#YR.N:^=%:E2>B\\^`S.K`B'ES#`V=A$&4? M>U1P(;N^9'=QSP_=O]Y7*X3\G+7OW%#NX^^C,+J@/KO(/6&?F8@C+KUDPO$\ MCG^A_H=@$D8S*GUG+M@/:/4SF[P[8:%_]6EH=^VN`?]8MF4:OP.)&U<7EX,K MJV-=U4W+-ENV>66>$.Z].^'>E66U&LV6?64.!];`'+6,3L=J&HVZ/32Z]4'; MZ+7ZS:%C-QK=3O_*NK).WL_"B)%X2@,2\(#%]\2C]V)!K&=,9IDJ_Y%Y&)GG MW+"(7K.S!-/3G4\NIC1BYTDL8AIX*75=H/B`^PD\_>T$20*NWA+8@S@A'G/Y MC/KBW8EA/Z"7W:Y;#:?=,ZQVRS(:/KV!99B]4:L[ZK1,IS>ZLJ^LQLG[ M3JM5MZ';!8V^;6K+Y+F(08ZFH>^Q2`S_3GA\?Q;&;,"%ZXU2C5(M6$"#U($L$L#KS MN]RGG.73,M-%S3.66GZ:%JMSNA8HG_BWB\OS_K]_/?\(@'6Q<)AU84+#W[]\ MN/ROA(IQ#B*;W-4(/7?CR*^-%ZCS"$U:2)(ESWOC'QMII-KY-BI]",B_:)#0 MZ+Y:P2R/-5!I1OKA;$Z#>SR<\HAEUVP;_S2(4@D23@B/!0C4;`;0(U`""0\( MK5;F`.#@6AFQ<82C M(1L&`W!#<\P@S7:K9C<[Z;BP^T@D%.@`G4&_-(HY/,7N6.1B1"1TB@TF`2C+ M+8`1J,PR2S&DDOI^&&-8)0GG$EJWF4.U#AT&?,$F43A3+Z1$:1&Z`2Z M!4SQ,.@!*)0/!CY4*Q[H;9@$0%Q0?4E@+@0"I?P<0E/1@KCL;LX"`?R8TWMI MT<;`Q`+%@'R8$0[`\+M&Y[1-9MSWH:U3XOA^1HL%1Q4WJQ7%SEL6I:.&UXMD MC6]#PN![&/T-OL[\"8G8-0=,E^"-#=!8)6,]?50EUH-!_0TE_PSXC9"[3O1E M("W,G0LJ%;0Q`GB7$=,3KU&PH@\^.Z6QU-R M$?,)\VL@*=P-?9J(%=3!/PL.?@C<[)Z2IQI5KRNY(;=3[DZ7F$YF])Z`T"1, MBHQ@P.MDCIS[KFG6`./Q#_)[29>KE25E5G(+U),NN!`[>7G1?`_JZ?N))&N+/@;2!A?'!`,9,3@-WBB,17W_.&+D1C3(+>BF MM?J3ET7+JZF5)?Z:1;U<06?4:-O;K+G,MT)9!^T$0B7H/VB%I"H* MNB0KBL`$$WG?(,E)(E!.!&P>95I.Z"XIT!FD&`@-JO5]FF/V!T`%%$N!4(U` MK:1264()"=_S`%$E3`1HNOCAI^W-D;E^:?I/4CQ_JR_HM''7JH:UO/_MGW_\ MZ'RZ@";`$/AT+M@)&8/JL^C="8B`"]`MYM0%HN2?Y[CX23_?OCNQ3/,? MZQ+*+E2F!^8Y2#>]OS+J+2T_5X)!TT:[T.93#TC35UH;WWB!K[?-K_^5X^^= MGJCO;P+A"WZWF,=OT-;TL7SZXXC\^.WPL-+U$)87WEMU]J\D8(N)VF9M\0$Q M^+$MW?,%Y>FG_==PCCX!9Q$-O::V#JR1\#+`H MCO@X46^E!Y352L3F M820?\VA\J.LH70!"0]^10-_6(3K//;]?=@Z_1?!O`_! M.4"G4VZVF8??,KM$8F!W#Z?0& M1K=M]@?FT.J;S2:&[-1/WAM6LUOO+L6@/'U2R\08TBB`G\4G%LEXE9>/ORE0 MX`I&<_4P'J?^S>$X-M#"/*W7%W3XRGQ6(K6"F'OX`VS3%X%-PSMEXT91.$-W M*!@VE*;SR6K;S@Q]_*\3HM1\0)/VJ-]Q1NVFT;2';:-A=X`F3AV$9#!HC^`_ M/7/8!YJ8)^^MIM3E0A#72\QS)5[)G3(O\1D\/9O[X3V#AJ,;[K*,ZLS#-ED@ M9*..#WJ8-H]*>AW@>N"37%3T0Q&+E_>U.4VK-1J-ZD:[:6((7`=];4[/Z#6< MH6E;[6'+:6_C:WNS6!ZY$DL#.(PQ4E(>*&6DS.)%R"V%I9>BJW33$O2AT^($@22\W_!Z(?^X]WQ2&/$6T1& M[#@LX*@)KPNY:XD_+L+O4N*/*@+I\Z:-[T,::5_!LWVA#9T;Y7"9V];,/5CF M-INE2YNAF?MTYNXX`&ZO(D%?H)+[ZHDYWH+*CLP/=%VQ'[&B;RFD;+TAND(N-PMW1TZ MS>7MK51-GVT=!Y^M=K=L?#Z@>/5#N!.HZ:;IINFV_W3;ZP-D=:&N$,4MD[,] M".,^T`W<3GTA':MT)Q*:N4_MO%M?<\5=,_+5;Q\N7F\^C:PJ/RC?[82`WKJK!P/ND,M6FK8YX M0`.74_\BSY;^FC4;>FW';%MURVB-L&9#LU,W'-ML&VUK9#J]X:AIFEOE#U9I MVE^O9H/UK)H-OPS/AI^=CU(4QKF0;-HK[VMIAC^XB]>Y'V2`7\KP3\F`^?06 MA)ADCX%\U?".M\H?F+V*B7><><3]!9FL;JNPGQ,9&,L>X(%D[P M[_&:>+62EGL`^0V3")-W"XZ9Q.(IYME)D\2G#^31]*003"\#X*XC.A.GY+*0 MJ3Y[GHGB&X*,>3@'M9Q1ER6Q(D(:00>_R6OM82`[G,/$9.[GP9D#K_O\AD7W M)&;N-`C]\)JS/.V\RD0.#V?7UN.(T;3*PX0(5.Q$Y1?B$V;$4_R5!5E)!@:= M[G2!4BJ;`:1DY*E!D0BD>X-I7S)F>8(0"(ET#_4WJ# MV;59D%[\1^KG52ZRW/ZR6D>"V?BSSFJP%H]DC]EOBR;Q/,N5[:BD\#Z06V68 M#P#ZJA7!9%4.<@_#7)$@^"8064MJ'!MS&1":)?07JA##LHRI&_]C5)8P4@() M(HMD2*L$Q!%UH9$HPOQ4A6:NL6A(('M`"F."C%/R&QB)KS!$48:X6.,'TU,) M53HA8G\G'.A42(..H1MYR9--[,*B'&$4%RLJ`&7C+)4HB+_K\T#.5$XH^P`= M8YH7511DS:!0RW$`-S)[(&CZZIO+PX[8=>(C"0$[YM#\U MGE[*,D$4U"C&\_=)MEHCB^(V:S-I8L9J6\EU5O`$C0E3:"3X'9F%\E8YPUOE M&]Z7KZN*-`NX!06>4U60!M31!-9'B7 MYMGKYR6&5'6983_32F@6NTD"J>1II1)9VR1-^8++`U"`>:'XPI<`Z47DFE8@ M`/B@RFER/XZ7)/EL/3&E`HD"SJ054`0%<1QC`C#`I>!+&BRE9(TQ5A%HJXC%>+X2NMP@7, MHE9-2E69X#!EODC\6#ZP@A780_:XRLHH\E$P#\MOJ=^R%N20PS@?-H=12\JF:K<<)7&ZN'U$.J>JIO*"7IRZ/+-Z2*BA) M"8;:C1.U$$#:HW5*?!P_UJ(B2)U(K=W391D:LIQN#_1L`Q/$5#8ZQOZI5&\@ MR)])H/(^99BSP<(^JL*9)$HYD2CX6/+_Y23IN.9W@@!G_UF2A6"]L1%H9F%3 M8QK_AIZQZED.C8!JWV)M7J\N(<>_8-J]&L'_RG)BL%):().JW"2AY:Y7SD"A/^4JVPQT%ZP6`*Q[8:EZ)Z:-GAXI>U["=DK54UA M"X$MJ?TU#-^31>%F"_:()POE&,0OD!40/2=V3=P)05\;O)F.O[60^!I38DKA#D5H>L36_ M?JNJN\FF#A^)'4L.`P2V)1Y=1U<]=70WX1Q/@!N8.RX>H0KA7)J*`Q`G\*6? M2NV@I:12+QC-/UH^G!%,DHP*80X$/FHB33H2PO(B3QA;C_I3":3$F/]DR=)$O/-[W*2(' M+J>'*KN`WG$16DVC+":C-`'F^P1T41`J+1$7Y`K7N>#I;^R-I9VP`GXER5RR MC!SW.T9/1PE+/;$'.!Q@2@*DO+&U>_,$,Z;+HPG-,@\M=B)*21BZA(0/WK(W M=>U&0LI3CG0!,KT5-RD;C!/A+6GNFX9V#ZH>.%L1;BB#X2817K\2*1V,V?IR MPLF9OR/A57"U2-JJ`TS+&[RJ/*=P8G0`N>$&B!L@DL?8!$\V56G4;\[@W+=] MZP-V;WW94RUU6S['2DOIM&#PQRFF2@P>J."_2!HC%F6TI2R=72`R+(4EOO/> MLB55SIJ2M!QSW:2?J%`:L$$,)#,3N>1$L(D@2>2=!;XKW0]AI\Q/Y*`(=YU. M).:0:2&PR`"@5__(8!7113&+,.3/:<5C`,^Z" MI]%NRMT&\&X<^#-7P4QY33X':W@*.74)-\B]0'HBN*`(A`)P?J0$?`PB,)=C#22WFM$R7 MA1YPW1<61!>@U"%$QFJ79\E9M+E@,4)Y#L=7XP; M9/B)'FM!`#$F%2"+5*I."KW>D84@4Q8%>RU'9UV*:[2[Y=E7GGR%7UQ_"#JH MD@;`,])PIP+D-55BIGJ]2M/)+%0`]H*REX2.H]*Q*= M8"R#/%FM=%H$\\O`G7"(+QUM`I19X>N[ILLD!!;"EQJC-/=(YCT("C/M;;.@ M)>;[,8Y>SB@\N5UFWB8&HOQU72V,@`!#P&+BOY3`2;TVS(&R;J?'O=KVU8@(4 M9998(7\="N=0F+$8.?E8.:G*;X)IT*?R4*+FBILW1.5W4")'<';,(0X% M6U08?TJQ:\:=23B34)%1'("Y%;>/LQ24!E4&+)$H45&`2FMBUF[XAZ:41[9@ M5:`;TC*R4[)V7S)4'L1_(MJ44UAA!#2:FFDD^RF+KFN>BEQ;7O8IJF'*ANUN M0<@C!26[`GV3UGIQ-F-%SP0I@1H?*(EF2LKYJBW.0;X!6"`5M'3B@TZX&Y**,@S1K?=[D$F4`]+H!9>YDE5/-<2: M,`;K_-84;,/VB*JSIET:YZCBBH4FFAE,Y!CE;-EK`'8MDU^"P)TAM,0F-,M1@I#I<()C\FI?$ MM5XYR>QDS8F0&@G4*`N68'B5(J^]VRU&JRX\K0"*X/NT^PKE@X!:<"R.1EUOI4!EA MB+#)0AFL\=<4U@"OQ<9D?(D-`YPR) M622G9Y'&6(LPUG3(XU/"N\C,D*IC*7OCE\;G4G\;>#54VC$OM%A`<5+W2#0T MP>\X]1&>/T8YHEAUI<@TH4HSYL@;WO[-(@6(_L;724+SD\_0F-B@3Y\LE#8' M9WE1.Q5SO!3OT]PL\EBYAQ)L5&UO.;\(WL!0-MA[0\T#4I6QJE&T+^:V<'"?6^ZOZ\RK-,[XO>T,MHY0;`6YF]/HA,N^9:M%1[[@)DX3+O M>BWAUBGW*&XN&E^UF)MZ9DL-+-N\B#`MLN$%=`.[;D1IDGHD90217Y8KS31O MS2Q&%!?`BV)7F3E?MSQ:TEP(3-:L-^>/SIO65*%VLES]R;+E_L^-/GK(/>)SO!8>@EQ;4',098PF M#ZW,3R9>8DH9*:&P4/1ST$F'>2J%',$-QWPH]PP771?$JF&&M4=*B-#1C**5 M;+%`E<(V`O3DA.S%TH+U62(PGWHJV_G4C%0F$AM#P*#8'03P6Y7%#<4<6-#$ M0["9R#R+&)ELI*/N3W(+&(+B7_J-/OQ4"5Q!F+I?1.):B55]C)A/MF1RT9]W M(YO+T'X6!TR>4C-JSBF]9ITV"B\C"[9">-:IM?E-N?OV@4VW5$<6=>*E MR(L%*PCS><%%;;'#Q`TFLLT6NZ'=3'*3\GA,)TR2?2=]2$9S*X';*5?TK;<4 M;SF<:KVG^"'48:OX-O+8;NJ>SC`]83'P.8OL>.P+<_*8^/CH`@+O*).@_R!, MX)!$1PM$_N.&F1NO"B9;JIE=3[BZ7D3]W@79V.P=>FZ,S<2?E@@LJ;KF7'VJ ML3\C;1D?/LPP0?\*#]A_>YEWMX)NB>-B$^I;*!J=SD6CDZ,U.IT3%.^7&IW. MJ-'IM'CX`#A#V5TORC/T,*JM@T*D`R`YQ)"^6*6I?(-J#!9AKF@6]HI,39'0 ME*!_FZ?7^VSS/NXHWMZNO;:<)!#+H_2F<5%[H(A`QFJRF0C0R4XB5?Q4+#G% MUY;9B([\[JF<+Y<,]16X&RMNGWHI[-VG3U_`XR>KIU\WVQJ-K,;(,8U&N]\R M&MU1S^AV&I;1:78;[7:KTVDW6X]:-UMAL0J+55BLPF(OB,4V;?4]UK1L>K56 M^K-PP,Q1NXY=G&D.-:X_YUX'UM!Q^KV^9;0[[:[1 M&'4Z1F^(NQZ,.G9KV![6F^;@,3;[^8`D[4W0^*ZM#F!<_SV\=GH?AKC*Y=/E MV?79\*IV?.1\=LX^T,>C\TMVY7P8'OAN"-=ZOI]*"RX#,TBMRIA:W6RKW[Y( MXXVH;KSN$^@MTWR&(^BM1Q]!O_O0^B?YN'KML[_V$<=+;]MN;?ON03N/6WW+ M_CH;7/\!1J2U3+_#9-QYJKIRPP\TB-6QM,0C",XA4/]''(6^@VW%">E/\$+< M9^DN$7V_6)[AD:]!TI_R!7,_2M3O`1Y6HOXI1(W)B4K4+R!J$:+]*#%_QE:7 M%Y3S3W6*^:?3JU/:T`SB:;5-P%Z@F=>S_W"KUJR.)'R]XJW.=WJUHBVJ<(TG M844E^4.1/-CL^L&="+W7)].\SSO^C&2)-5UJU2:8NHS]TG8NKQ2$?(?=>$+- M;M<@FC@TS:[D7/FN2@4>.XJ#._2DDO$W`)5NMWUH7`GZ59RKN!)I0*/=EV5C%^]C-&<'QP,W>L\"G9$BEU6N>@W]3BM M":A0R;,>(6G:E;EZ_7*N4$FE`I4*_.PJ<)#6_A4=&%RT.FW1B2<_@?0;W[;E MXHIO%=\JOAT6W[XO%7W8WO9%.RRL;JUA'5QJH))OU1;WTXNVJL^\6M&B53:K MV.?E,%4=4(X79>.`_Q!0]:VOVT,T6G&NXES%N>^.@)*_'3+:*L] M#JH]#G[*U[[0'@>MQE/N<;#[W$,B<9Q3OA?UY?U=)UOM<_"S2+K:YZ`2];.) MNMKGH-KGX`?(N=KG8!_0S"O*'9HUJ]Y\]`BJW/"AR+<2[6L5;=7T]K-*GHSV MH1=\]@MJ5#L=[$D;9[/6-`]N;6PEZ,I[52I08=-*QEOM^:%#E7W/DU1['?Q` MA;9`H:MFNMM&B5ZP!QK9W^8IG/3X:/M)]#7V2^NTS19^$/A1R*(I2^>\U&3,;G@,?T_FW,L" M;$5.([9PTPP^C+(T\3V.=T4A9RONQJ?L>LY9/UHLW7#%/-\#EY,='B7_+%L") M><)XZ'&/;2?NE#GTU%VDAS#JXR-!L_Z>N>NQ,>I$WIBU2'R;/A_F9^NKG(ZX$LL@`*[KV,7 M][!P@-]I,O"3"0P:!'C-;]->$$W^?G=\Q-B_U5L"+U;&^ M(-/-5MW\8IXPW_O]Q/>^6%:KT6S5OYC#@34P1RVCT[&:1L.N#XVN/6@;O5:_ M.73JC4:WT_]BP8WO0C_D*6B6NQ(ZQ).DX,_#1UZF^))_Y6$&DO]F>K+0%W?Y M2=2PK?:73U>#$^;QB;]P@^3W$Z.^07.];5L-I]TSK';+,AH]JV[T>@/+,'NC M5G?4:9E.;_0%+CMY5S?K:-8*.M5XRU3@K(OYG(>)_Y6?A9-HP?_DZ?GTVKW] MH80UZKU!V^D-C$;=;!OPD6DXG:YE-/M.P[3,1KL_6$`BJF_E[2W2)/; M)>(?1$V9`>=+'KM@D6=".W"Y^S[.VRZIM]4LS]PM@[]'O&=AZH8S'Q@BS/=> MBA:(M2W[;LFN$[+F=)3G'T7QE:M+_WT,3+J4[A;WL4"F@4UX/D9L^J=^?=3K M]YVFT6Z#:VI8#=OH#NV>T;$&CFD/^FW+&2$?3MYI''@\2666C%P_IE7^@E\? M:?4Y]\[#2WQ0#$K46$Y0\.LUYU.LS7LU%O((U"R7[>KO'+/$=CZO_QT/H\" M1"W(/3"$'(@%DPCN`7R#2UAK#V>"#>X:G=RVF?!8^G9H@]0#?"0^Y5,8C1,> M?T5%.PN7&;X'&#/Q`Y^>4E864B6E'V"#@@S@\UEX#@@XWN)Z?[AQ?:`266A< M.YT2FU^,0??A$G@!]^GU>VF\.\#+5O<>2*+14"87K-9^^V'+%HZX52^16!KW M&L"X0];[#*@;2*A5)O,AM-P#0"[B"$!+NKH(W!`#3HRGEGC)/BJSU08DTJ[? MC41V4E3FQ`=_`BSC<,$5F`_X(Y%QUS,2WMP@'/2ZU1K53:-IVH[1,)T.6,1F MP^CTK59[4!^-!H.A"(TI2-3HWCG^AZE[@2?^$(Y*6<7S4,LQQ'X"7PTR-*`7 M//8C;Y^GB/V(*?*]]-_G%IS)),I`+4$]T:Z"F.`3`%;>!]\=@W/:US@.L'[= M;M[C+QY"7)E!']TPF[J3E#B).Q/NI3>!&+;=,LL!_.;(RY2]YR$$?0'RP%OX MH9^D&`)^Y<-;A'K/:4V^F4RPHJUNMYR9N8>,#5B`N3>PM%]]`%"]U:<$8=3( M#]T0M]=U)G#KWJJXC:[4MM8!PP,I>FB>ZOF]R;>[47`G1ON^2;Y&2)GNPXG9 M8$Y;W69Y3C\D(MN:8TZ$$UAGUC[2;3>!\$Z[3/ACB%H#CG$TX=Q+1G&T.$N2 M#*8%/Y\"^Q91>)5&D[_WD@>`".J=,FZZEY`'F3I1J]E_4PL4<-R+*-K M]YK&:#`T[4:GW^G795%MP^0_C)K=-@]3O%2/12"8KLZG!U.8:6+VOMYH[;2" M#R)M1Y5&\FTOT7P'"+>MM>F_,7)!&`30P6_.+.:46-Q617^R:OC0&K7,$9:_ M3:<.2@SW]D9.T[#;-ABKQL`:]08BY,C26?[F1K?VW\8R*V(NZ=; MNX<>^)MS=3W\\,&Y.CYRWE\.AQ^'?UY?4?O#..^6N+=U8KR^I?!6/K1^5+_- M6Q+F147\]M)D&'^HL9NHCCP;L!UP]OC:.4&Z,);TD43@$L\!G>"&93C(_46N-S+)C*VAP]P0$L8_,+WL)=G$F&B M)1_3-(H78N'^9)5&"SYS`P`D<980+_H?/P,;@M4D@J>F'*[OX:M_A:^6\RB! M_^KS5A/XX%,RGSAV=0&"J;,WU\##Y+-[JZBU;/OMO]@X2P4O\>+CH_[JXV<@ MU@_UJ^YNZ7GA=J]/)%B4)NC:(LE;G#;5K59HS]+U/>9B3U3,IZ`:U-:6+:)@N,,8Z MO'8FTQ-PG[@.[U9RAS?-^<)-HV7D`\J9`(?Y@@[[@8M!(Y:8%\:Q^TL?N42$ M@2)(RN"+:!92\]Y%D-1I8L455A&JX.4D-US=2MII$?0)3@S8!611+E([DX\8>.5!G MBXQLYU#/C[*Q[S/Z@C^VLEF69(*_I0]MKL0S/1A>N86%-F=+9?@ MXW?Y;FR4K<'-$<@IPA(#L`9D!HH-$!&>*(0'HT*E]B/\VTW7E![FQ3CP9XJW M\HUR$%[A3%&G"X?+,AAA&H&]R\$"/%G]H7MV&`I!W!KHC>=/5V(.BCA(F=Q? MNKJI!Z%O6.Y$4JF\=GX!\F`>1]ELKH\N<+-03%O]K6"NLXGH*A:F0,`6'Q\" M[PUY*KN$P2$MP-1/_5O@@&CR9IX_\U-Y!R$1N"_.OP;KH'WOWZ>+""I_%0VY MB=[2G7?CWA$:!'#9E?.>>@`I=AX`'+]$9'A9H#A]`=VS^ZU#+/=ABBY#:_I M-DTJ,0Y-")!LIV>J+@M9+7L<,1H#^M(40/SX'B'K2V2]']HJ`.$@O*:@=\?8 M->K^`GKY^71Z/G7&H-&@]-X%<"+,C-'V264RRERR,?V_`^[)A[?56J),H&"!M\P9<(5,_ MY1ZA]EF^O3T^0D(XBF5+X%?Z1/`F`L211Y`H@YR6YZ.S`.>`\`Y"NPP+4?0F M=5GNG<2RD8A6M:@1Q3R/3<"_Q'0<*"=#AE@3JQM1"!$0N/>$FBY/I<#04(-_ M&1>WLS%F"LE)Y+4SNH:!QBF$-`F%J'(#7<6'K3?DCT_Y9!Y&031; M(44E^'DSYV$^QKL=WIIG^]X)K]F.H@-%7KK'QM\^>=>659`[QZZ1-TP`OZ&N M4=OA^92*0Y0X=F['=A>H-5792Y'[0%ITQ^[^?WM'MMLVDGPWX'\0\K0#F#'O8^$)H',GV(D= MC#V[F"=#D:B8L[(HD%0<_?U659/B8=FF2+'5E!4,!I9$-EE'UUW5X4,A39AK M1TJM@:8TPJ`WL@>:JDH#RP2M!Z25;$# M-*8/4KQU;O,'?(BN%0@>"OG!'^!YII`AH4,/O"H0B9/DJ@?O^P,Y,7#=--=G M"-X3RF*PU1>@*!Y9L@%_B?VB*FPA\!9P)=00]/I3\B0>4_)D7IG@&?]P6;?@!+RKT)MY MJ`U`W@.BQM_)1>A@C.=99R-%E4)47NF;DA1/U\$;2;/1&M@$`-XC2"%49^A5 M,<>)M-T&),32^=GC>(U**NE`Q'`I`?K-7?NQ[YDL_&T\QPQW)WQPPJ[CAQ1-;`^=E&*3YK+(5[,-!(CK7/DBZ` M\`L$>@&**PS'P?KC^=GM"O1_`4G`3D%`"(HZL[$78)_P"N/>2.E,;>G%)-]$$W@:4+T(,_ND2D+4@7@U1]F%U/BCE+,",N:,U&`.Y!W0RZY,) M1'3!YE5TH%_O:64MK>A!KRCJA8XN(FO\\X+T>,`-IZF*<#?A[BNVV`/<2=,C,FX!$10+2B%PDXS6M(_4&HZZD6O)@Z-C= M+FC7>Q75BZIF56EY<+*FDK_X?@;ZW])=\,_OIR??;[^S_#V[DA2BVF6I!"I M#$%D=:(GOS-F,9D.B;:,L,EI%M"4P',2"H:<>&7:$KT2)E4IWZ.G,4#4K;$, M]1;HLV!"$Y0\"D$FD)@(2MKU2X32S\]87!K#_"12Z9G9W$H^PDS"5>B(E M+4LD#3H/[AP=UZU$6\=649$["WHHN]S'PR(S@2,)"^*S<"E M%Y&1A3H@9-E!V:9A#&-R^E?SZ"([KT>..)@443PGN#4T.M^]?T@;]6,7QD:D5\;;#4V'()9 M,TLPNM+M,`%?GM+-\`N:.+&A1@DOH7D7(416(Y-@DYK;&HG8SFQ(GM6WO\%T MI#3$:A%G!IC5AVD.LDF\&=@=P`N$.N2?2<30FUITL=V(::1T;3=Q53NKR`,S M#'$\AN5":CEPF2/2F*9B3097K!8D=+L&>Q6?L"R4-R';-122-EO+O171B3H"\X MQFCQP).!:A,D!`45T`S-HS\_AF5=D)&XAS=F%6""F7J?C$OS#_;:O\2N!Z7H_J&`4@$C\!>6:-9,_+"#_B6L,#=I2R'!&U-T M\G2:LBAD@,_)4*GHD\7T4CL9Y84Q5=0-Q*OHX-&^RF%UN[P!@?+"RYV?(7N# MNI2WJ,LNO##;6N@'S&%?(KESQ`0W.M%8-`QH,U\F83M66)!RS\N"_?E4GS?M M_HQ[D-:D4C@NCL9]QT!.QDW:3GX=62`4?M MPR?YHZRJ,=B5X,G@(T47>)O4P;>9%2-B<%FA5&HFD_K*^V>=0C<"R7DSZY/V M&+CA)/"6]6K*BR%44Y5[NFD#X1Q\?Q,\0D4?2(X^&/:PH7+4-YE'F"G%"5QJ MHXU-+X\*^=!BH[>E8!^S!MD&1>V\B`,<';@32[?`BG]RYR`78KF4:,,X)$7? MSE&-`NGG\\.GHQJVIC97_:[(,F4[%-7*3VRI4@#/"R6V M8VK-H41%E`"/&WMH">"$$=U69*?!%@G$"`ZK4NW:&/FOBP-W0=*#X3/^[EZO M'K_A9J,5,M(=QV],L.?&FZ]VS)JIB"'UF1@/\0GA/B2X?J]@[82A%X8<50.M M5/_8I@VA6O_8"RC9Z?\XA:F47`QI'`R'%2/+P!3T%R@(,\Q1_`8$[#YL.?S$W`/AS<:JN(=MK- MK+AVEVG81K;-\^"X->K;W9%E2(8VM"1=LP$G715X9#"P1O"_GCSL`TZPNU`O MS*78"YSU!SC6WB$EV0)[S32Y,#&AT0F.M2$K-4U#IPF.EE-HGSK,`$=NX@YU MHE)K@&-FC,AX[M[,'YE=Q(;^)H(579/MR-WP!+ M7G(+!UC:LI6?U\EW?B4WTN+\2MEYG;"OSZ_D,<20%SIPB*%B;!_G66^(X=Z& MX_%"A?WADZE;;XC[_0_'X[7'R7JWS.?3'WC-QN-EJN!`'\W(=[B+,AN/FY2S M/GS2-8%FX^T(>,79>%2AH\AJP0MIT70\7IM$Q?X7O=0>:=MP/%Y[C*9^:X6@ MV>''X_'2)V`B&[J<=W4YCL?C!::%8%H%7^CPX_&XV8>@377;5.6BU7#X`7G< M="D.R'/>FIK<\(`\7L#B@#Q;SQL.AQR0QXW/<3"2)1<&0>YG0AX+F+Q\1("( M^,`5KPA#*FN#7ZH"@R4.BV:7 M<$,JN>DD\&+9[%P5*83+`\[**,V84O5K5,!D^;4 M&Y313'MS?*&F\9EYG-?/U*\0Y8:3YFGFRZ139K(P1)EQ0;F`8T9UF M&!M#=O=FP6`DE':%/AC]E=3&(;@ZZ8P1-U6BD;_]$S"I10DI:`GRV6/P)>W.4HB M@,78"P4;I8#)GM6PS>J^]>?3;@0\1;?M#KI6&?12C@3-7&7U\HFF+0%&!NBD M`V5+6RG>DT5#3Q=]B_)+`HZT9@[T#(%F:4V]`7%5!@B+Q3I)QO3>+[N3! M`\.5/LR^;(89[XP-NS(KF/V!/7)D10*7>23IPSYHDP&8WX8RZMFR,3*-08]A MPS'RO%`9O+U7;SDR8D&IL2%*%6]16YZZP4+)XBV&K$VS-D/;'_$PS#^7/A4E M)$,<;F9QZ<8='A0P8.<)E,=#;<%0"@^Q89'GAAH`\NW02Y#47(,>2T[;IFKO MOT%O;TUI+Z&AL9XTM6T]:3LP2L66-%8-JA3DB1`M:2788S];AO&VF0[3UW[))J3 MNJL[/QK/L[^C^W/M1W^Y4:JVF-,W\H/,Z59*9516J20B\?I5^("W#EREXD$*!7B=8DL(SP`O!]IA M@-!V[0#K.`5X.'(IS9HK)I?:&>#D@3-T!8:(%>3GL&Q,C MX(5H(.<@+P2)9T71])O>%0E09]61T-^L:H9YJ,5'@D5@S* M#N_Y5B'M;VZU0MI=R?C<"RP)>5HW^%HA;1X,+H'[QH^D5'(E3D($[GD()3QB M):X6$"%RS_]4#Q)=AB+>$18O(*3QR#T3`KJHD7O^1WJ0/C#EROB(`:3'5P:0 MEH+%\.#A:!U_@L_)4<1N0(<[/KJ_?GB(HN4_+R^?GIX^AN[DXW?_QV7_\[\_ M?$((;,61#8`CO2U=*G2_TZBA*SS!=>K]T_VYG'L3+_KB8B"^,_4>T:WT%[]^ MR,QN`]%PBT^.%3K#LS7A=(E*^!/V4:A:UZ=;GU89^N+I.W MB>&^S`%^M4Q[&-B[1^,@&L![8*Y9DV1=DA588_/MYD(7_(3T,E/29%QZFKGH MZC*S^-5E3+V]D))MWO:1LI2S]2X)2NJIO01](USPCDC:.!';B9WM>?+V,?SA ME)%:CI0J=U*>E-&Q$?2DC(Z$I&(I(X&PP_I%1<..4@X[&CB:S6`GUU4L%':4 M,=N&CL"\@YMF5$E.;\S^>'586/MH*8`+)2I%3S[4L=!4.(5T M>/2<\DO[BEV7H663T=D7:'E22$='T9-".A::BJ60!$`/A:U4147G&AC>L1P9 M&-ZQ-45,AA^-/5;QUEMO_OP-UD2)M?X=Y56>]S<7?5XL5U%(5VC[Y7AO@6V1 M$3,=X#_T])/O&J>481M'3"GUF"AE:>;Q4DHY!DKA%$8TX&Q#4'7_9?RW']RM MEVYX,QNXWY+CZ:)UIHLH1ZJ^'RQ]T/8N7IU>=$3$LE1#/Q9BN4'$3DUCMRS] M,%G_*$BERXZ@3N[.I/KS]E_^#S=8X'-NE_XB]`-W.@3L!,O`"]WP:+>;9EO- M&]&\:'B'1]VN@O5Q4H=#)\:K#,>V&2-M%%T4RU9<[Y2U3:VLLFTGX^BN!`AF_>%:>TB#CD9;8L MCO,2J:IYF:=(4@W.>6>\TB;R8$3B2`SO*A&)D_5=@V_>%:>TB3@8NSH2;;W7 MV-5)B==@J!,+M8UJ&/X\$MU>(?QY4NTUV.8],8KXM#EX(1!/F!7Q8%::ACDM MXFM3V%3`L.6F^HP;I5IA70MHQ!Z`4FTP@`2T0#A2ZE33U#YBB1L)$KRFB3^I MQ'7CVUK3Q)^&XGIG8M:8#(E3-]K)C*C*-^^*4]I$G%,WF@"[_9BT1(&A MVJPEVLM0QZ0^Q*V+;$][(W^JY=L;6^V>$R^::$KMMWFB-AL#N[A\OOP81RX MX0:ZJ?<#WBQ]*MYWO7H$:R+R4]T'/SR2EG(_Q>N!XAI<729?;FZ_W'X_+3MP M%_ZCMWAI8?9B+ZWY_.:KR\R[LXM>!GT#[YM@;%VI@+377GGK_4OX]=G=^&6) M>S\O?KAAA`K_V0ITW%KZ^PN+,4,"_O@_4$L#!!0````(`#-[`4/"5Q<*8`T` M`*BL```5`!P`=FEC;"TR,#$S,#8S,%]C86PN>&UL550)``,RMOI1,K;Z475X M"P`!!"4.```$.0$``.U=6V_C-A9^+]#_H'6!Q2ZPCIVDG>T$DQ:.D\P:R$P, MVVD'^S*@)=KFEB9=DDKB_OHE)5F2;5$WRZ%DS,M,+/%ROL-#\MQ(??CU=8FM M9\@XHN2Z=7[6;5F0V-1!9'[=>AJW>^/^8-#Z]9?OO_OPMW;;&HVL6TH(Q!BN MK2\VQ)`!`:T)>*6$+M=6'V#;Q4#(UJP'1/Z8`@[_9:E_'4L^^G(S>K`NSLXM M:R'$ZJK3>7EY.6/,V31Y9M-EQVJW-]W]YA-V9;T[NY"TQ=Z,J$N<*^O'V*,^ M@W['CB3IRKKHGE^VNS^WN^>3;O?JLGMU?OG?>&FZ6C,T7PCK'_8_9>'N3VU5 MPQJ=C-WB:+G"L!4\6S`XNVX](QM[G.^^N^RJ^C_<4MM= M0B(V_P/BW!&!Q'I`9I0M/>I;EFK_:338@B';`MB3(1$(9$<5Z^1JL7,HW2-9 M\^M82.%3?3S.[A&1HX4`'E*.5!=]##A',P2=8N3G;/,M`0P!@P4'H4##8@&% M:J5Z2`.YMBUA:<*#ZI63]2@1,[7&,+B`A*-G>""AV@8K)[T/^.(>TQ<^(`YB MT!:E:=YOZ6!B;Q&W,>4N@Q\AD5L5[CF.)W``EU],\K59(>UC0>T_;M0>JD94 M#J?7P]A=+@%;/\XF5`"<7.;N5?U94(RJ[/CH7*AT0(MT42$R;[+>`*SV]O$" M0M&S;:G>"!YR>O-@"-9@BF&/./()!.`ET M!ZTY/1%V4)8K;TCAF_&U9POT++5_*;D]SF$B-4]<6L!C-"=2*[4!$4^$3I6] MI\`-R,H5I9>6-Z&MZGUW0;$C;7$UUF)=_9Z;H_D*$?6XD,8]X+TY@[#ZA21O M\]6HXI^I@'Q"0Y,J5*CY(YL#@O[R.NM3PBE&CJ_0$&?((%>&L/H9L\>BRA&< M"7P5-U@.4C%^O"%=36/D4#9@%U9.#-!W;,;&]-!97.,>02R+2"6F20#1CA(: M5#[#%E19%A)'17/]IZJ_ZN+1?O^='0*.2%7.,+-'@:1!J:@)33!&0DW-?%=;@R:QF&$NZ3-5$^TGP/N@(3BAI@F)/O0HD.&O9 M22YK@NHA"]:0S"4^J:09BND*,K$>8D"4VTY-JI4:=KEN:$E/J6("PPC:$'G! M>;7:I4_(Y+)FJ.:"(5N%=`[0=8JV8@:IK!!?56AL)N-S4GS&ZW+.A M-IU1G?EB429)]DZK_-3MMJP7J$YD>+_EKQ5#5!H(Z^O61_"..[4\"8OI!'8/]]"F#SZ<<1Z)]/`;1&)8I0OF\:RIVM.@XVYYX8@3\_ M(?`Y7#D1\(L3`EY8)XK8<'E2;$A4:".P/S8';%ZS?VN_3C"O0_#G#1+X,N#3 M_6X1&QHD\&78D&A*1^A/?`8DE8K`-VBCUWO*MC:\(O''B`_=4^.#SE\=06Z0 MFI-/TO=#(A'8!AF?^P_W,*O7DJ\I=8\!6CI:/#!`1+-@[?L#4HB8\EYL#]7)_ M=9:((&EM278_P_`8>Z(;,ZM6,20:CD:^.=F/-U/\X=J/0V06KX2>!V0K<++U M$5T#+-8I0ZPM:V*,/P'BSJ2\N4RNMMYI$Z5,TIM)F>32AJ*AD&Y^2J?SZVLU,@":LK-MR_AF(6YDA"`GR@0YT`1ZV_7&N[MOADNTULYJ9.!/"U-O M;!P6YS-D:&LOQS.349-[!W1G=,G(L7W&-8&>M:.0N61!R0:]ZHZR:`FMJ M'I8-=V07K=_@7!M3@;Z@BK'1THXA[?0_U^GX15I MPLRY-2ES-O)&4OZ-87#96&])F0@N(M-@RU752.PI6FN\:;&5L!QF*^M"4/DJ MFSFKMRTP`Y(GFT6#LV1C]<"]R5[I+P";%X"X6Z]>:)+C?OGKU0--+*4T-Y)X M'4.&KUJBY5Q_1G+GNED_<2C7YR#7@,R#JUSULZE``S7"YX MR[+XDAKXYIC1GO`,;H@,[H^<4*F`_H[$8N&;`$I-#6^3C-\WJ0%4NCF3V">T M9TLE@<'=@T,9(/7U:H$F^4+^?(A2[M`WC$I[DBTO-'T#ADY8VQ`Z7-F%`\Y= M=5^G=[/K)NU5!RNSGFDTWE<)U$V/*J(JUH^S(O)8N)TZH(U]BF+O:%9.H*E- MU`-CX0E8H`4CY[6+[&^5[%Z:G,+?Y3!+[LRD#$P!<2A1V;$BX3:.K-)F_;,E M'#`[/NK<:F$CSWH/Q*!$PS!DT$6#)*BXY;MS%4"6QG'8(8-F M%?SG)KBW@6=#&5K/HT\GU8M@W(HPHT\PGP@E_*9K)I3S:<]PPK8 MO9ISSZ?-GR)V22//C%8L/_N^+'!]A(3#EZ-;=F"*+*#&:,"37",6CO6_2Z,O5X_L7>3\? ML5O>!/5WRQ6F:P@#;W=N>I%*J\?&>4\ M.N"J_-NQJS&JK'V4BVW[M?/&)GSOJG8TW@/$O`O? M/T&@?GM4A@K43FIPXB@0)P%GT)K3$V$']449Q(G64H[\E)T$ZI_491QC-"?> M51-$/!$ZY9!Y$=@!6;F"&P]/;-V!7CM!ZW$!,0:\-V<0UFDN?*8"\@D-KTX/ M+]K@CVP.2)"ITZ>$4XP<$&3Q#!GDLHSW,W;O>E0Y0CZ1I-U@E>]]PMB&L@$[ M-*?J@3$6%YO%PW:!*]*[>C1*,@D3^>HX7`="F?B)(C4"-'97*^S]"7`\8!D! MK>=`%*&[?ER/[=`JW6$JO'3YS:;N[QQ;6WL?,O79D`D#ZG"&OSO6?&4[%L;Z MC6:"WE7+$4G2OGR=J>:B5(CP^LF'.FJ&`KM#BCDE*BD*$K5-UYSQ^_JL*EMS MHB/-MA"A'SJ*@*GH/]!YP*'*W!^[^YUC4T+YVW/0-($ME,L[LN"EL:Q M;BG2)2DG[J\O*+P;TO]ZUCRT>?SX8W5:;0M:R;$O-=L/CT] M-1AS5BTV;.HUK7I])>WW$%?/>M_H2&BQ;X;4)T[/^BGVZ((!"@0[$E'/ZK3: MW7KKYWJK/6ZU>MU6K]W]7[PTG2^9^S@3UK_L'V7AUKNZJF$-&\-&C.(_K1$E M7);VYH@LK3[&UE#5XM80.+`%.(VH41S1M:1""3^KQ1@^3QAN4/;8E&*ZS57! MVO??66'AWC-WMRH\=5?%V\W/MSP8>JKN$"T3LK8JJL:2J[0\?/C2#;^.E M)0Y'K(O'8;UKAE^&I;G;XX',&VH'.M6@8Z664)_JJV)U]:C>[M2[[<8S=VJ_ M*($?&<4PA*D5(.Z)Y1S.:MSUYAAJT;,9@^E9;>':..BGUOMN2]7_X9+:O@=$ MK/Z/B'-%A"N6`S*ES`O0URS5_L-PL$5#MH5P,.)$-'J;JEA3J\7F2W$/9Q;%^%[RH/Y#O72YC2GW&7P"(O<8,`A?/ABHM>F0>PC0>VOYVK'53TJNS.0 M,/(]#['EW71,!<+)9:Z>U9\YAY%)P85KP6B'YA%AD%DP6<\15I;`:`8@^K8M MC2'!UYI>/;A'2S3!T">.?,)\<"(]\T,9FQ!M4!.WB'T%H>2,P/:95#OP_@*Y M6#VZIFR$Y#=K9*LOIN$7294/U8MY($?6DM%Y<;A`@ZQO*'D<`_,&9`%5VI#O/K#=Q=2O?)Y8B\0)P%WU)K3%VL! MAVKEB`B/IM>^+=R%M/[ER.US#HEH'KATET?N(Y%6J8V(>"!THKQ#16Y`YKXX M>&DY"C;3^^Z,8D=Z[JJOQ=+\GJO1O$%&?2X`2X^C_\@`S"\DNLV;,<5_HP+X MF*Y=JK5!S>_8(R+NGX&P"THXQ:X3&C3$N6?`E2.L/L;\L4WE#9TQ/(MS+#LI MGSZ.B.O4%'DO&[!S&R`91%IA'.Y,LX0@\`FEQ9H4,OX M@'PIC(JK::SV!6.#S0R8HE4V\N>RD2#6A^/NS0:]^6&42V:5%&!V@!P@N6AE MQ`S/`;F$B9`+X\96#:V.+8OU`IA`+ADSI$Y-0D.LP!VQ,'RGJEBS([)@E$4K M.<%],CX",V4433#)(PK]F`+G7#ZAE5*!V=EQB.BBU2$-"\^-8C!R.E(BY#P$ MHHS2`H=$3JF%;^$[GK$J6R!_?8%%4]^XS@72S182443,UF69FR,)UUWI!*&]K" M+"<9$$>E081/55/F$CE"\*38#WT>?T1H7E3&3=- MP(*OGM3#9,5VE!3W0_3X2Q\'C8.SB9$E)FR$DC&:`#ZKY:S<+('7E=R%Z!)@ M!$SV'"0#C/`'H>@AV/21N'_*10B82\/`H1PF,)`3@* MG!Y<,`EV`5'OW4;V0B)_O;IEL`J7R_7RM+2_)U) M/)>P`$SG2FDZLU>G9AF,5#*ZXV.XFYI97X,@48H.BI&UUMK&XNBS;?U)Q:\@ M14"&FH787'.=+7A$?U1\V:RV:9=+O.:IV:Y7.I2CH/+<.BNN(;;[JD3M&U MWE9:;K3:2LDS\3*$T\.9_2U!&W.H;P"J-(D;'HTRH*:,FBQQ,J4Y_[F:,^)[94C\Q MROD#88"PDOU)KI%R[/B>'R2T#4@L)R+)2377>!F^W\Y`7"/?YJ'9GZG5"^G' M5#7?R$\OZP>1I_H`AA1N\QHKG[@P4#E/0"3'@7_=JO-7#@/:JH< MSF,6Y",NM9FE5B@WQI9S9X@[ESD6I_*#4%JQMV,HXU1BRSI#?__O%+^6;[0AOW/Y;!//4P\R$1+/BK<:_V\XN._ M%ZLQ?XBK_&.^`M5B.G)V"H=%9I5U8'CJ%$Z8C$^V]+CC*1XZ:7JA.][D+`>T>$`5W/611,71[C"N7I'A@IKE*3R&Y661?0QL$SW!73-RCA5 M+64%A,VU7P'M).`-`.Z\-TREOA!;L@QVNO-E4#WXM5CF&4AAXMYT=["XDHZ; MUG3BB#(./M/+EXQ^_>=_76`J$7)YH](@]:AD52Z55_A>AP!,.W-?S*I1%0:= MW`PZ%6/0SZ48@_$P^<&70%7O'I2.'=D!&_.9T(KG&W,G&@[K$N2\]=J)RZOG4E M(@UUJIS=4;0?><#!=W6S08ZIK#3#YQ320XZI)[T,H^JFDAQU`NIFWI24>U(Q M=;TT?^O#FQ;WG3FME=4N/Q\T*SMV;\`PP]0WJ-W2;2Z]]-E*:*L:^;6YAY=& M1#=1>WIQH"HI1&\`%:F/:@R1',MUGF!?HE:2(NNGD!Y8B`8ZNQJH;LY?(1KH M[FI`+YFO>HE%AFZD*O<%!QH73)4&4/>^J",#/.(%3J^6V?HFIZ5`:W M_DTLE8&$O4$L#!!0````(`#-[`4.+_N?R3#X``!`! M`P`5`!P`=FEC;"TR,#$S,#8S,%]L86(N>&UL550)``,RMOI1,K;Z475X"P`! M!"4.```$.0$``-Q=Z6_C.);_/L#\#]S,8C`#Q(DE7W&A:P:N2JHWNZER(4D- M>K:Q*#`2;:M;ECRDG&/^^N6AVSHH62;5_:7*L<5WZ?T>'_EX_/#WUZT+GA$F MCN^]/S,NAF<`>99O.][Z_=FWA\'BX>/M[=G?__;'/_SP'X,!N+\'U[[G(==% M;^`G"[D(PP"!1_CJ>_[V#=S!)^02<.=XOSY!@LX!^]<&O@=^^G!_!\P+`X!- M$.S>75Z^O+Q<8&Q'U"XL?WL)!H.(TS^$3._`],*D8J5^N??WGOT.C%-??<0( M!O1I8%-IW@%S:(P&PZO!T'@<#M^-AN^,T?^FG_9W;]A9;P+P%^NO].'A9,!: M@/N+^XN4>G\&#[Y'Z-/;'?3>P,)UP3UK1<`](@@_(_LB).J&Z@)J3(^\/TMI M^/J$W0L?KR\IF]%E].#9'_\`Q,/O7HF3:?`RBAXW+G_Z?/=@;=`6#AR/!-"S M,@T9L:*FQGP^O^2_BJ>)\XYP*G>^Q:TD(2`H?8+]-8@>&["O!H8Y&!D7K\0^ M^QMC^`/V772/5H#+\"YXVZ'W9\39[EQT%GZWP6A5+(6+\25K?^FA-7V7-N,P M9QR,*>/PI_!K[F=G@#WY[?ZV5*%YAI9H="F$=-D?S$\S8J+7`'DVLB-!6?,* M(G<@$3?#(0[&Z&1 M_Q1^_7UA610)`47J5]]U+`>1Q1,),+2"B!O7\?V91(/+6'[6)*,!1L3?8PLU M,HEX/0VE^.X^L49;ES9AX0=Y@V\/9\"QWY\Y]G?#F(XGT]'WN7DUGUU]-[X; M9W]+:(&(&/@Y(O=_/P@YNE4MH'$)W9U>/[.=?@N<]3^(K4A.^K%&P?")2\NG MH687##*O<87]K90O1?Q]:9M0>0T>OL!='7H/65Z/S+N3-%VVBL.3$UP71"II$W8@]#5*$KI M#T@-'7`TFTU*8D^?8DP;K0K#28^P(P^3'B!BO]V[+,E?!AN$V9@-HPT-1LXS MNJ7CV2VZ\PGY@H+EBHY5RU]I(RIJ,=1$-%DW')OF*`97Q`!P#B##`@@>@#$! ME`M8KMB@7QOT3F8,,V\,GQO#RAC#X3PT([6-P^<@W-B*S;#][%@N1^QP.AIR MO+)OOB]LVV'3$-!=;%D0N4<6HBSM;SO?^^30KYU_\VF*Y>I'Y"$,W4?L0/<: M$6?MY3SB>'H=8]CVJ5%I).0,NQ96SI&-(?TTG'T?<4^.V0'(^0$<,@1[RA&L M4BR!OP)KP10$C"NP.=N+DZ"\*-HIMI"1LY#@!R*&@'$$:98LZH5,`><*!%NU M85"QEG0:2S``]3Z3?5H+<#,BR(^@S4.4,DIT MJ`)"6KKQV%ZQ?*>[HY0&CD?!5ZJ8>B05.EHQ;`XMH0LSNUXZX45.,\\F-75VD[!2BDZ MNY=?MOXU-\=1?2^1`CSZ():#3T&DIR3HC[QCCJ0!']X`DX<%@U@BD(BDOTJH MV[YFWKZ!SW+ZT+X>M:_+#$N_99]YI[]G!J5!R(\-"F,9WND-2:?#=3:>G>BE M=3.OLL8(<>&N'6+1M[?'B*4D'RB17PO'D)4-E,^,5$DCZ=JSR6P\#F<^8G+` MCNFIGLKH3"4CIU)"#_S,*`).4G$LZUA'$9%(@%P7$I#0U3=G(`.H9%*@UA!: M4AZ7$T?VPP9B](&MQF,3O<@C'(@WHF);UDG)-5:9EDA)).EVXZ%Y-0RA%=$% MG##@E$&:-`AI:TH7NM?;3(KZ)*`N.A!+-:VTSJA<9V5]>R,'SO36\C9KCTR" MK(NU_WQI(T>`DG[(8Y%^]7U!(X/-HL,G%ZYS+_GP=P6(.F`JFST:\W$T=1XU M!ZR]6F`<)[XI)_ZI?;S4,9@;%VO83::X]7'@_)OA@00+S_X$'?P/Z.[1-7H* M'N*)O)(A;BL2RK/)9O+))BJC>9Q?1@P`X\`G1!D/P)D`Q@4D;$X]W"S/0$]H M!J/`#`NM9JC)5$]H"[-KEU"3X+:+`TG*V\*B706PO1>$BX^^>3;"=X[%>O,X M"5]Z"VOCH&?QQ^HS':?3+,?+9[K'4M,0UEJ**NG.D^GD*HEPK-`;+?3<,V[` M%>P`C/BQO3TPX4E>0"L)HLL!/2>L+H MT7)+HF(^,L:C=$QE.P@3SH"R9I&AR1),C?FDFGQ% MF$^/"?7+9A\[H:URFK@+@647;!C3:52N3K%-#_4BQH!Q!BG6#'\1EZQW MU(Z$R:)UVKI+.&9FM3M[/UJB%"$H(&6N)WY4&23M-FSR; MRYS>OUDJN3)D9%P@X]J)9OI\LVY=5_8AY;[:^"R!\628]EG]"Y_:JR%2V8>' MF\<'_0YQ.8 MJS;]'NBKW:NEHG7^65U>WC3H38WQI,C;>Q+#C]%*Y/P9U]>[@K3*J4HQT),( MGY3=XH5GE2^NZ'GEF"@00CZGG8\SN$A766-J.J%QK'(<'HE6^I%1X6*'Z"C3 MOIMJQMYB(]M[&*2&O_^%7'L1?(6";>'4JT0SY56(>IEDM^I>SI,D$O*2QM/2S1;)]1MLGA,OZ@8H6*OO:N)Z)\STQ35VZ0V.OE#5J^0]TRL<`,+L/;6.X`=>F8]2MC!N,<"_3WF,TKNR:#U]PO]+>8I!6I[T%QM+2 M73]#QV4K%S_Y^`&Z^67=Z=7?'R!Q2NNZ3T,K'"-C(9ET`S8P+GF0+FFB`H-V>DXC&SN"`D9X#2F1`6%1) M]8G.=@<%S50SU7F/GCGUCU)3$_$^>BSVS/V_CXE$UMV_-4G_(0MP_Q,G]B0);[SO37"B_4: M\TMO[G@`.2;VGUX(W7W$R364QM]X9#3M2_B2UZ;]0["AXZ4-?$:T$T(>?SY< M.QLJRD]Z#%Z02Q_9R=^G9.RSKA5(=4")GNA?BVRPB48%A`B$L M6&(@Q`6QO$`(W.\^JV?OQ4EG'4=J;JGGO?9@426E:7<6H;:=QVN-`&.GEC+/A1"K::2UF=*IM>#`R M_A4%7-TD=IP7=+M]FN$H==6J*8UB8_4+>=G1/]AJ73SNF MX)@;#6M:/WT*Y:<).GNP>*ZAQ\KAL,`Z?89C?7V_.:$>0K1Y<7QFFL,68-6_ M-N"T%I'(T<6=`G0`ZN\#XMA\.8'.)/QX2+1!_E'K#$X=`_@$VGUJ^BR\3*JQ M3Y42ZD4,*)-.^M*Q^50J!HCIZOO,9'5T&5O?HD`G-N%1X#Y;,>%34%%!A,4$ MPB?(JD)%/Z-!'3CDHD&EG4\\(9V;'^='8'0RR=R$<'\FCAM(W:08,VHS&2Q3 M5V1X^EU4%16\`NGHG)_&_8U,S)[,FD>06GUN/AH5M47CL@F(O\KE:,:6WN<[C&R8K0T>:(4C=^)1BV;?\KEL; MB>E4Q\O?,[C(Y04WAO'ED$T;:`HA7L MS=HJ#!]2`DEOD3"OPARC[(Y)PA9TQ_LG3K>J6X#OQK.KPD+WNH]CW=F)V?RF MJ?0!8#``B'Y/DU\AWPE5?P@@#M0J/ZE5_@G14.;QR:Z3FJ"V0^A>>;-2>9T1 MNU&X2L=F>2/U)PI_Y4YUZUDT627H&HG_&WE!"0GM,;E8+FDGG0Z'=:%9<``1 M"Q#QT%-2.YD5>%F-W;KH1(KRVTA_,]"M]O%Z!%>8L.]`KCDCJ16IG@*[X5E$ M(R/>I=,>7Z+T2WQ0$Y.V8F)B3&I'9,E'$%%\.!L^Q0?3F"HL%27,4?_(D(S<-1' MA@:&[*06Q\CGAQ6>G:Q#3&:!!.?*JW_;$U-=<$@ MG"*[>#9RQUDJ+H$ILD@2_@ZGHZA!4@M@4[/9@J/N.XD56G$(Y;Q#EBAN.AX7*8"OON=OWR[`-W8Y=^`#^C9=9`7B)I3P M`.4=.V9"W(;"OG8=^.2XHD/^B[T7-5$GV:;&UM&%7[''/58<=%,#>^O-HC([ MJW"/VU]5YS='OV81[4(R@-,!(2$=V4[AJI:J$P"RL60G<^;3H=1$I`0$U,6:7*:,H". M]#/S^O'21)U^RKK_>O?+=/\U1ND9@I*CONO*#8UH]`-EAX+)^N5P.#8D<)%D=BC$9TL[]`"UY2XOB>,2<_86V64SBBV)]`W;#6>!YN9H'IW&*0]N M;1-C"DQ1C^_>([EPTNL(T^G"LN\]L)LTOT*\Q`\!&[;RA4?1+9`5OE'74C%J M:\21KV>G^V$Z5.94^2FY2PP$X?`&F?@:5GWX[%+I@]M5S_4>E-O"2_,8E#&/ M9N!Q0(8+T"HK9=%0.'$&K)Z!IH5@Y8)Q2 MS;2!)>MIE4!)F:(7(%GN`Q+0=)LFI+)O,]U$)UQ24Q@ZQU=#(U7J!49DGET!0\UXD?[O#:(,\ M0NUVZUG^%GU!P7+U"%_+?:>TA5HPEHDAZ\VCT3A)^A)B0%!C9_JP]3F4H*9= M1!UIF+[F/*.GJ^DDB`:^E\-,I3VZ68KC>[P&L/#L'S'T@GOTC+SB6[W*'E6^ M(*=8#DD?F4^'D_"`F[`A0!![-!#;XG`WMC@E/!`@LX!FAWUVM(VX^HDM9B$( M4WG8>ESL/SLVI;#W;'XX,P*T1]J*8Z)X*9B)>\Y7W2"7H)<-PI6K;C[#-[;& MQ]W;"*S]9X0]9I"8$CD'6^CM5_2C$#GU`^LKH/VKL?'D7X78.$2GS)(1,!U=N+V\7QO@%&T]HCLMTQ]&O31&X`O M$-LA=P]059S@C?UAL351K/.C0H7FL,!NCW<^X2ND8L-2"ZW9JP9PC1'2<0)0 M%TX7AM[PE;"*#2<%0EHZ%@EUH)69T8KYGWA5N%PK-4N%JB-;LEJHP@9Z,A3J M_^RZN>RQB]7KABO;*,U2*@21'85>74W,""PAN8/32#6O'NY,33.KYI/OV?VX M]U?*#;/I2IU-NDE8Q&%6-"7*WI.S]`KO-+Q'EK_V"HHA1Q)3GO2TE53ZSDMS M,C7"IJ#L>M2$I8X^7HUYS&K/ MT;@#Z=B`D60*1UFR?2Y!079!AP&7-G)$&D$_Y+,'^M7W\*:$3PZQH/M/FJW? M>/8U%2GG%96/*L@5JOC+]IV40[2R.-R-($@!1@OY/"I(]F^)?.P%K2D)9!VHG%T=T0*)V*"N"<]2FNM M\M#0-H$IYUC%N#C07@\B=AA9#I_.H)]=Q#XL/#N\F[[J,&^IIDK14B^/K)?- M9W,CPDY"%<1D>5$@35@7E#I6V3Q0F=>I:A15AS)Y9\UB3M),6A`8[PU9KE@E M&7F$"W0O*H$??1(0OAKJ"1)D?X5O8H=)]3;*(XFJ1.U1DLHOSS:BG#'9;;5< M@31'$+($G"=(F(*(J_;-EPJ-9>:,Y5<9ZUQ8:]#(7,JB1B<`R\23XU]#KR/- MA[38==LZCZ7:QUA3+*KTXEQC.FT3;,"'''RT[P95:3`>I2;!/A9*^N,LS1.#PH M*B(+X@\L5Q8DY-?2&U M&\7,-HJIJ*36.EE42JVV@VHTL%JN'!:2)[4@(68OZR[&?#8NQ@&OO/<"!>V4 M*L1`M5+J$7#@6,7^G[6`.N__&MU15K*CHF'V\@9K<4DN@8G@^0.!8=15P[[CXH/<"CKI7"R<,:463]ALUV M":>/""9'2@%.DP^C0ZIZIOVZ5)5#1.C%AL:V(`$\%(CKZ'=4>5)VGI:J*3Y) MYTQ/X=6;=*FMFE+5Z4IN2]LH,Q*0,HQ-D#V+'?E("2Q?)%BZ7@'Y:KI*M.V(< MQBMG=XZ';@.T+3NWOVLN&@#BR"##GT?&-,0)""3*5ZTR!.Y&"U;X3.:)1 MOBA\_\QD`5P875VP1I.:Y28-U]*DA3A/V]1O;U/5P:EC-!>%LBY?7F\#WQ?? M>T:$1NP%.Z:#\)-STK\S7;[XP3]1D-?RDX_#K]ASQC%(Z$Z(OH7-SC23'A]/ MHHTL\E$U%A((*8$X/RGS#!.4/A@`*FI!D*#2@I2XP.AQW-7S3GA8_A89FA\E M%X9C*(R.7MF!;N*@G">4VE%_#EZ0L][0GP;P&6&XCH[>Z7T<[CRX-`[3W;[K MWU44Y\OBECM^)YQJ.&5X_QYB=EHAR;`P'DY&2D.U.(@S%/)W%I];VS\,RTFT MS0S#Z1\D\M?TY1(;20N7Q1,9ZT%DL(0SJ`$P*4DOKBZ/$*F4T54E$PK72FJ'):KKLR M;Y<_REVRD5H<='#6N3DBZIK$+X2![PWL!(JH#UR7$1 M_DASA;6/RSN1[%-*H9-A+1]O)Y,,5C@5$)'1!8WVNIB-=%'G^87NDW7U0Z55 M^?8]6CML*;X7?(';HA5BA8\I]>XL;WF7&&7SHX0,8'1T^?<1VIC-M%'GX<5. ME'7Q`KVUS+O\:T^%J=D2GWM(Y4Q&AK-T@6@4SP[S]MHWGQ^AABFMAK(!>:'+ M9$;.A^IVLN7RA@3.-KZ5<+GBN1`?DHO1-S_;NO@47-FFJC=:2LHE>T[IU=4X M.OD_IBSN;V%5S\/I^'-QD+GR\VQ/HK:155M<.KI&]#5LJCR) MYF;S%ZYM+V5#$,?;*)L8KI-H\PDZF/-:V+_L";^=F"T/;'4(=VM:JN-16T%E M]__^?W=7]]RXC>3_%3Q<59(J)RM1W_OFL2=9WTU&OK'G4EMYN*(ER.:>3&I) MRC/:O_[P28(?($&*0L/[DMACLM'=[%\#:#2ZO=EJ)!P4'4J8JI\-QC.;72S! M;4Z^N[I&V#KN@=7/Z[\S%,::-PR+C2D].JX#&H1U6_CG>M;-JNP!Y@8'>H_OJ7+IO M/I?E6`;V8XP=!VYH`JN65T4\OK[ZM`'G#MWXR0NBH>DW?\_]V^]^_'\X9=I2 M]M%L11>%SS\_XO@5W;'\+EY5,OL*?HKR;_9OX0,;+Y9>Z$,ZX!5KF&?@^:?I;6_=F M%U::ES?X9JWE:/=B'N)"NRA6&Q.+#L:L@7!6&L)/TSAX.G+?ED;L^0U7*GFL MW+=.(\9WZ/4HKQ@59_)T]M@6H-#0[G!G?7\TL[ M[-V^AM$3[>Q-K>,N/!Q9;G*X(0Z=G0M\.+'7;_;$`&ZC5R+4>9#H/IQ[OK"S M#,;;L(5L!-S-1:H,(<81*K*$/IPX'<2X0G]ROMQ8"\*HF3E54YTXYL)Z8[:' M9^OW%=ZOP^NXPSU[E'?GWCIOP);>5!NC.\^K.;>MM:K2\I[V>I,&;S0UC"X* MR_HM[%+1UX2J^2%X#H-=L*&)DE5E@U[TNA"6A_=_#NUB55=\_3UHW9U6GH=P M164FC*,ZJ]F\XE3*JQQ*$-HQG"5@=9&B%@:V MJ\%AFZ9`09DW]&GKS-?X"@0`:_@P;A2W'"TKL%/H@5]9&$S(\A&SN9#6,=9@ MBK7(TJD&%$]\(<\`/OX=OS[AN.T+U[P!@:8J&Z9N?+:85!>&G)R8LL;H3TX2 M&DUG"LG`9"*2=>SHS:X6.AH]N((0XW4TJN6LFBI:0([G('+Z"*D@ MIUDD2.1XW9#C.8B<26?D3-Q`SJ2;4:V6DQ;D3!Q$3A\A%>0TBP2)G$DWY$Q< M08Z2<,G9R]>4QJ<21C0@T&7"F*DI3E?3105OR@`2>TK?8(>."@;71%/BKA/8 M[&+8M6@U5IDK^$VJ81:S[`DC&L#XU3)F'`N8K*H!#W6`^HBC(UD+@VNBC%\S MB2%1W&K>;2AN5IPK*/XC2%\JYW])\0"P>%K(3CEDZM>=R,:["]?I"XYI*<@8 MO^`P"=X(J4WTBDV22*WS`^Q=K`AIG'^9-6C1K#0HMW6'Y^54A7)R`S_4R])8 MD62;YKDRQE&!<\19=R'EU>E/I:3*TOQ7);F5Y[1>(?R=#LJR6OWO*'@]^)OT MJI`X&S'U;PKJ#Q@[KKEAJ_ZIS:7;,X9W/CTP,I='&1_F?3IS1L:XJ/5TNKJ@ MC];>ZSE;F0?9\]:2W^VNU2GO.DF>W&":0O:?QQ"CR>@*491<4":+@J"[D_G/M0WAU.?FLPP=_C]>[^S@B!IB>[LFW M3>GUP,.KOB6AX>9>&GF?1D>DBHX-$.':3@]'(H;A+;%N:[F;&*Y`Y*&Z2.&AU/]$M\ MC&JK&)6^KNE;MFNCM;-D6K5O,I_,1[P*&K,TI?6&INZ9Y6)G0XN:NQ39Z_0Q MTA4R`ZA>-K2X7HG<[!=(@D[0 M9@99F)D--.,@MAHS/LS>=0=G75.+)IXIVH#308:7NP5\3N2*=#+=#E@$SA_A MT=$'LE9E&_&6Q'G=TQ91IV'!U-X6RYE81(I#D8P2>*+\$))Y/22SA:`64U,Q MTZ0*!U#R2;2R;KCMU?0&'%I4-HSM:C2>:1`CR8%>Y!I*Q'KH&(@(A)\Z(VS` M4$4O#N&H,;NI^1UX+'7+V1FO1N-6-(&F*@TG9ANB',A/,C)(`U0!YQ\1KF+L M)_@6\__?A=>;370,T^3>/]$#%;KZW&SB(U8+[ND-H`\QNTCLP:&I[<`)A@QM3@EN/QP@1@@JPKL^(Y MTGHE=&D%@P=8R2+-`*;JQ`V`K0\X9M5D;_Q#D/K[]C"E*0%0R.FX,K[`E279 MU&(O(X\$?1="G)=0`0,DKZ*;L"3L3'`_[ZVSS]=F?W4+K&W6W8S:1@VZ`=\O M>(,#EMAGOOA4WP$%J<*(\6V"N3=MP*5"T9WU9F\QIZ*5GGR;@8U?@^#H/<=;! MXD@F5O(C^?6)#,>N5DAJOX@;D5)"?E.,L^8_/\=LKD3^*PWHT9?XS!6JS9!D M.)/@*TK1@6SX@NB8[$]$WA0_1S&](GA%"/HI8RH(=S%1`E@8 M'I,C68C3%AM^>HRQY73'%)U$F/P""FL4/&9-X( MK\)NN+W!<>H'X6/LTX4=7^J95ZFZV'`P#F)0&ZB)`UOBUX3]- M?R](-C6_/$=O?^$;'NX#^<]E[\?_597C8?."MT>R=ZU?LAB\8,$#M7-A&G&? MC*;CJ@^1U,`6(`,+6%YPF`IX:+T\F4!U0X+1I%V#!J(E;"VI[+$`/^)]W_TTZ:W_#^ M#=,@1?K"@B.LM2:+%:3\7_QK!OA+!$QQN62CE^OA\3!@U\@T7EN,/`VE[K&A[O4.<&E+( M`80>!A*-9]=EX:A]R:2NT+992BOQAU:L9]&'9JU`;%N4'#VRO'A(R>+A)=IO MR;?EJP_-FK+U-8O;B#9>C`_P%@MQQ5=M$4]7^2I-L1&X#*1HM;6FI?R@HL[S M`F]*-@"+(B0*Y1]8#+M>8EMK\N MX[(IIM=):\`XO>$+T?;O+Q^$P9X8W706F'KR]I6*,D$$?(+K(XPRI<(Q_/$:U"!#07M-WD MFK'BTHSQF8C;%38U[\`@I\J(<:S?DVU/5?#D]%S"SYE2\@5:%#[_S*).#H)( M;X,:'&DT,DQ`--C0M"&RU/L2G?Q]>JJ_'M3\K/5PJ(81T[)U\^5B-1;14$Y* M7I!AB6!XB[8$LH"EJQ>KRAME]"@*/G<2;!E">VTP!U+O97):'[($W`.?BSZ MU%,:)$-'AQ/[VQ5*\>8E MC/;1\^F*9H"]^N%Q1^R,:^$01QN<$`:$MC-EE3/Q?*JL#?URSRR1+$E9-<`\ M;XT6&$TX/;Q-Z".2U#,K0$2??CKQF/%+$&^%&H^)_!B9>O;\NVVS6J6V8\2# MF.!8-4&ZCY8:!KF(-J!@GBH8#5W%1=.!"PJW^+L$MRD!YA5C&3H`<>$19PT MW^34/V]U]:)APO@R_V(\K\)$$H.]L#F,<)ZXFA(]A[R-1W%&@EVTM)A<<<'2 MI`T0Q)!5X"-9!"HGR[HO6?.D3914ASI6X+B6Q_7GKR_8&9DS/GT?+\7PEEN[4X,L&8GL9.)A( M>@P#YBH.+&..:Q,_96<]:`"H?$W8I@F(6>YW_Q]1_$A&2=8[71:VO@2DZ=L6 M9T-#EDP#J\NY)PXM&6'$*-.$G,8+"G"E(B\AOE<6/]HUWTV`+B/9T:C5^;>+ M_AS%:V.I2?/WW<)LI]J,WG(I[^]U0"UH2R MQLN)1$C-C4H'[IP.)R;#SL/QE=WE(6O2[++HS[LH_IEUT*Q5`BRD#"RTB*XV M=0VT`*7X34]_QWZ\WBF-YF2\J;EW9)?7[2]+C7DS/6!>>O/%0BY1.75T(N2I M%1::#NZS^#!88\F+B3\NB$_)T[UQH<5D'DL&;39Y,15X!1706V@U!T:`"]O. MF%;6N-U4-I`3^AZ\'E]9M^KU[B9Z?8U"EOU_ER1'Z@*_AEL<7S_'&-=TC.Y% MPKXSZL2?Z5[+FTS&TA^Q`?)281LV!K^WA0(Q"CK289`OQ['NDRZGA;&J!38" MN_G*M<`&07(4Q(9!V3@@KNERFO#ZVP.@S^KE`A2_U5V?(#L56G*/K^U^);I/ M&CMZ:AZVN3>IYH6D5`X.,S3F_\Y.4^CMZ"+=Y^.'U-\/8N_#4(_7!#PVYD0?+6U)RI`P&+ M.#+GRKPI\TQL^&DA7TH<2>KHPPE1^K1N538"RH>`N<=W(17,I0I8;=4?CU3N M(/R)1M*X,IY.:)DVBENN0O4@Y"2J.]_WGH]&/=$- M?I_JPEKA]Q2I1G;[Z%O";W_4(1STSE5_!/2#.OA%1PVK/%WMC(F[C@`\Q&NX M,IVU5M[*,X!V-H*K$_>Y*BA.W.ITG4_B0:8$IR?N!B,W0+-.D6ZCN-_$W43( M251WGJ*FWJPGNEV=N(?22NW$78=P%R=N`P3T@[JK$W?6-:OOQ%U'`![B-5R9 MYT1.3";NO*F8M0%^=:H#PBWO4_$I2AJ@J3QC M%WWYP.;MTB;S'&"B30HE`#8=]I3!DS+L+\:\`?9[,C]O8]XB@JL&7@)I2488 M''X3[C+.Y9EXVHWY#^1"H M.`;BY.7_X%/9+JH/>2>?-8W2J`06EOWLO8C<'@H$`3=A3<[YW-=\Y+W.VK:_ MK>_9A&\;,Z;VN9C*9DLJ23E3"Z+PV]A!Q65P+'3(^U&TN_L)=I]J:ID%W!FI M9I"HZ\WM7<6WZ(]MM;EC5^S^I;U>7'='G==BY7!]Y,TPIGR]5*))9R MZKJDP@0E9(B:&F&6,[DNIH.QHH/U#M57):!#(#X&XH,`I'!=3`5>?S,`R]_J M`?IXH2M'G M?)F"&P2R-6MKS4B=I>ME=\+J6Y:]^N25W6K:`!?W0XCG5>43D(# M=$7;:FR-&`$_1UD7%]8-4=FZ)R'PT3U`.,TJ8^2V<_$XK?%4T5.>.:\,E8@3 M23%A1*$;$T5S"%0G.P@`XF<_#/[%='=#U!?M@RW[A5V5QXG<4JUW(G_)WS_0 M(KULH=0CT]U5-C;*!X>?X:RKSBNK M[JJD.[^LNZB7[JPYCR&16'`W@WV:=^>@S/MP#S[,>W%;YS2$7LZ6PWDPIWIM M@ZJ4>;;?6'W[_;OU2(:=LR^B:!`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`G>$O]!W$>=;=]SB9G%X&]>#0.6DSDW3\Y$A)#H<>( M18R5T?C^BHZ'V(!('1%J:V5'0U-%172?\TW12NI_)Y#?$=V$9(F3X#3=8_D< M$3J-@PW5)R_1?`P#V".N=+S90G\!/2"*,JIBL-F:(0/)*^`0<6+03-9WKH.<<7\C$-B=+S>''N'UQ4]X MX]':**%32&PRW48T:M7E!"+O8WHC)CW=D^\F6Z(>:MJP]"``B4TM5\91FMEX MJ@>H)(\8_:QI\&'X=B-GX'0@'53!>I#2T^TM;I(;#*VM9MT(V6;-@>"6!L!8 MKC.+BMU'9#N!4\(JY8IF0)-_P*^'?<0D^8!#O`M2RGYBG&(\Z!`VL3\@W\;( MF,I(N1B=N0`>-2\RP*\U%%A`@@?F/!)W4I[!%,EC9H0Z.S$,0GZX^R2TY/.P M$ZA[N0#Z"@YH:,V#N"A""Q,6MJPQT[T?KV-V`6/+NC;=8QX#T-F>VG1E]^\I+8``LHC7"*1`*Q\DB(JVUP8@12>N@&=]3)/4#^EY48>/J[X%#".%%5.O/1]/ MO48L*33=`51?01M1%35+"@FM&LMLPU=91?`@8TM2HX_,GP0#$QO>^#AA-)O5 M`^A_=-L*VYCI+D\]3OYC],MHG.^8KM#L:C0:55=W5RB,0BQF*9Y0[2*T"O:H MAU.N/1@(11N,MPG-LV:=IHF0A?;36@MH>\\JO%J8,37.Y6J5K?PX27[K0A(M M-V2'0M^0XF:]/@Y29-[72HI$]W3B]P-?&@ MK]WK8&VN1A=@OM[I[X,;VDPC"4!P-_%E/"DMQV,MK@F4&VM!N`'IP=3@%=3` MYF7U"J+SR#8Q]290MRK2#3QWSC#J0`$4S6?GUZQ&4_TD3@YI#)H6%0F/.+L. M=A.%[,;H`X[)DY6-7->W;7>$,V?-L!/8>#1=+2>\(5Q.',6<.OD_OWF91F@C M!B!;&#Z"Y49PEQ)]7!)=4%GQYL.9OW7&=]7[KJ#^8 MV3G!1!,O9+5P2WC<1VR](/H.:2>4IG>LSM8-C)C7A!HM)"`Y.;;&50C*_EA0 MT_=00GH%(>D60_H_N@M_\/;WB M=IW>^'%\"L+GIH2@KE3L(K,+:\8EZ.?R0E<^`**D&5C9#\H@Z)KL:,4PD)E& MEU2&5U+&AI`&!FL?RRX!M[.Z8$"<^D&(MQ_]."3,)-=Y"V:AX2_1R=^GI_MH'VQ.NJ9OP]"T'Z\ZCV'3?O;>>+)8 MR"B6#&!D8U8C&.B9#LN6@C$?&!W8R-:#6C;U,U;UHXQ9#7`A-BQ;<8B!$1\9 ML,\=@,*8YZLHYTIHQU>T(_@"C(P-XVV4>-D`BH99LI09;W:LYN]97;"T,&/< M.L;+S\&JN`?']&7D]33RPBY8#,VRN%XQ40L@RG2)D-F?[6/&O`#8>%R$!E!; M^5Y\LZXNCY2T/+$!/O@MFD.-$4.>JW`&6BI<5QX#L-VNG<&(PYL4;1B\?/59 MHJB>&[8SFAQ>Q MH<2@R]8,(IS8?.17NJ[0X?A$IG\4[7:8=6,X4.*0*&DS/!4MC4H!0O,U[8)J-X#"< MNVN@*Y3U&G`)Q07S[HK@7(FPZ/W(BM9B+$XOZKO`7.\9+^2G]2Y/&.8]VVZB M)#5$^I!C@7B%`04PQ<]L/O*J'D0R(L_>M+V>4,X-?4]):!>]'AE'KO@<*/U6 M_%.]?G]^JNCW2E5PU$O!]EW:!3!?[_Z&_I[_%J[2.%0R]'COV65VC!Q,QLOQ MW(;;="<*`ZGHWQX*SPF1M5N5A_5^7=.D.S`,XE/M(@67DY)]??_'C+ M8$=^ M._"Q^#W"_"Q#+05I.>?.@D[&N4ZXSV4C(3$4$F/QJZ5YE4*X&KNV]"+:J\1R M%:EZ3F8V268WK/**8B29];`JHV!Y=F?YCRRYKK^J05:&75H8PS[FVPL8+H/.ED@?*E06*>ME;>.<#_3LO+L&!";J(,6[_ZUAS7]:#A4[0 MZQV]X//K/OK6EH74^(I-%#7P89S&L)C)S8FDQBKSTCMLC"!XLM)@4GI%*:,. M4EI#D8$Q%K#4IAM@1/T:A'ZX"?S]?92PW%AS9.E?A4&8EA_CM.?Y:E*#M(PN MDH1=0MPP4E>1UUEJ``2V&J\&B MW;A'^WPI3R84&H@3@4D9/U,8)7D\42C]P,KMUSK6P<&":&40^KRR?Q`AH;GJ[S36#Q<$YXW.4XML@V>RCY!BW MI]D:OP\**0U3IA:X&'L+/<(H<913=^&,YB(*J(&@?NJ%0V"+`3<#LDE/8/CD MG?ENC_2F`3^4X1W%/N-O[$_:;%:SEVTCLY4CX_W^.KSWXY3L`#]^Q_$F2/!Z]S4DKN1;'%!S6+_AV-_OHY3M%P_:@\&!A[!^ ML#DL_Z9E(<:CZ=031Y[,SD5SNRT'_XV(BI$WR*!\("T8H3HX**RA2>1%A M=]OGH9"J-/2CZQ`)/I!DA,:W5%90@1?$F8$X1H54)W?.4<4="S,UL,@?:DT2 M[KSU,JXP/XF]P-=R:,7&JL?U7+"5WH5?KQ49,JZ:/QNWNQE&VM75VAER:YI& M.KPM6?&=B%A$Y8=^#*^ M`>?)3JXJ=23((T9?B7(XD8IZ*34PL*Y9*X^B_/(Z+"A<>]AU`;5=M08!WHR# MEAA^]3F+,*P,;IS"[,DK-CF&P`/UYTGC=9+&%E:T9J0"HE[P_E:?X,TOS]'; M7[8XX`9/?BC;.?FG_WV,?9I-^'!Z?8K*'Z7Z=PMV71G4U&F.5S(^+EY'_'V[ MAGP>^YX9^Y>V7*UA4(NMEW"02-?7,,;^GJ;]_^8'X:4#X.R@9"RDB(#E4HG`#:GN;BBF&0S\?X.RH7Q!H_$89'-Z\D8\]H7K");QX5QP;+E8I3C5U)S":*#2,CGWE\>?D$I M)^<.VMH,KXBI1FU`(./0/$]J)(*HE9,-W?+Z6C. MM_2,%CV3HV?QOB2'#IR>Y1W\0(*-<\$(,58,+A-,T`/8H0\DG)<)][/NJX%M MOML1E>VV6[3!(24$^43>)+^3W\@/],(^^>7_`5!+`P04````"``S>P%#8#Q& M=-,<````L``00E#@``!#D!``#M76UOXSB2_K[`_@=?%CC<`9?7WIW;:4SOPGGK M"2X=!XFS,W-?&HI$VYJ6*1\IN>/Y]4=2LB7;)$5*E"DS_C*3EOE2]9`L5A6+ MQ9_^^3:->G.`XMA/%WT'A'``"9>0IKKW8?PVZN'P7_U MZ'^#'OGTZ^73?>_BY+S7FR3)[./IZ??OWT\0"I9MGOCQ]+1W?+SL[U\991][ M/YQ<$.)*OSS%*0P^]OY:^G2%0-9Q0&CZV+LX._]P?/;WX[/SX=G9QP]G'\\_ M_&^Y=#Q;H'`\27K_X?\G*7SVMV-:H_=T\G128O+?>\\QQ*3T=.;!1:\?1;TG M6@OWG@BK:`Z"D[S1*&>W1R"%^--1B<.W5Q2=Q&A\2KKY<+HL>/3G/_6RPA_? M<+A6X?N'9?'STU^_W#_[$S#UCD.($P_Z:Q5I8[RJYS_^^.,I^S4KC<./F+5R M'_L,)04">\(2]%_'RV+']-/Q^<7QA_.3-QP<_8-V^!.*(_`$1CU&P\=D,0.? MCG`XG47@*/\V06#TZ6@>^A%#_NR'#V>T_E^N8S^=DEFT_+\'@QN8A,GB#HYB M-&74'_5H^R]/=VMLD+:\B,VA))^1I[38J5*+ITWI?B(UOSZ3R0]H'X/1;0C) M:(5>]!CCD'9Q%7D8AZ,0!'KD*[:Y2P8>/00T!T&CX60"$MJ*>9;NB'";@MJ$ MY]6-DS4@'",J8Q"8`(C#.6A(J+!!XZ1?>7AR&\7?\1T,0@3\I#;-VRTU)O8Z MQ'X4XQ2!SP"2O2KJ!P&;<%Y47YBHM6F0]NF@Q M&`WCQ(OX96[>Z)^:T\ADQZVC8'1`=;HPR!E;K)=>1/?VYPD`2=_WB7J3X!72 MRP^/WL)[C4`?!N0+2D&0XXSKA?7I2"+\"C_V:]KN85W1!O_B\-YP1>\IT["C#@T)VW%O2350=U M4=DAA3O#M>\GX9QH_V3F]C$&7&I>,#&!G\,Q)%JI[\'D!<:OU-ZCS-W!69K4 M%BT[HA>8,<]7%"C'L/]\<(`/."1+5Y,ZKX0YP` M/(Q7)M5*H<8#-/9@^`?K["J&.(["(%-H8%!VU)3LL:)RP^`?E(&O"UE1,+]+4-;$D/'94U[B<0D2)$"<=$,DX\!)A.3C105LOXA&Q* M1L=A&M)]P=AD,T-,VY`]IS/2"//U167SIJ#>_#32ZK-+`)B=(#5Z;AN,DN)Y M!Z_!:T($8Z&K9EK'FL9Z!5#BA7"(/'H2DBEB+>Z(K=&WK\":G9$M4]DVR!SS MR?@,E/;1-H,\BRBS8UI<PG&M"PQBLI#&!`CW.S MK[1#(GN#':!WBO%-V3(^!?S*.YZWD3=>-A=YKR#Z=+3]^VGK]%REB![^WI+1\*+?@(=N8'!- M1HM#FK"H'I7;$Y-^^;HY/'W.\/1?<8(\>MRY1IQ^_?9Q79*1H?4(4!@'M^0; MY@`K+KMK.NFHJE%9E-P=C1DRX@G*+[<[^H:D60E9[.?VJ M_@?CBZ.>BDF3,:S[%AC/V':T'\* MG"X../&FT\:>5^#UX8`7#Z\M/:9`[*\'Q,2(K6FH!69_.V!6QFQC'RMP^N&` M4QDGOC92P/7?![BVX=I2V0N\_G[`JXR7V&E10/;C`;+M*;9ANZS0(DKJ`:WM M!2FU40OPVE;Q?SK=](BVZ2=5O/E2VV8<>?B5H9'BX['GS3+#$40)7G[9M"#S MSU^%8='WH?<:1NPD,1<-&S9FG1;J6\6-.$RG*0OJ$-TFN8\Q?@!D<(;>FYA+ MK5:L<+H*SWOTPN`.7GFS,/$V?0-5I:U0SHZF181F/]JC2^`B%Q2R1V?%.ETK M8YU*)5`WRUJA>O.ZQ"K"H@+ORGHVN*&1[O10>#W@O9]<>0@MR!ZE?D_V'R$$-?NABD5>SR,`
L@^#JFBQ20D43ANWOPHI?KSYS@.OH>1:,-7JFJ#IY*B2-;B M=O2&@)_*:EWDI6+;4ZYNF3?Y>NF(YK]-ACKZ7=`\2N04TE*=!4X=*UQLAV2* M:.>4M$$Q,_!R&5FUL?'+VJ#Z<>DLJ50B>"7M4!S/`$H6CY&7N9*(B)O182<[ MDY!T214;/#P!'X3LQB+=3^5BD5_6#M5$((0^O>?2P![0;<4.IS0"'@0W'H*$ M$%SRXQ"M+O1#\6!55K3!C\R36+$U*%6UPY.BQM<1'4];JU/1XW;HRI=[MZB_ MOL)CLW+37[@585(3F#(@=4)(:/J9?0>$J^45L+@5)Z(.BUS%*?!Q*R9$'1\U M=T:!DULQ(>HX"4R2`ABWHC]T!7$9B3IQ'?LB@05NC#(@B@J]JW$PVG@I'.^X M&@"CC96VV>AJ,$P-Y+AN@MW%N]C!1]<;OJ912KRW!6YN&B!F<2OCY:9]8@@O MGI>]@,Y-&Z8)=-)C]P(X-XV;)L#)2A>XN6GLF,6MC%<=&^C=R#;!R7J!GIMV M4_49\)HQH!,-Z^I]Q'K0B0)J7+V-J'5(SP>*%SU5^#'+NFF M35X7)_7=HIAI;MKF>CLE-WK"U9O!]2#:#E%U]1YP/7R$UR]LAO+3V@9($9VP&3F(T#LVF-U>+^PIN7;"=FM MS7Z:3,C,^*,81#$G6S4ZP<$=QJDZ]7GI3E`NSNJD5,5^;*KFHE"L;)\OQ:51 M4:DK?$@7B*1"5^BO7B95M9R.[[2@]2B.DL#F$$L-UQUQS7#;EDJNN^1,X+64 M?JZ[`$Q@Q4_AX:Q/H)YC3E4%9F^*A)S`1"KNWH M26L.EOR=91-IR&E@"(6Z#X//-'-=?D2XH<9*B]I0Q9<.RJ5LOO1PZ!/"KL,H M3826454M&YPL'WB&03^8AI`E$$S".5@]J\SEI*J6G?0'=%:NIFF%120J;22Y M?G'3A2#$_+)9=]N75RN+&Z'G/O3IL)#6G^*%%]%4D<)E)BQK8TR_>#`=D6%) M$5DW[-TUP7!R"MJ@EXQ8X707D+I>Q@J51*S/`%VQ<)R1DJ_;BC537<_*E?PE M2<5#X5SJM\MU@MH*S,7EK5)?.ZZX5P'I?)NT\Q=CY"10;/MCFH6`Z.SA*R==HKBZHVI$/Q^,%./Z92\T MFVK:4F#S)DT5C[#(:AQ.@J3IC#G0B3,?]8/?T\P>6L*;/65(ZB'@87`-LO]7 M'6NTWW&7\%1X1:BS3P?)""N$BY_M4:M!NB6;2G]P=9>/XV!4C&0#()KUUR7T M7B"9K1&-3_LYCEA*0R^$E,4!+,UY%&+RTS4S@;+I7A.\QMU9>U?.\`[9FJ>B MNYI=VS#N8A-Q_>QI=QNQRL@U%TZN&Y#=&B\#6W$]L_;';,`@&%,!]F$CX[V$NMR&9G-WOAN:`I6&^C^#N^@T&(``')RLNCRX'$PY@(J1CZ8036 M5*]A3"E]1/$\)!Q?+EXP(..\@07WQQ MI<6>H(FN\UBQ2FLU9><=2"*A_9#)9_)W!-B&"0-B2J$D_(-]%_"H5-7*=8]" MD6>JX-HC%*L7*$2W/M0J6[K\L39Q[J!*OD;QW9`ZC76#[V4.P:N)A\8:+&[6 MZQ8W_`LKZO6ZP:OWGC*&NH0OQR338]/7@.'@V)A%B5O MP>SJ)\"."H;QT'O[)4PFD\P_3-TW>4PVT2#B*8VPDNG'M9NSR?LP[OM$R45@ M\V6R"B;%]3K!S1!*^+J>*FOB!BR]A^P#$&#JRZH)XM<+N*D804OY"I2D9X1.;QJP>#&-+4O`F` M6WMI56FK+[RU>+*Q_BJ$BA_2]1/WMM&NG)>N!W[O:CJKNJ#KG8GO4T3"KA`7 M;5VN7U_<%;XZCEY7@PQ-'!2JQ&8Z^LRW*=C:F?*NOR5N<-(J^RI=?Y5<__1+ M+E+7SI;JW0/>)]W`-'QJQ^&NWQ@VC>K6\;3K+]NV!>`J6J'>$[?[M++K'\BN MYR&N=`@W>_VV^W/1$)"U3[;JO8_[_J:J3H1%L[<[NZ\5U3^]%RW^ZA,%U^]. MM8.IPIF4ZZG^#`&K=N!<+R^@`]*T*9R2@[9ZV0/?(:8ZIY>NIQEL:9IN!\W4 M2S;X_F:G3D1CLPQRW=>?5$ZSUZX`UO+LN?_^N1Z*=>9Q@:&;Y]&&,)3:4@6& M;AXYM[F:R^BY>:G:#'I;]R\+V&KX@&=L+`AE*'F'X'V]*,-7PP.S0(PHR>.SB*T33SC%FY9;XDA#M02^<>X5P0\Z;1@(TH MOCY,PH!FZ0[G):OYYLV/4C*0U&ZAOLDT&_#!:#-7>I;]1\2ZD;:MH"+T>CT1 MQ02%/J48\R>I`(L&+9IYJ@LD"4W5?D5$1IA<`^RC<,8AN**PE51G:.S!/![Q MBJ`41V'@Y;&*CR5Y5'IQ<26%*Y]!,M*VI0>(V+P!09/\![JM6$WV8G(>K`>W MJ`MYU\-AVP.YB4QU/4;6..I5,M_U-\9;F\;:8M?U8-CV!(89U71W@;&V;"86 MEK$51_"<3J<>6@Q&0^IQX)=9ONA@0\6.6.,@X$=!R!]25*QL);G/:EA8U,R* MIER)8.^-,*I?*=7+TXP*+;5AHU9>LI[.HG@!R,I%9`8#_D#EX\C6+PTJ'D.: M&S3SNS&FR'(!=T16B.XOFNZE@R]E?P'TC2T!_VIU._!J]GT^`OVW4)+"15BC M0QQN3-%K4[G7M"5SGJ5FE:NQ/H3$*3T MF-^,7!I2R<:_?3VAF/0J-T\Q2WI:U[3;=7U/Y<][8H[)(; M<>ZR+N.XZTIYEB@J\ZXZ@5K4?!2F8"N"L&=P6Q<#5@-S0[&IEN^N,Z$,QR\4QIS^R%F<8@@Z'_W4("9'[7\.V7L M(4Y^`\GFS+^-4?Z)ECMOXKPR1X13.+-U-F!KOI%OL''?1GPZ-S@)IW2ML#.C MP:B0(AE9[!'=0BZ573NJ58W066#(&L_;?J3IHF(XC$NW1`=I@A,/TIN./*KK M->2&=T)OQ%VW@,U[?78DK([8A4E0#5:L!*FNTZ?%C/UZ!;H M15>D")U&0Q1Z$<.(3%J.VL,M9^<)HF5^&9ADT6%R\,3E;5H5N:!3GL_5]:R] MY*R[-"LJ64J5SK)H+<6$%U4Y#F0UK'!`7W1D@6L,WD>R@2*0A(BY&:DOG'P` M;`[1#Y<`@E&8T)O<6'G[B=9LJY;.IJ(F9V,KELKBN!*=FO7 MK07-Z2?2K5P_Q=*$2:)(N9Z15Q.I*C7']6Q2S=:?W'IKEC"JNV].%S8X+[?3 MUHVBE3F^_&&4_!:373A.NP& M:64.+CTL#/#5;L:(;2[O]3.*,7Z!"'@1[9N^(4#663I-F9JZ3$7"'&?!?&M:!\G0_%\116;V4PU8>SP9DQ8Q"&DB)!Z-K,(MQF$@C MIV4UK'`0HUF,"#7K,T;.@[2.#2Z^>+_':$AZ89B^+O.Z)8N2=!/?>U"MW5'. MI/FUTE4NUFP95]6UP]_+\.9X#!*D4?I[1^Z=$[[V! MQ"`@NBS>W(JD@J564W9X'M)45"E:*',FK&##)&JB._/O=U3.;-=#XS6WH#** M&C+^@"(6AX'+5J7KOJ"&P-41X:[[BQI!6J%7NYY@O!EV,JNJ7C;Q_4&NEDHL M2_-3[2MR_=RO-J2FW5>NGP&:!;JF?\GU8T3C`D+L=&QVU+@'>79U#7--K?W= M78BK`:/F='X/5]A4CMH,7&C3=O-?Q3`)81JG&[+XD>IG-.+[X@LI,<$#=!_# M,4#]\1BQQQQH(6#H2*`M(KI\_/,00U\>6JO?4+?X93O\4TF)HJ/U`/3Y%39D M)X'1:GZ)=@AY?*9&`W8O[.OR64^31K%"K_NK$P#\9Q_/3D,FG;&UF?V^NRNQK>8-9VK0" M[4ZA@J%$E=DKI[\!#Q'SN@!H*7OE\.I4-T+O0TI=_(,19VN@HN":9<3*KAKS MZ-6I;H3>]44O62X\:M4KV]":U.?T2DO2&CU7]?<:N"GMF*YJYS7P4MDK7#T# M,#6]-E5?5^\4U&N(>U,&`HP'GK9%-=]6!E8PT[('V M(M!WQ;;(920LWQFWES3L6E;C<%_H_=X7*I05-L'IFBTN]2[7ZH"8&53R96FX MB1A$RW^RN+G[BGLI9OO85Y1D]UK,M=\!=#CT,@)?8/R*`9I3.N_@+&59\Z!/ MN&1[V.6"5;^*/"R_R-5:=U:Q*],CN:$G+F^9^M6?/X<`$;5LLKBGSQRHL2*K M;)6O8I^O"E"05K'*`YO\F`%Z+MV=9#6ZPL&%-@<7'>/@@S8''[K`0=D*V%ZN M:@);J0TK=XMC"!:9#7.;PD"NQ`D*'VZ<[HKG_;YQVJKFO>;#$)NXKGJY6]/7 MR[BJ*CW.1[OO"N5-Q7@)K+-W?W<#K!FYL\MK")T8#>/F;8T+GVZ=L=D`6J3Q MN7H$9P-CM2P$;AW:61$:JC?LW3K9LS.EF^6':/NPT/T1D!Y]K8`^=UP5$7F+ M)8J>P5%Q/?>.GEN;B[F:N^S=`"GQHYNV3=Y)EJU:CEDNUKSS`5>CDEM%[V(; M/;=BE%M%[\,V>J[>^).'5O6)@C,G9-_&:'WG+H5,O6`B[I[#,63.`IAL;>)6 MGOE2U#BN)AX<$S*W8SR;G?A+VCT<(IL[_OLE3";;\VU=:UP? LR[&X@WZ4 M!O2>+WN&@;X6B,"$OC`S!]ESZBHS8>?T[#GZO/NFK75SP$JYFZ\7W=C)=15T M8R@WTC1G[!+=<^*A9$\TIMWCK"MWWXWR:FG*DQ7?3,7-)OT-#!S%N;[RZ/[[ MO^S-XTD<$3YQEK7%0*H0,QMP3HY#9X`(`S2IPAQ`H?]07-X& M]0,T]F`^0:YH-%,4!IFH@L%C:=$-1G0J09_,G&?R)5\CY4UB:8MI?TL!X,W(S5JVQ3[1L>RK*9(IKCK^JUQ3`UL`:[KS>U@KB,"7%>X M6YK5#=0`5QVW#W$"\##FP-AH#`K-=4A(NR1;X3X=UI'*Y*BN6X'21&C9Q/'IX0V#>2GSV1 M;0R%/M$F^+\STA<"#ALU:281/&EZHWG2(2^C6]:K2-XU;,S&>-YX")*YA9=> M:3F#JK5LJ^1,1\\%W9I2_AEYD+Y4 M\A0OO"BI8,9,FS9&<9MHM6&KKM=]G:&I+'+=%Z&G>37;J5SW,>AAJ;`J77<9 M:"SAYL+<]0,ZO=E7J:.XGA9"#RY]16AW*1^Z8E(65B$[`)X!B/.05>83I0^B M8S;7+CT,@D=OP6I9]34ID_Q:)KG"NFS8J`T-L>G0-01"T*I-\6!F9I1%2&., MWY^3JB%D[,ZV%8_40:[DL6BKQ\=OIK,H7@"0:VO%J)4YZ4>,%N9V+([6LL@L MQEZ5Q&FO/[=D48OC\OZDU',ZFT7L3R^Z]"+R,X$1@*1T0\6JDN-:.(XAT:0S M:@)IH].$4T?S]4`\B`89/O:TE8.`D.LNN>6/\R@40CGY@E)03B/$1D]=/:G1 MI)L"I!'([T^@E)Z\NH,T+>#:.486H[_V5A9-_>J%<(B\@&:V8I=@.Q+H4^(E MYV2+?KELT6C`A@!I;:PJT3#;G4W!HS]'RM*EO1$X2!Y36-I3>UR7/[SS[2HA M(J^SOY*@`HOWMYPY;VC65`8$T3?2#CB1-=+R-I;/JO<**;!=SN8R$5*].DF7 M#\S[6PF\3#Q9YIV.Z,FN9OP3@US!E%(;>YFD2`V=PQJ5`F1/HS26:%IY*9CK M:'^?>-4$JW$O3F5]W2?I:'!5N1[6VU*://65N+M8WZ[L433G29CIT]3[$;-0 M00!I9&%'%$DE"BNDBEX;5FY3Z8U#`S:[H6S6&M7UAY[T`'M_ZN=V?DQ:MB.K MNOT,F0:S^RF!*#@\5:[?S319-7!X?RNMR)75>'6)\DI)>^`X)N45#IY)P%#N()/$%@,``"&;P``$0`< M`'9I8VPM,C`Q,S`V,S`N>'-D550)``,RMOI1,K;Z475X"P`!!"4.```$.0$` M`.U<7V_C-A)_+]#OP//#W1:HXSCI;KM!TL+K.+L!DCBPG;9W+P4CT3:O$NF2 M5!+WTW=(_:-D69%L;Q(#>MF5Q9GA#.='^/^Y67KEY^__>;T7^TV&HW0.6>,>!Y9HM\=XA&!%4$3_,09 M]Y=H[,R)C[]']U@2%W&&?O\TND)'!UV$YDHM3CJ=Q\?'`R'<6,B!P_T.:K?C M#GX-53E!'PZ.0!NK9<0#YIZ@'ZQ7?4&P`FKD@A(GZ.BP>]P^_*E]V)T<'IX< M'YYTC_]G4_/%4M#97*%WSG=`?/B^K3G0Z&!T8%GU;S3F3`*UO\!LB7J>AT:: M2Z(1D40\$/<@$BJ-L0A&D,FSEF7?X_$!%[,.=-'M_'Y]%0Y*Z]MO4$A[\G0O M/)KAT&]BGN,.95)AYA"+Q:/LSQ(.W:S'W.YDA252J_OQX\>.:;6H`]F>8;Q( MZ*=8WAOJJ*$3#FZW?=S-`76^\JT=$==8"H#51$4,=F?9YOA4?3N"IALP?Z?2=LM*@=@*42RRRY),[! MC#]THL;B07`"(6"NK6.-6C7OT0JO2V@Q&S04]T:>G'DQBVXIYJ'L@4A5S!6V M%?-)M1#%7+I%\W0M'H7%C*@;[!.YP`ZI@@M8=WS"U`47_CF9XL`#)?\*L$>G ME+@MA)42]#Y0)$,0L)3D9RWE%#/&E5E!S&_]9K&@;,JCG_!"3Y,3P3TR`;`@ M_7`WNERCHHI6P8XFZYQS)]!*QO]CY@Z8HFIY"1T(WW3;0M0]:U6B3%2*E7+) ME#)JE.\>=E$;Q>SV(XA"H2QD"3OMY"7DA0>P?`_9S^89S',"SS!>P>^(.:(H M8UP(6#"9VH`SU6P]7_0V]LTN7#8&70VPAM,+RF`%IMB[Y=(HTO>PE!&^M--& MP/!'189RWQV#PQ)!\/RI=]6[Z0_0^,M@,!DWOMK&5[<8%E$U)TI+J>TXP_V, M]WXH]1YZE]'@N\:;SWKS$L)/GQ3[*FHK]\C[G$?&D]YD<#VX`6\,+]#P=C#J M32Z'-\W,>MX70P"NT)&P('/")'T@9=Y92UWNKP^E_NH/KV]'@R^#F_'EKP-T M-1PW?GO>;WTLYQ<>?Y27S*6".*K88:MDY9[ZL=Q3O?$7='$U_*WQT!H/W7!% MY(0G.TXREG(H9IC1OXTI?3A^/N;>6F=9VE3*?4^EX7`:"3,B3^N1Q MYT_+WR_8:3EZ?M*!:<(%/SX31@3V&K3414LZBC"'8;V%Q=:8-2(P,,3M`Z!QR>=AKG%2\-5#QS;]E&.A8]Y+(P5,+6-+&1WUX"C+CC&P6(1'H^Q]PE[ M.H\TGA.BTN&NB81:`DO=WCW,N]V$#"B2BHQ8U'-,VD0VKJ_K^DN3DXD>S\F] M@H7\&HL_B<+W'AG\%5"U'!,G$*`TD=#8)T)ARB8"ZX1O3TJR^6[RU3HOAU0W M#ZFT3Y1V]SWJ/6#JF;=3+M`8>Z3!5UU\77$VFQ#A6ZZNAY%2`>5^/LK[66^,;O MM?T.099/PTFCUV+.%"S"!(C(QHZO*;+<\S_D/6])-VGMC/S&_[7#1!UPS[GG M$B'#S5G3;NKZZM+*O?Z^\%P0"?X/"D4WSJ[K[-Y,D.UR!>42RIWZ(>_4GE3$ M\[!$J=3&IZ^=,KH%`7HI?9744=)Y.9)^7)-"0N]B`'-YIQK8^*RD*-E+AG$*.[KN:[1`GNKE^JJ MT99[;B7I&,>;<(9)Q-DWZ]"[U'`PK MZ-V&[?2*(8_9D M!3<@*J&A,E^Y\U>RHX6W*!I';^_HHC1"&ESHF]%\YUYA8X/9+F M]E3201XJ+]AS.=A6TJ_K\AZ9/4DKB"P-OU^S)>F8J!B]L:8(*[O+!KN[P6[/ M4?2!JB7L06':M``9=Y*RV9C.&)U";TS=,7ZO_WA:.S%,IM5#[8[Z+,7K\4H: MMQ)>8]7,-ADJMPZ!1D-DJ8AL'5&H9(/3>IF`S*V3ZEF`"FSE:%G)ZA9=56EV MTNV]'-\622^+5/)R5;9R+Z]D@`ONKC1.AM?Z'UV!8D2FR!27.-'E%QYK<[;M3SKQ@J&`T.!X>>)F#VQ&\ZI MQ*MH,M`6F'RE)>R)M?EI7L%H8"DPVKZI563[:<>NAP&_LO4R3L%T+A1BA:4[ MUI2T06'5G"ON&$$E+/I7.^9KZU?M[E'[N'OP)-U(Q3H:I"-=3X.8KZX&A75C MJO8=,^A.WU?JKK3RSKIN39>%I7XZQ%,RD=5.9=4?_952.Y4&(<^E1^*C'O[N MAVU4L*H$U52#LYO--"DKI;2%8_2;NGYYKCA1J3I%?/&/[10I*'5431.;,?G5 M3L74UR57/ZF2&C&/?MAJ(/*5F"KUGC"9IZWZ7ZWI5$D#BRUZWDJ+?(VH2CHD M3.:IG;+;_4=EHXP"9ZTT9N_Y&L4CXA#Z0-R[!6?Z7I`7W6\>3J-;'Q-!L7=. M))S?P\.&WF/_V$Y,&$28@G`G/F=P7!#+2T5\'6&W$+Z72F!'G;6FV#-!@B&$ MX(%R=V)8W4!$QY^P[3[\OGC6<@0!Q5J(4<^D\<]:2NADH0Q`*%6!9OHL>+"( MNZ?0[9J1>O[/!\*A**<+;0VKN9VH^/V&UN["+!_02/\.+Q[WF)MDDO3]02L= M&JEE&UJ7TW8SO*-L5F1V:,G7MQI0&GU9OF,N$5?4T5^4$^\-6<^94_(050FY MIAY,:>B_,SGU]SBYV M($3*.R:(WO&(^QE39D'[DEE?:.S!V9W,K8
9_IAAXGMS6R\N.1E: M6MB\%WZ&V:^U`,=\%EB?QE@I(X++DH56EI*]M5CR&K-@"OT%&CVFI@9WPX7CFOCW1%B& M/4^:,<[E/BQ'K[:Q7F.MJ%K^EV"8/-9B&/NG<`6MQ66C=J8Y7M.-3]0/_"@D MT!6L.#.!P:6409(Z37*F&8MK!1MYP6C#I=.+KW&#UUG1NV5R+ MR[:70F0U(Z_HYS1ZB=;.9+N/3T9C(L#&#*CK,.W%2IR88>S2C'E#3!"<;C3K MTP+;BWIK*WI:U\:!TC-1EZ6P1F1#_F@88`S`,D>7 M,GB]$8B7+Y*9RL8P.!;<8C`%>X,GT)-*6/3,"O<(JSH1_\](!O4=&_!CFSFM8SH M#7Y>.>V$]QK@\1]02P$"'@,4````"``S>P%#RM1R:RMT```^V@4`$0`8```` M```!````I($`````=FEC;"TR,#$S,#8S,"YX;6Q55`4``S*V^E%U>`L``00E M#@``!#D!``!02P$"'@,4````"``S>P%#PE<7"F`-``"HK```%0`8```````! M````I(%V=```=FEC;"TR,#$S,#8S,%]C86PN>&UL550%``,RMOI1=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`,WL!0\D,(Z-!"@``NH8``!4`&``````` M`0```*2!)8(``'9I8VPM,C`Q,S`V,S!?9&5F+GAM;%54!0`#,K;Z475X"P`! M!"4.```$.0$``%!+`0(>`Q0````(`#-[`4.+_N?R3#X``!`!`P`5`!@````` M``$```"D@;6,``!V:6-L+3(P,3,P-C,P7VQA8BYX;6Q55`4``S*V^E%U>`L` M`00E#@``!#D!``!02P$"'@,4````"``S>P%#8#Q&=-,<```&UL550%``,RMOI1=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`,WL!0[B"3Q!8#```AF\``!$`&``` M`````0```*2!'-D550%``,RMOI1=7@+``$$ ?)0X```0Y`0``4$L%!@`````&``8`&@(``!7U```````` ` end XML 14 R6.xml IDEA: STATEMENTS OF CASH FLOWS 2.4.0.8107 - Statement - STATEMENTS OF CASH FLOWStruefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE3939----1310-Q0004_STD_182_20120630_0http://www.sec.gov/CIK0000819050duration2012-01-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 2us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Cash flows from operating activities:2false 3us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-19163000-19163USD$falsetruefalse2truefalsefalse-7624000-7624USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 false2Net loss3true 3us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Adjustments to reconcile net loss to net cash used in operating activities:4false 4us-gaap_DepreciationDepletionAndAmortizationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse10230001023falsefalsefalse2truefalsefalse981000981falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Depreciation and amortization5false 4vicl_WriteOffOfAbandonedPatentsvicl_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse8200082falsefalsefalse2truefalsefalse2200022falsefalsefalsexbrli:monetaryItemTypemonetaryWrite off of abandoned patents.No definition available.false2Write-off of abandoned patents6false 4us-gaap_GainLossOnSaleOfPropertyPlantEquipmentus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2truefalsefalse-8000-8falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Gain on sale of property and equipment7false 4us-gaap_ShareBasedCompensationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse19540001954falsefalsefalse2truefalsefalse18430001843falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Compensation expense related to stock options and awards8true 4us-gaap_IncreaseDecreaseInOperatingCapitalAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Changes in operating assets and liabilities:9false 5us-gaap_IncreaseDecreaseInReceivablesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse6900069falsefalsefalse2truefalsefalse-647000-647falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Receivables and other assets10false 5us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse325000325falsefalsefalse2truefalsefalse-1328000-1328falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Accounts payable and accrued expenses11false 5us-gaap_IncreaseDecreaseInDeferredRevenueus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-75000-75falsefalsefalse2truefalsefalse-99000-99falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Deferred revenue12false 5us-gaap_IncreaseDecreaseInDeferredChargesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-144000-144falsefalsefalse2truefalsefalse-114000-114falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Deferred rent13false 3us-gaap_NetCashProvidedByUsedInOperatingActivitiesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-15929000-15929falsefalsefalse2truefalsefalse-6974000-6974falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 true2Net cash used in operating activities14true 2us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Cash flows from investing activities:15false 3us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse37500003750falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585 false2Proceeds from the sale of marketable securities16false 3us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecuritiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse2134600021346falsefalsefalse2truefalsefalse94700009470falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585 false2Maturities of marketable securities17false 3us-gaap_PaymentsToAcquireMarketableSecuritiesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-3037000-3037falsefalsefalse2truefalsefalse-27211000-27211falsefalsefalsexbrli:monetaryItemTypemonetaryCash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 false2Purchases of marketable securities18false 3us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-273000-273falsefalsefalse2truefalsefalse-433000-433falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 false2Purchases of property and equipment19false 3us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipmentus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse80008falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585 false2Proceeds from the sale of property and equipment20false 3us-gaap_PaymentsToAcquireIntangibleAssetsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-212000-212falsefalsefalse2truefalsefalse-209000-209falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 false2Patent expenditures21false 3us-gaap_NetCashProvidedByUsedInInvestingActivitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse1782400017824falsefalsefalse2truefalsefalse-14625000-14625falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585 true2Net cash provided by (used in) investing activities22true 2us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Cash flows from financing activities:23false 3us-gaap_ProceedsFromIssuanceOfCommonStockus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse380000380falsefalsefalse2truefalsefalse4877200048772falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow from the additional capital contribution to the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 false2Net proceeds from issuance of common stock24false 3us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-401000-401falsefalsefalse2truefalsefalse-152000-152falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585 false2Payment of withholding taxes for net settlement of restricted stock units25false 3us-gaap_NetCashProvidedByUsedInFinancingActivitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-21000-21falsefalsefalse2truefalsefalse4862000048620falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585 true2Net cash (used in) provided by financing activities26false 2us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse18740001874falsefalsefalse2truefalsefalse2702100027021falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906 true2Net increase in cash and cash equivalents27false 2us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabel1truefalsefalse4315900043159falsefalsefalse2truefalsefalse3869600038696falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585 false2Cash and cash equivalents at beginning of period28false 2us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse4503300045033USD$falsetruefalse2truefalsefalse6571700065717USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585 false2Cash and cash equivalents at end of periodfalseSTATEMENTS OF CASH FLOWS (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/StatementOfCashFlowsIndirect228 XML 15 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation (Tables)
6 Months Ended

Jun. 30, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of total stock-based compensation expense

Total stock-based compensation expense was allocated to research and development, manufacturing and production and general and administrative expense as follows (in thousands):

 Three Months Ended
June 30, Six Months Ended
June 30,

 2013 2012 2013 2012

Research and development
 $ 242 $ 272 $ 554 $ 558

Manufacturing and production
 60 56 128 106

General and administrative
 514 595 1,272 1,179









Total stock-based compensation expense
 $ 816 $ 923 $ 1,954 $ 1,843









X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 16 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Jun. 30, 2012

Revenues:

Contract and grant revenue $ 1,170 $ 1,364 $ 2,306 $ 2,585

License and royalty revenue 286 201 724 10,440

Total revenues 1,456 1,565 3,030 13,025

Operating expenses:

Research and development 3,930 3,791 7,580 10,219

Manufacturing and production 3,891 2,933 7,604 5,405

General and administrative 3,478 2,778 6,996 5,478

Total operating expenses 11,299 9,502 22,180 21,102

Loss from operations (9,843) (7,937) (19,150) (8,077)

Other income (expense):

Investment and other income, net (38) 69 (13) 453

Net loss $ (9,881) $ (7,868) $ (19,163) $ (7,624)

Basic and diluted net loss per share $ (0.11) $ (0.09) $ (0.22) $ (0.09)

Weighted average shares used in computing basic and diluted net loss per share 86,730 86,282 86,623 85,412

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate costs incurred in the production of goods for sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_ManufacturingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, manufacturing contracts, and any other contract related to a particular project or product. Also may include revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.

+ References

No definition available.

+ Details

Name: vicl_ContractAndGrantRevenue

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Investment income is derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money. Other income includes the aggregate amount of other nonrecurring expenses, not previously categorized, that are infrequent in occurrence or unusual in nature.

+ References

No definition available.

+ Details

Name: vicl_InvestmentAndOtherIncomeNet

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

License revenue earned during the period relates to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, or manufacturing process. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's licensed property.

+ References

No definition available.

+ Details

Name: vicl_LicenseAndRoyaltyRevenue

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 17 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Marketable Securities, Available for Sale
6 Months Ended

Jun. 30, 2013

Investments Debt And Equity Securities [Abstract]

Marketable Securities, Available for Sale

4. MARKETABLE SECURITIES, AVAILABLE FOR SALE

The following is a summary of available-for-sale marketable securities (in thousands):

June 30, 2013
 Amortized
Cost Unrealized
Gain Unrealized
Loss Market
Value

U.S. treasuries
 $ 6,528 $ 2 $ — $ 6,530

Government-sponsored enterprise securities
 7,000 — 3 6,997

Corporate bonds
 4,859 — 6 4,853

Certificates of deposit
 1,026 — — 1,026









 $ 19,413 $ 2 $ 9 $ 19,406









December 31, 2012
 Amortized
Cost Unrealized
Gain Unrealized
Loss Market
Value

U.S. treasuries
 $ 10,135 $ 1 $ — $ 10,136

Government-sponsored enterprise securities
 15,507 — 1 15,506

Corporate bonds
 11,509 — 8 11,501

Certificates of deposit
 496 — — 496









 $ 37,647 $ 1 $ 9 $ 37,639









At June 30, 2013, $6.7 million of these securities were scheduled to mature outside of one year. The Company did not realize any gains or losses on sales of available-for-sale securities for the six months ended June 30, 2013. As of June 30, 2013, none of the securities had been in a continuous material unrealized loss position longer than one year.

X

- Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Debt Security

-URI http://asc.fasb.org/extlink&oid=6509901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Equity Security

-URI http://asc.fasb.org/extlink&oid=6511694

+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 19 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Balance Sheet Accounts - Summary of Accounts Payable and Accrued Expenses (Detail) (USD $)
In Thousands, unless otherwise specified

Jun. 30, 2013

Dec. 31, 2012

Payables And Accruals [Abstract]

Employee compensation $ 2,877 $ 3,858

Post-termination benefit accrual 252

Clinical trial accrual 644 660

Accounts payable 1,295 377

Deferred rent 337 307

Other accrued liabilities 579 427

Total accounts payable and accrued expenses $ 5,984 $ 5,629

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 25

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707

+ Details

Name: us-gaap_DeferredRentCreditCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The current liability recognized in the balance sheet that is associated with defined benefit pension plans and other postretirement and postemployment benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28361610&loc=d3e2417-114920

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28361610&loc=d3e2410-114920

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=28361610&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=21915240&loc=d3e1703-114919

+ Details

Name: us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of clinical-related obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

No definition available.

+ Details

Name: vicl_ClinicalTrialAccrual

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 20 R29.xml IDEA: Fair Value Measurements - Summary of Activity for Assets Measured at Fair Value Using Significant Unobservable Inputs (Detail) 2.4.0.8130 - Disclosure - Fair Value Measurements - Summary of Activity for Assets Measured at Fair Value Using Significant Unobservable Inputs (Detail)truefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1us-gaap_FairValueDisclosuresAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value Disclosures [Abstract]2false 2us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabel1truefalsefalse22250002225USD$falsetruefalsexbrli:monetaryItemTypemonetaryFair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Balance at December 31, 20123false 2us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-188000-188falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of gain (loss) recognized in other comprehensive income (loss) for financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Total net unrealized losses, excluding tax impact, included in other comprehensive income4false 2us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse20370002037falsefalsefalsexbrli:monetaryItemTypemonetaryFair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Balance at June 30, 20135false 2us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of unrealized (holding) gain (loss) which is included in the statement of income (or changes in net assets) related to those assets still held at the reporting date for which fair value is measured on a recurring basis using significant unobservable inputs (Level 3).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Total gains or losses for the period included in net loss attributable to the change in unrealized gains or losses relating to assets still held at the reporting datefalseFair Value Measurements - Summary of Activity for Assets Measured at Fair Value Using Significant Unobservable Inputs (Detail) (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfActivityForAssetsMeasuredAtFairValueUsingSignificantUnobservableInputs15 XML 21 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Balance Sheet Accounts (Tables)
6 Months Ended

Jun. 30, 2013

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following (in thousands):

 June 30,
2013 December 31,
2012

Employee compensation
 $ 2,877 $ 3,858

Post-termination benefit accrual
 252 —

Clinical trial accrual
 644 660

Accounts payable
 1,295 377

Deferred rent
 337 307

Other accrued liabilities
 579 427





Total accounts payable and accrued expenses
 $ 5,984 $ 5,629





X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R25.xml IDEA: Marketable Securities, Available for Sale - Summary of Available-for-Sale Marketable Securities (Detail) 2.4.0.8126 - Disclosure - Marketable Securities, Available for Sale - Summary of Available-for-Sale Marketable Securities (Detail)truefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE3939----1310-Q0004_STD_0_20121231_0http://www.sec.gov/CIK0000819050instant2012-12-31T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Schedule of Available-for-sale Securities [Line Items]2false 4us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasisus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse1941300019413USD$falsetruefalse2truefalsefalse3764700037647USD$falsetruefalsexbrli:monetaryItemTypemonetaryThis item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.No definition available.false2Amortized Cost3false 4vicl_AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestmentsvicl_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse20002USD$falsefalsefalse2truefalsefalse10001USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of accumulated pre-tax unrealized gains before deducting pre-tax unrealized losses on investments in available-for-sale securities impacting investments.No definition available.false2Unrealized Gain4false 4vicl_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestmentsvicl_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse90009USD$falsefalsefalse2truefalsefalse90009USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of accumulated pre-tax unrealized loss before deducting pre-tax unrealized gain on investments in available-for-sale securities impacting investments.No definition available.false2Unrealized Loss5false 4us-gaap_AvailableForSaleSecuritiesDebtSecuritiesus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse1940600019406USD$falsefalsefalse2truefalsefalse3763900037639USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of debt securities categorized neither as held-to-maturity nor trading.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 25 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (aa) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 2 -Subparagraph (b)-(g) -URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803 true2Market Value6false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_928628x923870http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseU.S. treasuries [Member]us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_USTreasurySecuritiesMemberus-gaap_MajorTypesOfDebtAndEquitySecuritiesAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0U.S. treasuries [Member]7true 3us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Schedule of Available-for-sale Securities [Line Items]8false 4us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasisus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse65280006528USD$falsefalsefalse2truefalsefalse1013500010135USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThis item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.No definition available.false2Amortized Cost9false 4vicl_AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestmentsvicl_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse20002USD$falsefalsefalse2truefalsefalse10001USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of accumulated pre-tax unrealized gains before deducting pre-tax unrealized losses on investments in available-for-sale securities impacting investments.No definition available.false2Unrealized Gain10false 4vicl_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestmentsvicl_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00  USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of accumulated pre-tax unrealized loss before deducting pre-tax unrealized gain on investments in available-for-sale securities impacting investments.No definition available.false2Unrealized Loss11false 4us-gaap_AvailableForSaleSecuritiesDebtSecuritiesus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse65300006530USD$falsefalsefalse2truefalsefalse1013600010136USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of debt securities categorized neither as held-to-maturity nor trading.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 25 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (aa) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 2 -Subparagraph (b)-(g) -URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803 true2Market Value12false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse5false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_928628x924099http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseGovernment-sponsored enterprise securities [Member]us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap_MajorTypesOfDebtAndEquitySecuritiesAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Government-sponsored enterprise securities [Member]13true 3us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Schedule of Available-for-sale Securities [Line Items]14false 4us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasisus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse70000007000USD$falsefalsefalse2truefalsefalse1550700015507USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThis item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.No definition available.false2Amortized Cost15false 4vicl_AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestmentsvicl_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00  USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of accumulated pre-tax unrealized gains before deducting pre-tax unrealized losses on investments in available-for-sale securities impacting investments.No definition available.false2Unrealized Gain16false 4vicl_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestmentsvicl_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse30003USD$falsefalsefalse2truefalsefalse10001USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of accumulated pre-tax unrealized loss before deducting pre-tax unrealized gain on investments in available-for-sale securities impacting investments.No definition available.false2Unrealized Loss17false 4us-gaap_AvailableForSaleSecuritiesDebtSecuritiesus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse69970006997USD$falsefalsefalse2truefalsefalse1550600015506USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of debt securities categorized neither as held-to-maturity nor trading.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 25 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (aa) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 2 -Subparagraph (b)-(g) -URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803 true2Market Value18false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse7false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_928628x928852http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseCorporate bonds [Member]us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CorporateDebtSecuritiesMemberus-gaap_MajorTypesOfDebtAndEquitySecuritiesAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Corporate bonds [Member]19true 3us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Schedule of Available-for-sale Securities [Line Items]20false 4us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasisus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse48590004859USD$falsefalsefalse2truefalsefalse1150900011509USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThis item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.No definition available.false2Amortized Cost21false 4vicl_AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestmentsvicl_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00  USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of accumulated pre-tax unrealized gains before deducting pre-tax unrealized losses on investments in available-for-sale securities impacting investments.No definition available.false2Unrealized Gain22false 4vicl_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestmentsvicl_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse60006USD$falsefalsefalse2truefalsefalse80008USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of accumulated pre-tax unrealized loss before deducting pre-tax unrealized gain on investments in available-for-sale securities impacting investments.No definition available.false2Unrealized Loss23false 4us-gaap_AvailableForSaleSecuritiesDebtSecuritiesus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse48530004853USD$falsefalsefalse2truefalsefalse1150100011501USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of debt securities categorized neither as held-to-maturity nor trading.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 25 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (aa) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 2 -Subparagraph (b)-(g) -URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803 true2Market Value24false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse9false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_928628x927254http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseCertificates of deposit [Member]us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CertificatesOfDepositMemberus-gaap_MajorTypesOfDebtAndEquitySecuritiesAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Certificates of deposit [Member]25true 3us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Schedule of Available-for-sale Securities [Line Items]26false 4us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasisus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse10260001026USD$falsefalsefalse2truefalsefalse496000496USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThis item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.No definition available.false2Amortized Cost27false 4vicl_AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestmentsvicl_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00  USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of accumulated pre-tax unrealized gains before deducting pre-tax unrealized losses on investments in available-for-sale securities impacting investments.No definition available.false2Unrealized Gain28false 4vicl_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestmentsvicl_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00  USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of accumulated pre-tax unrealized loss before deducting pre-tax unrealized gain on investments in available-for-sale securities impacting investments.No definition available.false2Unrealized Loss29false 4us-gaap_AvailableForSaleSecuritiesDebtSecuritiesus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse10260001026USD$falsetruefalse2truefalsefalse496000496USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of debt securities categorized neither as held-to-maturity nor trading.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 25 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (aa) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 2 -Subparagraph (b)-(g) -URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803 true2Market ValuefalseMarketable Securities, Available for Sale - Summary of Available-for-Sale Marketable Securities (Detail) (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/DisclosureMarketableSecuritiesAvailableForSaleSummaryOfAvailableforSaleMarketableSecurities229 XML 23 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Long-Term Investments - Additional Information (Detail) (USD $)
1 Months Ended 3 Months Ended 6 Months Ended

Mar. 31, 2012

Investment

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2012

Investments Schedule [Abstract]

Number of long-term investments sold during the period 2

Auction rate securities sold, at par value $ 4,000,000

Gain related to auction rate securities 300,000

Auction rate securities held, at par value 2,500,000

Maturity of long-term investment 2038

Recognized cumulative losses 600,000 600,000

Unrealized (losses) gains on auction rate securities (113,000) 36,000

Cumulative unrealized gains 200,000 200,000

Carrying value of auction rate security $ 2,000,000 $ 2,000,000

X

- Details

Name: invest_InvestmentsScheduleAbstract

Namespace Prefix: invest_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of securities that are debt instruments (corporate or municipal bonds) that typically have long-term nominal maturities for which the interest rate is reset through an auction process.

+ References

No definition available.

+ Details

Name: us-gaap_AuctionRateSecuritiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Auction rate securities held, at par value.

+ References

No definition available.

+ Details

Name: vicl_AuctionRateSecuritiesHeldAtParValue

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Auction rate securities sold, at par value.

+ References

No definition available.

+ Details

Name: vicl_AuctionRateSecuritiesSoldAtParValue

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Cumulative unrealized gain on auction rate securities recognized.

+ References

No definition available.

+ Details

Name: vicl_CumulativeUnrealizedGainOnAuctionRateSecuritiesRecognized

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair value adjustment loss on auction rate securities recognized.

+ References

No definition available.

+ Details

Name: vicl_FairValueAdjustmentLossOnAuctionRateSecuritiesRecognized

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Gain related to auction rate securities.

+ References

No definition available.

+ Details

Name: vicl_GainRelatedToAuctionRateSecurities

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Maturity year of auction rate long term securities.

+ References

No definition available.

+ Details

Name: vicl_MaturityYearOfAuctionRateLongTermSecurities

Namespace Prefix: vicl_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of long-term investments sold during the period .

+ References

No definition available.

+ Details

Name: vicl_NumberOfLongTermInvestmentsSoldDuringPeriod

Namespace Prefix: vicl_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Unrealized gain loss on auction rate securities.

+ References

No definition available.

+ Details

Name: vicl_UnrealizedGainLossOnAuctionRateSecurities

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 24 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Marketable Securities, Available for Sale - Additional Information (Detail) (USD $)
6 Months Ended

Jun. 30, 2013

Investments Debt And Equity Securities [Abstract]

Available-for-sale securities maturing outside of one year $ 6,700,000

Realized gains or losses on sales of available-for-sale securities 0

Available-for-sale securities in a continuous material loss position longer than one year $ 0

X

- Definition

Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of accumulated pre-tax unrealized loss on investments in available-for-sale securities that have been in a loss position for twelve months or longer impacting investments.

+ References

No definition available.

+ Details

Name: vicl_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 25 R19.xml IDEA: Marketable Securities, Available for Sale (Tables) 2.4.0.8120 - Disclosure - Marketable Securities, Available for Sale (Tables)truefalsefalse1false falsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_InvestmentsDebtAndEquitySecuritiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Investments Debt And Equity Securities [Abstract]2false 2us-gaap_MarketableSecuritiesTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> The following is a summary of available-for-sale marketable securities (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">  <tr> <td width="66%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> June 30, 2013 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Gain</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Loss</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Market Value</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,528</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,530</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,997</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,859</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,853</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,413</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,406</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> December 31, 2012 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Gain</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Loss</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Market Value</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,135</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,136</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,507</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,506</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,509</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,501</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—   </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,647</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,639</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.4) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.2,12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 5 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563 false0Summary of Available-for-Sale Marketable SecuritiesfalseMarketable Securities, Available for Sale (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables12 XML 26 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

Astellas Agreements - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
1 Months Ended 3 Months Ended 6 Months Ended

Aug. 31, 2012

Jun. 30, 2013

Jun. 30, 2012

Mar. 31, 2012

Mar. 31, 2011

Jun. 30, 2013

Jun. 30, 2012

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Recognized license revenue $ 25.0 $ 0.3 $ 10.2

Additional amount received upon finalization of the general trial design 10.0

Recognized revenue related to contract services 1.1 1.3 2.2 2.3

Amount payable under license agreement on achievement of milestone $ 95.0

X

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d),(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicenseAndServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Additional amount received upon finalization of general trial design.

+ References

No definition available.

+ Details

Name: vicl_AdditionalAmountReceivedUponFinalizationOfGeneralTrialDesign

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount payable under license agreement on achievement of milestone.

+ References

No definition available.

+ Details

Name: vicl_AmountPayableUnderLicenseAgreementOnAchievementOfMilestone

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Recognized revenue related to contract services.

+ References

No definition available.

+ Details

Name: vicl_RecognizedRevenueRelatedToContractServices

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 27 R9.xml IDEA: Other Balance Sheet Accounts 2.4.0.8110 - Disclosure - Other Balance Sheet Accountstruefalsefalse1false falsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Organization Consolidation And Presentation Of Financial Statements [Abstract]2false 2us-gaap_SupplementalBalanceSheetDisclosuresTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 3.      OTHER BALANCE SHEET ACCOUNTS  Accounts payable and accrued expenses consisted of the following (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="83%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">June 30, 2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Employee compensation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">  2,877</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Post-termination benefit accrual </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">252</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Clinical trial accrual </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">644</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">660</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Accounts payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,295</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">377</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Deferred rent </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">337</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">307</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Other accrued liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">579</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">427</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total accounts payable and accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,984</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,629</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.No definition available.false0Other Balance Sheet AccountsfalseOther Balance Sheet AccountsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock12 XML 28 R12.xml IDEA: Fair Value Measurements 2.4.0.8113 - Disclosure - Fair Value Measurementstruefalsefalse1false falsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_FairValueDisclosuresAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value Disclosures [Abstract]2false 2us-gaap_FairValueMeasurementInputsDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 6.      FAIR VALUE MEASUREMENTS  The Company measures fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="4%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left"> Level 1: Observable inputs such as quoted prices in active markets; </td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="4%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left"> Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and </td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="4%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left"> Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </td> </tr> </table> Cash equivalents, marketable securities and long-term investments measured at fair value are classified in the table below in one of the three categories described above (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="73%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center">Fair Value Measurements</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> June 30, 2013 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,845</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,845</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,530</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,530</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,853</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,853</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,997</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,997</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Auction rate securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,401</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,850</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,288</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="73%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center">Fair Value Measurements</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> December 31, 2012 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,500</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,136</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,136</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,501</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,501</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,506</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,506</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Auction rate securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,132</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,007</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,364</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The Company’s investments in U.S. treasury securities, certificates of deposit and money market funds are valued based on publicly available quoted market prices for identical securities as of June 30, 2013. The Company determines the fair value of corporate bonds and other government-sponsored enterprise related securities with the aid of valuations provided by third parties using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company validates the valuations received from its primary pricing vendors for its level 2 securities by examining the inputs used in that vendor’s pricing process and determines whether they are reasonable and observable. The Company also compares those valuations to recent reported trades for those securities. The Company did not adjust any of the valuations received from these independent third parties with respect to any of its level 2 securities at June 30, 2013. The Company did not reclassify any investments between level categories during the three months ended June 30, 2013. The valuation of the Company’s investments in auction rate securities, which includes significant unobservable inputs, is more fully described in Note 5.   Activity for assets measured at fair value using significant unobservable inputs (Level 3) is presented in the table below (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="90%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Six Months Ended June 30, 2013</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Total net unrealized losses, excluding tax impact, included in other comprehensive income </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(188</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total gains or losses for the period included in net loss attributable to the change in unrealized gains or losses relating to assets still held at the reporting date </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19279-110258 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19190-110258 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false0Fair Value MeasurementsfalseFair Value MeasurementsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementInputsDisclosureTextBlock12 XML 29 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Marketable Securities, Available for Sale - Summary of Available-for-Sale Marketable Securities (Detail) (USD $)
In Thousands, unless otherwise specified

Jun. 30, 2013

Dec. 31, 2012

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost $ 19,413 $ 37,647

Unrealized Gain 2 1

Unrealized Loss 9 9

Market Value 19,406 37,639

U.S. treasuries [Member]

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost 6,528 10,135

Unrealized Gain 2 1

Unrealized Loss

Market Value 6,530 10,136

Government-sponsored enterprise securities [Member]

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost 7,000 15,507

Unrealized Gain

Unrealized Loss 3 1

Market Value 6,997 15,506

Corporate bonds [Member]

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost 4,859 11,509

Unrealized Gain

Unrealized Loss 6 8

Market Value 4,853 11,501

Certificates of deposit [Member]

Schedule of Available-for-sale Securities [Line Items]

Amortized Cost 1,026 496

Unrealized Gain

Unrealized Loss

Market Value $ 1,026 $ 496

X

- Definition

This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.

+ References

No definition available.

+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of debt securities categorized neither as held-to-maturity nor trading.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-Subparagraph (b)-(g)

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of accumulated pre-tax unrealized gains before deducting pre-tax unrealized losses on investments in available-for-sale securities impacting investments.

+ References

No definition available.

+ Details

Name: vicl_AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of accumulated pre-tax unrealized loss before deducting pre-tax unrealized gain on investments in available-for-sale securities impacting investments.

+ References

No definition available.

+ Details

Name: vicl_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 30 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
6 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Cash flows from operating activities:

Net loss $ (19,163) $ (7,624)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 1,023 981

Write-off of abandoned patents 82 22

Gain on sale of property and equipment (8)

Compensation expense related to stock options and awards 1,954 1,843

Changes in operating assets and liabilities:

Receivables and other assets 69 (647)

Accounts payable and accrued expenses 325 (1,328)

Deferred revenue (75) (99)

Deferred rent (144) (114)

Net cash used in operating activities (15,929) (6,974)

Cash flows from investing activities:

Proceeds from the sale of marketable securities 3,750

Maturities of marketable securities 21,346 9,470

Purchases of marketable securities (3,037) (27,211)

Purchases of property and equipment (273) (433)

Proceeds from the sale of property and equipment 8

Patent expenditures (212) (209)

Net cash provided by (used in) investing activities 17,824 (14,625)

Cash flows from financing activities:

Net proceeds from issuance of common stock 380 48,772

Payment of withholding taxes for net settlement of restricted stock units (401) (152)

Net cash (used in) provided by financing activities (21) 48,620

Net increase in cash and cash equivalents 1,874 27,021

Cash and cash equivalents at beginning of period 43,159 38,696

Cash and cash equivalents at end of period $ 45,033 $ 65,717

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Write off of abandoned patents.

+ References

No definition available.

+ Details

Name: vicl_WriteOffOfAbandonedPatents

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 31 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation
6 Months Ended

Jun. 30, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

2. STOCK-BASED COMPENSATION

Total stock-based compensation expense was allocated to research and development, manufacturing and production and general and administrative expense as follows (in thousands):

 Three Months Ended
June 30, Six Months Ended
June 30,

 2013 2012 2013 2012

Research and development
 $ 242 $ 272 $ 554 $ 558

Manufacturing and production
 60 56 128 106

General and administrative
 514 595 1,272 1,179









Total stock-based compensation expense
 $ 816 $ 923 $ 1,954 $ 1,843









During the six months ended June 30, 2013 and 2012, the Company granted stock-based awards with a total estimated value of $3.8 million and $3.9 million, respectively. At June 30, 2013, total unrecognized estimated compensation expense related to unvested stock-based awards granted prior to that date was $4.1 million, which is expected to be recognized over a weighted-average period of 1.5 years. Stock-based awards granted during the six months ended June 30, 2013 and 2012, were equal to 2.2% of the outstanding shares of common stock at the end of the applicable period.

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R11.xml IDEA: Long-Term Investments 2.4.0.8112 - Disclosure - Long-Term Investmentstruefalsefalse1false falsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_TextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Text Block [Abstract]2false 2vicl_LongTermInvestmentsTextBlockvicl_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 5.      LONG-TERM INVESTMENTS  In March 2012, the Company sold two auction rate securities classified as long-term investments with a par value of $4.0 million. Included in interest and other income for the six months ended June 30, 2012, is a gain of $0.3 million related to the sale. As of June 30, 2013, the Company held an auction rate security with a par value of $2.5 million. This auction rate security has not experienced a successful auction since the liquidity issues experienced in the global credit and capital markets in 2008. As a result, the security is classified as a long-term investment as it is scheduled to mature in 2038. The security was rated BBB by Standard and Poor’s as of June 30, 2013. The security continues to pay interest according to its stated terms. The valuation of the Company’s auction rate security is subject to uncertainties that are difficult to predict. The fair value of the security is estimated utilizing a discounted cash flow analysis. The key drivers of the valuation model include the expected term, collateralization underlying the security investment, the creditworthiness of the counterparty, the timing of expected future cash flows, discount rates, liquidity and the expected holding period. The security was also compared, when possible, to other observable market data for securities with similar characteristics. Based on the valuation of the security, the Company has recognized cumulative losses of $0.6 million as of June 30, 2013. The losses when recognized are included in investment and other income. The market value of the security has partially recovered. Included in other comprehensive income are unrealized (losses) gains of $(113,000) and $36,000 for the six months ended June 30, 2013 and 2012, respectively. As of June 30, 2013, the Company had recorded cumulative unrealized gains of $0.2 million. The resulting carrying value of the auction rate security at June 30, 2013, was $2.0 million. Any future decline in market value may result in additional losses being recognized. </div>falsefalsefalsenonnum:textBlockItemTypenaLong term investments.No definition available.false0Long-Term InvestmentsfalseLong-Term InvestmentsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/NotesToFinancialStatementsLongTermInvestmentsTextBlock12 XML 33 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Long-Term Investments
6 Months Ended

Jun. 30, 2013

Text Block [Abstract]

Long-Term Investments

5. LONG-TERM INVESTMENTS

In March 2012, the Company sold two auction rate securities classified as long-term investments with a par value of $4.0 million. Included in interest and other income for the six months ended June 30, 2012, is a gain of $0.3 million related to the sale.

As of June 30, 2013, the Company held an auction rate security with a par value of $2.5 million. This auction rate security has not experienced a successful auction since the liquidity issues experienced in the global credit and capital markets in 2008. As a result, the security is classified as a long-term investment as it is scheduled to mature in 2038. The security was rated BBB by Standard and Poor’s as of June 30, 2013. The security continues to pay interest according to its stated terms.

The valuation of the Company’s auction rate security is subject to uncertainties that are difficult to predict. The fair value of the security is estimated utilizing a discounted cash flow analysis. The key drivers of the valuation model include the expected term, collateralization underlying the security investment, the creditworthiness of the counterparty, the timing of expected future cash flows, discount rates, liquidity and the expected holding period. The security was also compared, when possible, to other observable market data for securities with similar characteristics. Based on the valuation of the security, the Company has recognized cumulative losses of $0.6 million as of June 30, 2013. The losses when recognized are included in investment and other income. The market value of the security has partially recovered. Included in other comprehensive income are unrealized (losses) gains of $(113,000) and $36,000 for the six months ended June 30, 2013 and 2012, respectively. As of June 30, 2013, the Company had recorded cumulative unrealized gains of $0.2 million. The resulting carrying value of the auction rate security at June 30, 2013, was $2.0 million. Any future decline in market value may result in additional losses being recognized.

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Long term investments.

+ References

No definition available.

+ Details

Name: vicl_LongTermInvestmentsTextBlock

Namespace Prefix: vicl_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R14.xml IDEA: Stockholders' Equity 2.4.0.8115 - Disclosure - Stockholders' Equitytruefalsefalse1false falsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_EquityAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Equity [Abstract]2false 2us-gaap_StockholdersEquityNoteDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 8.      STOCKHOLDERS’ EQUITY  In January 2012, the Company sold 13,333,334 shares of its common stock in a public offering at a price to the public of $3.75 per share. In February 2012, the Company sold an additional 576,358 shares pursuant to a partial exercise of the underwriters’ overallotment option at a price to the public of $3.75 per share. Net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, totaled $48.7 million. All of the shares of common stock were offered pursuant to two effective shelf registration statements. In November 2012, the Company entered into an At-The-Market Equity Offering Sales Agreement, or Sales Agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, under which the Company may issue and sell up to $50,000,000 of shares of its common stock from time to time. Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, shares may be sold through Stifel acting as sales agent or directly to Stifel acting as principal, by means of ordinary brokers’ transactions on the Nasdaq Global Select Market, in privately negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.  </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Article 4 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(d),(e)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Preferred Stock -URI http://asc.fasb.org/extlink&oid=6521494 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644 Reference 17: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644 Reference 18: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph d -Article 4 Reference 19: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656 false0Stockholders' EquityfalseStockholders' EquityUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock12 XML 35 R2.xml IDEA: BALANCE SHEETS 2.4.0.8103 - Statement - BALANCE SHEETStruefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE3939----1310-Q0004_STD_0_20121231_0http://www.sec.gov/CIK0000819050instant2012-12-31T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_AssetsCurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Current assets:2false 4us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse4503300045033USD$falsetruefalse2truefalsefalse4315900043159USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585 false2Cash and cash equivalents3false 4us-gaap_AvailableForSaleSecuritiesCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse1940600019406falsefalsefalse2truefalsefalse3763900037639falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 25 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562 false2Marketable securities, available-for-sale4false 4us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse30590003059falsefalsefalse2truefalsefalse30590003059falsefalsefalsexbrli:monetaryItemTypemonetaryThe carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Restricted cash5false 4us-gaap_ReceivablesNetCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse20830002083falsefalsefalse2truefalsefalse21520002152falsefalsefalsexbrli:monetaryItemTypemonetaryThe total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3,4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 false2Receivables and other assets6false 3us-gaap_AssetsCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse6958100069581falsefalsefalse2truefalsefalse8600900086009falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 9 -Article 5 true2Total current assets7false 3us-gaap_LongTermInvestmentsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse20370002037falsefalsefalse2truefalsefalse22250002225falsefalsefalsexbrli:monetaryItemTypemonetaryThe total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Long-term investments8false 3us-gaap_PropertyPlantAndEquipmentNetus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse47350004735falsefalsefalse2truefalsefalse52840005284falsefalsefalsexbrli:monetaryItemTypemonetaryAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7 false2Property and equipment, net9false 3us-gaap_IntangibleAssetsNetExcludingGoodwillus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse27410002741falsefalsefalse2truefalsefalse28130002813falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 false2Intangible assets, net10false 3us-gaap_OtherAssetsNoncurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse191000191falsefalsefalse2truefalsefalse191000191falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 17 -Article 5 false2Other assets11false 3us-gaap_Assetsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse7928500079285falsefalsefalse2truefalsefalse9652200096522falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 true2Total assets12true 3us-gaap_LiabilitiesCurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Current liabilities:13false 4us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse59840005984falsefalsefalse2truefalsefalse56290005629falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Article 5 false2Accounts payable and accrued expenses14false 4us-gaap_DeferredRevenueCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse7500075falsefalsefalse2truefalsefalse150000150falsefalsefalsexbrli:monetaryItemTypemonetaryThe carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A false2Deferred revenue15false 3us-gaap_LiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse60590006059falsefalsefalse2truefalsefalse57790005779falsefalsefalsexbrli:monetaryItemTypemonetaryTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 21 -Article 5 true2Total current liabilities16true 3us-gaap_LiabilitiesNoncurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Long-term liabilities:17false 4us-gaap_DeferredRentCreditNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse14830001483falsefalsefalse2truefalsefalse16570001657falsefalsefalsexbrli:monetaryItemTypemonetaryFor a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 25 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.26(c)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Deferred rent18false 3us-gaap_CommitmentsAndContingenciesus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  falsefalsefalse2falsefalsefalse00  falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 25 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 7 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 17 -Article 9 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.(a),19) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 false2Commitments and contingencies19true 3us-gaap_StockholdersEquityAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Stockholders' equity:20false 4us-gaap_PreferredStockValueus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  falsefalsefalse2falsefalsefalse00  falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false2Preferred stock, $0.01 par value, 5,000 shares authorized, none issued and outstanding21false 4us-gaap_CommonStockValueus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse865000865falsefalsefalse2truefalsefalse861000861falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false2Common stock, $0.01 par value, 160,000 shares authorized, 86,495 and 86,136 shares issued and outstanding at June 30, 2013, and December 31, 2012, respectively22false 4us-gaap_AdditionalPaidInCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse437844000437844falsefalsefalse2truefalsefalse435915000435915falsefalsefalsexbrli:monetaryItemTypemonetaryExcess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.30(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Additional paid-in capital23false 4us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-367100000-367100falsefalsefalse2truefalsefalse-347937000-347937falsefalsefalsexbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Accumulated deficit24false 4us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse134000134falsefalsefalse2truefalsefalse247000247falsefalsefalsexbrli:monetaryItemTypemonetaryAccumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669686-108580 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e681-108580 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 false2Accumulated other comprehensive income25false 3us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse7174300071743falsefalsefalse2truefalsefalse8908600089086falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 true2Total stockholders' equity26false 3us-gaap_LiabilitiesAndStockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse7928500079285USD$falsetruefalse2truefalsefalse9652200096522USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.32) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 32 -Article 5 true2Total liabilities and stockholders' equityfalseBALANCE SHEETS (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/StatementOfFinancialPositionClassified226 XML 36 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Balance Sheet Accounts
6 Months Ended

Jun. 30, 2013

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Other Balance Sheet Accounts

3. OTHER BALANCE SHEET ACCOUNTS

Accounts payable and accrued expenses consisted of the following (in thousands):

 June 30,
2013 December 31,
2012

Employee compensation
 $ 2,877 $ 3,858

Post-termination benefit accrual
 252 —

Clinical trial accrual
 644 660

Accounts payable
 1,295 377

Deferred rent
 337 307

Other accrued liabilities
 579 427





Total accounts payable and accrued expenses
 $ 5,984 $ 5,629





X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.

+ References

No definition available.

+ Details

Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements - Summary of Cash Equivalents, Marketable Securities and Long-Term Investments Measured at Fair Value (Detail) (USD $)
In Thousands, unless otherwise specified

Jun. 30, 2013

Dec. 31, 2012

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value $ 39,288 $ 58,364

Certificates of deposit [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value 1,026 496

Money market funds [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value 17,845 18,500

U.S. treasuries [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value 6,530 10,136

Corporate bonds [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value 4,853 11,501

Government-sponsored enterprise securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value 6,997 15,506

Auction rate securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value 2,037 2,225

Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value 25,401 29,132

Level 1 [Member] | Certificates of deposit [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value 1,026 496

Level 1 [Member] | Money market funds [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value 17,845 18,500

Level 1 [Member] | U.S. treasuries [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value 6,530 10,136

Level 1 [Member] | Corporate bonds [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value

Level 1 [Member] | Government-sponsored enterprise securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value

Level 1 [Member] | Auction rate securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value

Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value 11,850 27,007

Level 2 [Member] | Certificates of deposit [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value

Level 2 [Member] | Money market funds [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value

Level 2 [Member] | U.S. treasuries [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value

Level 2 [Member] | Corporate bonds [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value 4,853 11,501

Level 2 [Member] | Government-sponsored enterprise securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value 6,997 15,506

Level 2 [Member] | Auction rate securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value

Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value 2,037 2,225

Level 3 [Member] | Certificates of deposit [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value

Level 3 [Member] | Money market funds [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value

Level 3 [Member] | U.S. treasuries [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value

Level 3 [Member] | Corporate bonds [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value

Level 3 [Member] | Auction rate securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value $ 2,037 $ 2,225

X

- Definition

Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R24.xml IDEA: Other Balance Sheet Accounts - Summary of Accounts Payable and Accrued Expenses (Detail) 2.4.0.8125 - Disclosure - Other Balance Sheet Accounts - Summary of Accounts Payable and Accrued Expenses (Detail)truefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE3939----1310-Q0004_STD_0_20121231_0http://www.sec.gov/CIK0000819050instant2012-12-31T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1us-gaap_PayablesAndAccrualsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Payables And Accruals [Abstract]2false 2us-gaap_EmployeeRelatedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse28770002877USD$falsetruefalse2truefalsefalse38580003858USD$falsetruefalsexbrli:monetaryItemTypemonetaryTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Employee compensation3false 2us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse252000252falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe current liability recognized in the balance sheet that is associated with defined benefit pension plans and other postretirement and postemployment benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=28361610&loc=d3e2417-114920 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=28361610&loc=d3e2410-114920 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=28361610&loc=d3e1928-114920 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=21915240&loc=d3e1703-114919 false2Post-termination benefit accrual4false 2vicl_ClinicalTrialAccrualvicl_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse644000644falsefalsefalse2truefalsefalse660000660falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of clinical-related obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).No definition available.false2Clinical trial accrual5false 2us-gaap_AccountsPayableCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse12950001295falsefalsefalse2truefalsefalse377000377falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Accounts payable6false 2us-gaap_DeferredRentCreditCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse337000337falsefalsefalse2truefalsefalse307000307falsefalsefalsexbrli:monetaryItemTypemonetaryFor a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 25 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707 false2Deferred rent7false 2us-gaap_OtherAccruedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse579000579falsefalsefalse2truefalsefalse427000427falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765 false2Other accrued liabilities8false 2us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse59840005984USD$falsetruefalse2truefalsefalse56290005629USD$falsetruefalsexbrli:monetaryItemTypemonetarySum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Article 5 true2Total accounts payable and accrued expensesfalseOther Balance Sheet Accounts - Summary of Accounts Payable and Accrued Expenses (Detail) (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/DisclosureOtherBalanceSheetAccountsSummaryOfAccountsPayableAndAccruedExpenses28 XML 39 R10.xml IDEA: Marketable Securities, Available for Sale 2.4.0.8111 - Disclosure - Marketable Securities, Available for Saletruefalsefalse1false falsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_InvestmentsDebtAndEquitySecuritiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Investments Debt And Equity Securities [Abstract]2false 2us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 4.      MARKETABLE SECURITIES, AVAILABLE FOR SALE  The following is a summary of available-for-sale marketable securities (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="71%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> June 30, 2013 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Gain</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Loss</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Market Value</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,528</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,530</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,997</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,859</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,853</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,413</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,406</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="71%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> December 31, 2012 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Gain</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Unrealized Loss</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Market Value</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,135</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,136</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,507</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,506</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,509</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,501</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,647</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,639</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> At June 30, 2013, $6.7 million of these securities were scheduled to mature outside of one year. The Company did not realize any gains or losses on sales of available-for-sale securities for the six months ended June 30, 2013. As of June 30, 2013, none of the securities had been in a continuous material unrealized loss position longer than one year.  </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for investments in certain debt and equity securities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -Glossary Debt Security -URI http://asc.fasb.org/extlink&oid=6509901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -Glossary Equity Security -URI http://asc.fasb.org/extlink&oid=6511694 false0Marketable Securities, Available for SalefalseMarketable Securities, Available for SaleUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock12 XML 40 R5.xml IDEA: STATEMENTS OF COMPREHENSIVE LOSS 2.4.0.8106 - Statement - STATEMENTS OF COMPREHENSIVE LOSStruefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE3939----1310-Q0004_STD_91_20130630_0http://www.sec.gov/CIK0000819050duration2013-04-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE3939----1310-Q0004_STD_91_20120630_0http://www.sec.gov/CIK0000819050duration2012-04-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$eol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$eol_PE3939----1310-Q0004_STD_182_20120630_0http://www.sec.gov/CIK0000819050duration2012-01-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1vicl_AmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeLossAbstractvicl_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Amounts Reclassified Out Of Accumulated Other Comprehensive Income Loss [Abstract]2false 2us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-9881000-9881USD$falsetruefalse2truefalsefalse-7868000-7868USD$falsetruefalse3truefalsefalse-19163000-19163USD$falsetruefalse4truefalsefalse-7624000-7624USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 false2Net loss3true 2us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Unrealized (losses) gains on available-for-sale and long-term marketable securities:4false 3us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-100000-100falsefalsefalse2truefalsefalse3800038falsefalsefalse3truefalsefalse-113000-113falsefalsefalse4truefalsefalse234000234falsefalsefalsexbrli:monetaryItemTypemonetaryAmount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 10A -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669646-108580 false2Unrealized (losses) gains arising during holding period5false 3us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTaxus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse-590000-590falsefalsefalsexbrli:monetaryItemTypemonetaryAmount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e689-108580 false2Less: Reversal of unrealized losses in accumulated other comprehensive loss upon the sale of long-term marketable securities included in investment and other income6false 3us-gaap_OtherComprehensiveIncomeLossNetOfTaxus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-100000-100falsefalsefalse2truefalsefalse3800038falsefalsefalse3truefalsefalse-113000-113falsefalsefalse4truefalsefalse-356000-356falsefalsefalsexbrli:monetaryItemTypemonetaryAmount after tax and reclassification adjustments of other comprehensive income (loss).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669619-108580 true2Other comprehensive (loss) gain7false 3us-gaap_ComprehensiveIncomeNetOfTaxus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-9981000-9981USD$falsetruefalse2truefalsefalse-7830000-7830USD$falsetruefalse3truefalsefalse-19276000-19276USD$falsetruefalse4truefalsefalse-7980000-7980USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Comprehensive Income -URI http://asc.fasb.org/extlink&oid=16317811 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e557-108580 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 true2Total comprehensive lossfalseSTATEMENTS OF COMPREHENSIVE LOSS (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/StatementOfOtherComprehensiveIncome47 EXCEL 41 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]B,V%A,#`Q-E]B-39A7S1F.#A?.#EA9E\U,V9C M-61A.34R8S(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/DUA#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DQO;F=497)M7TEN=F5S=&UE;G1S/"]X.DYA;64^#0H@("`@/'@Z M5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K0F%S961?0V]M<&5N#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D]T:&5R7T)A;&%N8V5? M4VAE971?06-C;W5N='-?5#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DUA#I7;W)K#I7;W)K#I7;W)K#I7;W)K M#I7;W)K#I7 M;W)K#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DQO;F=497)M7TEN=F5S=&UE;G1S M7T%D9&ET:6]N83PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D9A:7)?5F%L=65?365A#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D9A:7)?5F%L=65?365A#I7;W)K#I7;W)K#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H965T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,V%A,#`Q M-E]B-39A7S1F.#A?.#EA9E\U,V9C-61A.34R8S(-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO8C-A83`P,39?8C4V85\T9C@X7S@Y869?-3-F8S5D M83DU,F,R+U=O'0O:'1M;#L@8VAA2!) M;F9O2!);F9O M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA2!296=I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'10 M87)T7V(S86$P,#$V7V(U-F%?-&8X.%\X.6%F7S4S9F,U9&$Y-3)C,@T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B,V%A,#`Q-E]B-39A7S1F.#A? M.#EA9E\U,V9C-61A.34R8S(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6%B;&4@86YD(&%C8W)U960@97AP M96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQAF5D+"`X-BPT.34@86YD M(#@V+#$S-B!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A="!*=6YE M(#,P+"`R,#$S+"!A;F0@1&5C96UB97(@,S$L(#(P,3(L(')E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]B,V%A,#`Q-E]B-39A7S1F.#A?.#EA9E\U,V9C M-61A.34R8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C-A83`P M,39?8C4V85\T9C@X7S@Y869?-3-F8S5D83DU,F,R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,#QS<&%N/CPO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]B,V%A,#`Q-E]B-39A7S1F.#A?.#EA9E\U,V9C M-61A.34R8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C-A83`P M,39?8C4V85\T9C@X7S@Y869?-3-F8S5D83DU,F,R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XR.#8\'!E;G-E'!E;G-E*3H\+W-T7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XQ+#`R,SQS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'!E;G-E(')E;&%T M960@=&\@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S2`H=7-E9"!I;BD@:6YV97-T:6YG(&%C=&EV:71I97,\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/C$N)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[ M)B-X03`[1T5.15)!3#PO8CX\+V9O;G0^/"]P/@T*/"$M+2!X8G)L+&)O9'D@ M+2T^#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4 M.B`T)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/E9I8V%L#0I) M;F-O$$P.S$Y.#<@ M86YD(&AA"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!;&P@;V8@=&AE#0I#;VUP M86YY)B-X,C`Q.3MS('!O=&5N=&EA;"!P2!E87)N28C>#(P M,3D[2!E>'!E8W1S('1O(&-O;G1I;G5E M#0IT;R!I;F-U65A6QE/3-$)TU!4D=)3BU43U`Z(#$R M<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H92!U;F%U9&ET960-"F9I;F%N8VEA;"!S=&%T96UE;G1S(&%T M($IU;F4F(WA!,#LS,"P@,C`Q,RP@86YD(&9O6QE/3-$)TU!4D=)3BU43U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ M(#!P>"<^/&9O;G0@"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#87-H(&%N9"!C87-H#0IE<75I M=F%L96YT2!L:7%U:60@2!D87ES(&]R#0IL97-S+B!);G9E M2!D871E#0IM87D@8F4@;VYE('EE87(@;W(@ M;6]R92!B97EO;F0@=&AE(&-U2X@4F5A;&EZ960@9V%I;G,@86YD(&QO"P-"G)E8VQA2P- M"F%R92!D971E6QE/3-$)TU!4D=)3BU43U`Z(#$X M<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@"<^ M#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!I2!B92!A8FQE('1O#0IE;&EM:6YA=&4@=&AE(&YE960@9F]R('1H M92!L971T97(@;V8@8W)E9&ET+B!!6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQI/E)E=F5N=64-"E)E8V]G;FET:6]N/"]I/CPO9F]N=#X\+W`^ M#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T M)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/E)E=F5N=64@:7,- M"G)E8V]G;FEZ960@=VAE;B!T:&4@9F]U$$P.V1E;&EV97)Y(&AA28C>#(P,3D[#L@34%21TE. M+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#%P>"<^#0HF(WA!,#L\+W`^#0H\ M<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[(%1%6%0M24Y$14Y4.B`T)3L@ M34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/E1H92!#;VUP86YY(&AA M2!I9&5N=&EF:65S('1H90T* M9&5L:79E#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]4 M5$]-.B`P<'@G/@T*/&9O;G0@#L@ M5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@ M'!E2!E=FED96YC92!O9@T*&ES=',L('1H92!#;VUP86YY('5S97,@:71S(&)EF5D('5P;VX@=&AE(&1E;&EV97)Y#0IO9B!T M:&4@;&EC96YS92P@87-S=6UI;F<@=&AE(&]T:&5R(')E=F5N=64@2!O9B!T:&4@;&EC96YS90T*:7,@;&EM:71E M9"!T;R!T:&4@=7!FF5D M(&%S('1H;W-E(&ET96US(&%R92!D96QI=F5R960N/"]F;VYT/CPO<#X-"CQP M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)3L@ M34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/E1H92!T97)M6UE;G1S('5P;VX@86-H:65V96UE M;G0@;V8@8V5R=&%I;B!R96=U;&%T;W)Y(&%N9"!C;VUM97)C:6%L#0IE=F5N M=',N(%1H92!#;VUP86YY(')E8V]G;FEZ97,@8V]N2!A2!I M9B!T:&4@;6EL97-T;VYE#0II2!B92!A8VAI M979E9"!B87-E9"!I;B!W:&]L92!O28C>#(P,3D[$$P.W1H M870@=V]U;&0@2X\+V9O;G0^/"]P/@T*/'`@#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CX\:3Y#;VYT6QE/3-$)TU!4D=)3BU43U`Z M(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T* M/&9O;G0@6%L=&EE M#L@34%21TE.+4)/ M5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CX\:3Y.970@3&]S6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/D)A2!A2!A$$P.S,P M+"`R,#$S(&%N9"`R,#$R+"!R97-P96-T:79E;'DL('=E#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#%P M>"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[ M($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@6QE M/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM M0D]45$]-.B`P<'@G/@T*/&9O;G0@$$P.S(P,3,M,#(L("8C M>#(P,4,[4F5P;W)T:6YG(&]F($%M;W5N=',-"E)E8VQA&)R;"QN("TM/CPO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB M/C(N)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[4U1/0TLM M0D%3140-"D-/35!%3E-!5$E/3CPO8CX\+V9O;G0^/"]P/@T*/"$M+2!X8G)L M+&)O9'D@+2T^#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'@[(%1%6%0M M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1O M=&%L#0IS=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS92!W87,@86QL M;V-A=&5D('1O(')E6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE. M+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*)B-X03`[/"]P/@T* M/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]LF4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0Q/CQB/E-I>"!-;VYT:',-"D5N9&5D/"]B/CPO9F]N=#X\8G(@+SX-"CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/DIU;F4F(WA!,#LS,"P\+V(^/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*/"]TF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.R8C>$$P.R8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.R8C>$$P.R8C>$$P.SPO8CX\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.R8C>$$P.R8C M>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`],T1N;W=R87`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`],T1N;W=R M87`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`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@ M$$P M.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X- M"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\ M+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG M;CTS1'1O<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)' M24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;"!S=&]C:RUB87-E9`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`],T1N;W=R87`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`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\ M=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X- M"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^ M#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\(2TM($5N9"!486)L92!";V1Y M("TM/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!4 M15A4+4E.1$5.5#H@-"4[($U!4D=)3BU"3U143TTZ(#!P>"<^#0H\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY$=7)I;F<@=&AE('-I>`T*;6]N=&AS(&5N9&5D($IU;F4F(WA!,#LS,"P@ M,C`Q,R!A;F0@,C`Q,BP@=&AE($-O;7!A;GD@9W)A;G1E9`T*'!E8W1E9"!T;R!B M92!R96-O9VYI>F5D(&]V97(@82!W96EG:'1E9"UA=F5R86=E('!E65A$$P.S,P+"`R M,#$S(&%N9"`R,#$R+"!W97)E(&5Q=6%L('1O(#(N,B4@;V8@=&AE#0IO=71S M=&%N9&EN9R!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%T('1H92!E;F0@;V8@ M=&AE(&%P<&QI8V%B;&4-"G!E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879AF%T:6]N($-O;G-O M;&ED871I;VX@06YD(%!R97-E;G1A=&EO;B!/9B!&:6YA;F-I86P@4W1A=&5M M96YT6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/CQB/C,N)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[ M3U1(15(@0D%,04Y#12!32$5%5`T*04-#3U5.5%,\+V(^/"]F;VYT/CPO<#X- M"CPA+2T@>&)R;"QB;V1Y("TM/@T*/'`@"<^#0H\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY!8V-O=6YT'!E;G-E M6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%2 M1TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*)B-X03`[/"]P M/@T*/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0Q/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/D1E8V5M8F5R)B-X03`[,S$L/"]B/CPO M9F]N=#X\8G(@+SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*/"]T6QE/3-$)U1%6%0M24Y$14Y4 M.B`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`@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/E!O6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)U1%6%0M24Y$ M14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$969EF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS M,S<\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]T:&5R(&%C8W)U960-"FQI86)I;&ET:65S/"]F;VYT M/CPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU-SD\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D M/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X- M"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^ M#0H\=&0^)B-X03`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`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^ M)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"@T*#0H\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/CQB/C0N)B-X03`[)B-X03`[)B-X M03`[)B-X03`[)B-X03`[)B-X03`[34%22T5404),12!314-54DE42453+`T* M059!24Q!0DQ%($9/4B!304Q%/"]B/CPO9F]N=#X\+W`^#0H\(2TM('AB2`M+3X-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U) M3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@#L@1D].5"U325I%.B`Q,G!X)SX-"B8C>$$P.SPO<#X-"CQT M86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!B;W)D M97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@] M,T0Q,#`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`P,#`@ M,7!X('-O;&ED.R!724142#H@-#9P="<^#0H\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY*=6YE)B-X M03`[,S`L(#(P,3,\+V(^/"]F;VYT/CPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF5D/"]B/CPO9F]N=#X\8G(@+SX- M"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/D-OF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0Q/CQB/E5NF4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY5+E,N('1R96%S=7)I97,\+V9O;G0^/"]P/@T*/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXV+#4R.#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`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`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D=O=F5R;FUE;G0M6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/"]TF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXT+#@U.3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXV/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C0L.#4S/"]F;VYT/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@ M=F%L:6=N/3-$=&]P/@T*/'`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`@$$P.SPO<#X-"CPO=&0^#0H\=&0^ M)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF M(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C M>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X M03`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`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T* M/"]T6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/33H@,'!X.R!& M3TY4+5-)6D4Z(#$R<'@G/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$ M)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0Q/CQB/D1E8V5M8F5R)B-X03`[,S$L(#(P M,3(\+V(^/"]F;VYT/CPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]LF5D/"]B/CPO9F]N=#X\8G(@+SX-"CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q M/CQB/D-OF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/E5NF4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)U1% M6%0M24Y$14Y4.B`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`[)B-X03`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`[)B-X03`[/"]F;VYT M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D-O6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`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`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C0Y-CPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*/'`@$$P.SPO=&0^#0H\+W1R/@T* M/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*/'`@#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]4 M5$]-.B`P<'@G/@T*/&9O;G0@F4@86YY#0IG86EN&)R;"QN("TM/@T*#0H\+V1I=CX\'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/&1I=CX-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X M<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@2`M+3X-"CQP M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!- M05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM M0D]45$]-.B`P<'@G/@T*/&9O;G0@'!E0T*4W1A;F1A$$P.S,P+"`R,#$S+B!4:&4@6QE/3-$)TU!4D=)3BU4 M3U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X M)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H92!V86QU871I;VX-"F]F('1H92!#;VUP86YY)B-X M,C`Q.3MS(&%U8W1I;VX@2!I7-I2!I;G9E2P@=&AE('1I;6EN9R!O9B!E>'!E M8W1E9"!F=71U'!E8W1E9"!H;VQD:6YG#0IP97)I;V0N(%1H92!S M96-U2!W87,@86QS;R!C;VUP87)E9"P@=VAE;B!P;W-S:6)L92P@=&\@ M;W1H97(-"F]B2!H87,@F5D(&%R92!I;F-L=61E9"!I;B!I;G9E2!H87,@ M<&%R=&EA;&QY(')E8V]V97)E9"X@26YC;'5D960-"FEN(&]T:&5R(&-O;7!R M96AE;G-I=F4@:6YC;VUE(&%R92!U;G)E86QI>F5D("AL;W-S97,I(&=A:6YS M(&]F#0HD*#$Q,RPP,#`I(&%N9"`D,S8L,#`P(&9O6EN9R!V86QU92!O M9B!T:&4@875C=&EO;B!R871E('-E8W5R:71Y(&%T($IU;F4F(WA!,#LS,"P@ M,C`Q,RP-"G=A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B M,V%A,#`Q-E]B-39A7S1F.#A?.#EA9E\U,V9C-61A.34R8S(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C-A83`P,39?8C4V85\T9C@X7S@Y869? M-3-F8S5D83DU,F,R+U=O'0O:'1M;#L@8VAA6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/CQB/C8N)B-X03`[)B-X03`[)B-X M03`[)B-X03`[)B-X03`[)B-X03`[1D%)4B!604Q510T*345!4U5214U%3E13 M/"]B/CPO9F]N=#X\+W`^#0H\(2TM('AB2`M+3X-"CQP('-T>6QE M/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM M0D]45$]-.B`P<'@G/@T*/&9O;G0@#L@1D]. M5"U325I%.B`V<'@G/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)T)/ M4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DQE=F5L(#$Z($]B6QE/3-$)TU! M4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z M(#9P>"<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1'1O<"!W:61T:#TS1#,E(&%L:6=N/3-$;&5F=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(W@R,#(R.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T M:#TS1#$E/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^#0H\<"!A;&EG;CTS1&QE9G0^ M/&9O;G0@3L-"F%N9#PO9F]N M=#X\+W`^#0H\+W1D/@T*/"]T#L@1D].5"U325I% M.B`V<'@G/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU# M3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DQE=F5L(#,Z(%5N;V)S97)V86)L92!I;G!U=',@:6X@=VAI M8V@@=&AE2!T;R!D979E;&]P(&ET"<^#0H\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#87-H M#0IE<75I=F%L96YT#L@1D].5"U325I%.B`Q,G!X)SX-"B8C>$$P M.SPO<#X-"CQT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA M<'-E)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS M1#`@=VED=&@],T0Q,#`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`C,#`P,#`P(#%P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS M1&-E;G1EF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/DIU;F4F(WA!,#LS,"P@,C`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`],T1N;W=R87`^/&9O;G0@F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L,#(V/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DUO;F5Y(&UA6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$W+#@T-3PO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T M.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`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`],T1N M;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV+#4S,#PO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4 M.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#;W)P;W)A=&4@ M8F]N9',\+V9O;G0^/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>#(P,30[)B-X03`[)B-X03`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`[)B-X03`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`[)B-X03`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`[)B-X03`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`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`@ M$$P M.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X- M"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\ M+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO M<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO M=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@8F=C;VQOF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXQ,2PX-3`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`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X- M"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^ M#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T M9#X-"CQT9#XF(WA!,#L\+W1D/@T*/"]T6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@ M34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*)B-X03`[ M/"]P/@T*/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/D9A:7(@5F%L=64-"DUE87-U6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D-E6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C0Y-CPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`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`[)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$X+#4P,#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`M M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY5+E,N('1R96%S=7)I M97,\+V9O;G0^/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$P+#$S M-CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`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`],T1N;W=R87`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`[)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C$U+#4P-CPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ M-2PU,#8\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/"]TF4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#(R-3PO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXR+#(R-3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X- M"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO M<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`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`P-SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"CQT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\+W1R/@T*/"$M+2!%;F0@5&%B M;&4@0F]D>2`M+3X\+W1A8FQE/@T*/'`@#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T* M/&9O;G0@$$P.S,P M+"`R,#$S+B!4:&4@0V]M<&%N>2!D971E2!T:&ER9"!P87)T:65S M#0IU2!V86QU871I;VX@;6]D96QS(&%N9"!A;F%L M>71I8V%L('1O;VQS+B!4:&5S90T*=F%L=6%T:6]N(&UO9&5L#(P,3D[2!A2!O9B!T:&4@=F%L=6%T:6]N2!D:60@;F]T(')E8VQA$$P.S,P+"`R,#$S+B!4:&4-"G9A;'5A M=&EO;B!O9B!T:&4@0V]M<&%N>28C>#(P,3D[6QE/3-$)TU! M4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I% M.B`Q<'@G/@T*)B-X03`[/"]P/@T*/'`@"<^#0H\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY!8W1I=FET>2!F;W(-"F%S"<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@$$P.S,P M+"8C>$$P.S(P,3,\+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5& M5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY"86QA;F-E(&%T#0I$96-E;6)E$$P.S,Q M+"`R,#$R/"]F;VYT/CPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T"!I;7!A8W0L M(&EN8VQU9&5D(&EN(&]T:&5R(&-O;7!R96AE;G-I=F4-"FEN8V]M93PO9F]N M=#X\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@"<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X- M"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D)A;&%N8V4@870@2G5N928C>$$P.S,P+`T* M,C`Q,SPO9F]N=#X\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C(L,#,W/"]F M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\ M='(@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^ M)B-X03`[/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P/@T* M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1O=&%L(&=A:6YS(&]R(&QO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"CQT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO M9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX-"CQP M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ(#!P M>"<^/&9O;G0@&)R;"QB;V1Y("TM/@T*/'`@"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>0T*<')O6QE M/3-$)TU!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE. M+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/DEN('1H92!O0T*8V]U M2!M87D@8F5C;VUE(&$@<&%R M='D@=&\@;&%W2!P96YD:6YG(&%G86EN2!O28C>#(P,3D[&)R;"QN("TM/@T*#0H\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=CX-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'@[($U!4D=) M3BU"3U143TTZ(#!P>"<^/&9O;G0@2`M+3X-"CQP('-T M>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)' M24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@0T*,C`Q,BP@ M=&AE($-O;7!A;GD@#(P,3D[#0IO=F5R86QL;W1M96YT(&]P=&EO;B!A M="!A('!R:6-E('1O('1H92!P=6)L:6,@;V8@)#,N-S4@<&5R('-H87)E+@T* M3F5T('!R;V-E961S(&9R;VT@=&AE(&]F9F5R:6YG+"!A9G1E'!E;G-E2P@=&]T86QE9"`D-#@N-R!M:6QL:6]N+B!!;&P@;V8@=&AE('-H87)E M#L@5$58 M5"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@2!I2!W:6QL('-E="!T:&4@<&%R86UE=&5R2!N;W0@8F4@;6%D92X@4W5B:F5C="!T M;R!T:&4@=&5R;7,@86YD(&-O;F1I=&EO;G,@;V8@=&AE#0I386QE2!M96%N#(P,3D[('1R86YS86-T:6]N&)R;"QN("TM/@T*#0H\+V1I=CX\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VL@6T%B'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CX\8CXY+B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.T%3 M5$5,3$%3#0I!1U)%14U%3E13/"]B/CPO9F]N=#X\+W`^#0H\(2TM('AB2`M+3X-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U) M3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@2`R,#$Q+`T*=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&QI8V5N2UB96%R:6YG(&QI8V5N6QE/3-$)TU! M4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/ M33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E5N9&5R('1H92!T97)M2!A;'-O(')E8V5I=F5D(&$-"B0Q,"XP(&UI;&QI M;VX@;6EL97-T;VYE('!A>6UE;G0@:6X@36%R8V@@,C`Q,B!U<&]N(&9I;F%L M:7IA=&EO;B!O9@T*=&AE(&=E;F5R86P@=')I86P@9&5S:6=N(&9O2X\+V9O;G0^ M/"]P/@T*/'`@#L@5$585"U)3D1% M3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@F5D("0Q+C$@;6EL M;&EO;B!A;F0@)#(N,B!M:6QL:6]N+"!R97-P96-T:79E;'DL(&]F(')E=F5N M=64-"G)E;&%T960@=&\@=&AE"!M;VYT:',-"F5N9&5D($IU;F4F(WA!,#LS M,"P@,C`Q,BP@=&AE($-O;7!A;GD@2P@;V8@#L@5$585"U)3D1%3E0Z M(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@2!A;65N9&5D(&ET'1E;F0@=&AE('1I;64@<&5R:6]D('1H870@=&AE($-O M;7!A;GD@:7,-"F]B;&EG871E9"!T;R!S=7!P;'D@;&EC96YS960@<')O9'5C M=',@9F]R(&-O;6UE'!E;G-E+"!M;V1I9GD@=&AE(&%L;&]C871I;VX@;V8- M"B0Y-2XP(&UI;&QI;VX@;V8@;6EL97-T;VYE('!A>6UE;G1S(&%M;VYG(&-E M6%L=&EE2!T M;R!T:65R960@9&]U8FQE#0ID:6=I="!R;WEA;'1I97,N/"]F;VYT/CPO<#X- M"CPA+2T@+WAB3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]B,V%A,#`Q-E]B-39A7S1F.#A?.#EA9E\U M,V9C-61A.34R8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C-A M83`P,39?8C4V85\T9C@X7S@Y869?-3-F8S5D83DU,F,R+U=O'0O:'1M;#L@8VAA'0^ M/&1I=CX-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`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`R,#$R+"!R97-T'0^/&1I=CX-"CQP('-T>6QE M/3-$)TU!4D=)3BU43U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O M;G0@6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E M.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@$$P.W!E2!I2!A M$$P.SPO<#X-"CQP M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@5$585"U)3D1%3E0Z(#0E.R!- M05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@7II;F<@=&AE#0IA2!D96QI=F5R86)L97,@2!B M92!A;B!O8FQI9V%T:6]N('1O(&1E;&EV97(@"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@9&5L:79E28C>#(P,3D["<^#0H\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY!(&1E;&EV97)E9`T*:71E;2!I2!E=FED96YC92!O9B!S96QL M:6YG('!R:6-E#0II9B!64T]%(&1O97,@;F]T(&5X:7-T+B!)9B!N96ET:&5R M(%933T4@;F]R('1H:7)D+7!A&5D(&]R M#0ID971EF5D('5N M9&5R(&%N>2!A9W)E96UE;G0N($EF(&9A8W1S#0IA;F0@8VER8W5MF5D M('5P;VX@=&AE(&1E;&EV97)Y(&]F('1H92!L:6-E;G-E#0II#L@5$585"U)3D1%3E0Z(#0E.R!- M05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@28C>#(P,3D[2X@02!M:6QE28C>#(P,3D[2!T M;R!P87-T('!E$$P.W1H870@8V%N(&]N;'D@8F4@86-H:65V960@8F%S960@:6X-"G=H;VQE M(&]R(&EN('!A$$P.V9O0T*870@=&AE(&1A=&4@=&AE(&%R6UE;G1S#0IB96EN9R!D=64@=&\@=&AE($-O;7!A;GDN M/"]F;VYT/CPO<#X-"CPO9&EV/CQS<&%N/CPO6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/CQI/D-O;G1R86-T(%-E6%L='D@4F5V96YU93PO:3X\+V9O;G0^/"]P M/@T*/'`@"<^#0H\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N M>0T*'!E;F1I='5R M97,-"F%R92!I;F-U2!T:&4@0V]M M<&%N>28C>#(P,3D[28C>#(P,3D['0^ M/&1I=CX-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'@[($U!4D=)3BU" M3U143TTZ(#!P>"<^/&9O;G0@"<^#0H\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY"87-I8R!A;F0-"F1I;'5T960@;F5T(&QO&-L=61E&5R8VES92!O9@T*$$P.S,P+"`R,#$S(&%N9`T*,C`Q,BP@"!M;VYT:',@96YD960-"DIU;F4F(WA!,#LS M,"P@,C`Q,R!A;F0@,C`Q,BP@'0^/&1I=CX-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@ M34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\:3Y296-E;G0@06-C;W5N M=&EN9PT*4')O;F]U;F-E;65N=#PO:3X\+V9O;G0^/"]P/@T*/'`@"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY%9F9E8W1I=F4-"DIA;G5A2!A9&]P=&5D($%C8V]U;G1I;F<@4W1A M;F1A2!A;F0@ M9&ED(&YO="!H879E(&%N(&EM<&%C="!O;B!T:&4@0V]M<&%N>28C>#(P,3D[ M7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@"<^#0H\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY4;W1A;`T*#L@1D].5"U325I%.B`Q,G!X)SX-"B8C M>$$P.SPO<#X-"CQT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O M;&QA<'-E)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`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`P,#`@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/E-I>"!-;VYT:',@16YD960\8G(@+SX-"DIU;F4F M(WA!,#LS,"P\+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]TF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]LF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`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`],T1N;W=R87`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`],T1N;W=R87`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`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\+W1R M/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<#X-"CQP('-T>6QE/3-$)U1%6%0M M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A M;"!S=&]C:RUB87-E9`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`],T1N;W=R87`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`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\ M(2TM($5N9"!486)L92!";V1Y("TM/CPO=&%B;&4^#0H\+V1I=CX\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6%B;&4@86YD($%C8W)U960@17AP96YS M97,\+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/D%C8V]U;G1S#0IP87EA8FQE M(&%N9"!A8V-R=65D(&5X<&5N"<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,P+#QBF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`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`@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/E!O6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X M03`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)U1% M6%0M24Y$14Y4.B`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`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@ M$$P M.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X- M"CPO=&0^#0H\=&0^)B-X03`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`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^ M#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\+W1R/@T*/"$M+2!%;F0@5&%B;&4@0F]D M>2`M+3X\+W1A8FQE/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]B,V%A,#`Q-E]B-39A7S1F.#A?.#EA9E\U,V9C M-61A.34R8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C-A83`P M,39?8C4V85\T9C@X7S@Y869?-3-F8S5D83DU,F,R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H M92!F;VQL;W=I;F<-"FES(&$@2!O9B!A=F%I;&%B;&4M9F]R+7-A M;&4@;6%R:V5T86)L92!S96-U"<^#0HF(WA!,#L\+W`^#0H\ M=&%B;&4@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!724142#H@-#9P="<^#0H\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY*=6YE)B-X M03`[,S`L(#(P,3,\+V(^/"]F;VYT/CPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF5D/"]B/CPO9F]N=#X\8G(@+SX- M"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/D-OF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0Q/CQB/E5NF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/E5NF4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q M/CQB/DUAF4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY5+E,N('1R96%S=7)I97,\ M+V9O;G0^/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV+#4R.#PO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`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`@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/D=O=F5R;FUE M;G0M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>#(P,30[)B-X03`[)B-X03`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`],T1N;W=R87`^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`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`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/D-E6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/"]T"<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@ M$$P M.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`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`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X- M"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^ M#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T M9#X-"CQT9#XF(WA!,#L\+W1D/@T*/"]TF4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L6QE/3-$)U1%6%0M24Y$14Y4.B`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`[)B-X03`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`[)B-X03`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`[)B-X03`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`[)B-X03`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`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X- M"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R(&)G M8V]L;W(],T0C0T-%149&/@T*/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,W+#8T-SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`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`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^ M#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T M9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO M=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\(2TM($5N9"!486)L92!" M;V1Y("TM/CPO=&%B;&4^#0H\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M2!O9B!#87-H($5Q=6EV M86QE;G1S+"!-87)K971A8FQE(%-E8W5R:71I97,@86YD($QO;F#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P M<'@G/@T*/&9O;G0@"<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1EF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M/"]T6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0Q/CQB/DIU;F4F(WA!,#LS M,"P@,C`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`],T1N;W=R87`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`@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/DUO;F5Y(&UA6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C$W+#@T-3PO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-RPX-#4\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/"]TF4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXV+#4S,#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXV+#4S,#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY#;W)P;W)A=&4@8F]N9',\+V9O;G0^/"]P/@T*/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`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`[)B-X03`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`[)B-X03`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`[)B-X03`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`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`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^ M#0H\='(@8F=C;VQOF4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,2PX-3`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`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/"]TF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/D9A:7(@5F%L=64-"DUE87-U6QE M/3-$)U1%6%0M24Y$14Y4.B`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`[)B-X M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`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`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ M."PU,#`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`[)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/C$Q+#4P,3PO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)U1% M6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY' M;W9EF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`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`@$$P.SPO<#X-"CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\ M=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT M9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D M/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^ M)B-X03`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`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA! M,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X M03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF M(WA!,#L\+W1D/@T*/"]T2!O9B!!8W1I=FET>2!F;W(@07-S971S M($UE87-U'0^/&1I=CX-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@5$585"U) M3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@ M34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*)B-X03`[ M/"]P/@T*/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P MF4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0Q/CQB/D5N9&5D/"]B/CPO9F]N M=#X\8G(@+SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/DIU;F4F(WA!,#LS,"PF(WA!,#LR,#$S M/"]B/CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\(2TM($5N9"!4 M86)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"CQT6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C(L,C(U/"]F;VYT/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@ M=F%L:6=N/3-$=&]P/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/E1O=&%L(&YE="!U;G)E86QI M>F5D#0IL;W-S97,L(&5X8VQU9&EN9R!T87@@:6UP86-T+"!I;F-L=61E9"!I M;B!O=&AE6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B@Q.#@\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA! M,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X- M"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R M(&)G8V]L;W(],T0C0T-%149&/@T*/'1D('9A;&EG;CTS1'1O<#X-"CQP('-T M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY"86QA;F-E(&%T($IU;F4F(WA!,#LS,"P-"C(P,3,\+V9O;G0^ M/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#`S-SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^ M#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<#X-"CQP('-T>6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY4;W1A;"!G86ENF4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT M9#XF(WA!,#L\+W1D/@T*/"]T'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQAF%T:6]N($-O;G-O;&ED M871I;VX@06YD(%!R97-E;G1A=&EO;B!/9B!&:6YA;F-I86P@4W1A=&5M96YT M&EM=6T@<&5R:6]D(&9O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M;6]R92!T:&%N(&YI;F5T>2!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!F86-I;&ET M:65S(&QE87-E+"!W:&EC:"!E;F1S(&EN($%U9W5S="`R,#$W+CQS<&%N/CPO M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&-L=61E9"!F'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]B,V%A,#`Q-E]B-39A7S1F.#A?.#EA9E\U,V9C-61A.34R8S(- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C-A83`P,39?8C4V85\T M9C@X7S@Y869?-3-F8S5D83DU,F,R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!O9B!4;W1A;"!3=&]C:RU" M87-E9"!#;VUP96YS871I;VX@17AP96YS92`H1&5T86EL*2`H55-$("0I/&)R M/DEN(%1H;W5S86YD'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@Q-CQS M<&%N/CPO'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M65E(%-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'!E;G-E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XV,#QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$65E(%-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]B,V%A,#`Q-E]B-39A7S1F.#A?.#EA9E\U,V9C-61A M.34R8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C-A83`P,39? M8C4V85\T9C@X7S@Y869?-3-F8S5D83DU,F,R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M6UE M;G1S(%M!8G-T'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF5D(&-O;7!E;G-A=&EO;B!C;W-T(')E M;&%T960@=&\@=6YV97-T960@;W!T:6]N3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,V%A,#`Q-E]B-39A M7S1F.#A?.#EA9E\U,V9C-61A.34R8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO8C-A83`P,39?8C4V85\T9C@X7S@Y869?-3-F8S5D83DU,F,R M+U=O'0O M:'1M;#L@8VAA7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!O9B!!=F%I;&%B;&4M9F]R+5-A;&4@ M36%R:V5T86)L92!396-UF5D($-OF5D($-OF5D($=A M:6X\+W1D/@T*("`@("`@("`\=&0@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^ M)FYBF5D($QOF5D($-OF5D M($=A:6X\+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A2!396-U65AF5D(&=A:6YS(&]R(&QO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!O9B!L;VYG+71E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,C`S.#QS<&%N/CPO M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6EN9R!V86QU92!O9B!A=6-T:6]N M(')A=&4@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^)FYB'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^ M)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!O9B!!8W1I=FET>2!F;W(@07-S971S($UE87-U M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^)FYB3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,V%A,#`Q-E]B-39A7S1F.#A? M.#EA9E\U,V9C-61A.34R8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO8C-A83`P,39?8C4V85\T9C@X7S@Y869?-3-F8S5D83DU,F,R+U=O'0O:'1M;#L@ M8VAA&5R8VES92!O9B!U;F1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAAF%T:6]N($-O;G-O;&ED871I;VX@06YD(%!R M97-E;G1A=&EO;B!/9B!&:6YA;F-I86P@4W1A=&5M96YTF%T:6]N(&]F('1H92!G96YE'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC XML 42 R4.xml IDEA: STATEMENTS OF OPERATIONS 2.4.0.8105 - Statement - STATEMENTS OF OPERATIONStruefalseIn Thousands, except Per Share data, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE3939----1310-Q0004_STD_91_20130630_0http://www.sec.gov/CIK0000819050duration2013-04-01T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE3939----1310-Q0004_STD_91_20120630_0http://www.sec.gov/CIK0000819050duration2012-04-01T00:00:002012-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$eol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$eol_PE3939----1310-Q0004_STD_182_20120630_0http://www.sec.gov/CIK0000819050duration2012-01-01T00:00:002012-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 2us-gaap_RevenuesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Revenues:2false 3vicl_ContractAndGrantRevenuevicl_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse11700001170USD$falsetruefalse2truefalsefalse13640001364USD$falsetruefalse3truefalsefalse23060002306USD$falsetruefalse4truefalsefalse25850002585USD$falsetruefalsexbrli:monetaryItemTypemonetaryRevenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, manufacturing contracts, and any other contract related to a particular project or product. Also may include revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.No definition available.false2Contract and grant revenue3false 3vicl_LicenseAndRoyaltyRevenuevicl_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse286000286falsefalsefalse2truefalsefalse201000201falsefalsefalse3truefalsefalse724000724falsefalsefalse4truefalsefalse1044000010440falsefalsefalsexbrli:monetaryItemTypemonetaryLicense revenue earned during the period relates to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, or manufacturing process. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's licensed property.No definition available.false2License and royalty revenue4false 3us-gaap_Revenuesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse14560001456falsefalsefalse2truefalsefalse15650001565falsefalsefalse3truefalsefalse30300003030falsefalsefalse4truefalsefalse1302500013025falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 true2Total revenues5true 2us-gaap_OperatingExpensesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Operating expenses:6false 3us-gaap_ResearchAndDevelopmentExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse39300003930falsefalsefalse2truefalsefalse37910003791falsefalsefalse3truefalsefalse75800007580falsefalsefalse4truefalsefalse1021900010219falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 false2Research and development7false 3us-gaap_ManufacturingCostsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse38910003891falsefalsefalse2truefalsefalse29330002933falsefalsefalse3truefalsefalse76040007604falsefalsefalse4truefalsefalse54050005405falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate costs incurred in the production of goods for sale.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 false2Manufacturing and production8false 3us-gaap_GeneralAndAdministrativeExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse34780003478falsefalsefalse2truefalsefalse27780002778falsefalsefalse3truefalsefalse69960006996falsefalsefalse4truefalsefalse54780005478falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 false2General and administrative9false 3us-gaap_OperatingExpensesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse1129900011299falsefalsefalse2truefalsefalse95020009502falsefalsefalse3truefalsefalse2218000022180falsefalsefalse4truefalsefalse2110200021102falsefalsefalsexbrli:monetaryItemTypemonetaryGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.No definition available.true2Total operating expenses10false 2us-gaap_OperatingIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-9843000-9843falsefalsefalse2truefalsefalse-7937000-7937falsefalsefalse3truefalsefalse-19150000-19150falsefalsefalse4truefalsefalse-8077000-8077falsefalsefalsexbrli:monetaryItemTypemonetaryThe net result for the period of deducting operating expenses from operating revenues.No definition available.true2Loss from operations11true 2us-gaap_NonoperatingIncomeExpenseAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Other income (expense):12false 3vicl_InvestmentAndOtherIncomeNetvicl_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-38000-38falsefalsefalse2truefalsefalse6900069falsefalsefalse3truefalsefalse-13000-13falsefalsefalse4truefalsefalse453000453falsefalsefalsexbrli:monetaryItemTypemonetaryInvestment income is derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money. Other income includes the aggregate amount of other nonrecurring expenses, not previously categorized, that are infrequent in occurrence or unusual in nature.No definition available.false2Investment and other income, net13false 3us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-9881000-9881USD$falsetruefalse2truefalsefalse-7868000-7868USD$falsetruefalse3truefalsefalse-19163000-19163USD$falsetruefalse4truefalsefalse-7624000-7624USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 true2Net loss14false 2us-gaap_EarningsPerShareBasicAndDilutedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-0.11-0.11USD$falsetruefalse2truefalsefalse-0.09-0.09USD$falsetruefalse3truefalsefalse-0.22-0.22USD$falsetruefalse4truefalsefalse-0.09-0.09USD$falsetruefalsenum:perShareItemTypedecimalThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.No definition available.false3Basic and diluted net loss per share15false 2us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDilutedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse8673000086730falsefalsefalse2truefalsefalse8628200086282falsefalsefalse3truefalsefalse8662300086623falsefalsefalse4truefalsefalse8541200085412falsefalsefalsexbrli:sharesItemTypesharesAverage number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).No definition available.false1Weighted average shares used in computing basic and diluted net loss per sharefalseSTATEMENTS OF OPERATIONS (USD $)ThousandsThousandsNoRoundingUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/StatementOfIncome415 XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 HtmlAndXml 79 141 1 false 16 0 false 5 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.vical.com/taxonomy/role/DocumentDocumentandEntityInformation Document and Entity Information R1.xml true false R2.htm 103 - Statement - BALANCE SHEETS Sheet http://www.vical.com/taxonomy/role/StatementOfFinancialPositionClassified BALANCE SHEETS R2.xml false false R3.htm 104 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://www.vical.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical BALANCE SHEETS (Parenthetical) R3.xml false false R4.htm 105 - Statement - STATEMENTS OF OPERATIONS Sheet http://www.vical.com/taxonomy/role/StatementOfIncome STATEMENTS OF OPERATIONS R4.xml false false R5.htm 106 - Statement - STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.vical.com/taxonomy/role/StatementOfOtherComprehensiveIncome STATEMENTS OF COMPREHENSIVE LOSS R5.xml false false R6.htm 107 - Statement - STATEMENTS OF CASH FLOWS Sheet http://www.vical.com/taxonomy/role/StatementOfCashFlowsIndirect STATEMENTS OF CASH FLOWS R6.xml false false R7.htm 108 - Disclosure - General Sheet http://www.vical.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock General R7.xml false false R8.htm 109 - Disclosure - Stock-Based Compensation Sheet http://www.vical.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation R8.xml false false R9.htm 110 - Disclosure - Other Balance Sheet Accounts Sheet http://www.vical.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock Other Balance Sheet Accounts R9.xml false false R10.htm 111 - Disclosure - Marketable Securities, Available for Sale Sheet http://www.vical.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Marketable Securities, Available for Sale R10.xml false false R11.htm 112 - Disclosure - Long-Term Investments Sheet http://www.vical.com/taxonomy/role/NotesToFinancialStatementsLongTermInvestmentsTextBlock Long-Term Investments R11.xml false false R12.htm 113 - Disclosure - Fair Value Measurements Sheet http://www.vical.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementInputsDisclosureTextBlock Fair Value Measurements R12.xml false false R13.htm 114 - Disclosure - Commitments and Contingencies Sheet http://www.vical.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies R13.xml false false R14.htm 115 - Disclosure - Stockholders' Equity Sheet http://www.vical.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity R14.xml false false R15.htm 116 - Disclosure - Astellas Agreements Sheet http://www.vical.com/taxonomy/role/NotesToFinancialStatementsAgreementsDisclosureTextBlock Astellas Agreements R15.xml false false R16.htm 117 - Disclosure - General (Policies) Sheet http://www.vical.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies General (Policies) R16.xml false false R17.htm 118 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.vical.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation (Tables) R17.xml false false R18.htm 119 - Disclosure - Other Balance Sheet Accounts (Tables) Sheet http://www.vical.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables Other Balance Sheet Accounts (Tables) R18.xml false false R19.htm 120 - Disclosure - Marketable Securities, Available for Sale (Tables) Sheet http://www.vical.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables Marketable Securities, Available for Sale (Tables) R19.xml false false R20.htm 121 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vical.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementInputsDisclosureTextBlockTables Fair Value Measurements (Tables) R20.xml false false R21.htm 122 - Disclosure - General - Additional Information (Detail) Sheet http://www.vical.com/taxonomy/role/DisclosureGeneralAdditionalInformation General - Additional Information (Detail) R21.xml false false R22.htm 123 - Disclosure - Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense (Detail) Sheet http://www.vical.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpense Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense (Detail) R22.xml false false R23.htm 124 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.vical.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) R23.xml false false R24.htm 125 - Disclosure - Other Balance Sheet Accounts - Summary of Accounts Payable and Accrued Expenses (Detail) Sheet http://www.vical.com/taxonomy/role/DisclosureOtherBalanceSheetAccountsSummaryOfAccountsPayableAndAccruedExpenses Other Balance Sheet Accounts - Summary of Accounts Payable and Accrued Expenses (Detail) R24.xml false false R25.htm 126 - Disclosure - Marketable Securities, Available for Sale - Summary of Available-for-Sale Marketable Securities (Detail) Sheet http://www.vical.com/taxonomy/role/DisclosureMarketableSecuritiesAvailableForSaleSummaryOfAvailableforSaleMarketableSecurities Marketable Securities, Available for Sale - Summary of Available-for-Sale Marketable Securities (Detail) R25.xml false false R26.htm 127 - Disclosure - Marketable Securities, Available for Sale - Additional Information (Detail) Sheet http://www.vical.com/taxonomy/role/DisclosureMarketableSecuritiesAvailableForSaleAdditionalInformation Marketable Securities, Available for Sale - Additional Information (Detail) R26.xml false false R27.htm 128 - Disclosure - Long-Term Investments - Additional Information (Detail) Sheet http://www.vical.com/taxonomy/role/DisclosureLongTermInvestmentsAdditionalInformation Long-Term Investments - Additional Information (Detail) R27.xml false false R28.htm 129 - Disclosure - Fair Value Measurements - Summary of Cash Equivalents, Marketable Securities and Long-Term Investments Measured at Fair Value (Detail) Sheet http://www.vical.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsMarketableSecuritiesAndLongTermInvestmentsMeasuredAtFairValue Fair Value Measurements - Summary of Cash Equivalents, Marketable Securities and Long-Term Investments Measured at Fair Value (Detail) R28.xml false false R29.htm 130 - Disclosure - Fair Value Measurements - Summary of Activity for Assets Measured at Fair Value Using Significant Unobservable Inputs (Detail) Sheet http://www.vical.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfActivityForAssetsMeasuredAtFairValueUsingSignificantUnobservableInputs Fair Value Measurements - Summary of Activity for Assets Measured at Fair Value Using Significant Unobservable Inputs (Detail) R29.xml false false R30.htm 131 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.vical.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation Stockholders' Equity - Additional Information (Detail) R30.xml false false R31.htm 132 - Disclosure - Astellas Agreements - Additional Information (Detail) Sheet http://www.vical.com/taxonomy/role/DisclosureAstellasAgreementsAdditionalInformation Astellas Agreements - Additional Information (Detail) R31.xml false false All Reports Book All Reports 'Monetary' elements on report '127 - Disclosure - Marketable Securities, Available for Sale - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '128 - Disclosure - Long-Term Investments - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '131 - Disclosure - Stockholders' Equity - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - BALANCE SHEETS Process Flow-Through: Removing column 'Jun. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 104 - Statement - BALANCE SHEETS (Parenthetical) Process Flow-Through: 105 - Statement - STATEMENTS OF OPERATIONS Process Flow-Through: 106 - Statement - STATEMENTS OF COMPREHENSIVE LOSS Process Flow-Through: 107 - Statement - STATEMENTS OF CASH FLOWS vicl-20130630.xml vicl-20130630.xsd vicl-20130630_cal.xml vicl-20130630_def.xml vicl-20130630_lab.xml vicl-20130630_pre.xml true true XML 44 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

BALANCE SHEETS (Parenthetical) (USD $)
In Thousands, except Per Share data, unless otherwise specified

Jun. 30, 2013

Dec. 31, 2012

Statement Of Financial Position [Abstract]

Preferred stock, par value $ 0.01 $ 0.01

Preferred stock, shares authorized 5,000 5,000

Preferred stock, shares issued

Preferred stock, shares outstanding

Common stock, par value $ 0.01 $ 0.01

Common stock, shares authorized 160,000 160,000

Common stock, shares issued 86,495 86,136

Common stock, shares outstanding 86,495 86,136

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity
6 Months Ended

Jun. 30, 2013

Equity [Abstract]

Stockholders' Equity

8. STOCKHOLDERS’ EQUITY

In January 2012, the Company sold 13,333,334 shares of its common stock in a public offering at a price to the public of $3.75 per share. In February 2012, the Company sold an additional 576,358 shares pursuant to a partial exercise of the underwriters’ overallotment option at a price to the public of $3.75 per share. Net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, totaled $48.7 million. All of the shares of common stock were offered pursuant to two effective shelf registration statements.

In November 2012, the Company entered into an At-The-Market Equity Offering Sales Agreement, or Sales Agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, under which the Company may issue and sell up to $50,000,000 of shares of its common stock from time to time. Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, shares may be sold through Stifel acting as sales agent or directly to Stifel acting as principal, by means of ordinary brokers’ transactions on the Nasdaq Global Select Market, in privately negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R20.xml IDEA: Fair Value Measurements (Tables) 2.4.0.8121 - Disclosure - Fair Value Measurements (Tables)truefalsefalse1false falsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_FairValueDisclosuresAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value Disclosures [Abstract]2false 2us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Cash equivalents, marketable securities and long-term investments measured at fair value are classified in the table below in one of the three categories described above (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">  <tr> <td width="69%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center">Fair Value Measurements</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> June 30, 2013 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,026</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,845</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,845</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,530</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,530</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,853</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,853</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,997</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,997</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Auction rate securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,401</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,850</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,288</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="16"></td> <td height="16" colspan="16"></td> </tr> <tr> <td valign="bottom">  </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center">Fair Value Measurements</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> December 31, 2012 </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">496</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,500</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> U.S. treasuries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,136</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,136</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Corporate bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,501</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,501</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Government-sponsored enterprise securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,506</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,506</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Auction rate securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,132</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,007</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,364</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a,b,bb) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2C -URI http://asc.fasb.org/extlink&oid=25499696&loc=SL7498348-110258 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19279-110258 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19190-110258 false0Summary of Cash Equivalents, Marketable Securities and Long-Term Investments Measured at Fair Value3false 2us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Activity for assets measured at fair value using significant unobservable inputs (Level 3) is presented in the table below (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="90%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Six Months Ended June 30, 2013</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,225</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Total net unrealized losses, excluding tax impact, included in other comprehensive income </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(188</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,037</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total gains or losses for the period included in net loss attributable to the change in unrealized gains or losses relating to assets still held at the reporting date </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19279-110258 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false0Summary of Activity for Assets Measured at Fair Value Using Significant Unobservable InputsfalseFair Value Measurements (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementInputsDisclosureTextBlockTables13 XML 47 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

STATEMENTS OF COMPREHENSIVE LOSS (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Jun. 30, 2012

Amounts Reclassified Out Of Accumulated Other Comprehensive Income Loss [Abstract]

Net loss $ (9,881) $ (7,868) $ (19,163) $ (7,624)

Unrealized (losses) gains on available-for-sale and long-term marketable securities:

Unrealized (losses) gains arising during holding period (100) 38 (113) 234

Less: Reversal of unrealized losses in accumulated other comprehensive loss upon the sale of long-term marketable securities included in investment and other income (590)

Other comprehensive (loss) gain (100) 38 (113) (356)

Total comprehensive loss $ (9,981) $ (7,830) $ (19,276) $ (7,980)

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=16317811

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669619-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e689-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: vicl_AmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeLossAbstract

Namespace Prefix: vicl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified

Jun. 30, 2013

Dec. 31, 2012

Current assets:

Cash and cash equivalents $ 45,033 $ 43,159

Marketable securities, available-for-sale 19,406 37,639

Restricted cash 3,059 3,059

Receivables and other assets 2,083 2,152

Total current assets 69,581 86,009

Long-term investments 2,037 2,225

Property and equipment, net 4,735 5,284

Intangible assets, net 2,741 2,813

Other assets 191 191

Total assets 79,285 96,522

Current liabilities:

Accounts payable and accrued expenses 5,984 5,629

Deferred revenue 75 150

Total current liabilities 6,059 5,779

Long-term liabilities:

Deferred rent 1,483 1,657

Commitments and contingencies

Stockholders' equity:

Preferred stock, $0.01 par value, 5,000 shares authorized, none issued and outstanding

Common stock, $0.01 par value, 160,000 shares authorized, 86,495 and 86,136 shares issued and outstanding at June 30, 2013, and December 31, 2012, respectively 865 861

Additional paid-in capital 437,844 435,915

Accumulated deficit (367,100) (347,937)

Accumulated other comprehensive income 134 247

Total stockholders' equity 71,743 89,086

Total liabilities and stockholders' equity $ 79,285 $ 96,522

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669686-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e681-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

+ Details

Name: us-gaap_AvailableForSaleSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 25

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.26(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DeferredRentCreditNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.12)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_ReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 49 R7.xml IDEA: General 2.4.0.8108 - Disclosure - Generaltruefalsefalse1false falsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_AccountingPoliciesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Accounting Policies [Abstract]2false 2us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 1.      GENERAL  Vical Incorporated, or the Company, a Delaware corporation, was incorporated in April 1987 and has devoted substantially all of its resources since that time to its research and development programs. The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. All of the Company’s potential products are in research and development phases. No revenues have been generated from the sale of any such products, nor are any such revenues expected for at least the next several years. The Company earns revenue from research and development agreements with pharmaceutical collaborators and grant and contract arrangements with government entities. Most of the Company’s product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. There can be no assurance that the Company’s research and development efforts, or those of its collaborators, will be successful. The Company expects to continue to incur substantial losses and not generate positive cash flows from operations for at least the next several years. No assurance can be given that the Company can generate sufficient product revenue to become profitable or generate positive cash flows from operations. The unaudited financial statements at June 30, 2013, and for the three and six months ended June 30, 2013 and 2012, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC, and with accounting principles generally accepted in the United States applicable to interim financial statements. These unaudited financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company’s financial position as of the interim date and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year or future periods. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. These unaudited financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2012, included in its Annual Report on Form 10-K filed with the SEC. Cash, Cash Equivalents and Marketable Securities Cash and cash equivalents consist of cash and highly liquid securities with original maturities at the date of acquisition of ninety days or less. Investments with an original maturity of more than ninety days are considered marketable securities and have been classified by management as available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from sales of these securities to fund its operations, as necessary. Such investments are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Realized gains and losses from the sale of available-for-sale securities or the amounts, net of tax, reclassified out of accumulated other comprehensive income, if any, are determined on a specific identification basis. Restricted Cash The Company is required to maintain a letter of credit securing an amount equal to twelve months of the current monthly installment of base rent for the term of its primary facilities lease, which ends in August 2017. Under certain circumstances, the Company may be able to eliminate the need for the letter of credit. As of June 30, 2013, and December 31, 2012, restricted cash of $3.1 million was pledged as collateral for this letter of credit. Revenue Recognition Revenue is recognized when the four basic criteria of revenue recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Certain of the Company’s revenue is generated through manufacturing contracts and stand-alone license agreements.   The Company has entered into multiple-element arrangements. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The delivered item(s) must have value to the customer on a standalone basis and, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the Company’s control. A delivered item is considered a separate unit of accounting when the delivered item has value to the partner on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the partner and the availability of research expertise in this field in the general marketplace. Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence, or VSOE, of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement. If facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of drug products, the license is identified as a separate unit of accounting and the amounts allocated to the license are recognized upon the delivery of the license, assuming the other revenue recognition criteria have been met. However, if the amounts allocated to the license through the relative selling price allocation exceed the upfront license fee, the amount recognized upon the delivery of the license is limited to the upfront fee received. If facts and circumstances dictate that the license does not have standalone value, the transaction price, including any upfront license fee payments received, are allocated to the identified separate units of accounting and recognized as those items are delivered. The terms of the Company’s partnership agreements provide for milestone payments upon achievement of certain regulatory and commercial events. The Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following three criteria: (1) the consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (2) the consideration relates solely to past performance, and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due to the Company. Contract Services, Grant and Royalty Revenue The Company recognizes revenues from contract services and federal government research grants during the period in which the related expenditures are incurred and related payments for those services are received or collection is reasonably assured. Royalties to be received based on sales of licensed products by the Company’s partners incorporating the Company’s licensed technology are recognized when received. Net Loss Per Share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted average number of shares used to compute diluted net loss per share excludes any assumed exercise of stock options and warrants, and any assumed issuance of common stock under restricted stock units as the effect would be antidilutive. Common stock equivalents of 1.4 million and 1.1 million for the three months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect. Common stock equivalents of 1.5 million and 1.4 million for the six months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect.   Recent Accounting Pronouncement Effective January 1, 2013, the Company adopted Accounting Standards Update, or ASU, No. 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.” The adoption of ASU No. 2013-02 concerns presentation and disclosure only and did not have an impact on the Company’s financial position or results of operations. The Company elected to present the information required by ASU No. 2013-02 in the Statements of Comprehensive Loss. </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -SubTopic 15 -URI http://asc.fasb.org/subtopic&trid=2122524 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2197480 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 915 -SubTopic 235 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2209116 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2134480 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2122150 false0GeneralfalseGeneralUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock12 XML 50 R17.xml IDEA: Stock-Based Compensation (Tables) 2.4.0.8118 - Disclosure - Stock-Based Compensation (Tables)truefalsefalse1false falsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]2false 2us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Total stock-based compensation expense was allocated to research and development, manufacturing and production and general and administrative expense as follows (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">  <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended June  30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">242</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">272</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">554</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">558</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Manufacturing and production </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">60</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">128</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">106</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">514</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">595</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,272</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,179</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">816</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">923</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,954</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,843</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Summary of total stock-based compensation expensefalseStock-Based Compensation (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables12 XML 51 R16.xml IDEA: General (Policies) 2.4.0.8117 - Disclosure - General (Policies)truefalsefalse1false falsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_AccountingPoliciesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Accounting Policies [Abstract]2false 2vicl_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlockvicl_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Cash, Cash Equivalents and Marketable Securities Cash and cash equivalents consist of cash and highly liquid securities with original maturities at the date of acquisition of ninety days or less. Investments with an original maturity of more than ninety days are considered marketable securities and have been classified by management as available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from sales of these securities to fund its operations, as necessary. Such investments are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Realized gains and losses from the sale of available-for-sale securities or the amounts, net of tax, reclassified out of accumulated other comprehensive income, if any, are determined on a specific identification basis. </div>falsefalsefalsenonnum:textBlockItemTypenaCash, cash equivalents and marketable securities policy.No definition available.false0Cash, Cash Equivalents and Marketable Securities3false 2us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Restricted Cash The Company is required to maintain a letter of credit securing an amount equal to twelve months of the current monthly installment of base rent for the term of its primary facilities lease, which ends in August 2017. Under certain circumstances, the Company may be able to eliminate the need for the letter of credit. As of June 30, 2013, and December 31, 2012, restricted cash of $3.1 million was pledged as collateral for this letter of credit. </div>falsefalsefalsenonnum:textBlockItemTypenaEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 305 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2122427 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.1(a)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Subparagraph a -Article 9 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Financial Reporting Release (FRR) -Number 203 -Paragraph 02-03 false0Restricted Cash4false 2us-gaap_RevenueRecognitionPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Revenue Recognition Revenue is recognized when the four basic criteria of revenue recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Certain of the Company’s revenue is generated through manufacturing contracts and stand-alone license agreements.   The Company has entered into multiple-element arrangements. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The delivered item(s) must have value to the customer on a standalone basis and, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the Company’s control. A delivered item is considered a separate unit of accounting when the delivered item has value to the partner on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the partner and the availability of research expertise in this field in the general marketplace. Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence, or VSOE, of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement. If facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of drug products, the license is identified as a separate unit of accounting and the amounts allocated to the license are recognized upon the delivery of the license, assuming the other revenue recognition criteria have been met. However, if the amounts allocated to the license through the relative selling price allocation exceed the upfront license fee, the amount recognized upon the delivery of the license is limited to the upfront fee received. If facts and circumstances dictate that the license does not have standalone value, the transaction price, including any upfront license fee payments received, are allocated to the identified separate units of accounting and recognized as those items are delivered. The terms of the Company’s partnership agreements provide for milestone payments upon achievement of certain regulatory and commercial events. The Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following three criteria: 1) the consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, 2) the consideration relates solely to past performance, and 3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due to the Company. </div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section B -Paragraph Question 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.B.Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790 false0Revenue Recognition5false 2vicl_RevenueRecognitionContractServicesGrantAndRoyaltyPolicyTextBlockvicl_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Contract Services, Grant and Royalty Revenue The Company recognizes revenues from contract services and federal government research grants during the period in which the related expenditures are incurred and related payments for those services are received or collection is reasonably assured. Royalties to be received based on sales of licensed products by the Company’s partners incorporating the Company’s licensed technology are recognized when received. </div>falsefalsefalsenonnum:textBlockItemTypenaRevenue recognition contract services grant and royalty policy.No definition available.false0Contract Services, Grant and Royalty Revenue6false 2us-gaap_EarningsPerSharePolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Net Loss Per Share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted average number of shares used to compute diluted net loss per share excludes any assumed exercise of stock options and warrants, and any assumed issuance of common stock under restricted stock units as the effect would be antidilutive. Common stock equivalents of 1.4 million and 1.1 million for the three months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect. Common stock equivalents of 1.5 million and 1.4 million for the six months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect. </div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2144384 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257 false0Net Loss Per Share7false 2us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Recent Accounting Pronouncement Effective January 1, 2013, the Company adopted Accounting Standards Update, or ASU, No. 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.” The adoption of ASU No. 2013-02 concerns presentation and disclosure only and did not have an impact on the Company’s financial position or results of operations. The Company elected to present the information required by ASU No. 2013-02 in the Statements of Comprehensive Loss.  </div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.No definition available.false0Recent Accounting PronouncementfalseGeneral (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies17 XML 52 R27.xml IDEA: Long-Term Investments - Additional Information (Detail) 2.4.0.8128 - Disclosure - Long-Term Investments - Additional Information (Detail)truefalsefalse1false USDfalsefalse$eol_PE3939----1310-Q0004_STD_31_20120331_0http://www.sec.gov/CIK0000819050duration2012-03-01T00:00:002012-03-31T00:00:00InvestmentStandardhttp://www.vical.com/20130630Investmentvicl0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE3939----1310-Q0004_STD_91_20130630_0http://www.sec.gov/CIK0000819050duration2013-04-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$eol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$eol_PE3939----1310-Q0004_STD_182_20120630_0http://www.sec.gov/CIK0000819050duration2012-01-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1invest_InvestmentsScheduleAbstractinvest_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Investments Schedule [Abstract]2false 2vicl_NumberOfLongTermInvestmentsSoldDuringPeriodvicl_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse22falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerNumber of long-term investments sold during the period .No definition available.false256Number of long-term investments sold during the period3false 2vicl_AuctionRateSecuritiesSoldAtParValuevicl_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse40000004000000USD$falsetruefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAuction rate securities sold, at par value.No definition available.false2Auction rate securities sold, at par value4false 2vicl_GainRelatedToAuctionRateSecuritiesvicl_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse300000300000falsefalsefalsexbrli:monetaryItemTypemonetaryGain related to auction rate securities.No definition available.false2Gain related to auction rate securities5false 2vicl_AuctionRateSecuritiesHeldAtParValuevicl_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse25000002500000falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAuction rate securities held, at par value.No definition available.false2Auction rate securities held, at par value6false 2vicl_MaturityYearOfAuctionRateLongTermSecuritiesvicl_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse002038falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:gYearItemTypepositiveintegerMaturity year of auction rate long term securities.No definition available.false0Maturity of long-term investment7false 2vicl_FairValueAdjustmentLossOnAuctionRateSecuritiesRecognizedvicl_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse600000600000falsefalsefalse3truefalsefalse600000600000falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFair value adjustment loss on auction rate securities recognized.No definition available.false2Recognized cumulative losses8false 2vicl_UnrealizedGainLossOnAuctionRateSecuritiesvicl_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-113000-113000falsefalsefalse4truefalsefalse3600036000falsefalsefalsexbrli:monetaryItemTypemonetaryUnrealized gain loss on auction rate securities.No definition available.false2Unrealized (losses) gains on auction rate securities9false 2vicl_CumulativeUnrealizedGainOnAuctionRateSecuritiesRecognizedvicl_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse200000200000falsefalsefalse3truefalsefalse200000200000falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCumulative unrealized gain on auction rate securities recognized.No definition available.false2Cumulative unrealized gains10false 2us-gaap_AuctionRateSecuritiesNoncurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse20000002000000USD$falsetruefalse3truefalsefalse20000002000000USD$falsetruefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of securities that are debt instruments (corporate or municipal bonds) that typically have long-term nominal maturities for which the interest rate is reset through an auction process.No definition available.false2Carrying value of auction rate securityfalseLong-Term Investments - Additional Information (Detail) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/DisclosureLongTermInvestmentsAdditionalInformation410 XML 53 R18.xml IDEA: Other Balance Sheet Accounts (Tables) 2.4.0.8119 - Disclosure - Other Balance Sheet Accounts (Tables)truefalsefalse1false falsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Organization Consolidation And Presentation Of Financial Statements [Abstract]2false 2us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Accounts payable and accrued expenses consisted of the following (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">  <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">June 30, 2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Employee compensation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,877</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Post-termination benefit accrual </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">252</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Clinical trial accrual </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">644</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">660</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Accounts payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,295</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">377</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Deferred rent </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">337</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">307</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Other accrued liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">579</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">427</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total accounts payable and accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,984</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,629</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.No definition available.false0Summary of Accounts Payable and Accrued ExpensesfalseOther Balance Sheet Accounts (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables12 XML 54 R3.xml IDEA: BALANCE SHEETS (Parenthetical) 2.4.0.8104 - Statement - BALANCE SHEETS (Parenthetical)truefalseIn Thousands, except Per Share data, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0USDUSD$2false USDfalsefalse$eol_PE3939----1310-Q0004_STD_0_20121231_0http://www.sec.gov/CIK0000819050instant2012-12-31T00:00:000001-01-01T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0USDUSD$1true 1us-gaap_StatementOfFinancialPositionAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Statement Of Financial Position [Abstract]2false 2us-gaap_PreferredStockParOrStatedValuePerShareus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse0.010.01USD$falsetruefalse2truefalsefalse0.010.01USD$falsetruefalsenum:perShareItemTypedecimalFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false3Preferred stock, par value3false 2us-gaap_PreferredStockSharesAuthorizedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse50000005000falsefalsefalse2truefalsefalse50000005000falsefalsefalsexbrli:sharesItemTypesharesThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false1Preferred stock, shares authorized4false 2us-gaap_PreferredStockSharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  falsefalsefalse2falsefalsefalse00  falsefalsefalsexbrli:sharesItemTypesharesTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false1Preferred stock, shares issued5false 2us-gaap_PreferredStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  falsefalsefalse2falsefalsefalse00  falsefalsefalsexbrli:sharesItemTypesharesAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false1Preferred stock, shares outstanding6false 3us-gaap_CommonStockParOrStatedValuePerShareus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse0.010.01USD$falsetruefalse2truefalsefalse0.010.01USD$falsetruefalsenum:perShareItemTypedecimalFace amount or stated value per share of common stock.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false3Common stock, par value7false 3us-gaap_CommonStockSharesAuthorizedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse160000000160000falsefalsefalse2truefalsefalse160000000160000falsefalsefalsexbrli:sharesItemTypesharesThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Common stock, shares authorized8false 3us-gaap_CommonStockSharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse8649500086495falsefalsefalse2truefalsefalse8613600086136falsefalsefalsexbrli:sharesItemTypesharesTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Common stock, shares issued9false 3us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse8649500086495falsefalsefalse2truefalsefalse8613600086136falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Common stock, shares outstandingfalseBALANCE SHEETS (Parenthetical) (USD $)UnKnownThousandsNoRoundingUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical29 XML 55 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements - Summary of Activity for Assets Measured at Fair Value Using Significant Unobservable Inputs (Detail) (USD $)
In Thousands, unless otherwise specified
6 Months Ended

Jun. 30, 2013

Fair Value Disclosures [Abstract]

Balance at December 31, 2012 $ 2,225

Total net unrealized losses, excluding tax impact, included in other comprehensive income (188)

Balance at June 30, 2013 2,037

Total gains or losses for the period included in net loss attributable to the change in unrealized gains or losses relating to assets still held at the reporting date

X

- Definition

Amount of unrealized (holding) gain (loss) which is included in the statement of income (or changes in net assets) related to those assets still held at the reporting date for which fair value is measured on a recurring basis using significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of gain (loss) recognized in other comprehensive income (loss) for financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1a)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 56 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2012

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Estimated value of stock-based awards, granted $ 3.8 $ 3.9

Unrecognized compensation cost related to unvested options $ 4.1 $ 4.1

Unvested stock-based awards expected to be recognized, weighted-average period 1 year 6 months

Portion of stock-based awards granted from outstanding common shares 2.20% 2.20%

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Unrecognized cost of unvested options awarded to employees as compensation.

+ References

No definition available.

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Estimated value of stock-based awards, granted.

+ References

No definition available.

+ Details

Name: vicl_EstimatedValueOfStockBasedAwardsGranted

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Share based award granted portion to common stock outstanding.

+ References

No definition available.

+ Details

Name: vicl_ShareBasedAwardGrantedPortionToCommonStockOutstanding

Namespace Prefix: vicl_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 57 R31.xml IDEA: Astellas Agreements - Additional Information (Detail) 2.4.0.8132 - Disclosure - Astellas Agreements - Additional Information (Detail)truefalseIn Millions, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE3939----1310-Q0004_STD_31_20120831_0http://www.sec.gov/CIK0000819050duration2012-08-01T00:00:002012-08-31T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE3939----1310-Q0004_STD_91_20130630_0http://www.sec.gov/CIK0000819050duration2013-04-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$eol_PE3939----1310-Q0004_STD_91_20120630_0http://www.sec.gov/CIK0000819050duration2012-04-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$eol_PE3939----1310-Q0004_STD_91_20120331_0http://www.sec.gov/CIK0000819050duration2012-01-01T00:00:002012-03-31T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDfalsefalse$eol_PE3939----1310-Q0004_STD_90_20110331_0http://www.sec.gov/CIK0000819050duration2011-01-01T00:00:002011-03-31T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false USDfalsefalse$eol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7false USDfalsefalse$eol_PE3939----1310-Q0004_STD_182_20120630_0http://www.sec.gov/CIK0000819050duration2012-01-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Organization Consolidation And Presentation Of Financial Statements [Abstract]2false 2us-gaap_LicenseAndServicesRevenueus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse2500000025.0USD$falsetruefalse6truefalsefalse3000000.3USD$falsetruefalse7truefalsefalse1020000010.2USD$falsetruefalsexbrli:monetaryItemTypemonetaryRevenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 false2Recognized license revenue3false 2vicl_AdditionalAmountReceivedUponFinalizationOfGeneralTrialDesignvicl_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse1000000010.0falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional amount received upon finalization of general trial design.No definition available.false2Additional amount received upon finalization of the general trial design4false 2vicl_RecognizedRevenueRelatedToContractServicesvicl_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse11000001.1falsefalsefalse3truefalsefalse13000001.3falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse22000002.2falsefalsefalse7truefalsefalse23000002.3falsefalsefalsexbrli:monetaryItemTypemonetaryRecognized revenue related to contract services.No definition available.false2Recognized revenue related to contract services5false 2vicl_AmountPayableUnderLicenseAgreementOnAchievementOfMilestonevicl_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse9500000095.0USD$falsetruefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount payable under license agreement on achievement of milestone.No definition available.false2Amount payable under license agreement on achievement of milestonefalseAstellas Agreements - Additional Information (Detail) (USD $)HundredThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/DisclosureAstellasAgreementsAdditionalInformation75 XML 58 R30.xml IDEA: Stockholders' Equity - Additional Information (Detail) 2.4.0.8131 - Disclosure - Stockholders' Equity - Additional Information (Detail)truefalsefalse1false USDfalsefalseeol_PE3939----1310-Q0004_STD_29_20120229_0http://www.sec.gov/CIK0000819050duration2012-02-01T00:00:002012-02-29T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0$2false USDfalsefalse$eol_PE3939----1310-Q0004_STD_31_20120131_0http://www.sec.gov/CIK0000819050duration2012-01-01T00:00:002012-01-31T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0USDUSD$3false USDfalsefalse$eol_PE3939----1310-Q0004_STD_0_20121130_0http://www.sec.gov/CIK0000819050instant2012-11-30T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1us-gaap_EquityAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Equity [Abstract]2false 2us-gaap_StockIssuedDuringPeriodSharesNewIssuesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse1333333413333334falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of new stock issued during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Number of shares of common stock sold in public offering3false 2us-gaap_SaleOfStockPricePerShareus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse3.753.75USD$falsetruefalse2truefalsefalse3.753.75USD$falsetruefalse3falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.No definition available.false3Common stock, public offering price4false 2us-gaap_StockIssuedDuringPeriodValueNewIssuesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse4870000048700000USD$falsetruefalse3falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Net proceeds from offering5false 2vicl_StockIssuedDuringPeriodSharesOnPartialExerciseOfUnderwritersOverallotmentOptionvicl_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse576358576358falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesStock issued during period shares on partial exercise of underwriters overallotment option.No definition available.false1No of common stock issued on partial exercise of underwriters' overallotment option6false 2vicl_MaximumValueOfCommonStockIssuableUnderAgreementvicl_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse5000000050000000USD$falsetruefalsexbrli:monetaryItemTypemonetaryMaximum value of common stock issuable under agreement.No definition available.false2Maximum value of common stock issuable under agreementfalseStockholders' Equity - Additional Information (Detail) (USD $)NoRoundingNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation36 XML 59 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies
6 Months Ended

Jun. 30, 2013

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

7. COMMITMENTS AND CONTINGENCIES

The Company prosecutes its intellectual property estate vigorously to obtain the broadest valid scope for its patents. Due to uncertainty of the ultimate outcome of patent enforcement actions, their impact on future operating results or the Company’s financial condition is not subject to reasonable estimates.

In the ordinary course of business, the Company may become a party to lawsuits involving various matters. The Company is unaware of any such lawsuits presently pending against it which, individually or in the aggregate, are deemed to be material to the Company’s financial condition or results of operations.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 60 R21.xml IDEA: General - Additional Information (Detail) 2.4.0.8122 - Disclosure - General - Additional Information (Detail)truefalseIn Thousands, except Share data in Millions, unless otherwise specifiedfalse1false USDfalsefalseeol_PE3939----1310-Q0004_STD_91_20130630_0http://www.sec.gov/CIK0000819050duration2013-04-01T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170$2false falsefalseeol_PE3939----1310-Q0004_STD_91_20120630_0http://www.sec.gov/CIK0000819050duration2012-04-01T00:00:002012-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares03false USDfalsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170$4false falsefalseeol_PE3939----1310-Q0004_STD_182_20120630_0http://www.sec.gov/CIK0000819050duration2012-01-01T00:00:002012-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares05false USDfalsefalse$eol_PE3939----1310-Q0004_STD_0_20121231_0http://www.sec.gov/CIK0000819050instant2012-12-31T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Organization Consolidation And Presentation Of Financial Statements [Abstract]2false 2us-gaap_AdditionalCashAndCashEquivalentRelatedTextus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00ninety days or lessfalsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringAn element designated to encapsulate any additional information related to cash and cash equivalents not otherwise addressed by the existing taxonomy. Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 false0Maximum period for cash and highly liquid securities with original maturities3false 2us-gaap_AvailableForSaleSecuritiesRestrictionsAdditionalInformationus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00more than ninety daysfalsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringAn entity may opt to provide the reader with additional narrative text to better understand the nature of available-for-sale security restrictions.No definition available.false0Minimum period for marketable securities classified as available-for-sale with original maturities4false 2vicl_LetterOfCreditDescriptionvicl_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00Company is required to maintain a letter of credit securing an amount equal to twelve months of the current monthly installment of base rent for the term of its primary facilities lease, which ends in August 2017.falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringLetter of credit securing an amount equal to twelve months of the current monthly installment of base rent for the term of the primary facility lease, which ends in August of 2017.No definition available.false0Amount of letter of credit, description5false 2us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse30590003059USD$falsetruefalse2falsefalsefalse00falsefalsefalse3truefalsefalse30590003059USD$falsetruefalse4falsefalsefalse00falsefalsefalse5truefalsefalse30590003059USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Restricted cash6false 2us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse14000001.4falsefalsefalse2truefalsefalse11000001.1falsefalsefalse3truefalsefalse15000001.5falsefalsefalse4truefalsefalse14000001.4falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Antidilution -URI http://asc.fasb.org/extlink&oid=6505113 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Diluted Earnings Per Share -URI http://asc.fasb.org/extlink&oid=6510752 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Contingent Stock Agreement -URI http://asc.fasb.org/extlink&oid=6508534 false1Common stock equivalents excluded from the calculation of diluted net loss per sharefalseGeneral - Additional Information (Detail) (USD $)ThousandsHundredThousandsUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/DisclosureGeneralAdditionalInformation56 XML 61 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity - Additional Information (Detail) (USD $)
1 Months Ended

Feb. 29, 2012

Jan. 31, 2012

Nov. 30, 2012

Equity [Abstract]

Number of shares of common stock sold in public offering 13,333,334

Common stock, public offering price $ 3.75 $ 3.75

Net proceeds from offering $ 48,700,000

No of common stock issued on partial exercise of underwriters' overallotment option 576,358

Maximum value of common stock issuable under agreement $ 50,000,000

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Maximum value of common stock issuable under agreement.

+ References

No definition available.

+ Details

Name: vicl_MaximumValueOfCommonStockIssuableUnderAgreement

Namespace Prefix: vicl_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition

Stock issued during period shares on partial exercise of underwriters overallotment option.

+ References

No definition available.

+ Details

Name: vicl_StockIssuedDuringPeriodSharesOnPartialExerciseOfUnderwritersOverallotmentOption

Namespace Prefix: vicl_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 62 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

General (Policies)
6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Cash, Cash Equivalents and Marketable Securities

Cash, Cash Equivalents and Marketable Securities

Cash and cash equivalents consist of cash and highly liquid securities with original maturities at the date of acquisition of ninety days or less. Investments with an original maturity of more than ninety days are considered marketable securities and have been classified by management as available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from sales of these securities to fund its operations, as necessary. Such investments are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Realized gains and losses from the sale of available-for-sale securities or the amounts, net of tax, reclassified out of accumulated other comprehensive income, if any, are determined on a specific identification basis.

Restricted Cash

Restricted Cash

The Company is required to maintain a letter of credit securing an amount equal to twelve months of the current monthly installment of base rent for the term of its primary facilities lease, which ends in August 2017. Under certain circumstances, the Company may be able to eliminate the need for the letter of credit. As of June 30, 2013, and December 31, 2012, restricted cash of $3.1 million was pledged as collateral for this letter of credit.

Revenue Recognition

Revenue Recognition

Revenue is recognized when the four basic criteria of revenue recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Certain of the Company’s revenue is generated through manufacturing contracts and stand-alone license agreements.

The Company has entered into multiple-element arrangements. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.

The delivered item(s) must have value to the customer on a standalone basis and, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the Company’s control.

A delivered item is considered a separate unit of accounting when the delivered item has value to the partner on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the partner and the availability of research expertise in this field in the general marketplace. Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence, or VSOE, of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement. If facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of drug products, the license is identified as a separate unit of accounting and the amounts allocated to the license are recognized upon the delivery of the license, assuming the other revenue recognition criteria have been met. However, if the amounts allocated to the license through the relative selling price allocation exceed the upfront license fee, the amount recognized upon the delivery of the license is limited to the upfront fee received. If facts and circumstances dictate that the license does not have standalone value, the transaction price, including any upfront license fee payments received, are allocated to the identified separate units of accounting and recognized as those items are delivered.

The terms of the Company’s partnership agreements provide for milestone payments upon achievement of certain regulatory and commercial events. The Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following three criteria: 1) the consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, 2) the consideration relates solely to past performance, and 3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due to the Company.

Contract Services, Grant and Royalty Revenue

Contract Services, Grant and Royalty Revenue

The Company recognizes revenues from contract services and federal government research grants during the period in which the related expenditures are incurred and related payments for those services are received or collection is reasonably assured. Royalties to be received based on sales of licensed products by the Company’s partners incorporating the Company’s licensed technology are recognized when received.

Net Loss Per Share

Net Loss Per Share

Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted average number of shares used to compute diluted net loss per share excludes any assumed exercise of stock options and warrants, and any assumed issuance of common stock under restricted stock units as the effect would be antidilutive. Common stock equivalents of 1.4 million and 1.1 million for the three months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect. Common stock equivalents of 1.5 million and 1.4 million for the six months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect.

Recent Accounting Pronouncement

Recent Accounting Pronouncement

Effective January 1, 2013, the Company adopted Accounting Standards Update, or ASU, No. 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.” The adoption of ASU No. 2013-02 concerns presentation and disclosure only and did not have an impact on the Company’s financial position or results of operations. The Company elected to present the information required by ASU No. 2013-02 in the Statements of Comprehensive Loss.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122427

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.1(a))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph a

-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

+ Details

Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144384

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Cash, cash equivalents and marketable securities policy.

+ References

No definition available.

+ Details

Name: vicl_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock

Namespace Prefix: vicl_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Revenue recognition contract services grant and royalty policy.

+ References

No definition available.

+ Details

Name: vicl_RevenueRecognitionContractServicesGrantAndRoyaltyPolicyTextBlock

Namespace Prefix: vicl_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 63 R22.xml IDEA: Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense (Detail) 2.4.0.8123 - Disclosure - Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense (Detail)truefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE3939----1310-Q0004_STD_91_20130630_0http://www.sec.gov/CIK0000819050duration2013-04-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE3939----1310-Q0004_STD_91_20120630_0http://www.sec.gov/CIK0000819050duration2012-04-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$eol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$eol_PE3939----1310-Q0004_STD_182_20120630_0http://www.sec.gov/CIK0000819050duration2012-01-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]2false 4us-gaap_AllocatedShareBasedCompensationExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse816000816USD$falsetruefalse2truefalsefalse923000923USD$falsetruefalse3truefalsefalse19540001954USD$falsetruefalse4truefalsefalse18430001843USD$falsetruefalsexbrli:monetaryItemTypemonetaryRepresents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F false2Total stock-based compensation expense3false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5false USDtruefalse$eol_PE3939----1310-Q0004_STD_91_20130630_0_927015x928963http://www.sec.gov/CIK0000819050duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseResearch and development [Member]us-gaap_IncomeStatementLocationAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_IncomeStatementLocationAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Research and development [Member]4true 3us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]5false 4us-gaap_AllocatedShareBasedCompensationExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse242000242USD$falsefalsefalse2truefalsefalse272000272USD$falsefalsefalse3truefalsefalse554000554USD$falsefalsefalse4truefalsefalse558000558USD$falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F false2Total stock-based compensation expense6false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse9false USDtruefalse$eol_PE3939----1310-Q0004_STD_91_20130630_0_927015x948109http://www.sec.gov/CIK0000819050duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseManufacturing and production [Member]us-gaap_IncomeStatementLocationAxisxbrldihttp://xbrl.org/2006/xbrldivicl_ManufacturingAndProductionMemberus-gaap_IncomeStatementLocationAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Manufacturing and production [Member]7true 3us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]8false 4us-gaap_AllocatedShareBasedCompensationExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse6000060USD$falsefalsefalse2truefalsefalse5600056USD$falsefalsefalse3truefalsefalse128000128USD$falsefalsefalse4truefalsefalse106000106USD$falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F false2Total stock-based compensation expense9false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse13false USDtruefalse$eol_PE3939----1310-Q0004_STD_91_20130630_0_927015x925832http://www.sec.gov/CIK0000819050duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseGeneral and administrative [Member]us-gaap_IncomeStatementLocationAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_GeneralAndAdministrativeExpenseMemberus-gaap_IncomeStatementLocationAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0General and administrative [Member]10true 3us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]11false 4us-gaap_AllocatedShareBasedCompensationExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse514000514USD$falsetruefalse2truefalsefalse595000595USD$falsetruefalse3truefalsefalse12720001272USD$falsetruefalse4truefalsefalse11790001179USD$falsetruefalsexbrli:monetaryItemTypemonetaryRepresents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F false2Total stock-based compensation expensefalseStock-Based Compensation - Summary of Total Stock-Based Compensation Expense (Detail) (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpense411 XML 64 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements
6 Months Ended

Jun. 30, 2013

Fair Value Disclosures [Abstract]

Fair Value Measurements

6. FAIR VALUE MEASUREMENTS

The Company measures fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

•
Level 1: Observable inputs such as quoted prices in active markets;

•
Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

•
Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Cash equivalents, marketable securities and long-term investments measured at fair value are classified in the table below in one of the three categories described above (in thousands):

 Fair Value Measurements

June 30, 2013
 Level 1 Level 2 Level 3 Total

Certificates of deposit
 $ 1,026 $ — $ — $ 1,026

Money market funds
 17,845 — — 17,845

U.S. treasuries
 6,530 — — 6,530

Corporate bonds
 — 4,853 — 4,853

Government-sponsored enterprise securities
 — 6,997 — 6,997

Auction rate securities
 — — 2,037 2,037









 $ 25,401 $ 11,850 $ 2,037 $ 39,288









 Fair Value Measurements

December 31, 2012
 Level 1 Level 2 Level 3 Total

Certificates of deposit
 $ 496 $ — $ — $ 496

Money market funds
 18,500 — — 18,500

U.S. treasuries
 10,136 — — 10,136

Corporate bonds
 — 11,501 — 11,501

Government-sponsored enterprise securities
 — 15,506 — 15,506

Auction rate securities
 — — 2,225 2,225









 $ 29,132 $ 27,007 $ 2,225 $ 58,364









The Company’s investments in U.S. treasury securities, certificates of deposit and money market funds are valued based on publicly available quoted market prices for identical securities as of June 30, 2013. The Company determines the fair value of corporate bonds and other government-sponsored enterprise related securities with the aid of valuations provided by third parties using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company validates the valuations received from its primary pricing vendors for its level 2 securities by examining the inputs used in that vendor’s pricing process and determines whether they are reasonable and observable. The Company also compares those valuations to recent reported trades for those securities. The Company did not adjust any of the valuations received from these independent third parties with respect to any of its level 2 securities at June 30, 2013. The Company did not reclassify any investments between level categories during the three months ended June 30, 2013. The valuation of the Company’s investments in auction rate securities, which includes significant unobservable inputs, is more fully described in Note 5.

Activity for assets measured at fair value using significant unobservable inputs (Level 3) is presented in the table below (in thousands):

 Six Months
Ended
June 30, 2013

Balance at December 31, 2012
 $ 2,225

Total net unrealized losses, excluding tax impact, included in other comprehensive income
 (188 )



Balance at June 30, 2013
 $ 2,037



Total gains or losses for the period included in net loss attributable to the change in unrealized gains or losses relating to assets still held at the reporting date
 $ —



X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19190-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementInputsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 65 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

General
6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

General

1. GENERAL

Vical Incorporated, or the Company, a Delaware corporation, was incorporated in April 1987 and has devoted substantially all of its resources since that time to its research and development programs. The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

All of the Company’s potential products are in research and development phases. No revenues have been generated from the sale of any such products, nor are any such revenues expected for at least the next several years. The Company earns revenue from research and development agreements with pharmaceutical collaborators and grant and contract arrangements with government entities. Most of the Company’s product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. There can be no assurance that the Company’s research and development efforts, or those of its collaborators, will be successful. The Company expects to continue to incur substantial losses and not generate positive cash flows from operations for at least the next several years. No assurance can be given that the Company can generate sufficient product revenue to become profitable or generate positive cash flows from operations.

The unaudited financial statements at June 30, 2013, and for the three and six months ended June 30, 2013 and 2012, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC, and with accounting principles generally accepted in the United States applicable to interim financial statements. These unaudited financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company’s financial position as of the interim date and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year or future periods. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. These unaudited financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2012, included in its Annual Report on Form 10-K filed with the SEC.

Cash, Cash Equivalents and Marketable Securities

Cash and cash equivalents consist of cash and highly liquid securities with original maturities at the date of acquisition of ninety days or less. Investments with an original maturity of more than ninety days are considered marketable securities and have been classified by management as available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from sales of these securities to fund its operations, as necessary. Such investments are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Realized gains and losses from the sale of available-for-sale securities or the amounts, net of tax, reclassified out of accumulated other comprehensive income, if any, are determined on a specific identification basis.

Restricted Cash

The Company is required to maintain a letter of credit securing an amount equal to twelve months of the current monthly installment of base rent for the term of its primary facilities lease, which ends in August 2017. Under certain circumstances, the Company may be able to eliminate the need for the letter of credit. As of June 30, 2013, and December 31, 2012, restricted cash of $3.1 million was pledged as collateral for this letter of credit.

Revenue Recognition

Revenue is recognized when the four basic criteria of revenue recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Certain of the Company’s revenue is generated through manufacturing contracts and stand-alone license agreements.

The Company has entered into multiple-element arrangements. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.

The delivered item(s) must have value to the customer on a standalone basis and, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the Company’s control.

A delivered item is considered a separate unit of accounting when the delivered item has value to the partner on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the partner and the availability of research expertise in this field in the general marketplace. Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence, or VSOE, of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement. If facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of drug products, the license is identified as a separate unit of accounting and the amounts allocated to the license are recognized upon the delivery of the license, assuming the other revenue recognition criteria have been met. However, if the amounts allocated to the license through the relative selling price allocation exceed the upfront license fee, the amount recognized upon the delivery of the license is limited to the upfront fee received. If facts and circumstances dictate that the license does not have standalone value, the transaction price, including any upfront license fee payments received, are allocated to the identified separate units of accounting and recognized as those items are delivered.

The terms of the Company’s partnership agreements provide for milestone payments upon achievement of certain regulatory and commercial events. The Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following three criteria: (1) the consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (2) the consideration relates solely to past performance, and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due to the Company.

Contract Services, Grant and Royalty Revenue

The Company recognizes revenues from contract services and federal government research grants during the period in which the related expenditures are incurred and related payments for those services are received or collection is reasonably assured. Royalties to be received based on sales of licensed products by the Company’s partners incorporating the Company’s licensed technology are recognized when received.

Net Loss Per Share

Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted average number of shares used to compute diluted net loss per share excludes any assumed exercise of stock options and warrants, and any assumed issuance of common stock under restricted stock units as the effect would be antidilutive. Common stock equivalents of 1.4 million and 1.1 million for the three months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect. Common stock equivalents of 1.5 million and 1.4 million for the six months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect.

Recent Accounting Pronouncement

Effective January 1, 2013, the Company adopted Accounting Standards Update, or ASU, No. 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.” The adoption of ASU No. 2013-02 concerns presentation and disclosure only and did not have an impact on the Company’s financial position or results of operations. The Company elected to present the information required by ASU No. 2013-02 in the Statements of Comprehensive Loss.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 66 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 67 R13.xml IDEA: Commitments and Contingencies 2.4.0.8114 - Disclosure - Commitments and Contingenciestruefalsefalse1false falsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_CommitmentsAndContingenciesDisclosureAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Commitments And Contingencies Disclosure [Abstract]2false 2us-gaap_CommitmentsAndContingenciesDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 7.      COMMITMENTS AND CONTINGENCIES  The Company prosecutes its intellectual property estate vigorously to obtain the broadest valid scope for its patents. Due to uncertainty of the ultimate outcome of patent enforcement actions, their impact on future operating results or the Company’s financial condition is not subject to reasonable estimates. In the ordinary course of business, the Company may become a party to lawsuits involving various matters. The Company is unaware of any such lawsuits presently pending against it which, individually or in the aggregate, are deemed to be material to the Company’s financial condition or results of operations.  </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for commitments and contingencies.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308 false0Commitments and ContingenciesfalseCommitments and ContingenciesUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock12 XML 68 R23.xml IDEA: Stock-Based Compensation - Additional Information (Detail) 2.4.0.8124 - Disclosure - Stock-Based Compensation - Additional Information (Detail)truefalseIn Millions, unless otherwise specifiedfalse1false USDfalsefalseeol_PE3939----1310-Q0004_STD_91_20130630_0http://www.sec.gov/CIK0000819050duration2013-04-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170$2false USDfalsefalse$eol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:00pureStandardhttp://www.xbrl.org/2003/instancepure0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$eol_PE3939----1310-Q0004_STD_182_20120630_0http://www.sec.gov/CIK0000819050duration2012-01-01T00:00:002012-06-30T00:00:00pureStandardhttp://www.xbrl.org/2003/instancepure0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]2false 2vicl_EstimatedValueOfStockBasedAwardsGrantedvicl_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse38000003.8USD$falsetruefalse3truefalsefalse39000003.9USD$falsetruefalsexbrli:monetaryItemTypemonetaryEstimated value of stock-based awards, granted.No definition available.false2Estimated value of stock-based awards, granted3false 2us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptionsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse41000004.1USD$falsetruefalse2truefalsefalse41000004.1USD$falsetruefalse3falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryUnrecognized cost of unvested options awarded to employees as compensation.No definition available.false2Unrecognized compensation cost related to unvested options4false 2us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse001 year 6 monthsfalsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaWeighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Unvested stock-based awards expected to be recognized, weighted-average period5false 2vicl_ShareBasedAwardGrantedPortionToCommonStockOutstandingvicl_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2truetruefalse0.0220.022falsefalsefalse3truetruefalse0.0220.022falsefalsefalsenum:percentItemTypepureShare based award granted portion to common stock outstanding.No definition available.false0Portion of stock-based awards granted from outstanding common sharesfalseStock-Based Compensation - Additional Information (Detail) (USD $)HundredThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation35 XML 69 R26.xml IDEA: Marketable Securities, Available for Sale - Additional Information (Detail) 2.4.0.8127 - Disclosure - Marketable Securities, Available for Sale - Additional Information (Detail)truefalsefalse1false USDfalsefalse$eol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1us-gaap_InvestmentsDebtAndEquitySecuritiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Investments Debt And Equity Securities [Abstract]2false 2us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse67000006700000USD$falsetruefalsexbrli:monetaryItemTypemonetaryTotal of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 25 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562 false2Available-for-sale securities maturing outside of one year3false 2us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNetus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThis item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563 false2Realized gains or losses on sales of available-for-sale securities4false 2vicl_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestmentsvicl_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of accumulated pre-tax unrealized loss on investments in available-for-sale securities that have been in a loss position for twelve months or longer impacting investments.No definition available.false2Available-for-sale securities in a continuous material loss position longer than one yearfalseMarketable Securities, Available for Sale - Additional Information (Detail) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/DisclosureMarketableSecuritiesAvailableForSaleAdditionalInformation14 XML 70 R28.xml IDEA: Fair Value Measurements - Summary of Cash Equivalents, Marketable Securities and Long-Term Investments Measured at Fair Value (Detail) 2.4.0.8129 - Disclosure - Fair Value Measurements - Summary of Cash Equivalents, Marketable Securities and Long-Term Investments Measured at Fair Value (Detail)truefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE3939----1310-Q0004_STD_0_20121231_0http://www.sec.gov/CIK0000819050instant2012-12-31T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]2false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse3928800039288USD$falsetruefalse2truefalsefalse5836400058364USD$falsetruefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value3false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x927254http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseCertificates of deposit [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CertificatesOfDepositMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Certificates of deposit [Member]4true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]5false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse10260001026USD$falsefalsefalse2truefalsefalse496000496USD$falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value6false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse5false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x932359http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseMoney market funds [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MoneyMarketFundsMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Money market funds [Member]7true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]8false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse1784500017845USD$falsefalsefalse2truefalsefalse1850000018500USD$falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value9false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse7false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x923870http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseU.S. treasuries [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_USTreasurySecuritiesMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0U.S. treasuries [Member]10true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]11false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse65300006530USD$falsefalsefalse2truefalsefalse1013600010136USD$falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value12false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse9false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x928852http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseCorporate bonds [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CorporateDebtSecuritiesMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Corporate bonds [Member]13true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]14false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse48530004853USD$falsefalsefalse2truefalsefalse1150100011501USD$falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value15false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse11false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x924099http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseGovernment-sponsored enterprise securities [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Government-sponsored enterprise securities [Member]16true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]17false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse69970006997USD$falsefalsefalse2truefalsefalse1550600015506USD$falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value18false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse13false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x931362http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseAuction rate securities [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AuctionRateSecuritiesMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Auction rate securities [Member]19true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]20false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse20370002037USD$falsefalsefalse2truefalsefalse22250002225USD$falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value21false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse15false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_929790x925736http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 1 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel1Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 1 [Member]22true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]23false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse2540100025401USD$falsefalsefalse2truefalsefalse2913200029132USD$falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value24false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse17false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x927254_929790x925736http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 1 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel1Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseCertificates of deposit [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CertificatesOfDepositMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 1 [Member] | Certificates of deposit [Member]25true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]26false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse10260001026USD$falsefalsefalse2truefalsefalse496000496USD$falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value27false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse19false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x932359_929790x925736http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 1 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel1Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseMoney market funds [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MoneyMarketFundsMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 1 [Member] | Money market funds [Member]28true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]29false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse1784500017845USD$falsefalsefalse2truefalsefalse1850000018500USD$falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value30false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse21false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x923870_929790x925736http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 1 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel1Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseU.S. treasuries [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_USTreasurySecuritiesMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 1 [Member] | U.S. treasuries [Member]31true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]32false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse65300006530USD$falsefalsefalse2truefalsefalse1013600010136USD$falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value33false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse23false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x928852_929790x925736http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 1 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel1Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseCorporate bonds [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CorporateDebtSecuritiesMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 1 [Member] | Corporate bonds [Member]34true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]35false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value36false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse24false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x924099_929790x925736http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 1 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel1Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseGovernment-sponsored enterprise securities [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 1 [Member] | Government-sponsored enterprise securities [Member]37true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]38false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value39false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse25false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x931362_929790x925736http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 1 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel1Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseAuction rate securities [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AuctionRateSecuritiesMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 1 [Member] | Auction rate securities [Member]40true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]41false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value42false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse26false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_929790x925851http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 2 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel2Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 2 [Member]43true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]44false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse1185000011850USD$falsefalsefalse2truefalsefalse2700700027007USD$falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value45false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse28false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x927254_929790x925851http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 2 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel2Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseCertificates of deposit [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CertificatesOfDepositMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 2 [Member] | Certificates of deposit [Member]46true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]47false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value48false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse29false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x932359_929790x925851http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 2 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel2Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseMoney market funds [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MoneyMarketFundsMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 2 [Member] | Money market funds [Member]49true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]50false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value51false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse30false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x923870_929790x925851http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 2 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel2Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseU.S. treasuries [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_USTreasurySecuritiesMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 2 [Member] | U.S. treasuries [Member]52true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]53false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value54false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse31false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x928852_929790x925851http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 2 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel2Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseCorporate bonds [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CorporateDebtSecuritiesMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 2 [Member] | Corporate bonds [Member]55true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]56false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse48530004853USD$falsefalsefalse2truefalsefalse1150100011501USD$falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value57false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse33false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x924099_929790x925851http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 2 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel2Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseGovernment-sponsored enterprise securities [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 2 [Member] | Government-sponsored enterprise securities [Member]58true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]59false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse69970006997USD$falsefalsefalse2truefalsefalse1550600015506USD$falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value60false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse35false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x931362_929790x925851http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 2 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel2Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseAuction rate securities [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AuctionRateSecuritiesMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 2 [Member] | Auction rate securities [Member]61true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]62false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value63false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse36false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_929790x929831http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 3 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel3Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 3 [Member]64true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]65false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse20370002037USD$falsefalsefalse2truefalsefalse22250002225USD$falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value66false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse38false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x927254_929790x929831http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 3 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel3Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseCertificates of deposit [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CertificatesOfDepositMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 3 [Member] | Certificates of deposit [Member]67true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]68false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value69false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse39false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x932359_929790x929831http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 3 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel3Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseMoney market funds [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MoneyMarketFundsMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 3 [Member] | Money market funds [Member]70true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]71false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value72false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse40false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x923870_929790x929831http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 3 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel3Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseU.S. treasuries [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_USTreasurySecuritiesMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 3 [Member] | U.S. treasuries [Member]73true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]74false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value75false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse41false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x928852_929790x929831http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 3 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel3Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseCorporate bonds [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CorporateDebtSecuritiesMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 3 [Member] | Corporate bonds [Member]76true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]77false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair Value78false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse42false USDtruefalse$eol_PE3939----1310-Q0004_STD_0_20130630_0_926956x931362_929790x929831http://www.sec.gov/CIK0000819050instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseLevel 3 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel3Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseAuction rate securities [Member]us-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AuctionRateSecuritiesMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Level 3 [Member] | Auction rate securities [Member]79true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]80false 4us-gaap_AssetsFairValueDisclosureus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse20370002037USD$falsetruefalse2truefalsefalse22250002225USD$falsetruefalsexbrli:monetaryItemTypemonetaryFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair ValuefalseFair Value Measurements - Summary of Cash Equivalents, Marketable Securities and Long-Term Investments Measured at Fair Value (Detail) (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsMarketableSecuritiesAndLongTermInvestmentsMeasuredAtFairValue280 XML 71 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Marketable Securities, Available for Sale (Tables)
6 Months Ended

Jun. 30, 2013

Investments Debt And Equity Securities [Abstract]

Summary of Available-for-Sale Marketable Securities

The following is a summary of available-for-sale marketable securities (in thousands):

June 30, 2013
 Amortized
Cost Unrealized
Gain Unrealized
Loss Market
Value

U.S. treasuries
 $ 6,528 $ 2 $ — $ 6,530

Government-sponsored enterprise securities
 7,000 — 3 6,997

Corporate bonds
 4,859 — 6 4,853

Certificates of deposit
 1,026 — — 1,026









 $ 19,413 $ 2 $ 9 $ 19,406









December 31, 2012
 Amortized
Cost Unrealized
Gain Unrealized
Loss Market
Value

U.S. treasuries
 $ 10,135 $ 1 $ — $ 10,136

Government-sponsored enterprise securities
 15,507 — 1 15,506

Corporate bonds
 11,509 — 8 11,501

Certificates of deposit
 496 — — 496









 $ 37,647 $ 1 $ 9 $ 37,639









X

- Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.4)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2,12)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_MarketableSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 72 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Astellas Agreements
6 Months Ended

Jun. 30, 2013

Text Block [Abstract]

Astellas Agreements

9. ASTELLAS AGREEMENTS

In July 2011, the Company entered into license agreements with Astellas Pharma Inc., or Astellas, granting Astellas exclusive, worldwide, royalty-bearing licenses under certain of the Company’s know-how and intellectual property to develop and commercialize certain products containing plasmids encoding certain forms of cytomegalovirus, or CMV, glycoprotein B and/or phosphoprotein 65, including ASP0113 (TransVax™) but excluding CyMVectin™.

Under the terms of the license agreements, Astellas paid a nonrefundable upfront license fee of $25.0 million in 2011. The Company also received a $10.0 million milestone payment in March 2012 upon finalization of the general trial design for a Phase 3 registration trial of ASP0113 in hematopoietic stem cell transplant recipients. The Company recognized $0.3 million and $10.2 million in license revenue under the Astellas agreements during the six months ended June 30, 2013 and 2012, respectively.

Under the terms of the agreements, the Company is also performing research and development services which are being paid for by Astellas. During the three and six months ended June 30, 2013, the Company recognized $1.1 million and $2.2 million, respectively, of revenue related to these contract services. During the three and six months ended June 30, 2012, the Company recognized $1.3 million and $2.3 million, respectively, of revenue related to these contract services.

In August 2012, the Company amended its license and supply agreements with Astellas to, among other things, extend the time period that the Company is obligated to supply licensed products for commercial use to Astellas, at Astellas’ expense, modify the allocation of $95.0 million of milestone payments among certain milestones through commercial launch and modify the structure of the royalties on net sales from a fixed double digit royalty to tiered double digit royalties.

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Agreements disclosure.

+ References

No definition available.

+ Details

Name: vicl_AgreementsDisclosureTextBlock

Namespace Prefix: vicl_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 73 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Jun. 30, 2012

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Total stock-based compensation expense $ 816 $ 923 $ 1,954 $ 1,843

Research and development [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Total stock-based compensation expense 242 272 554 558

Manufacturing and production [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Total stock-based compensation expense 60 56 128 106

General and administrative [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Total stock-based compensation expense $ 514 $ 595 $ 1,272 $ 1,179

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 74 R15.xml IDEA: Astellas Agreements 2.4.0.8116 - Disclosure - Astellas Agreementstruefalsefalse1false falsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_TextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Text Block [Abstract]2false 2vicl_AgreementsDisclosureTextBlockvicl_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 9.      ASTELLAS AGREEMENTS  In July 2011, the Company entered into license agreements with Astellas Pharma Inc., or Astellas, granting Astellas exclusive, worldwide, royalty-bearing licenses under certain of the Company’s know-how and intellectual property to develop and commercialize certain products containing plasmids encoding certain forms of cytomegalovirus, or CMV, glycoprotein B and/or phosphoprotein 65, including ASP0113 (TransVax™) but excluding CyMVectin™. Under the terms of the license agreements, Astellas paid a nonrefundable upfront license fee of $25.0 million in 2011. The Company also received a $10.0 million milestone payment in March 2012 upon finalization of the general trial design for a Phase 3 registration trial of ASP0113 in hematopoietic stem cell transplant recipients. The Company recognized $0.3 million and $10.2 million in license revenue under the Astellas agreements during the six months ended June 30, 2013 and 2012, respectively. Under the terms of the agreements, the Company is also performing research and development services which are being paid for by Astellas. During the three and six months ended June 30, 2013, the Company recognized $1.1 million and $2.2 million, respectively, of revenue related to these contract services. During the three and six months ended June 30, 2012, the Company recognized $1.3 million and $2.3 million, respectively, of revenue related to these contract services. In August 2012, the Company amended its license and supply agreements with Astellas to, among other things, extend the time period that the Company is obligated to supply licensed products for commercial use to Astellas, at Astellas’ expense, modify the allocation of $95.0 million of milestone payments among certain milestones through commercial launch and modify the structure of the royalties on net sales from a fixed double digit royalty to tiered double digit royalties. </div>falsefalsefalsenonnum:textBlockItemTypenaAgreements disclosure.No definition available.false0Astellas AgreementsfalseAstellas AgreementsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/NotesToFinancialStatementsAgreementsDisclosureTextBlock12 XML 75 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements (Tables)
6 Months Ended

Jun. 30, 2013

Fair Value Disclosures [Abstract]

Summary of Cash Equivalents, Marketable Securities and Long-Term Investments Measured at Fair Value

Cash equivalents, marketable securities and long-term investments measured at fair value are classified in the table below in one of the three categories described above (in thousands):

 Fair Value Measurements

June 30, 2013
 Level 1 Level 2 Level 3 Total

Certificates of deposit
 $ 1,026 $ — $ — $ 1,026

Money market funds
 17,845 — — 17,845

U.S. treasuries
 6,530 — — 6,530

Corporate bonds
 — 4,853 — 4,853

Government-sponsored enterprise securities
 — 6,997 — 6,997

Auction rate securities
 — — 2,037 2,037









 $ 25,401 $ 11,850 $ 2,037 $ 39,288









 Fair Value Measurements

December 31, 2012
 Level 1 Level 2 Level 3 Total

Certificates of deposit
 $ 496 $ — $ — $ 496

Money market funds
 18,500 — — 18,500

U.S. treasuries
 10,136 — — 10,136

Corporate bonds
 — 11,501 — 11,501

Government-sponsored enterprise securities
 — 15,506 — 15,506

Auction rate securities
 — — 2,225 2,225









 $ 29,132 $ 27,007 $ 2,225 $ 58,364









Summary of Activity for Assets Measured at Fair Value Using Significant Unobservable Inputs

Activity for assets measured at fair value using significant unobservable inputs (Level 3) is presented in the table below (in thousands):

 Six Months
Ended
June 30, 2013

Balance at December 31, 2012
 $ 2,225

Total net unrealized losses, excluding tax impact, included in other comprehensive income
 (188 )



Balance at June 30, 2013
 $ 2,037



Total gains or losses for the period included in net loss attributable to the change in unrealized gains or losses relating to assets still held at the reporting date
 $ —



X

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a,b,bb)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2C

-URI http://asc.fasb.org/extlink&oid=25499696&loc=SL7498348-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19279-110258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19190-110258

+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 76 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
6 Months Ended

Jun. 30, 2013

Jul. 25, 2013

Document Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2013

Document Fiscal Year Focus 2013

Document Fiscal Period Focus Q2

Trading Symbol VICL

Entity Registrant Name VICAL INC

Entity Central Index Key 0000819050

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 86,711,402

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: vicl_DocumentDocumentAndEntityInformationAbstract

Namespace Prefix: vicl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 77 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

General - Additional Information (Detail) (USD $)
In Thousands, except Share data in Millions, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Jun. 30, 2012

Dec. 31, 2012

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Maximum period for cash and highly liquid securities with original maturities ninety days or less

Minimum period for marketable securities classified as available-for-sale with original maturities more than ninety days

Amount of letter of credit, description Company is required to maintain a letter of credit securing an amount equal to twelve months of the current monthly installment of base rent for the term of its primary facilities lease, which ends in August 2017.

Restricted cash $ 3,059 $ 3,059 $ 3,059

Common stock equivalents excluded from the calculation of diluted net loss per share 1.4 1.1 1.5 1.4

X

- Definition

An element designated to encapsulate any additional information related to cash and cash equivalents not otherwise addressed by the existing taxonomy. Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_AdditionalCashAndCashEquivalentRelatedText

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

An entity may opt to provide the reader with additional narrative text to better understand the nature of available-for-sale security restrictions.

+ References

No definition available.

+ Details

Name: us-gaap_AvailableForSaleSecuritiesRestrictionsAdditionalInformation

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Letter of credit securing an amount equal to twelve months of the current monthly installment of base rent for the term of the primary facility lease, which ends in August of 2017.

+ References

No definition available.

+ Details

Name: vicl_LetterOfCreditDescription

Namespace Prefix: vicl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 78 R1.xml IDEA: Document and Entity Information 2.4.0.8101 - Document - Document and Entity Informationtruefalsefalse1false falsefalseeol_PE3939----1310-Q0004_STD_181_20130630_0http://www.sec.gov/CIK0000819050duration2013-01-01T00:00:002013-06-30T00:00:002false falsefalseeol_PE3939----1310-Q0004_STD_0_20130725_0http://www.sec.gov/CIK0000819050instant2013-07-25T00:00:000001-01-01T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares01true 1vicl_DocumentDocumentAndEntityInformationAbstractvicl_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Document Document And Entity Information [Abstract]2false 2dei_DocumentTypedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse0010-Qfalsefalsefalse2falsefalsefalse00falsefalsefalsedei:submissionTypeItemTypestringThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".No definition available.false0Document Type3false 2dei_AmendmentFlagdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:booleanItemTypenaIf the value is true, then the document is an amendment to previously-filed/accepted document.No definition available.false0Amendment Flag4false 2dei_DocumentPeriodEndDatedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse002013-06-30falsefalsetrue2falsefalsefalse00falsefalsefalsexbrli:dateItemTypedateThe end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.No definition available.false0Document Period End Date5false 2dei_DocumentFiscalYearFocusdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse002013falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:gYearItemTypepositiveintegerThis is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.No definition available.false0Document Fiscal Year Focus6false 2dei_DocumentFiscalPeriodFocusdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00Q2falsefalsefalse2falsefalsefalse00falsefalsefalsedei:fiscalPeriodItemTypenaThis is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.No definition available.false0Document Fiscal Period Focus7false 2dei_TradingSymboldei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00VICLfalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:normalizedStringItemTypenormalizedstringTrading symbol of an instrument as listed on an exchange.No definition available.false0Trading Symbol8false 2dei_EntityRegistrantNamedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00VICAL INCfalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:normalizedStringItemTypenormalizedstringThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false0Entity Registrant Name9false 2dei_EntityCentralIndexKeydei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse000000819050falsefalsefalse2falsefalsefalse00falsefalsefalsedei:centralIndexKeyItemTypenaA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false0Entity Central Index Key10false 2dei_CurrentFiscalYearEndDatedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00--12-31falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:gMonthDayItemTypemonthdayEnd date of current fiscal year in the format --MM-DD.No definition available.false0Current Fiscal Year End Date11false 2dei_EntityFilerCategorydei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00Accelerated Filerfalsefalsefalse2falsefalsefalse00falsefalsefalsedei:filerCategoryItemTypestringIndicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.No definition available.false0Entity Filer Category12false 2dei_EntityCommonStockSharesOutstandingdei_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse8671140286711402falsefalsefalsexbrli:sharesItemTypesharesIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.No definition available.false1Entity Common Stock, Shares OutstandingfalseDocument and Entity InformationUnKnownNoRoundingUnKnownUnKnowntruefalsefalseSheethttp://www.vical.com/taxonomy/role/DocumentDocumentandEntityInformation212

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenues:
Contract and grant revenue	$ 1,170	$ 1,364	$ 2,306	$ 2,585
License and royalty revenue	286	201	724	10,440
Total revenues	1,456	1,565	3,030	13,025
Operating expenses:
Research and development	3,930	3,791	7,580	10,219
Manufacturing and production	3,891	2,933	7,604	5,405
General and administrative	3,478	2,778	6,996	5,478
Total operating expenses	11,299	9,502	22,180	21,102
Loss from operations	(9,843)	(7,937)	(19,150)	(8,077)
Other income (expense):
Investment and other income, net	(38)	69	(13)	453
Net loss	$ (9,881)	$ (7,868)	$ (19,163)	$ (7,624)
Basic and diluted net loss per share	$ (0.11)	$ (0.09)	$ (0.22)	$ (0.09)
Weighted average shares used in computing basic and diluted net loss per share	86,730	86,282	86,623	85,412

Other Balance Sheet Accounts - Summary of Accounts Payable and Accrued Expenses (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Payables And Accruals [Abstract]
Employee compensation	$ 2,877	$ 3,858
Post-termination benefit accrual	252
Clinical trial accrual	644	660
Accounts payable	1,295	377
Deferred rent	337	307
Other accrued liabilities	579	427
Total accounts payable and accrued expenses	$ 5,984	$ 5,629

Long-Term Investments - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended	6 Months Ended
	Mar. 31, 2012 Investment	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2012
Investments Schedule [Abstract]
Number of long-term investments sold during the period	2
Auction rate securities sold, at par value	$ 4,000,000
Gain related to auction rate securities				300,000
Auction rate securities held, at par value		2,500,000
Maturity of long-term investment		2038
Recognized cumulative losses		600,000	600,000
Unrealized (losses) gains on auction rate securities			(113,000)	36,000
Cumulative unrealized gains		200,000	200,000
Carrying value of auction rate security		$ 2,000,000	$ 2,000,000

Marketable Securities, Available for Sale - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2013
Investments Debt And Equity Securities [Abstract]
Available-for-sale securities maturing outside of one year	$ 6,700,000
Realized gains or losses on sales of available-for-sale securities	0
Available-for-sale securities in a continuous material loss position longer than one year	$ 0

Astellas Agreements - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	1 Months Ended	3 Months Ended				6 Months Ended
	Aug. 31, 2012	Jun. 30, 2013	Jun. 30, 2012	Mar. 31, 2012	Mar. 31, 2011	Jun. 30, 2013	Jun. 30, 2012
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Recognized license revenue					$ 25.0	$ 0.3	$ 10.2
Additional amount received upon finalization of the general trial design				10.0
Recognized revenue related to contract services		1.1	1.3			2.2	2.3
Amount payable under license agreement on achievement of milestone	$ 95.0

Marketable Securities, Available for Sale - Summary of Available-for-Sale Marketable Securities (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 19,413	$ 37,647
Unrealized Gain	2	1
Unrealized Loss	9	9
Market Value	19,406	37,639
U.S. treasuries [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	6,528	10,135
Unrealized Gain	2	1
Unrealized Loss
Market Value	6,530	10,136
Government-sponsored enterprise securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	7,000	15,507
Unrealized Gain
Unrealized Loss	3	1
Market Value	6,997	15,506
Corporate bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	4,859	11,509
Unrealized Gain
Unrealized Loss	6	8
Market Value	4,853	11,501
Certificates of deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,026	496
Unrealized Gain
Unrealized Loss
Market Value	$ 1,026	$ 496

STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Cash flows from operating activities:
Net loss	$ (19,163)	$ (7,624)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,023	981
Write-off of abandoned patents	82	22
Gain on sale of property and equipment		(8)
Compensation expense related to stock options and awards	1,954	1,843
Changes in operating assets and liabilities:
Receivables and other assets	69	(647)
Accounts payable and accrued expenses	325	(1,328)
Deferred revenue	(75)	(99)
Deferred rent	(144)	(114)
Net cash used in operating activities	(15,929)	(6,974)
Cash flows from investing activities:
Proceeds from the sale of marketable securities		3,750
Maturities of marketable securities	21,346	9,470
Purchases of marketable securities	(3,037)	(27,211)
Purchases of property and equipment	(273)	(433)
Proceeds from the sale of property and equipment		8
Patent expenditures	(212)	(209)
Net cash provided by (used in) investing activities	17,824	(14,625)
Cash flows from financing activities:
Net proceeds from issuance of common stock	380	48,772
Payment of withholding taxes for net settlement of restricted stock units	(401)	(152)
Net cash (used in) provided by financing activities	(21)	48,620
Net increase in cash and cash equivalents	1,874	27,021
Cash and cash equivalents at beginning of period	43,159	38,696
Cash and cash equivalents at end of period	$ 45,033	$ 65,717

Long-Term Investments	6 Months Ended
Long-Term Investments	Jun. 30, 2013
Text Block [Abstract]
Long-Term Investments	5. LONG-TERM INVESTMENTS In March 2012, the Company sold two auction rate securities classified as long-term investments with a par value of $4.0 million. Included in interest and other income for the six months ended June 30, 2012, is a gain of $0.3 million related to the sale. As of June 30, 2013, the Company held an auction rate security with a par value of $2.5 million. This auction rate security has not experienced a successful auction since the liquidity issues experienced in the global credit and capital markets in 2008. As a result, the security is classified as a long-term investment as it is scheduled to mature in 2038. The security was rated BBB by Standard and Poor’s as of June 30, 2013. The security continues to pay interest according to its stated terms. The valuation of the Company’s auction rate security is subject to uncertainties that are difficult to predict. The fair value of the security is estimated utilizing a discounted cash flow analysis. The key drivers of the valuation model include the expected term, collateralization underlying the security investment, the creditworthiness of the counterparty, the timing of expected future cash flows, discount rates, liquidity and the expected holding period. The security was also compared, when possible, to other observable market data for securities with similar characteristics. Based on the valuation of the security, the Company has recognized cumulative losses of $0.6 million as of June 30, 2013. The losses when recognized are included in investment and other income. The market value of the security has partially recovered. Included in other comprehensive income are unrealized (losses) gains of $(113,000) and $36,000 for the six months ended June 30, 2013 and 2012, respectively. As of June 30, 2013, the Company had recorded cumulative unrealized gains of $0.2 million. The resulting carrying value of the auction rate security at June 30, 2013, was $2.0 million. Any future decline in market value may result in additional losses being recognized.

Fair Value Measurements - Summary of Cash Equivalents, Marketable Securities and Long-Term Investments Measured at Fair Value (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 39,288	$ 58,364
Certificates of deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	1,026	496
Money market funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	17,845	18,500
U.S. treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	6,530	10,136
Corporate bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	4,853	11,501
Government-sponsored enterprise securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	6,997	15,506
Auction rate securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	2,037	2,225
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	25,401	29,132
Level 1 [Member] \| Certificates of deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	1,026	496
Level 1 [Member] \| Money market funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	17,845	18,500
Level 1 [Member] \| U.S. treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	6,530	10,136
Level 1 [Member] \| Corporate bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value
Level 1 [Member] \| Government-sponsored enterprise securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value
Level 1 [Member] \| Auction rate securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	11,850	27,007
Level 2 [Member] \| Certificates of deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value
Level 2 [Member] \| Money market funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value
Level 2 [Member] \| U.S. treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value
Level 2 [Member] \| Corporate bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	4,853	11,501
Level 2 [Member] \| Government-sponsored enterprise securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	6,997	15,506
Level 2 [Member] \| Auction rate securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	2,037	2,225
Level 3 [Member] \| Certificates of deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value
Level 3 [Member] \| Money market funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value
Level 3 [Member] \| U.S. treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value
Level 3 [Member] \| Corporate bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value
Level 3 [Member] \| Auction rate securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 2,037	$ 2,225

BALANCE SHEETS (Parenthetical) (USD $) In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	160,000	160,000
Common stock, shares issued	86,495	86,136
Common stock, shares outstanding	86,495	86,136

Stockholders' Equity	6 Months Ended
Stockholders' Equity	Jun. 30, 2013
Equity [Abstract]
Stockholders' Equity	8. STOCKHOLDERS’ EQUITY In January 2012, the Company sold 13,333,334 shares of its common stock in a public offering at a price to the public of $3.75 per share. In February 2012, the Company sold an additional 576,358 shares pursuant to a partial exercise of the underwriters’ overallotment option at a price to the public of $3.75 per share. Net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, totaled $48.7 million. All of the shares of common stock were offered pursuant to two effective shelf registration statements. In November 2012, the Company entered into an At-The-Market Equity Offering Sales Agreement, or Sales Agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, under which the Company may issue and sell up to $50,000,000 of shares of its common stock from time to time. Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, shares may be sold through Stifel acting as sales agent or directly to Stifel acting as principal, by means of ordinary brokers’ transactions on the Nasdaq Global Select Market, in privately negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.

BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 45,033	$ 43,159
Marketable securities, available-for-sale	19,406	37,639
Restricted cash	3,059	3,059
Receivables and other assets	2,083	2,152
Total current assets	69,581	86,009
Long-term investments	2,037	2,225
Property and equipment, net	4,735	5,284
Intangible assets, net	2,741	2,813
Other assets	191	191
Total assets	79,285	96,522
Current liabilities:
Accounts payable and accrued expenses	5,984	5,629
Deferred revenue	75	150
Total current liabilities	6,059	5,779
Long-term liabilities:
Deferred rent	1,483	1,657
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000 shares authorized, none issued and outstanding
Common stock, $0.01 par value, 160,000 shares authorized, 86,495 and 86,136 shares issued and outstanding at June 30, 2013, and December 31, 2012, respectively	865	861
Additional paid-in capital	437,844	435,915
Accumulated deficit	(367,100)	(347,937)
Accumulated other comprehensive income	134	247
Total stockholders' equity	71,743	89,086
Total liabilities and stockholders' equity	$ 79,285	$ 96,522

Fair Value Measurements - Summary of Activity for Assets Measured at Fair Value Using Significant Unobservable Inputs (Detail) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2013
Fair Value Disclosures [Abstract]
Balance at December 31, 2012	$ 2,225
Total net unrealized losses, excluding tax impact, included in other comprehensive income	(188)
Balance at June 30, 2013	2,037
Total gains or losses for the period included in net loss attributable to the change in unrealized gains or losses relating to assets still held at the reporting date

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2013
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. COMMITMENTS AND CONTINGENCIES The Company prosecutes its intellectual property estate vigorously to obtain the broadest valid scope for its patents. Due to uncertainty of the ultimate outcome of patent enforcement actions, their impact on future operating results or the Company’s financial condition is not subject to reasonable estimates. In the ordinary course of business, the Company may become a party to lawsuits involving various matters. The Company is unaware of any such lawsuits presently pending against it which, individually or in the aggregate, are deemed to be material to the Company’s financial condition or results of operations.

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended
	Feb. 29, 2012	Jan. 31, 2012	Nov. 30, 2012
Equity [Abstract]
Number of shares of common stock sold in public offering		13,333,334
Common stock, public offering price	$ 3.75	$ 3.75
Net proceeds from offering		$ 48,700,000
No of common stock issued on partial exercise of underwriters' overallotment option	576,358
Maximum value of common stock issuable under agreement			$ 50,000,000

General (Policies)	6 Months Ended
General (Policies)	Jun. 30, 2013
Accounting Policies [Abstract]
Cash, Cash Equivalents and Marketable Securities	Cash, Cash Equivalents and Marketable Securities Cash and cash equivalents consist of cash and highly liquid securities with original maturities at the date of acquisition of ninety days or less. Investments with an original maturity of more than ninety days are considered marketable securities and have been classified by management as available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from sales of these securities to fund its operations, as necessary. Such investments are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Realized gains and losses from the sale of available-for-sale securities or the amounts, net of tax, reclassified out of accumulated other comprehensive income, if any, are determined on a specific identification basis.
Restricted Cash	Restricted Cash The Company is required to maintain a letter of credit securing an amount equal to twelve months of the current monthly installment of base rent for the term of its primary facilities lease, which ends in August 2017. Under certain circumstances, the Company may be able to eliminate the need for the letter of credit. As of June 30, 2013, and December 31, 2012, restricted cash of $3.1 million was pledged as collateral for this letter of credit.
Revenue Recognition	Revenue Recognition Revenue is recognized when the four basic criteria of revenue recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Certain of the Company’s revenue is generated through manufacturing contracts and stand-alone license agreements. The Company has entered into multiple-element arrangements. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The delivered item(s) must have value to the customer on a standalone basis and, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the Company’s control. A delivered item is considered a separate unit of accounting when the delivered item has value to the partner on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the partner and the availability of research expertise in this field in the general marketplace. Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence, or VSOE, of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement. If facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of drug products, the license is identified as a separate unit of accounting and the amounts allocated to the license are recognized upon the delivery of the license, assuming the other revenue recognition criteria have been met. However, if the amounts allocated to the license through the relative selling price allocation exceed the upfront license fee, the amount recognized upon the delivery of the license is limited to the upfront fee received. If facts and circumstances dictate that the license does not have standalone value, the transaction price, including any upfront license fee payments received, are allocated to the identified separate units of accounting and recognized as those items are delivered. The terms of the Company’s partnership agreements provide for milestone payments upon achievement of certain regulatory and commercial events. The Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following three criteria: 1) the consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, 2) the consideration relates solely to past performance, and 3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due to the Company.
Contract Services, Grant and Royalty Revenue	Contract Services, Grant and Royalty Revenue The Company recognizes revenues from contract services and federal government research grants during the period in which the related expenditures are incurred and related payments for those services are received or collection is reasonably assured. Royalties to be received based on sales of licensed products by the Company’s partners incorporating the Company’s licensed technology are recognized when received.
Net Loss Per Share	Net Loss Per Share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted average number of shares used to compute diluted net loss per share excludes any assumed exercise of stock options and warrants, and any assumed issuance of common stock under restricted stock units as the effect would be antidilutive. Common stock equivalents of 1.4 million and 1.1 million for the three months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect. Common stock equivalents of 1.5 million and 1.4 million for the six months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect.
Recent Accounting Pronouncement	Recent Accounting Pronouncement Effective January 1, 2013, the Company adopted Accounting Standards Update, or ASU, No. 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.” The adoption of ASU No. 2013-02 concerns presentation and disclosure only and did not have an impact on the Company’s financial position or results of operations. The Company elected to present the information required by ASU No. 2013-02 in the Statements of Comprehensive Loss.

General	6 Months Ended
General	Jun. 30, 2013
Accounting Policies [Abstract]
General	1. GENERAL Vical Incorporated, or the Company, a Delaware corporation, was incorporated in April 1987 and has devoted substantially all of its resources since that time to its research and development programs. The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. All of the Company’s potential products are in research and development phases. No revenues have been generated from the sale of any such products, nor are any such revenues expected for at least the next several years. The Company earns revenue from research and development agreements with pharmaceutical collaborators and grant and contract arrangements with government entities. Most of the Company’s product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. There can be no assurance that the Company’s research and development efforts, or those of its collaborators, will be successful. The Company expects to continue to incur substantial losses and not generate positive cash flows from operations for at least the next several years. No assurance can be given that the Company can generate sufficient product revenue to become profitable or generate positive cash flows from operations. The unaudited financial statements at June 30, 2013, and for the three and six months ended June 30, 2013 and 2012, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC, and with accounting principles generally accepted in the United States applicable to interim financial statements. These unaudited financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company’s financial position as of the interim date and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year or future periods. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. These unaudited financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2012, included in its Annual Report on Form 10-K filed with the SEC. Cash, Cash Equivalents and Marketable Securities Cash and cash equivalents consist of cash and highly liquid securities with original maturities at the date of acquisition of ninety days or less. Investments with an original maturity of more than ninety days are considered marketable securities and have been classified by management as available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from sales of these securities to fund its operations, as necessary. Such investments are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Realized gains and losses from the sale of available-for-sale securities or the amounts, net of tax, reclassified out of accumulated other comprehensive income, if any, are determined on a specific identification basis. Restricted Cash The Company is required to maintain a letter of credit securing an amount equal to twelve months of the current monthly installment of base rent for the term of its primary facilities lease, which ends in August 2017. Under certain circumstances, the Company may be able to eliminate the need for the letter of credit. As of June 30, 2013, and December 31, 2012, restricted cash of $3.1 million was pledged as collateral for this letter of credit. Revenue Recognition Revenue is recognized when the four basic criteria of revenue recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Certain of the Company’s revenue is generated through manufacturing contracts and stand-alone license agreements. The Company has entered into multiple-element arrangements. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The delivered item(s) must have value to the customer on a standalone basis and, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the Company’s control. A delivered item is considered a separate unit of accounting when the delivered item has value to the partner on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the partner and the availability of research expertise in this field in the general marketplace. Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence, or VSOE, of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement. If facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of drug products, the license is identified as a separate unit of accounting and the amounts allocated to the license are recognized upon the delivery of the license, assuming the other revenue recognition criteria have been met. However, if the amounts allocated to the license through the relative selling price allocation exceed the upfront license fee, the amount recognized upon the delivery of the license is limited to the upfront fee received. If facts and circumstances dictate that the license does not have standalone value, the transaction price, including any upfront license fee payments received, are allocated to the identified separate units of accounting and recognized as those items are delivered. The terms of the Company’s partnership agreements provide for milestone payments upon achievement of certain regulatory and commercial events. The Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following three criteria: (1) the consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (2) the consideration relates solely to past performance, and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due to the Company. Contract Services, Grant and Royalty Revenue The Company recognizes revenues from contract services and federal government research grants during the period in which the related expenditures are incurred and related payments for those services are received or collection is reasonably assured. Royalties to be received based on sales of licensed products by the Company’s partners incorporating the Company’s licensed technology are recognized when received. Net Loss Per Share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted average number of shares used to compute diluted net loss per share excludes any assumed exercise of stock options and warrants, and any assumed issuance of common stock under restricted stock units as the effect would be antidilutive. Common stock equivalents of 1.4 million and 1.1 million for the three months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect. Common stock equivalents of 1.5 million and 1.4 million for the six months ended June 30, 2013 and 2012, respectively, were excluded from the calculation because of their antidilutive effect. Recent Accounting Pronouncement Effective January 1, 2013, the Company adopted Accounting Standards Update, or ASU, No. 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.” The adoption of ASU No. 2013-02 concerns presentation and disclosure only and did not have an impact on the Company’s financial position or results of operations. The Company elected to present the information required by ASU No. 2013-02 in the Statements of Comprehensive Loss.

Astellas Agreements	6 Months Ended
Astellas Agreements	Jun. 30, 2013
Text Block [Abstract]
Astellas Agreements	9. ASTELLAS AGREEMENTS In July 2011, the Company entered into license agreements with Astellas Pharma Inc., or Astellas, granting Astellas exclusive, worldwide, royalty-bearing licenses under certain of the Company’s know-how and intellectual property to develop and commercialize certain products containing plasmids encoding certain forms of cytomegalovirus, or CMV, glycoprotein B and/or phosphoprotein 65, including ASP0113 (TransVax™) but excluding CyMVectin™. Under the terms of the license agreements, Astellas paid a nonrefundable upfront license fee of $25.0 million in 2011. The Company also received a $10.0 million milestone payment in March 2012 upon finalization of the general trial design for a Phase 3 registration trial of ASP0113 in hematopoietic stem cell transplant recipients. The Company recognized $0.3 million and $10.2 million in license revenue under the Astellas agreements during the six months ended June 30, 2013 and 2012, respectively. Under the terms of the agreements, the Company is also performing research and development services which are being paid for by Astellas. During the three and six months ended June 30, 2013, the Company recognized $1.1 million and $2.2 million, respectively, of revenue related to these contract services. During the three and six months ended June 30, 2012, the Company recognized $1.3 million and $2.3 million, respectively, of revenue related to these contract services. In August 2012, the Company amended its license and supply agreements with Astellas to, among other things, extend the time period that the Company is obligated to supply licensed products for commercial use to Astellas, at Astellas’ expense, modify the allocation of $95.0 million of milestone payments among certain milestones through commercial launch and modify the structure of the royalties on net sales from a fixed double digit royalty to tiered double digit royalties.

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2013	Jul. 25, 2013
Document Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2
Trading Symbol	VICL
Entity Registrant Name	VICAL INC
Entity Central Index Key	0000819050
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		86,711,402